Copd 2024

2024
REPORT
TE
U
IB
STR
I
D
T
O
N
O
-D
L
IA
TER
A
M
T
H
IG
R
PY
O
C
Global Strategy for the Diagnosis, Management, and

GLOBAL INITIATIVE FOR
CHRONIC OBSTRUCTIVE LUNG
DISEASE
GLOBAL STRATEGY FOR THE DIAGNOSIS, MANAGEMENT,

AND PREVENTION OF CHRONIC OBSTRUCTIVE PULMONARY
DISEASE
(2024 REPORT)
TE
U
IB
TR
IS
D
T
O
N
O
-D
L
IA
ER
AT
M
T
H
IG
R
PY
O
C
© 2023, 2024 Global Initiative for Chronic Obstructive Lung Disease, Inc.
Important Purpose & Liability Disclaimer
The information provided by Global Initiative for Chronic Obstructive Lung Disease (“GOLD”) for inclusion in its materials,
website, and applications (including but not limited to web based or digital applications) is provided for the convenience of
users to help them understand the conclusions of GOLD as of the date of the specific information’s approval by GOLD. That
information’s relevance to, and/or application to, a particular patient or case must be carefully assessed, evaluated, and
determined by a qualified health care professional treating that patient or case. Users need to be aware of the fact that only
the English language version of GOLD’s information has been reviewed and approved by GOLD, and that users must ensure
that they have the most current version of GOLD’s information since GOLD’s information may have been updated or changed
after its original release. Especially in light of the above, GOLD expressly disclaims any liability arising out of any use or misuse
of the information it provides.
Be sure to read and understand the paragraph entitled Important Purpose & Liability Disclaimer i
GOLD BOARD OF DIRECTORS GOLD SCIENCE COMMITTEE*
(2023) (2023)
Alvar Agusti, MD, Chair Claus Vogelmeier, MD, Chair Obianuju Ozoh, MD
Respiratory Institute University of Marburg University of Lagos
Hospital Clinic, IDIBAPS Marburg, Germany Lagos, Nigeria
Univ. Barcelona and Ciberes
Barcelona, Spain Alvar Agusti, MD Alberto Papi, MD
Respiratory Institute University of Ferrara
Bartolome R. Celli, MD Hospital Clinic, IDIBAPS Ferrara, Italy
Harvard Medical School Univ. Barcelona and Ciberes
Boston, Massachusetts, USA Barcelona, Spain Ian Pavord, DM FMedSci
Respiratory Medicine Unit and Oxford
Gerard Criner, MD Antonio Anzueto, MD Respiratory NIHR Biomedical Research Centre,
Temple University School of Medicine South Texas Veterans Health Care Nuffield Department of Medicine
Philadelphia, Pennsylvania, USA System, University of Oxford
University of Texas, Health Oxford, UK
David Halpin, MD San Antonio, Texas, USA
University of Exeter Medical School Nicolas Roche, MD
College of Medicine and Health Peter Barnes, DM, FRS – Retired, 2023 Pneumologie, Hôpital Cochin
University of Exeter, Exeter National Heart & Lung Institute AP-HP.Centre – Université Paris Cité
Devon, UK Imperial College UMR 1016
London, United Kingdom Institut Cochin
TE
M. Victorina López Varela, MD – Retired, 2023 Paris, France
Universidad de la República Jean Bourbeau, MD
U
IB
Hospital Maciel McGill University Health Centre Don D. Sin, MD
TR
Montevideo, Uruguay McGill University St. Paul’s Hospital
Montreal, Canada IS University of British Columbia
D
Maria Montes de Oca, MD Vancouver, Canada
T
Hospital Universitario de Caracas Gerard Criner, MD

O
Universidad Central de Venezuela Temple University School of Medicine Dave Singh, MD

N
O
Centro Médico de Caracas Philadelphia, Pennsylvania, USA University of Manchester

-D
Caracas, Venezuela Manchester, UK

David Halpin, MD
L
IA
Obianuju Ozoh, MD University of Exeter Medical School Robert Stockley, MD DSc

ER
University of Lagos College of Medicine and Health University Hospital

AT
Lagos, Nigeria University of Exeter, Exeter Birmingham, UK

Devon, UK
M
Sundeep Salvi, MD M. Victorina López Varela, MD– Retired, 2023

T
H
Pulmocare Research and Education MeiLan K. Han, MD MS Universidad de la República

IG
(PURE) Foundation University of Michigan Hospital Maciel

R
Pune, India
PY
Ann Arbor, MI, USA Montevideo, Uruguay

O
Claus Vogelmeier, MD
C
Fernando J. Martinez, MD MS Jadwiga A. Wedzicha, MD

University of Marburg Weill Cornell Medical Center/ National Heart & Lung Institute
Marburg, Germany New York-Presbyterian Hospital Imperial College London
New York, NY, USA London, UK
Jinping Zheng, MD
Guangzhou Institute of Respiratory Maria Montes de Oca, MD Jinping Zheng, MD
Health, First Affiliated Hospital of Hospital Universitario de Caracas Guangzhou Institute of Respiratory Health,
Guangzhou Medical University, Universidad Central de Venezuela First Affiliated Hospital of Guangzhou Medical
Guangzhou, China Centro Médico de Caracas University
Caracas, Venezuela Guangzhou, China
GOLD EXECUTIVE DIRECTOR EDITORIAL ASSISTANCE ACKNOWLEDGEMENTS

Katie Langefeld, BS Ruth Hadfield, PhD Contributor: Anna Podolanczuk, MD
Illinois, USA Macquarie University AIHI Assistant Professor of Medicine
Sydney, Australia Weill Cornell Medical College
Graphic Design: Imbue Creative
*
Disclosure forms for GOLD Committees are posted on the GOLD Website, www.goldcopd.org
Be sure to read and understand the paragraph entitled Important Purpose & Liability Disclaimer ii
GLOBAL STRATEGY FOR THE DIAGNOSIS, MANAGEMENT, AND PREVENTION OF COPD
(2024)
GOLD ASSEMBLY
The GOLD National Leaders are individuals from around the world with an interest in promoting the goals of GOLD
within their home country. The group meets periodically to share information about programs of health education,
COPD management, and prevention.
ARGENTINA IRAN RUSSIA

Andrés Echazarreta, MD, PhD Dr Masjedi Mohammad Reza Prof Zaurbek Aisanov, MD
Head of Pneumonology Service Tehran, Iran Moscow, Russia
San Juan de Dios de La Plata, Argentina Mohammad Ashkan Moslehi, MD Prof Alexandre Vizel, MD
BANGLADESH Shiraz, Iran Kazan, Tatarstan Republic, Russian Federation
Dr Kazi S. Bennoor IRELAND Sergey Fedosenko, MD, PhD
Dhaka, Bangladesh Timothy J. McDonnell, MD Siberian State Medical University, Tomsk,
Prof Md Mostafizur Rahman Dublin, Ireland Russia
Dhaka, Bangladesh ISRAEL SAUDI ARABIA
BELGIUM Zvi G. Fridlender, MD, MSc Mohammed Al Ghobain, MD
Prof Wim Janssens Jerusalem, Israel Riyadh, Saudi Arabia
Leuven, Belgium ITALY SINGAPORE
BULGARIA Prof Lorenzo Corbetta Kian-Chung Ong, MD
Dr Yavor Ivanov Florence, Italy Wan-Cheng Tan, MD,
Pleven, Bulgaria JAPAN Chair, Asian Pacific COPD Roundtable
CHINA Takahide Nagase, MD SLOVAK REPUBLIC
TE
Fu-Qiang Wen, MD, PhD Tokyo, Japan Ivan Solovič
Chengdu, China KAZAKHSTAN Propad, Slovakia
U
IB
COLOMBIA Tair Nurpeissov SOUTH AFRICA
TR
Alejandro Casas, MD KOREA Prof Richard van Zyl-Smit
General Director of the Fundación Yeon-Mok Oh, MD SPAIN
Neumológica Colombiana Seoul, South Korea IS Dr Patricia Sobradillo
D
CROATIA KUWAIT SWITZERLAND
T
O
Neven Miculinic, MD Professor Mousa Khadadah Daiana Stolz, MD

N
Zagreb, Croatia Kuwait University Basel, Switzerland

O
CZECH REPUBLIC KYRGYZSTAN SYRIA

-D
Stanislav Kos, MD, PhD., FCCP Talant Sooronbaev, MD Yousser Mohammad, MD

Mirosov, Czech Republic Bishkek, Kyrgyzstan Lattakia, Syria
L
IA
EGYPT LEBANON TRINIDAD & TOBAGO

ER
Hisham Tarraf, MD Mirna Waked, MD, FCCP Dr. Sateesh Madhava Sakhamuri
Cairo, Egypt Balamand University, Lebanon The University of the West Indies,
AT
FINLAND LITHUANIA Trinidad and Tobago

M
Mazur Witold MD, PhD Prof Kestutis Malakauskas, MD, PhD TURKEY
T
Helsinki, Finland Kaunas, Lithuania Prof Dr. Hakan Gunen

H
FRANCE MALTA Malatya, Turkey

IG
Prof Gaetan Deslée Prof Joseph M Cacciotolo Prof Nurdan Kokturk, MD

R
Reims, France Pieta, Malta Ankara, Turkey

PY
GEORGIA MEXICO UGANDA

O
Maia Gotua, MD, PhD Ana Sofía Ramírez-García Luna, MD Patricia Alupo, MBChB., MMED
C
Tbilisi, Georgia Mexico City, Mexico Makerere University Lung Institute in Uganda,
GERMANY MOLDOVA Africa
Daiana Stolz MD MPH Alexandru Corlateanu, MD, PhD UKRAINE
University Medical Center Freiburg ERS National Delegate Vitalii Poberezhets, MD
Freiburg, Germany Republic of Moldova National Pirogov Memorial Medical
GREECE NEPAL University, Department of Propedeutics of
Prof Konstantinos Kostikas Navin Kumar Mishra MD Internal Medicine
Ioannina, Greece Kathmandu Medical College Vinnytsia, Ukraine
HONG KONG CHINA Nepal, Asia UNITED STATES OF AMERICA
David S.C. Hui, MD PAKISTAN Ed Portilllo, PharmD
Shatin, N.T. Hong Kong Prof Javaid Khan University of Wisconsin-Madison School
ICELAND Karachi, Pakistan of Pharmacy
Dr Gunnar Gudmundsson Dr Jamil Ur Rehman Tahir Madison, Wisconsin
Reykjavik, Iceland Kammanwala, Sialkot Cantt, Pakistan VIETNAM
INDIA Dr Mohammad Osman Yusuf Le Thi Tuyet Lan, MD, PhD
Dr R. Narasimhan, MD Islamabad, Pakistan Ho Chi Minh City, Vietnam
Chennai, India POLAND Sy Duong-Quy, MD, PhD, FCCP
Dr Kshitij Agarwal, MD Pawel Sliwinski, MD, PhD Lam Dong Medical College, Vietnam
New Delhi, India Warsaw, Poland Prof Chau Ngo Quy
INDONESIA ROMANIA Tam Anh General Hospital, Ha Noi
Prof Faisal Yunus Florin Mihaltan, MD
Jakarta, Indonesia Ruxandra Ulmeanu, MD
Bucharest, Romania
Be sure to read and understand the paragraph entitled Important Purpose & Liability Disclaimer iii
GOLD 2024 REPORT HIGHLIGHTS
The GOLD report is revised annually and has been used worldwide by healthcare professionals as a tool to implement
effective management programs based on local healthcare systems.
In the 2024 revision of the GOLD report several important changes have been made as follows:
i. Chapter 3 and Chapter 4 have been consolidated into one chapter to reduce repetitive information
ii. Some tables have been consolidated to remove repetition; all table and figure numbers have been changed to
consecutive figure numbers only.
iii. PubMed links (where available) have now been included in the reference list and all references can now be found
at the end of the GOLD report (rather than at the end of each chapter).
iv. Information about PRISm (preserved ratio but impaired spirometry) has been expanded (Page 13)
v. A new section on Hyperinflation has been added (Page 17)
vi. In the Spirometry section further clarification about pre-bronchodilator spirometry has been added (Page 26)
vii. A new section on Screening for COPD in Targeted Populations (Page 29) has been added with information on
Leveraging Lung Cancer Imaging for COPD screening (Page 29), including spirometry screening in targeted
populations, and Leveraging Incidental Lung Imaging Abnormalities for COPD Screening (Page 30)
TE
viii. In the Initial Assessment section, the paragraphs on Blood Eosinophil Count have been updated (Page 34)
U
ix. Interstitial Lung Abnormalities are now covered (Page 38)
IB
TR
x. The section on Smoking Cessation has been revised (Page 43)
xi. IS
Vaccination Recommendations for people with COPD have been updated in line with current guidance from the
D
US Centers for Disease Control (CDC) (Page 46)
T
O
xii. Managing Inhaled Therapy has been expanded (Page 53) and includes information on a patient’s Ability to use
N
O
the Delivery System Correctly (Page 54) and Choice of Inhaler Device (Page 54)
-D
xiii. A new section on Pharmacotherapies for Smoking Cessation has been added (Page 68)
L
IA
ER
GOLD has been fortunate to have a network of international distinguished health professionals from multiple disciplines.
AT
Many of these experts have initiated investigations into the causes and prevalence of COPD in their countries and have
M
developed innovative approaches for the dissemination and implementation of the GOLD management strategy. The
T
H
GOLD initiative will continue to work with National Leaders and other interested healthcare professionals to bring COPD to
IG
R
the attention of governments, public health officials, healthcare workers, and the general public, to raise awareness of the
PY
burden of COPD and to develop programs for early detection, prevention and approaches to management.
O
C
Alvar G. Agusti, MD Claus Vogelmeier, MD

Chair, GOLD Board of Directors Chair, GOLD Science Committee
Be sure to read and understand the paragraph entitled Important Purpose & Liability Disclaimer iv
GLOBAL STRATEGY FOR THE DIAGNOSIS, MANAGEMENT
AND PREVENTION OF COPD 2024 UPDATE1
METHODOLOGY
When the Global Initiative for Chronic Obstructive Lung Disease (GOLD) program was initiated in 1998, a goal was to
produce recommendations for management of COPD based on the best scientific information available. The first
report, Global Strategy for the Diagnosis, Management and Prevention of COPD was issued in 2001. In 2006 and again
in 2011 a complete revision was prepared based on published research. These reports, and their companion
documents, have been widely distributed and translated into many languages and can be found on the GOLD website
(www.goldcopd.org).
The GOLD Science Committee2 was established in 2002 to review published research on COPD management and
prevention, to evaluate the impact of this research on recommendations in the GOLD documents related to
management and prevention, and to post yearly updates on the GOLD website. Its members are recognized leaders in
COPD research and clinical practice with the scientific credentials to contribute to the task of the Committee and are
TE
invited to serve in a voluntary capacity.
U
IB
TR
This 2024 GOLD Report is an update of the 2023-revised report. The 2023 GOLD Report was the 5th major revision of
IS
GOLD, and incorporated a reassessment and revision of recommendations for the diagnosis, assessment and
D
T
treatment of COPD. Updates of the 2017-revised report were made in 2018, 2019, 2020, 2021 and 2022. Updates of
O
N
the 2011-revised report were released in January 2013, 2014, 2015, and 2016.
O
-D
Process: To produce the GOLD report, a PubMed search (National Center for Biotechnology Information, U.S. National
L
IA
ER
Library of Medicine, Bethesda MD, USA) was completed using search fields established by the Committee: 1) COPD or
AT
Chronic Obstructive Pulmonary Disease (All Fields) AND 2) Clinical Trials or Meta-analysis (All Fields) OR 3) articles in
M
the top 20 medical or respiratory journals (available on request) or The Cochrane Database of Systematic Reviews.
T
H
IG
R
Publications in peer reviewed journals not captured by the PubMed searches may be submitted to the Chair, GOLD
PY
Science Committee, providing the full paper, including abstract, is submitted in (or translated into) English.
O
C
Members of the Committee receive a summary of citations and all abstracts. Each abstract is assigned to two
Committee members, although all members are offered the opportunity to provide input on any abstract. Members
evaluate the abstract or, subject to her/his judgment, the full publication, by answering four specific written questions
from a short questionnaire, to indicate if the scientific data presented impacts on recommendations in the GOLD
report. If so, the member is asked to specifically identify modifications that should be made.
The GOLD Science Committee meets twice yearly to discuss each publication that was considered by at least one
member of the Committee to potentially have an impact on the management of COPD. The full Committee then
reaches a consensus on whether to include it in the report, either as a reference supporting current recommendations,
or to change the report. In the absence of consensus, disagreements are decided by an open vote of the full
Committee. Only high-quality systematic reviews and meta-analyses that provide strong evidence for changing clinical
1 The Global Strategy for Diagnosis, Management and Prevention of COPD (updated 2024), the Pocket Guide (updated 2024) and the complete list of references
examined by the Committee is available on the GOLD website: www.goldcopd.org.
2
GOLD Science Committee Members (2023-2024): C. Vogelmeier, Chair, A. Agusti, A. Anzueto, P. Barnes, J. Bourbeau, G. Criner, D. Halpin, M. Han, F. Martinez, M.
Montes de Oca, O. Ozoh, A. Papi, I. Pavord, N. Roche, D. Sin, D. Singh, R. Stockley, M. Victorina Lopez Varela, J. Wedzicha, J. Zheng.
Be sure to read and understand the paragraph entitled Important Purpose & Liability Disclaimer v
practice are cited in the GOLD report with preference given to citing the original randomized controlled trial(s).
Recommendations by the GOLD Committees for use of any medication are based on the best evidence available from
the published literature and not on labeling directives from government regulators. The Committee does not make
recommendations for therapies that have not been approved by at least one major regulatory agency.
NEW REFERENCES
The GOLD 2024 report is an update GOLD 2023 report which was a major revision. Following systematic literature
searches and double-blind review by the GOLD Science Committee, the GOLD report has been updated to include key
peer-reviewed research publications from January 2022 to July 2023. In total, 148 new references have been added
to the GOLD 2024 report.
TE
U
IB
TR
IS
D
T
O
N
O
-D
L
IA
ER
AT
M
T
H
IG
R
PY
O
C
Be sure to read and understand the paragraph entitled Important Purpose & Liability Disclaimer vi
TABLE OF CONTENTS
GOLD 2024 REPORT HIGHLIGHTS......................................................................................................................................................................... IV
GLOBAL STRATEGY FOR THE DIAGNOSIS, MANAGEMENT AND PREVENTION OF COPD 2024 UPDATE ................................................................. V
METHODOLOGY ................................................................................................................................................................................................... V
NEW REFERENCES................................................................................................................................................................................................ VI
TABLE OF CONTENTS .......................................................................................................................................................................................... VII
GLOBAL STRATEGY FOR THE DIAGNOSIS, MANAGEMENT, AND PREVENTION OF COPD .................................................................................. 1
INTRODUCTION ....................................................................................................................................................................................................1
BACKGROUND ......................................................................................................................................................................................................1
LEVELS OF EVIDENCE ............................................................................................................................................................................................2
CHAPTER 1: DEFINITION AND OVERVIEW ....................................................................................................................................................... 4
KEY POINTS: ....................................................................................................................................................................................................4

WHAT IS COPD? ....................................................................................................................................................................................................5
Definition.........................................................................................................................................................................................................5
Causes and risk factors ....................................................................................................................................................................................5
Diagnostic criteria ...........................................................................................................................................................................................5
Clinical presentation........................................................................................................................................................................................5
TE
New opportunities ...........................................................................................................................................................................................5
U
BURDEN OF COPD .................................................................................................................................................................................................6
IB
TR
Prevalence .......................................................................................................................................................................................................6
IS
Morbidity ........................................................................................................................................................................................................6
D
Mortality .........................................................................................................................................................................................................7
T
O
Economic burden.............................................................................................................................................................................................7
N
Social burden ...................................................................................................................................................................................................8

O
PATHOGENESIS.....................................................................................................................................................................................................8
-D
Environmental risk factors ..............................................................................................................................................................................8

L
IA
Genetic factors ..............................................................................................................................................................................................10

ER
Trajectories of lung function: development and aging ..................................................................................................................................10

AT
Asthma and airway hyper-reactivity .............................................................................................................................................................13

M
Chronic bronchitis .........................................................................................................................................................................................14

T
Infections.......................................................................................................................................................................................................15
H
IG
Sex .................................................................................................................................................................................................................15
R
Race and ethnicity .........................................................................................................................................................................................15

PY
Socioeconomic status ....................................................................................................................................................................................16

O
C
PATHOBIOLOGY ..................................................................................................................................................................................................16
Inflammatory changes ..................................................................................................................................................................................16
Structural changes ........................................................................................................................................................................................16
PATHOPHYSIOLOGY............................................................................................................................................................................................17
Airflow obstruction and gas trapping............................................................................................................................................................17
Hyperinflation ...............................................................................................................................................................................................17
Pulmonary gas exchange abnormalities .......................................................................................................................................................18
Pulmonary hypertension ...............................................................................................................................................................................18
Exacerbations ................................................................................................................................................................................................18
Multimorbidity ..............................................................................................................................................................................................18
TAXONOMY ........................................................................................................................................................................................................19
CHAPTER 2: DIAGNOSIS AND ASSESSMENT ...................................................................................................................................................20
KEY POINTS: ..................................................................................................................................................................................................20

DIAGNOSIS .........................................................................................................................................................................................................20
CLINICAL PRESENTATION ....................................................................................................................................................................................20
Symptoms......................................................................................................................................................................................................20
Dyspnea.........................................................................................................................................................................................................21
Chronic cough................................................................................................................................................................................................22
Sputum production........................................................................................................................................................................................22
Be sure to read and understand the paragraph entitled Important Purpose & Liability Disclaimer vii
Wheezing and chest tightness.......................................................................................................................................................................22
Fatigue ..........................................................................................................................................................................................................23
Additional clinical features in severe disease ................................................................................................................................................23
DIFFERENTIAL DIAGNOSIS OF COPD ...................................................................................................................................................................23
MEDICAL HISTORY ..............................................................................................................................................................................................23
PHYSICAL EXAMINATION ....................................................................................................................................................................................24
SPIROMETRY.......................................................................................................................................................................................................25
SCREENING AND CASE-FINDING .........................................................................................................................................................................28
Screening for COPD in targeted populations .................................................................................................................................................29
INITIAL ASSESSMENT ..........................................................................................................................................................................................30
Severity of airflow obstruction ......................................................................................................................................................................31
Symptoms......................................................................................................................................................................................................31
Exacerbation risk ...........................................................................................................................................................................................33
Blood eosinophil count ..................................................................................................................................................................................34
Multimorbidity ..............................................................................................................................................................................................34
Combined initial COPD assessment ...............................................................................................................................................................35
ADDITIONAL INVESTIGATIONS............................................................................................................................................................................36
Physiological tests .........................................................................................................................................................................................36
Imaging .........................................................................................................................................................................................................37
Alpha-1 antitrypsin deficiency (AATD)...........................................................................................................................................................39
Composite scores ..........................................................................................................................................................................................39
Biomarkers ....................................................................................................................................................................................................39
TE
Treatable traits .............................................................................................................................................................................................39
U
IB
CHAPTER 3: PREVENTION & MANAGEMENT OF COPD ...................................................................................................................................40
TR
KEY POINTS: ..................................................................................................................................................................................................40
D
IS
INTRODUCTION ..................................................................................................................................................................................................41
T
IDENTIFY AND REDUCE EXPOSURE TO RISK FACTORS .........................................................................................................................................41

O
N
SMOKING CESSATION ................................................................................................................................................................................................43

O
Advice and counseling interventions .............................................................................................................................................................44

-D
HOUSEHOLD AND OUTDOOR AIR POLLUTION ...................................................................................................................................................................45

L
OCCUPATIONAL EXPOSURES........................................................................................................................................................................................45
IA
ER
VACCINATIONS ........................................................................................................................................................................................................46
AT
Influenza vaccine ...........................................................................................................................................................................................46

M
Pneumococcal vaccines .................................................................................................................................................................................46

T
Respiratory syncytial virus (RSV) vaccine ......................................................................................................................................................47

H
IG
Other vaccines ...............................................................................................................................................................................................47

R
PHARMACOLOGICAL TREATMENT OF STABLE COPD ..........................................................................................................................................47

PY
ALGORITHMS FOR THE INITIATION AND FOLLOW-UP OF PHARMACOLOGICAL TREATMENT ...........................................................................................................49

O
Managing inhaled therapy ............................................................................................................................................................................53

C
NON-PHARMACOLOGICAL TREATMENT OF STABLE COPD .................................................................................................................................56

ALGORITHMS FOR THE INITIATION AND FOLLOW-UP OF NON-PHARMACOLOGICAL TREATMENT ...................................................................................................56
REHABILITATION, EDUCATION & SELF-MANAGEMENT ......................................................................................................................................................57
Pulmonary rehabilitation ..............................................................................................................................................................................57
Education, self-management and integrative care .......................................................................................................................................59
OXYGEN THERAPY AND VENTILATORY SUPPORT ...............................................................................................................................................................60
Oxygen therapy .............................................................................................................................................................................................60
Ventilatory support .......................................................................................................................................................................................61
MONITORING AND FOLLOW-UP .........................................................................................................................................................................62
Telehealth and remote monitoring ...............................................................................................................................................................63
SUPPORTIVE, PALLIATIVE, END-OF-LIFE & HOSPICE CARE ..................................................................................................................................64
Symptom control and palliative care ............................................................................................................................................................64
Therapy relevant to all people with COPD.....................................................................................................................................................65
End-of-life and hospice care ..........................................................................................................................................................................66
THERAPEUTIC INTERVENTIONS THAT REDUCE COPD MORTALITY .........................................................................................................................................66
OVERVIEW OF THE EVIDENCE: PHARMACOTHERAPY ..........................................................................................................................................................68
Pharmacotherapies for smoking cessation ...................................................................................................................................................68
Pharmacotherapy to treat stable COPD ........................................................................................................................................................70
Bronchodilators .............................................................................................................................................................................................70
Methylxanthines ...........................................................................................................................................................................................73
Be sure to read and understand the paragraph entitled Important Purpose & Liability Disclaimer viii
Combination bronchodilator therapy ............................................................................................................................................................74
Anti-inflammatory agents .............................................................................................................................................................................75
Inhaled corticosteroids (ICS) ..........................................................................................................................................................................77
Triple therapy (LABA+LAMA+ICS) ..................................................................................................................................................................79
Oral glucocorticoids ......................................................................................................................................................................................80
Phosphodiesterase-4 (PDE4) inhibitor ...........................................................................................................................................................80
Antibiotics .....................................................................................................................................................................................................80
Mucolytic (mucokinetics, mucoregulators) and antioxidant agents (N-acetylcysteine, carbocysteine, erdosteine) ....................................80
Other drugs with potential to reduce exacerbations.....................................................................................................................................81
ADHERENCE TO INHALED COPD MEDICATIONS ...............................................................................................................................................................82
Other pharmacological treatments ...............................................................................................................................................................83
Management of mucus hypersecretion.........................................................................................................................................................84
OVERVIEW OF THE EVIDENCE: NON-PHARMACOLOGICAL THERAPY .......................................................................................................................................85
Self-management ..........................................................................................................................................................................................85
Integrated care programs .............................................................................................................................................................................86
Physical activity .............................................................................................................................................................................................86
Exercise training ............................................................................................................................................................................................86
Pulmonary rehabilitation ..............................................................................................................................................................................87
Tele-rehabilitation .........................................................................................................................................................................................89
Nutritional support........................................................................................................................................................................................90
INTERVENTIONAL & SURGICAL THERAPIES FOR COPD ........................................................................................................................................91
Lung surgical treatments for patients with emphysema ...............................................................................................................................92
TE
Bronchoscopic interventions in COPD ...........................................................................................................................................................93
U
SURGERY IN THE COPD PATIENT .................................................................................................................................................................................97
IB
General surgery .............................................................................................................................................................................................97
TR
IS
CHAPTER 4: MANAGEMENT OF EXACERBATIONS ..........................................................................................................................................99
D
T
KEY POINTS: ..................................................................................................................................................................................................99

O
N
DEFINITION .........................................................................................................................................................................................................99
O
Considerations...............................................................................................................................................................................................99
-D
TREATMENT OPTIONS ......................................................................................................................................................................................104

L
Treatment setting .......................................................................................................................................................................................104

IA
ER
Pharmacological treatment ........................................................................................................................................................................106

AT
Respiratory support.....................................................................................................................................................................................108
M
Hospital discharge and follow-up................................................................................................................................................................111

T
Prevention of exacerbations........................................................................................................................................................................113
H
IG
CHAPTER 5: COPD AND COMORBIDITIES ..................................................................................................................................................... 114

R
PY
KEY POINTS: ................................................................................................................................................................................................114

O
INTRODUCTION ................................................................................................................................................................................................114
C
Cardiovascular diseases (CVD) ....................................................................................................................................................................115

Heart failure ................................................................................................................................................................................................115
Ischaemic heart disease (IHD) .....................................................................................................................................................................115
Arrhythmias ................................................................................................................................................................................................115
Peripheral vascular disease .........................................................................................................................................................................116
Hypertension ...............................................................................................................................................................................................116
Lung cancer .................................................................................................................................................................................................116
Bronchiectasis .............................................................................................................................................................................................118
Obstructive sleep apnea & insomnia ...........................................................................................................................................................118
Periodontitis & dental hygiene ....................................................................................................................................................................119
Metabolic syndrome and diabetes ..............................................................................................................................................................119
Gastroesophageal reflux (GERD) .................................................................................................................................................................119
Osteoporosis ...............................................................................................................................................................................................119
Anemia ........................................................................................................................................................................................................120
Polycythemia ...............................................................................................................................................................................................120
Anxiety and depression................................................................................................................................................................................121
Cognitive impairment ..................................................................................................................................................................................121
Frailty ..........................................................................................................................................................................................................121
COPD as part of multimorbidity ..................................................................................................................................................................122
Other considerations ...................................................................................................................................................................................122
Be sure to read and understand the paragraph entitled Important Purpose & Liability Disclaimer ix
CHAPTER 6: COVID-19 AND COPD ................................................................................................................................................................ 123
KEY POINTS: ................................................................................................................................................................................................123

INTRODUCTION ................................................................................................................................................................................................123
RISK OF INFECTION WITH SARS-COV-2 ..............................................................................................................................................................123
INVESTIGATIONS ..............................................................................................................................................................................................125
Testing for SARS-CoV-2 infection.................................................................................................................................................................125
Spirometry & pulmonary function testing ...................................................................................................................................................125
Bronchoscopy ..............................................................................................................................................................................................125
Radiology ....................................................................................................................................................................................................126
PROTECTIVE STRATEGIES FOR PATIENTS WITH COPD .......................................................................................................................................127
Vaccination .................................................................................................................................................................................................127
DIFFERENTIATING COVID-19 INFECTION FROM DAILY SYMPTOMS OF COPD ...................................................................................................128
MAINTENANCE PHARMACOLOGICAL TREATMENT FOR COPD DURING THE COVID-19 PANDEMIC ..................................................................128
Use of nebulizers .........................................................................................................................................................................................129
PULMONARY REHABILITATION .........................................................................................................................................................................130
REVIEW OF COPD PATIENTS..............................................................................................................................................................................130
TREATMENT OF COVID-19 IN PATIENTS WITH COPD ........................................................................................................................................130
EXACERBATIONS OF COPD ................................................................................................................................................................................131
Systemic corticosteroids ..............................................................................................................................................................................132
Antibiotics ...................................................................................................................................................................................................132
PULMONARY AND EXTRA-PULMONARY COMPLICATIONS ...............................................................................................................................133
Anticoagulation ...........................................................................................................................................................................................133
TE
VENTILATORY SUPPORT FOR COPD PATIENTS WITH COVID-19 PNEUMONIA ...................................................................................................133
U
IB
REHABILITATION...............................................................................................................................................................................................134
TR
FOLLOW-UP OF COPD PATIENTS WHO DEVELOPED COVID-19 .........................................................................................................................135
IS
REMOTE COPD PATIENT FOLLOW-UP ...............................................................................................................................................................136
D
Introduction ................................................................................................................................................................................................136
T
O
Triage and prioritizing process ....................................................................................................................................................................136

N
Consideration and instruction for remote COPD follow-up .........................................................................................................................136

O
-D
COPD FOLLOW-UP CHECKLIST ..........................................................................................................................................................................138

REFERENCES .....................................................................................................................................................................................................140
L
IA
ER
AT
M
T
H
IG
R
PY
O
C
Be sure to read and understand the paragraph entitled Important Purpose & Liability Disclaimer x
GLOBAL STRATEGY FOR THE DIAGNOSIS, MANAGEMENT,
AND PREVENTION OF COPD
INTRODUCTION
The aim of the GOLD Report is to provide a non-biased review of the current evidence for the assessment, diagnosis
and treatment of people with COPD. One of the strengths of GOLD reports is the treatment objectives. These have
stood the test of time, and are organized into two groups: objectives that are directed towards relieving and reducing
the impact of symptoms, and objectives that reduce the risk of adverse health events that may affect the patient at
some point in the future (exacerbations are an example of such events). This emphasizes the need for clinicians to
focus on both the short-term and long-term impact of COPD on their patients.
A second strength of the original strategy was the simple, intuitive system for classifying COPD severity. This was based
on FEV1 and was called a staging system because it was believed, at the time, that the majority of patients followed a
path of disease progression in which the severity of COPD tracked the severity of airflow obstruction. Much is now
known about the characteristics of patients in the different GOLD stages – for example, their risk of exacerbations,
TE
hospitalization, and death. However, at an individual patient level, FEV1 is an unreliable marker of the severity of
U
IB
breathlessness, exercise limitation, health status impairment, and risk of exacerbation.
TR
IS
D
At the time of the original report, improvement in both symptoms and health status was a GOLD treatment objective,
T
O
but symptoms assessment did not have a direct relation to the choice of management, and health status measurement
N
was a complex process largely confined to clinical studies. Now, there are simple and reliable questionnaires designed
O
-D
for use in routine daily clinical practice. These are available in many languages. These developments have enabled an
L
assessment system to be developed that draws together a measure of the impact of the patient’s symptoms and an
IA
ER
assessment of the patient’s risk of having a serious adverse health event. This management approach can be used in
AT
any clinical setting anywhere in the world and moves COPD treatment towards individualized medicine – matching the
M
patient’s therapy more closely to his or her needs.

T
H
IG
R
PY
BACKGROUND
O
C
Chronic Obstructive Pulmonary Disease (COPD) is now one of the top three causes of death worldwide and 90% of
these deaths occur in low- and middle-income countries (LMICs).(1,2) More than 3 million people died of COPD in 2012
accounting for 6% of all deaths globally. COPD represents an important public health challenge that is both preventable
and treatable. COPD is a major cause of chronic morbidity and mortality throughout the world; many people suffer
from this disease for years and die prematurely from it or its complications. Globally, the COPD burden is projected to
increase in coming decades because of continued exposure to COPD risk factors and aging of the population.(3)
In 1998, with the cooperation of the National Heart, Lung, and Blood Institute, National Institutes of Health and the
World Health Organization the Global Initiative for Chronic Obstructive Lung Disease (GOLD) was implemented. Its
goals were to increase awareness of the burden of COPD and to improve prevention and management of COPD
through a concerted worldwide effort of people involved in all facets of healthcare and healthcare policy. An important
and related goal was to encourage greater research interest in this highly prevalent disease.
In 2001, GOLD released its first report, Global Strategy for the Diagnosis, Management, and Prevention of COPD. This
report was not intended to be a comprehensive textbook on COPD, but rather to summarize the current state of the
Be sure to read and understand the paragraph entitled Important Purpose & Liability Disclaimer 1
field. It was developed by individuals with expertise in COPD research and patient care and was based on the best-
validated concepts of COPD pathogenesis at that time, along with available evidence on the most appropriate
management and prevention strategies. It provided state-of-the-art information about COPD for pulmonary specialists
and other interested physicians and served as a source document for the production of various communications for
other audiences, including an Executive Summary, a Pocket Guide for Healthcare Professionals, and a Patient Guide.
Immediately following the release of the first GOLD report in 2001, the GOLD Board of Directors appointed a Science
Committee, charged with keeping the GOLD documents up to date by reviewing published research, evaluating the
impact of this research on the management recommendations in the GOLD documents, and posting yearly updates of
these documents on the GOLD website.
In 2018 GOLD held a one-day summit to consider information about the epidemiology, clinical features, approaches
to prevention and control, and the availability of resources for COPD in LMICs.(1) Major conclusions of the summit
included that: there are limited data about the epidemiological and clinical features of COPD in LMICs but the data
available indicate there are important differences in these features around the world; there is widespread availability
of affordable tobacco products as well as other exposures (e.g., household air pollution) thought to increase the risk
of developing COPD; diagnostic spirometry services are not widely available and there are major problems with access
to affordable quality-assured pharmacological and non-pharmacological therapies. GOLD is therefore concerned that
TE
COPD is not being taken seriously enough at any level, from individuals and communities, to national governments
U
and international agencies.(4) It is time for this to change and the GOLD Board of Directors challenge all relevant
IB
TR
stakeholders to work together in coalition with GOLD to address the avoidable burden of COPD worldwide. GOLD is
IS
committed to improving the health of people at risk of and with COPD, wherever they happen to have been born, and
D
T
wishes to do its bit to help achieve the United Nations Sustainable Development Goal 3.4 to reduce premature
O
N
mortality from non-communicable diseases - including COPD - by one third by 2030.(5)

O
-D
L
IA
LEVELS OF EVIDENCE
ER
AT
M
Levels of evidence have been assigned to evidence-based recommendations where appropriate (Table A). Evidence
T
H
levels are indicated in boldface type enclosed in parentheses after the relevant statement e.g., (Evidence A). The
IG
R
methodological issues concerning the use of evidence from meta-analyses were carefully considered when i)
PY
treatment effect (or effect size) was consistent from one study to the next, and we needed to identify the common
O
C
effect; ii) the effect varied from one study to the next, and there was a need to identify the reason for the variation.
TE
U
IB
TR
IS
D
T
O
N
O
-D
L
IA
ER
AT
M
T
H
IG
R
PY
O
C
CHAPTER 1: DEFINITION AND OVERVIEW
KEY POINTS:
Definition
 Chronic Obstructive Pulmonary Disease (COPD) is a heterogeneous lung condition characterized by
chronic respiratory symptoms (dyspnea, cough, sputum production and/or exacerbations) due to
abnormalities of the airways (bronchitis, bronchiolitis) and/or alveoli (emphysema) that cause
persistent, often progressive, airflow obstruction.
Causes and Risk Factors
 COPD results from gene(G)-environment(E) interactions occurring over the lifetime(T) of the
individual (GETomics) that can damage the lungs and/or alter their normal development/aging
processes.
 The main environmental exposures leading to COPD are tobacco smoking and the inhalation of
toxic particles and gases from household and outdoor air pollution, but other environmental and
host factors (including abnormal lung development and accelerated lung aging) can also contribute.
 The most relevant (albeit rare) genetic risk factor for COPD identified to date are mutations in the
TE
U
SERPINA1 gene that lead to α-1 antitrypsin deficiency. A number of other genetic variants have also
IB
TR
been associated with reduced lung function and risk of COPD, but their individual effect size is small.
Diagnostic Criteria IS
D
 In the appropriate clinical context (see ‘Definition’ & ‘Causes and Risk Factors’ above), the presence
T
O
N
of non-fully reversible airflow obstruction (i.e., FEV1/FVC < 0.7 post-bronchodilation) measured by
O
spirometry confirms the diagnosis of COPD.

-D
 Some individuals can have respiratory symptoms and/or structural lung lesions (e.g., emphysema)
L
IA
and/or physiological abnormalities (including low FEV1, gas trapping, hyperinflation, reduced lung
ER
diffusing capacity and/or rapid FEV1 decline) without airflow obstruction (FEV1/FVC ≥ 0.7 post-
AT
M
bronchodilation). These subjects are labeled ‘Pre-COPD’. The term ‘PRISm’ (Preserved Ratio
T
Impaired Spirometry) has been proposed to identify those with normal ratio but abnormal
H
IG
spirometry. Subjects with Pre-COPD or PRISm are at risk of developing airflow obstruction over
R
PY
time, but not all of them do.

O
Clinical Presentation
C
 Patients with COPD typically complain of dyspnea, activity limitation and/or cough with or without
sputum production and may experience acute respiratory events characterized by increased
respiratory symptoms called exacerbations that require specific preventive and therapeutic
measures.
 Patients with COPD frequently harbor other comorbid diseases that influence their clinical
condition and prognosis and require specific treatment as well. These comorbid conditions can
mimic and/or aggravate an acute exacerbation.
New Opportunities
 COPD is a common, preventable, and treatable disease, but extensive under-diagnosis and
misdiagnosis leads to patients receiving no treatment or incorrect treatment. Appropriate and
earlier diagnosis of COPD can have a very significant public-health impact.
 The realization that environmental factors other than tobacco smoking can contribute to COPD,
that it can start early in life and affect young individuals, and that there are precursor conditions
(Pre-COPD, PRISm), opens new windows of opportunity for its prevention, early diagnosis, and
prompt and appropriate therapeutic intervention.
WHAT IS COPD?
Definition
Chronic Obstructive Pulmonary Disease (COPD) is a heterogeneous lung condition characterized by chronic respiratory
symptoms (dyspnea, cough, sputum production and/or exacerbations) due to abnormalities of the airways (bronchitis,
bronchiolitis) and/or alveoli (emphysema) that cause persistent, often progressive, airflow obstruction.(6)
Causes and risk factors

COPD results from gene(G)-environment(E) interactions occurring over the lifetime(T) of the individual (GETomics)
that can damage the lungs and/or alter their normal development/aging processes.(7)
The main environmental exposures leading to COPD are tobacco smoking and the inhalation of toxic particles and
gases from household and outdoor air pollution, but other environmental(8,9) and host factors (including abnormal lung
development and accelerated lung aging) can also contribute.(7)
The most relevant (albeit epidemiologically rare) genetic risk factor for COPD identified to date are mutations in the
TE
SERPINA1 gene, leading to α1-antitrypsin deficiency, but other genetic variants, with a low individual effect size, are
U
IB
associated with reduced lung function and risk of COPD too.(10)
TR
IS
Diagnostic criteria
D
T
O
In the appropriate clinical context (See ‘Definition’ and ‘Causes and Risk Factors’ above), the presence of non-fully
N
O
reversible airflow obstruction (FEV1/FVC < 0.7 post-bronchodilation) measured by spirometry confirms the diagnosis
-D
of COPD.
L
IA
ER
Yet, some individuals may present with structural lung lesions (e.g., emphysema) and/or physiological abnormalities
AT
(including low FEV1, gas trapping, hyperinflation, reduced lung diffusing capacity and/or rapid FEV1 decline) without
M
T
airflow obstruction (FEV1/FVC ≥ 0.7 post-bronchodilation). These subjects are labeled ‘Pre-COPD’. The term ‘PRISm’
H
IG
(Preserved Ratio Impaired Spirometry) has been proposed to identify those with normal ratio but abnormal
R
PY
spirometry. Subjects with Pre-COPD or PRISm are at risk of developing airflow obstruction over time, but not all of
O
them do.(11,12) Research is needed to determine what is the best treatment for these individuals (beyond smoking
C
cessation).
Clinical presentation
Patients with COPD typically complain of dyspnea, wheezing, chest tightness, fatigue, activity limitation, and/or cough
with or without sputum production, and may experience acute events characterized by increased respiratory
symptoms called exacerbations that influence their health status and prognosis, and require specific preventive and
therapeutic measures.
Patients with COPD frequently harbor other comorbid diseases that also influence their clinical condition and
prognosis and require specific treatment as well. These comorbid conditions can mimic and/or aggravate an acute
exacerbation.
New opportunities
COPD is a common, preventable, and treatable disease, but extensive under and misdiagnosis leads to patients
receiving no treatment or incorrect treatment. The realization that environmental factors other than tobacco smoking
can contribute to COPD, that it can start early in life and affect young individuals, and that there are precursor
conditions (Pre-COPD, PRISm), opens new windows of opportunity for its prevention, early diagnosis, and prompt and
appropriate therapeutic intervention.(13)
BURDEN OF COPD
COPD is a leading cause of morbidity and mortality worldwide with an economic and social burden that is both
substantial and increasing.(14,15) COPD prevalence, morbidity and mortality vary across countries.(16,17) The prevalence
of COPD is often directly related to the prevalence of tobacco smoking, but in many countries outdoor, occupational
and household air pollution (resulting from the burning of wood and other biomass fuels) are important COPD risk
factors.(18,19)
The prevalence and burden of COPD are projected to increase over the coming decades due to a combination of
continued exposure to COPD risk factors and aging of the world’s population.(3) Information on the burden of COPD
can be found on international websites, such as the World Health Organization (WHO)(20) and the World Bank/WHO
Global Burden of Disease (GBD) Study.(21,22)
TE
Prevalence
U
IB
Existing COPD prevalence data vary widely due to differences in survey methods, diagnostic criteria, and analytical
TR
approaches.(3) Of note, all of these epidemiologic studies defined COPD by spirometry alone. The lowest estimates of
IS
D
prevalence are those based on self-reporting of a doctor’s diagnosis of COPD, or equivalent condition. For example,
T
O
most national data show that < 6% of the adult population have been told that they have COPD. (23) This is likely to be
N
O
a reflection of the widespread under-recognition and under-diagnosis of COPD.(24)

-D
L
IA
Data are emerging that enable more accurate estimates of COPD prevalence. A number of systematic reviews and
ER
meta-analyses provide evidence that the prevalence of COPD is appreciably higher in smokers and ex-smokers
AT
compared to non-smokers, in those ≥ 40 years of age compared to those < 40, and in men compared to women. (25-27)
M
T
The Latin American Project for the Investigation of Obstructive Lung Disease (PLATINO)(28) examined the prevalence of
H
IG
post-bronchodilator airflow obstruction among persons ≥ 40 years in one major city from each of five Latin American
R
PY
countries – Brazil, Chile, Mexico, Uruguay, and Venezuela. The prevalence of COPD increased steeply with age, with
O
the highest prevalence among those > 60 years. Prevalence in the total population ranged from 7.8% in Mexico City
C
to 19.7% in Montevideo, Uruguay. The prevalence was appreciably higher in men than in women,(28) which contrasts
with findings from European cities such as Salzburg, Austria.(29) Analyses of the GBD database suggests an overall
increase in COPD prevalence in females while it has decreased in males and in some countries in the European Union
between 2001 and 2019.(30) The Burden of Obstructive Lung Diseases (BOLD) program used standardized methodology
comprising questionnaires and pre- and post-bronchodilator spirometry to assess prevalence and risks for COPD
globally in people aged ≥ 40 years.(29,31,32) BOLD reported an overall prevalence of COPD of 11.8% (standard error (SE)
7.9) for men and 8.5% (SE 5.8) for women(33) and a substantial prevalence of COPD of 3%-11% among never-smokers.(33)
BOLD examined the prevalence of COPD in north and sub-Saharan Africa and Saudi Arabia and found similar results.(34-
37) Based on BOLD and other large scale epidemiological studies, it is estimated that the global prevalence of COPD is
10.3% (95% confidence interval (CI) 8.2%,12.8%).(25,38) With the increasing prevalence of smoking in LMICs, and aging
populations in high-income countries, the prevalence of COPD is expected to rise.(39)
Morbidity
Morbidity measures traditionally include physician visits, emergency department visits, and hospitalizations. To date
studies indicate that morbidity due to COPD increases with age,(23,24,28) and in patients with COPD the development of
comorbidities are seen at an earlier age.(40,41) Morbidity in COPD may also be influenced by concomitant chronic
conditions (e.g., cardiovascular disease, musculoskeletal impairment, diabetes mellitus)(42) that are related to smoking,
aging and/or COPD.(43)
Mortality
The World Health Organization (WHO) publishes mortality statistics for selected causes of death annually for all WHO
regions.(44) However, data must be interpreted with caution because of the inconsistent use of COPD terminology. In
the 10th revision of the International Statistical Classification of Diseases and Related Health Problems (ICD-10), deaths
from COPD or chronic airways obstruction are included in the broad category of “COPD and allied conditions” (ICD-10
codes J42-46).
Under-recognition and under-diagnosis of COPD reduces the accuracy of mortality data.(45,46) Furthermore, the
accuracy of COPD diagnosis codes recorded in administrative health databases is also uncertain.(47,48) In some
jurisdictions, reliance on administrative health data, particularly those that only record hospitalizations, may
underestimate the burden of COPD.(49) The reliability of recording of COPD-related deaths in mortality data is also
problematic. Although COPD is often a primary cause of death, it is more likely to be listed as a contributory cause of
death or omitted from the death certificate entirely.(50) However, it is clear that COPD is one of the most important
causes of death in most countries. For instance, in 2011, COPD was the third leading cause of death in the United
States.(51) This increase in COPD-related mortality has mainly been driven by the expanding epidemic of smoking;
TE
reduced mortality from other common causes of death (e.g., ischemic heart disease, infectious diseases); the aging of
U
IB
the world’s population, particularly in high-income countries; and scarcity of effective disease modifying therapies.
TR
Data from the GBD Study 2017 estimated a COPD-attributable death rate was 42/100,000 (4.72% of all-cause
D
IS
deaths)(3,52)
T
O
N
O
With these caveats in mind, it can be estimated that globally there are around three million deaths annually due to
-D
COPD.(53) It is estimated that the increased prevalence of smoking in LMICs coupled with aging populations in high-
L
IA
income countries will result in over 5.4 million annual deaths from COPD and related conditions by 2060.(54,55)
ER
AT
Economic burden
M
T
H
COPD is associated with significant economic burden. In the European Union, the total direct costs of respiratory
IG
disease are estimated to be about 6% of the total annual healthcare budget, with COPD accounting for 56% (38.6
R
PY
billion Euros) of the cost of respiratory disease.(56) In the United States the costs attributable to COPD are expected to
O
increase over the next 20 years, with projected costs of $800.90 billion or $40 billion per year.(57,58) Dynamic modeling
C
also predicts that women are expected to incur higher direct costs than men and lose more quality-adjusted life
years.(58) COPD exacerbations account for the greatest proportion of the total COPD burden on the healthcare
system.(59) Not surprisingly, there is a striking direct relationship between the severity of COPD and the cost of care,
and the cost distribution changes as the disease progresses. For example, hospitalization and ambulatory oxygen costs
soar as COPD severity increases. Any estimate of direct medical expenditure for home-based care under-represents
the true cost of home-based care to society because it ignores the economic value of the care provided by family
members to people with COPD.
In LMICs both direct and indirect medical costs may be substantial. Recent work from the WHO and other organizations
suggest that inhaled medicines for COPD are poorly available and largely unaffordable in LMICs.(60) Most inhaled
medications are still branded and there are few options currently available for generic inhalers. The situation is similar
for access to diagnostic spirometry. Because the healthcare sector might not provide long-term supportive care
services for severely disabled individuals, COPD may force at least two individuals to leave the workplace – the affected
individual and a family member who must now stay home to care for their disabled relative.(61) Since human capital is
often the most important national asset for LMICs, the indirect costs of COPD may represent a serious threat to their
economy.
Social burden
Since mortality offers only a limited perspective on the human burden of a disease, it is desirable to find other
measures of disease burden that are consistent and measurable within and between nations. The GBD study designed
a method to estimate the fraction of mortality and disability attributable to major diseases and injuries using a
composite measure of the burden of each health problem: the Disability-Adjusted Life Years (DALY).(62) The DALY for a
specific condition are the sum of years lost because of premature mortality and years of life lived with disability,
adjusted for the severity of disability. The GBD Study found that from 1990 to 2019, COPD was the primary driver of
increased DALY worldwide, especially in LMICs.(21,63) The global health burden caused by COPD increasing by 25.7%
from 59.2 million DALY in 1990 to 74.4 DALY in 2019 with largest increases in South East Asia, India, Sub-Saharan Africa
and South America.(64) In 2005 COPD was the eighth leading cause of DALY lost across the world but by 2013 COPD
was ranked as the fifth leading cause of DALY lost.(52,65) In the United States, COPD is the second leading cause of
reduced DALY, trailing only ischemic heart disease.(66) Data from GBD 2017 estimated that the DALY rate was
1068.02/100,000 for COPD.(52)
PATHOGENESIS
TE
COPD is the end-result of complex, cumulative and dynamic gene-environment interactions over the lifetime that can
U
damage the lungs and/or alter their normal developmental or aging processes.(7) Understanding the relationships and
IB
TR
interactions between the genetic (G) background of the host and varied environmental (E) risk factors over the lifetime
IS
(T) requires further investigation. The term GETomics has been recently proposed to illustrate the complex and
D
dynamic series of interactions between Genetics and Environment over Time.(7) According to this GETomics proposal,
T
O
N
the end result of a given GxE interaction depends not only on G and E, but also on T, as determined by both the age of
O
the individual at which that particular interaction occurs (development vs aging) and the previous history of GxE
-D
interactions that the individual has encountered earlier in her/his life (biological memory).(7)
L
IA
ER
Environmental risk factors

AT
M
Cigarette smoking
T
H
IG
Cigarette smoking is a key environmental risk factor for COPD. Cigarette smokers have a higher prevalence of
R
respiratory symptoms and lung function abnormalities, a greater annual rate of decline in FEV1, and a greater COPD
PY
O
mortality rate than non-smokers.(67) Yet fewer than 50% of heavy smokers develop COPD(68) and it is estimated that
C
half of all COPD cases worldwide are due to risk factors other than tobacco so other pathogenic factors beyond
smoking need to be considered.(9)
Genetics modify the risk of COPD in smokers, but there may also be other risk factors involved. For example, gender
and social pressure may influence whether a person takes up smoking or experiences certain occupational or
environmental exposures; socioeconomic status may be linked to birthweight (which may impact lung growth and
development, and in turn susceptibility to developing COPD);(69) and longer life expectancy will allow greater lifetime
exposure to risk factors.
Other types of tobacco (e.g., pipe, cigar, water pipe)(70-72) and marijuana(73) are also risk factors for COPD. Passive
exposure to cigarette smoke, also known as environmental tobacco smoke (ETS) and second-hand smoking, may also
contribute to respiratory symptoms and COPD,(74) especially after long-term exposure.(75) Smoking during pregnancy
poses a risk for the fetus, by altering lung growth and development in utero, and possibly priming the immune system
by inducing specific epigenetic changes.(76) This is a good example of the GETomics approach discussed above. The
fetus exposed to ‘passive smoking’ is likely to respond differently to a second GxE hit later in life.(7)
Biomass exposure
Tobacco smoking has been recognized as a major risk factor associated with COPD for over five decades, but this was
largely because most research was conducted in high income countries. As more studies from LMICs were
conducted,(19) it became apparent that non-smoking risk factors were more important in these parts of the world.
Whilst tobacco smoking remains the leading risk factor for COPD in high income countries, accounting for over 70% of
the cases, in LMICs tobacco smoking contributes to around 30% to 40% of the total burden.(9) Because the LMICs
together contribute to over 85% of the total burden of COPD globally, non-smoking risk factors now contribute to over
50% of the global burden of COPD.(9)
Wood, animal dung, crop residues, and coal, typically burned in open fires or poorly functioning stoves, may lead to
very high levels of household air pollution.(77) Household air pollution exposure is associated with an increased risk of
developing COPD in LMICs(78) although the extent to which household air pollution versus other poverty-related
exposures explain the association is unclear.(79-82) Almost three billion people worldwide use biomass and coal as their
main source of energy for cooking, heating, and other household needs, so the population at risk worldwide is very
large.(83,84) There is limited research about household air pollution related COPD or the interventions that could reduce
the risk of developing it.(85)
Many of the environmental exposures in LMICs are currently unregulated and, in combination with poverty and poor
TE
nutrition, amplify the risk of airway and lung parenchymal damage. Advocacy efforts to minimize exposure to risk
U
IB
factors must continue, based on robust evidence from epidemiological, translational, clinical and implementation
TR
research.(9) There are no randomized controlled trials (RCTs) that have addressed the appropriate pharmacotherapy
IS
D
of non-smoking COPD. There is therefore an urgent need to conduct robust RCTs to better understand the most
T
effective treatment that can be offered to non-smoking COPD. Phenotypic differences between smoking and non-
O
N
smoking COPD have been reported in only a few studies. In brief, compared to COPD in smokers, non-smoking COPD
O
-D
is more common in females, in younger age groups, exhibits similar (or milder) respiratory symptoms and quality of
L
life, a lesser rate of decline in lung function over time, lower neutrophils and a trend towards higher eosinophil
IA
ER
numbers in the airway sputum, similar spirometric indices, greater small airways obstruction (respiratory oscillometry
AT
and radiology), less emphysema and a similar defect in macrophage phagocytosis of pathogenic bacteria.(86-88)
M
Potential molecular mechanisms for non-smoking COPD include inflammation, oxidative stress, airway remodeling and
T
H
lung aging.(9) However, there are still several knowledge gaps that exist. Research is urgently needed to fill these gaps,
IG
R
as COPD related to biomass exposure, tobacco smoking or various other causes (see below) might exhibit different
PY
clinical features and trajectories, and benefit from different approaches to both pharmacological and non-
O
C
pharmacological treatments.(9)
Occupational exposures
Occupational exposures, including organic and inorganic dusts, chemical agents and fumes, are an under-appreciated
environmental risk factor for COPD.(18,89) Individuals with exposure to inhalation of high doses of pesticides have a
higher incidence of respiratory symptoms, airways obstruction and COPD.(90,91) A study of the population-based UK
biobank cohort identified occupations including sculptors, gardeners and warehouse workers that were associated
with an increased COPD risk among never-smokers without asthma.(92) A cross-sectional observational study
demonstrated that self-reported exposure to workplace dust and fumes is associated with not only increased airflow
obstruction and respiratory symptoms, but also more emphysema and gas trapping, as assessed by computed
tomography scan, in both men and women.(93) An analysis of the large U.S. population-based National Health and
Nutrition Examination Survey III survey of almost 10,000 adults aged 30-75 years estimated the fraction of COPD
attributable to workplace exposures was 19.2% overall, and 31.1% among never-smokers.(94) These estimates are
consistent with a statement published by the American Thoracic Society that concluded that occupational exposures
account for 10-20% of either symptoms or functional impairment consistent with COPD.(95) The risk from occupational
exposures in less regulated areas of the world is likely to be much higher than reported in studies from Europe and
North America.
Air pollution
Air pollution typically consists of particulate matter (PM), ozone, oxides of nitrogen or sulfur, heavy metals, and other
greenhouse gases, is a major worldwide cause of COPD, responsible for approximately 50% of the attributable risk for
COPD in low and middle income countries (LMICs).(96) In never smokers, air pollution is the leading known risk factor
for COPD.(97) The respiratory risk of air pollution to individuals is dose-dependent with no apparent “safe” thresholds.
Even in countries with low ambient air pollution levels, chronic exposure to PM2.5 and nitrogen dioxides significantly
impairs lung growth in children,(98) accelerates lung function decline in adults and increases the risk for COPD,
especially among those with additional risk factors for COPD.(99) Poor air quality from air pollution also increases the
risk of COPD exacerbations, hospitalizations and mortality.(100,101) Thus, reduction in both indoor and outdoor air
pollution is a key goal in the prevention and management of COPD.
Genetic factors
A significant familial risk of airflow obstruction has been observed in people who smoke and are siblings of patients
with severe COPD,(102) suggesting that genetics (in combination with environmental risk factors) could influence this
susceptibility. The best documented genetic risk factor for COPD are mutations in the SERPINA1 gene that leads to the
hereditary deficiency of α-1 antitrypsin (AATD),(103) a major circulating inhibitor of serine proteases. Although AATD
TE
U
deficiency is relevant to only a small part of the world’s population, it illustrates the interaction between genes and
IB
TR
environmental exposures that predispose an individual to COPD. A systematic review of 20 studies in European
IS
populations found AATD PiZZ genotypes in 0.12% of COPD patients (range 0.08-0.24%), and a prevalence ranging from
D
1 in 408 in Northern Europe to 1 in 1,274 in Eastern Europe.(104)
T
O
N
O
There has been a long-standing controversy concerning the risk of heterozygotes (MZ and SZ) for the development of
-D
COPD. This has largely reflected acquisition bias but is of critical importance due to the large numbers of such
L
IA
individuals worldwide(105) who may potentially benefit from augmentation therapy. Recent careful sibling
ER
studies(106,107) indicated no increased risk in these heterozygotes in the absence of smoking although lung function was
AT
reduced in smokers compared to MM siblings. This likely reflects the presence of low concentrations of the Z AAT
M
T
protein rather than an absolute lack of it(108) and is not an indication for augmentation therapy (discussed in more
H
IG
detail in Chapter 3).

R
PY
O
To date, hundreds of genetic variants associated with reduced lung function and risk of COPD have been identified,
C
including genes encoding matrix metalloproteinase 12 (MMP-12), glutathione S-transferase, the alpha-nicotinic
acetylcholine receptor, and the hedgehog interacting protein (HHIP).(109,110) Yet, their individual effect size is small(10)
and it remains uncertain whether these genes are directly responsible for COPD or are merely markers of other causal
genes.(111-115)
Trajectories of lung function: development and aging

At birth, the lung is not fully developed. It grows and matures until about 20-25 years of age (earlier in females), when
lung function reaches its peak (Figure 1.1).(67) This is followed by a not very well defined but relatively short plateau
and a final phase of mild lung function decline due to physiological lung aging. This constitutes the normal lung function
trajectories labeled TR1 in Figure 1.1.(116) This normal lung function trajectory can be altered by processes occurring
during gestation, birth, childhood, and adolescence that affect lung growth (hence, peak lung function) and/or
processes shortening the plateau phase and/or accelerating the aging phase (hence accelerating the normal rate of
lung function decline with age).(117)
TE
U
IB
TR
IS
D
T
O
N
O
-D
L
IA
ER
AT
M
T
H
IG
R
PY
O
C
Spirometrically measured reduced maximal attained lung function can identify individuals who are at increased risk
for the development of COPD.(16,118) A large study and meta-analysis confirmed a positive association between
birthweight and FEV1 in adulthood.(119) Factors in early life termed “childhood disadvantage factors” are key
determinants of lung function in adult life.(119-126) One study in three independent longitudinal cohorts (Framingham,
Copenhagen and Lovelace) found that approximately 50% of patients developed COPD due to accelerated decline in
FEV1 over time (the traditional Fletcher and Peto model),(127) while the other 50% developed COPD due to abnormal
lung growth and development (with normal lung function decline over time; Figure 1.1).(116)
Age is often listed as a risk factor for COPD because there is a physiologic decline in lung function with age. Yet, it is
unclear if healthy aging as such leads to COPD or if age reflects the sum of cumulative exposures throughout life. (128)
However, aging of the airways and parenchyma mimic some of the structural changes associated with COPD (128) and
there is evidence of accelerated aging in patients with COPD.(121) A prospective study showed an association between
accelerated telomere shortening (a marker of accelerated aging) and progressive worsening of pulmonary gas
exchange, lung hyperinflation and extrapulmonary affection in COPD patients followed over 10 years.(129) Further,
persistently shorter telomeres over this observation time increase the risk for all-cause mortality.(129) Age-related
epigenetic changes in DNA in immune cells are also associated with increased risk of exacerbations and mortality in
COPD patients.(130,131) In the Tasmanian Longitudinal Health Study, the mixed (low FVC and low FEV1/FVC ratio) and
the obstructive-only (low FEV1/FVC ratio) spirometric patterns showed the highest prevalence of COPD at age 53 (37%
and 22% respectively).(125)
The term dysanapsis refers to an anthropometric mismatch of airway tree calibre relative to lung volume.(132,133) It was
first proposed by Green and colleagues almost fifty years ago from maximal expiratory airflow variation among healthy
adults.(120) There are still major gaps in our understanding of the origins and clinical implications of dysanapsis, but
recent research using computed tomography (CT) has shown that: (1) it is common in the general
population;(120,124,134)(2) it is associated with FEV1/FVC from early adulthood;(135) (3) in explanted lungs from adult
healthy donors, central airway dysanapsis (detectable by CT) extended to peripheral airways (non-visible on CT);(135)
(4) dysanapsis is associated with baseline airflow obstruction and risk of incident COPD independently of age, sex,
height and race-ethnicity, but not with lung function decline over time.(124) This observation is consistent with the
trajectory of low peak lung function in early adulthood followed by normal lung function decline that accounts for 50%
of COPD in older adults;(116) (5) a computational study of airway tree fluid dynamics and an in vivo study of regional
TE
lung ventilation suggest that dysanapsis may contribute to obstructive lung disease pathophysiology and deposition
U
of aerosolized drugs;(136-138) and, (6) the mechanisms contributing to the development of dysanapsis are not well
IB
TR
understood. It is not clear whether it is due to genetic predisposition, in utero exposures to noxious particulates or
IS
pathogens, premature birth, low birth weight, neonatal lung injury, repeated respiratory infections in early life or a
D
T
combination of them, but factors affecting airway tree growth early in life(120,122,124) and factors affecting airway tree
O
N
homeostasis later in life have been implicated.(121,123) Of note, investigating the aetiology of dysanapsis earlier in life
O
-D
will require radiation-free (or lower dose radiation) methods in order to quantify lung structure in children.
L
IA
ER
The fact that COPD can result from reduced peak lung function in early adulthood and/or accelerated lung function
AT
decline later in life(117,139) opens novel opportunities for prevention, and earlier diagnosis and treatment of the
M
disease(13) but, at the same time, has generated several nosological terms that require proper definition to avoid
T
H
confusion and facilitate future research:(140)

IG
R
PY
Early COPD
O
C
The word “early” means “near the beginning of a process”. Because COPD can start early in life and take a long time
to manifest clinically, identifying “early” COPD is difficult. Further, a biological “early” related to the initial mechanisms
that eventually lead to COPD should be differentiated from a clinical “early”, which reflects the initial perception of
symptoms, functional limitation and/or structural abnormalities noted. Thus, we propose to use the term “early COPD”
only to discuss the “biological” first steps of the disease in an experimental setting.
Mild COPD
Some studies have used “mild” airflow obstruction as a surrogate for “early” disease.(141) This assumption is incorrect
because not all patients started their journey from a normal peak lung function in early adulthood, so some of them
may never suffer “mild” disease in terms of “severity” of airflow obstruction.(117) Further, “mild” disease can occur at
any age and may progress or not over time.(139) Accordingly, we propose that “mild” should not be used to identify
“early” COPD and used only to describe the severity of airflow obstruction measured spirometrically.
Young COPD
The term “young COPD” is seemingly straightforward because it directly relates to the chronological age of the patient.
Given that lung function peaks at around 20-25 years,(67) we propose to operationally consider “young COPD” in
patients aged 20–50 years.(142) Of note, this can include patients who had never achieved normal peak lung function
in early adulthood and/or those with shorter plateau and/or early lung function decline.(143,144) Young COPD may be
associated with significant structural and functional lung abnormalities (i.e., young COPD is not necessarily
synonymous with “mild” COPD) that can have a substantial impact on health and, importantly, is frequently not
diagnosed and thus not treated. A family history of respiratory diseases and/or early-life events (including
hospitalizations before the age of 5 years) is reported by a significant proportion of young patients with COPD, further
supporting the possibility of early-life origins of COPD.(140,144)
Pre-COPD
This term has been recently proposed to identify individuals (importantly, of any age) who have respiratory symptoms
and/or other detectable structural and/or functional abnormalities, in the absence of airflow obstruction on forced
spirometry. These patients may (or not) develop persistent airflow obstruction (i.e., COPD) over time.(145) A recent
publication highlights the need for RCTs, both in patients with ‘Pre-COPD’, and in young people with COPD.(146)
PRISm
The term PRISm (preserved ratio impaired spirometry) describes individuals with preserved ratio (FEV1/FVC ≥ 0.7 after
bronchodilation) but impaired spirometry (FEV1 < 80% of reference, after bronchodilation). (12,147) The prevalence of
PRISm in population-based studies ranges from 7.1% to 11%(148-151) and from 10.4% to 11.3% in a selected population
TE
of current and former smokers such as the COPDGene cohort.(152) The prevalence of PRISm is particularly high in
U
IB
current and former smokers, and it is associated with both high and low body mass index (BMI) values, female gender,
TR
obesity and multimorbidity.(148-151) PRISm is associated with increased risk of: cardiopulmonary disease; all-cause and
D
IS
cardiovascular mortality; hospitalization; and an increased risk of developing airways obstruction.(148,149,151,153-155)
T
O
N
PRISm is not always a stable phenotype and can transition to both normal and obstructed spirometry over time. It has
O
-D
been reported that around 20% to 30% of PRISm subjects transitioned to obstructed spirometry over time and the
L
IA
most important predictors of transition from PRISm spirometry to COPD are lower baseline FEV1%, and FEV1/FVC,
ER
higher age, current smoking, female gender, and a longer FET in the second assessment.(149,151,152) Despite an increasing
AT
body of literature on PRISm, significant knowledge gaps remain in relation to its pathogenesis and treatment.
M
T
H
IG
Not all individuals with pre-COPD or PRISm will eventually develop fixed airflow obstruction over time (and hence
R
COPD) but they should be considered “patients” (because they already suffer symptoms and/or have functional and/or
PY
structural abnormalities) and, as such, they deserve care and treatment. The challenge is that there is no evidence on
O
C
what the best treatment is for these patients yet.(156)
Asthma and airway hyper-reactivity

Asthma may also be a risk factor for the development of chronic airflow obstruction and COPD. In a report from a
longitudinal cohort of the Tucson Epidemiological Study of Airway Obstructive Disease, adults diagnosed of asthma
were found to have a 12-fold higher risk of acquiring COPD over time compared to those without asthma, after
adjusting for smoking.(157) Another longitudinal study of people with asthma found that around 20% developed
irreversible airflow obstruction and reduced diffusing lung capacity.(158) A third longitudinal study observed that self-
reported asthma was associated with excess loss of FEV1 in the general population.(159) A study examining the pattern
of lung-growth decline in children with asthma found that 11% met lung function impairment consistent with the
spirometric classification of COPD in early adulthood.(160) In the European Community Respiratory Health Survey,
airway hyper-responsiveness was second only to cigarette smoking as the leading risk factor for COPD, responsible for
15% of the population attributable risk (smoking had a population attributable risk of 39%).(161) The pathology of
chronic airflow obstruction in asthmatic non-smokers and non-asthmatic smokers is markedly different, suggesting
that the two disease entities may remain different even when presenting with similarly reduced lung
function.(157,162,163) However, separating asthma from COPD in adults may be clinically difficult at times. Further,
abnormal lung development in childhood and adolescence can cause asthma-like symptoms. Given that poor lung
development is associated with COPD in adulthood (Figure 1.1), these infants and adolescents may have been
mislabeled as asthma.
On the other hand, airway hyper-responsiveness can exist without a clinical diagnosis of asthma and has been shown
to be an independent predictor of COPD and respiratory mortality in population studies(164,165) as well as an indicator
of risk of excess decline in lung function in patients with mild COPD.(166)
Chronic bronchitis
Chronic bronchitis (CB) is a common, but variable condition in patients with COPD. CB is defined by the presence of
cough with expectorated sputum on a regular basis over a defined period. Variability in the prevalence of CB depends
upon the definition used which differs in the regularity or duration of CB symptoms.(167) The classic description defines
CB as chronic cough and sputum production for at least 3 months per year for two consecutive years, in the absence
of other conditions that can explain these symptoms (an important caveat that is often ignored). Using this definition,
the prevalence of CB ranges from 27-35% in large observational studies in patients with COPD.(168-170) Other factors
associated with increased prevalence of CB in COPD includes male sex, younger age, greater pack-years of smoking,
more severe airflow obstruction, rural location and increased occupational exposures.(167-173) Although the primary risk
for CB is smoking, 4-22% of CB is found in never smokers suggesting other factors are involved.(174,175) Inhalational
TE
exposures to dusts, biomass fuels, chemical fumes or domestic heating and cooking fuels may be important.(172,173,176)
U
IB
Gastroesophageal reflux is also associated with an increased incidence of CB.(177,178)
TR
IS
D
Normal airway mucus is a gel comprised of 97% water and 3% solids (mucins, non-mucin proteins, cellular debris, salts
T
O
and lipids ) that traps inhaled toxins which are subsequentially expectorated via the processes of ciliary beating and
N
O
cough.(179) Mucins are large glycoproteins, two of the secreted mucin polymers, MUC5AC and MUC5B, line the human
-D
airways.(180,181) In healthy normal individuals, MUC5AC is produced by proximal airway surface goblet cells while
L
IA
MUC5B is produced by surface secretory cells found throughout the airways and submucosal glands.(180-184) In COPD,
ER
MUC5B levels markedly increase due to submucosal gland hyperplasia and airway occlusion can occur.(185-187) Viruses,
AT
acrolein and many cytokines (IL-4, IL-13, IL-17, IL-23 and IL-25) can also increase MUC5AC production.(188-193)
M
T
H
IG
Lung health depends upon effective mucus clearance. In disease states, thick and viscoid mucus can lead to airway
R
inflammation and infection. Cough and dyspnea are the principal symptoms of impaired mucous clearance. (194,195)
PY
O
Cough and sputum production are predominately associated with mucus production in the large airways. However,
C
increased mucus production also occurs in the smaller conducting airways and is associated with luminal occlusion,
hallmarked by dyspnea but less cough and sputum production.(196,197) Radiographic manifestations of mucous plugging
may be present and persist in patients with COPD despite a lack of CB symptoms and is associated with greater airflow
obstruction, lower oxygen saturation and worsened quality of life(198,199) and all-cause mortality.(200) A high index of
suspicion for mucus hypersecretion should be maintained in all patients with COPD due to the protean clinical
problems that accompanies its presence.(201) How patients who have mucus hypersecretion evident on CT but do not
manifest symptoms differ phenotypically and vice versa is not fully understood.
The relationship between chronic mucus production and lung function, exacerbations and mortality has been the
subject of multiple investigations. In young adults without a history of asthma and normal lung function, the presence
of chronic cough with sputum identified a subgroup at high risk of developing COPD independently of smoking
habits.(202) In adults less than 50 years of age, CB without airflow obstruction represents an early marker for
susceptibility to the long-term risk of COPD and all-cause mortality.(203) In smokers between 36 to 43 years of age with
chronic mucus production, there was a significant higher risk of airflow obstruction, however, following smoking
cessation, mucus production returned to levels observed amongst never smokers.(204) Importantly, the longer chronic
mucus hypersecretion is present, the greater the concurrent decrease in FEV1. While both MUC5AC and MUC5B have
been associated with CB symptoms, among current smokers, it is sputum MUC5AC that has been associated more
specifically with increased exacerbation frequency, increased symptoms and greater lung function decline.(205,206)
Large epidemiologic studies have shown after adjustment for height, age and smoking history, men with cough or
phlegm and women with cough show accelerated loss of lung function.(207) Other studies have suggested an association
between chronic sputum production and lower lung function, or greater FEV1 decline in patients with COPD.(207-211)
The association of chronic mucus hypersecretion and mortality is unclear. Several studies report no predictive value
of mucus production on mortality when controlling for respiratory impairment and smoking;(212-214) other studies state
sputum production has an independent role in predicting both overall and COPD-specific mortality.(171,215-217) In the
Copenhagen city heart study, chronic mucus hypersecretion was associated with pulmonary infection that was
implicated in 54% of the deaths.(218) Moreover, chronic mucus hypersecretion was associated with excessive FEV1
decline and increased COPD hospitalizations.(210) In patients with advanced emphysema, chronic bronchitis has been
associated with increased hospitalizations and mortality.(219) In patients with non-obstructive chronic bronchitis,
increased all-cause and respiratory disease related mortality has been reported.(220,221)
Infections
A history of severe childhood respiratory infections has been associated with reduced lung function and increased
respiratory symptoms in adulthood.(161) The Medical Research Council National Survey of Health and Development
TE
documented a synergistic interaction between smoking and infant respiratory infections as well as early life home
U
IB
overcrowding with lung function at age 43.(222) Chronic bronchial infection, particularly with Pseudomonas aeruginosa,
TR
has been associated with accelerated FEV1 decline.(223) Tuberculosis (TB) is a risk factor for COPD (23 studies; pooled
D
IS
odds ratio 2.59 (95% CI 2.12,3.15); pooled prevalence of COPD in patients with prior pulmonary TB was 21% (95% CI:
T
O
16–25%)).(224,225) Tuberculosis is both a differential diagnosis for COPD and a potential comorbidity.(226,227) Finally, HIV
N
O
patients are at increased risk of COPD compared to HIV negative controls (11 studies; pooled odds ratio for 1.14 (95%
-D
CI 1.05,1.25))(228,229) probably due to methylation disruptions in airway epithelium.(230) IgG subclass deficiency has also
L
IA
been observed in hospitalized patients with COPD and this was associated with a significantly increased risk of
ER
mortality.(231)
AT
M
Sex
T
H
IG
Sex related differences in immune pathways and pattern of airway damage might be clinically important although
R
PY
more work in this area is needed. In the past, most studies have reported that COPD prevalence and mortality are
O
greater among men than women, but later data from developed countries has shown that the prevalence of COPD is
C
almost equal in males and females, probably reflecting the changing patterns of tobacco smoking.(232) Although
controversial, some studies have suggested that women may be more susceptible to the harmful effects of smoking
than men,(26,233-235) leading to more severe disease for the equivalent quantity of cigarettes consumed.(236) This notion
has been validated in animal studies and human pathology specimens, which have demonstrated a greater burden of
small airway disease in females compared with males with COPD despite a similar history of tobacco smoke
exposure.(237,238) A systematic review and meta-analysis of the global prevalence of COPD reported sex-based
prevalence differences across WHO Global Burden of Disease sub-regions. In females the highest prevalence of COPD
was observed in North America (8.07% vs 7.30%) and in urban settings (13.03% vs 8.34%). Using the World Bank’s
income categories prevalence was highest in upper-middle income countries for males (9.00%) and in high-income
countries for females.
Race and ethnicity

An ATS workshop report(239) has recommended replacing race- and ethnicity-specific equations with race-neutral
average reference equations in pulmonary function testing. It also emphasized the importance of further research
and education into the clinical and epidemiological consequences of these changes.(239)
Socioeconomic status
Poverty is consistently associated with airflow obstruction(240) and lower socioeconomic status is associated with an
increased risk of developing COPD.(241,242) It is not clear, however, whether this pattern reflects exposures to household
and outdoor air pollutants, crowding, poor nutrition, infections, or other factors related to low socioeconomic status.
PATHOBIOLOGY
In patients with COPD pathological changes can be found in the airways, lung parenchyma, and pulmonary
vasculature.(243) These include inflammatory and structural changes which increase with the severity of airflow
obstruction and can persist on smoking cessation (Figure 1.1).
Inflammatory changes
The inflammation observed in the lungs of COPD patients appears to be a modification of the normal inflammatory
response to chronic irritants such as cigarette smoke. The mechanisms for this amplified inflammation are not yet fully
understood but may, at least in part, be genetically determined.
TE
COPD is characterized by increased numbers of macrophages in peripheral airways, lung parenchyma and pulmonary
U
IB
vessels, together with increased activated neutrophils and increased lymphocytes. These inflammatory cells, together
TR
with epithelial cells and other structural cells release multiple inflammatory mediators(244) which attract inflammatory
D
IS
cells from the circulation (chemotactic factors), amplify the inflammatory process (via proinflammatory cytokines),
T
O
and induce structural changes (via growth factors).(245) Lung inflammation can persist after smoking cessation through
N
as yet unclear mechanisms, although autoantigens and perturbations in the lung microbiome may play a role.(246,247)
O
-D
Systemic inflammation may also be present and could play a role in the comorbid conditions frequently found in
L
patients with COPD.(244) The nature of the inflammatory response in non-smoking related COPD is much less well
IA
ER
characterized.
AT
M
Although both COPD and asthma are associated with chronic inflammation of the respiratory tract, there are
T
H
differences in the inflammatory cells and mediators involved in the two diseases.(248) albeit some patients with COPD
IG
R
have an inflammatory pattern with increased eosinophils and ILC2 cells, similar to that of asthma.(249)
PY
O
C
Oxidative stress can also contribute to COPD.(244,250) Biomarkers of oxidative stress (e.g., hydrogen peroxide, 8-
isoprostane) are increased in the exhaled breath condensate, sputum, and systemic circulation of COPD patients.
Oxidative stress is further increased during exacerbations. Oxidants are both generated by cigarette smoke and other
inhaled particulates and released from activated inflammatory cells such as macrophages and neutrophils.(226,251)
Structural changes
There is compelling evidence for an imbalance in the lungs of COPD patients between proteases derived from
inflammatory and epithelial cells that break down connective tissue components and antiproteases that
counterbalance this action.(252) Protease-mediated destruction of elastin, a major connective tissue component of the
lung parenchyma, is an important feature of emphysema but its role may be more difficult to establish in airway
changes.(253)
Peribronchiolar fibrosis and interstitial opacities have been reported in patients with COPD and in asymptomatic
smokers.(246,254-256) An excessive production of growth factors may be found in smokers and patients with COPD.(257)
Inflammation may precede the development of fibrosis or repeated injury of the airway wall itself may lead to
excessive production of muscle and fibrous tissue.(258) This may be a contributing factor to the development of small
airways obstruction.(259)
The lung vasculature can also be altered in patients with COPD, even those with mild disease.(260)
PATHOPHYSIOLOGY
Airflow obstruction and gas trapping
Airflow obstruction is usually measured by spirometry as this is the most widely available and reproducible test of lung
function. In COPD, airflow obstruction is caused by a mixture of small airways disease (which increases airway
resistance) and parenchymal destruction (emphysema, that reduces the normal elastic recoil of the lung parenchyma),
the relative contributions of which vary from person to person. Further, these changes do not always occur together
and may evolve at different rates over time. Chronic inflammation causes structural changes, narrowing of the small
TE
airways, luminal exudates in the small airways and destruction of the lung parenchyma that leads to the loss of alveolar
U
IB
attachments to the small airways and decreases lung elastic recoil. In turn, these changes diminish the ability of the
TR
airways to remain open during expiration. A loss of small airways may also contribute to airflow obstruction and
IS
D
mucociliary dysfunction.(261) The reduced number of small airways identified in patients with COPD(261) may be due to
T
an enhanced loss of airways and/or to deficient lung development (see dysanapsis above; Figure 1.1).(139) Collectively,
O
N
all these changes limit emptying of the lungs during forced expiration, decrease FEV1 and the FEV1/FVC ratio, and
O
-D
contribute to gas trapping and lung hyperinflation.(262)

L
IA
ER
Hyperinflation
AT
Hyperinflation occurs when gas volume in the lungs is increased compared to normal values at the end of spontaneous
M
T
expiration.(263,264) Hyperinflation is clinically relevant in patients with COPD and contributes to dyspnea,(265-268)impaired
H
IG
exercise tolerance,(269-271) increased number of hospitalizations,(272) development of respiratory failure(273) and

R
PY
increased mortality.(270,272,274) In patients with COPD, hyperinflation arises due to loss of elastic recoil and expiratory
O
flow obstruction.(275) Expiratory flow obstruction occurs when the expiratory flows generated during spontaneous
C
breathing are the maximal flows that can be generated at that operational lung volume.(263) Expiratory flow obstruction
is caused by the dual effects of emphysematous parenchymal destruction and airways abnormalities (e.g., mucus
obstruction, airway edema, heightened bronchial tone, airway wall remodeling). The lung can be hyperinflated at rest
(static hyperinflation due to the loss of elastic lung recoil as a consequence of emphysema) and/or during exercise
(dynamic hyperinflation as a consequence of airflow obstruction) when ventilatory demands are increased and
expiratory times are reduced.(263,264)
Hyperinflation is common in patients with COPD and can be found in patients with even mild obstruction at rest and
even more so during exercise.(276,277) In patients with moderate to severe obstruction, the level of dynamic
hyperinflation correlates more closely with the impairment in diffusion capacity and severity of small airways
obstruction and higher ventilatory response to exercise than FEV1 measurement.(263,269)
Lung volumes assessed by body plethysmography or gas dilution techniques (helium dilution or nitrogen washout)
represent the reference measurements to assess the presence and degree of hyperinflation, however, values may vary
due to differences in measuring compressible gas volumes or communicating gas volumes, respectively.(278,279)
Measurement of inspiratory capacity at rest and during exercise is an indirect measurement of increased end-
expiratory lung volumes and indicates the presence of static and/or dynamic hyperinflation.(280) Hyperinflation can
also be detected on chest imaging but standardization is lacking.(263)
Hyperinflation can be addressed with bronchodilators,(281,282) supplemental oxygen,(283,284) heliox,(285) pulmonary

rehabilitation,(286) pursed lip breathing,(287) inspiratory muscle training(288) or in selected cases of emphysema causing
severe hyperinflation, lung reduction surgery(289) or bronchoscopic lung reduction techniques.(290,291)
Pulmonary gas exchange abnormalities

Structural abnormalities in the airways, alveoli and pulmonary circulation in patients with COPD alter the normal
ventilation-perfusion (VA/Q) distributions. This is the main mechanism of abnormal pulmonary gas exchange resulting
in different degrees of arterial hypoxemia, without or with hypercapnia.(292) Rarely, reduced ventilation may also be
due to reduced ventilatory drive (e.g., sedatives and hypnotic drugs), causing hypercapnic respiratory failure and
acidosis.(293) Parenchymal destruction due to emphysema also leads to decreased lung diffusing capacity (DLco). In
general, pulmonary gas exchange worsens as the disease progresses.
Pulmonary hypertension
In smokers with normal spirometry and in COPD patients with mild airflow obstruction there may be abnormalities in
TE
the pulmonary circulation that include intimal hyperplasia and smooth muscle hypertrophy/hyperplasia.(294-297)
U
Moreover, an inflammatory response in vessels, similar to that seen in the airways, can be observed in these
IB
TR
individuals along with evidence of endothelial cell dysfunction. Yet, severe pulmonary hypertension in COPD is
IS
rare.(298,299) It may develop late in the course of COPD and it can be due to a combination of loss of pulmonary capillary
D
T
bed due to emphysema and/or hypoxic vasoconstriction of the small pulmonary arteries. Progressive pulmonary
O
N
hypertension may lead to right ventricular hypertrophy and eventually to right-sided heart failure (‘cor pulmonale’).
O
Severe pulmonary hypertension worsens survival.(300) Interestingly, the diameter of pulmonary artery as measured on
-D
computed tomography (CT) scans has been shown to relate to the risk of suffering exacerbations, independent of
L
IA
previous history of exacerbations.(301)

ER
AT
M
Exacerbations
T
H
IG
Exacerbations of respiratory symptoms in patients with COPD can be triggered by a number of different factors (alone
R
or in combination), including respiratory infections with bacteria or viruses (which may coexist), environmental
PY
pollutants, or unknown factors. During exacerbations there is evidence of increased airway and systemic inflammation,
O
C
increased gas trapping and hyperinflation with reduced expiratory flow, thus accounting for increased dyspnea,(302)
and worsening of VA/Q abnormalities that can result in arterial hypoxemia with or without hypercapnia.(303) Other
conditions, such as pneumonia, pulmonary, and/or heart failure, among others, may mimic or aggravate an
exacerbation of COPD, and need to be considered in the clinical management of these episodes.(304) See Chapter 4 for
an extended discussion on exacerbations.
Multimorbidity
Most patients with COPD suffer concomitant chronic comorbid diseases linked to the same risk factors i.e., smoking,
aging, and inactivity, which may have a major impact on health status and survival.(305) Airflow obstruction and
particularly hyperinflation affect cardiac function.(302) Inflammatory mediators in the circulation may contribute to
skeletal muscle wasting and cachexia, and may initiate or worsen comorbidities such as ischemic heart disease, heart
failure, osteoporosis, normocytic anemia, diabetes, and metabolic syndrome (see Chapter 5).
TAXONOMY
COPD has been traditionally understood as a single “disease” caused by tobacco smoking.(127) Accordingly, most efforts
have been devoted to the study of the pathogenetic mechanisms of only one major cause of COPD (cigarette smoking),
failing to expand the horizon about the heterogeneity of processes that we know can contribute to its final clinical
presentation.(7) It is therefore important to expand the taxonomy (classification) of COPD to include non-smoking
related COPD types, so specific studies can be designed and conducted for these different types of COPD or
etiotypes.(306) Figure 1.2 combines two recent taxonomic proposals developed independently.(6,307) This proposal has
relatively little impact on current clinical practice, other than illuminating this so-far ignored aspect of COPD, but it is
of the outmost importance to highlight the need to explore current and future therapies in these other etiotypes of
COPD.
TE
U
IB
TR
IS
D
T
O
N
O
-D
L
IA
ER
AT
M
T
H
IG
R
PY
O
C
CHAPTER 2: DIAGNOSIS AND ASSESSMENT
KEY POINTS:
 A diagnosis of COPD should be considered in any patient who has dyspnea, chronic cough or
sputum production, a history of recurrent lower respiratory tract infections and/or a history of
exposure to risk factors for the disease, but spirometry showing the presence of a post-
bronchodilator FEV1/FVC < 0.7 is mandatory to establish the diagnosis of COPD.
 The goals of the initial COPD assessment are to determine the severity of airflow obstruction, the
impact of disease on the patient’s health status, and the risk of future events (such as
exacerbations, hospital admissions, or death), to guide therapy.
 Additional clinical assessment, including the measurement of lung volumes, diffusion capacity,
exercise testing and/or lung imaging may be considered in COPD patients with persistent
symptoms after initial treatment.
TE
 Concomitant chronic diseases (multimorbidity) occur frequently in COPD patients, including
U
IB
TR
cardiovascular disease, skeletal muscle dysfunction, metabolic syndrome, osteoporosis,
IS
depression, anxiety, and lung cancer. These comorbidities should be actively sought, and treated
D
appropriately when present, because they influence health status, hospitalizations and mortality
T
O
N
independently of the severity of airflow obstruction due to COPD.

O
-D
L
IA
ER
AT
DIAGNOSIS
M
T
H
IG
A diagnosis of COPD should be considered in any patient who has dyspnea, chronic cough or sputum production,
R
PY
and/or a history of exposure to risk factors for the disease (Figure 2.1) but forced spirometry that demonstrates the
O
presence of a post-bronchodilator FEV1/FVC < 0.7 is mandatory to establish the diagnosis of COPD.(45)
C
CLINICAL PRESENTATION
Symptoms
Chronic dyspnea is the most characteristic symptom of COPD. Cough with sputum production is present in up to 30%
of patients. These symptoms may vary from day-to-day(308) and may precede the development of airflow obstruction
by many years. Individuals, particularly those with COPD risk factors, presenting with these symptoms should be
examined to search for the underlying cause(s). Airflow obstruction may also be present without chronic dyspnea
and/or cough and sputum production and vice versa.(309) Although COPD is defined on the basis of airflow obstruction,
in practice the decision to seek medical help is usually determined by the impact of symptoms on a patient’s functional
status. A person may seek medical attention either because of chronic respiratory symptoms or because of an acute,
transient episode of exacerbated respiratory symptoms.
TE
U
IB
TR
IS
D
T
O
N
O
-D
L
IA
ER
AT
Dyspnea
M
T
H
Dyspnea is a cardinal symptom of COPD and a major cause of the disability and anxiety associated with the disease.(310)
IG
R
Dyspnea comprises a sensory and an affective component.(311) Typically COPD patients describe their dyspnea as a
PY
sense of increased effort to breathe, chest heaviness, air hunger, or gasping.(312) However, the terms used to describe
O
C
dyspnea may vary both individually and culturally.(312)
Dyspnea is highly prevalent across all stages of airflow obstruction.(313) It occurs particularly during exertion or physical
activity. Moderate-to-severe dyspnea has been reported by > 40% of patients diagnosed with COPD in primary care.(314)
Dyspnea is complex and multiple mechanisms can be involved in its pathogenesis, including impaired respiratory
mechanics as a consequence of airflow obstruction and lung hyperinflation, gas exchange abnormalities, peripheral
muscle dysfunction related to deconditioning (and systemic inflammation in some patients), psychological distress,
dysfunctional breathing, cardiovascular or other comorbid diseases.(315,316)
Dyspnea measured by the 5-level modified Medical Research Council scale is integrated in the GOLD clinical
classification scheme (see below) because patients with high dyspnea scores incur higher healthcare resource
utilization and costs.(317) Dyspnea in daily life can be measured by a number of detailed questionnaires that are more
discriminant and sensitive to change.(318,319)
Chronic cough
Chronic cough is often the first symptom of COPD and is frequently discounted by the patient as an expected
consequence of smoking and/or environmental exposures. Initially, the cough may be intermittent, but subsequently
it may be present every day, often throughout the day. Chronic cough in COPD may be productive or non-
productive.(320) In some cases, significant airflow obstruction may develop without the presence of a cough. Other
causes of chronic cough are listed in Figure 2.2. Syncope during cough in patients with severe COPD can occur due to
rapid increases in intrathoracic pressure during prolonged attacks of coughing. Coughing spells may also cause rib
fractures, which are sometimes asymptomatic.
Sputum production
COPD patients commonly raise small quantities of tenacious sputum with coughing. Regular production of sputum for
three or more months in two consecutive years (in the absence of any other conditions that may explain it) is the
classical definition of chronic bronchitis,(321) but this is a somewhat arbitrary definition that does not reflect the entire
range of sputum production that occurs in COPD (see detailed discussion in Chapter 1). Sputum production is often
difficult to evaluate because patients may swallow sputum rather than expectorate it, a habit that is subject to
significant cultural and sex variation. Furthermore, sputum production can be intermittent with periods of flare-up
interspersed with periods of remission.(204) Patients producing large volumes of sputum may have underlying
TE
bronchiectasis.(322,323) The presence of purulent sputum reflects an increase in inflammatory mediators,(324,325) and its
U
IB
development may identify the onset of a bacterial exacerbation, though the association is relatively weak.(325,326)
TR
IS
D
T
O
N
O
-D
L
IA
ER
AT
M
T
H
IG
R
PY
O
C
Wheezing and chest tightness

Inspiratory and/or expiratory wheezes and chest tightness are symptoms that may vary between days, and over the
course of a single day. Alternatively, widespread inspiratory or expiratory wheezes can be present on auscultation.
Chest tightness often follows exertion, is poorly localized, is muscular in character, and may arise from isometric
contraction of the intercostal muscles. An absence of wheezing or chest tightness does not exclude a diagnosis of
COPD, nor does the presence of these symptoms confirm a diagnosis of asthma.
Fatigue
Fatigue is the subjective feeling of tiredness or exhaustion and is one of the most common and distressing symptoms
experienced by people with COPD.(327) People with COPD describe their fatigue as a feeling of “general tiredness” or
as a feeling of being “drained of energy”.(328,329) Fatigue impacts a patient’s ability to perform activities of daily living
and their quality of life.
Additional clinical features in severe disease

Weight loss, muscle mass loss, and anorexia are common problems in patients with severe and very severe COPD.(330-
332) They have prognostic importance(333,334) and can also be a sign of other diseases, such as tuberculosis or lung cancer,
and therefore should always be investigated. Ankle swelling may indicate the presence of cor pulmonale. Symptoms
of depression and/or anxiety merit specific enquiry when obtaining the medical history because they are common in
COPD,(335) are associated with poorer health status, increased risk of exacerbations, and emergency hospital admission,
and are treatable.(336)
DIFFERENTIAL DIAGNOSIS OF COPD

In some patients with COPD, a clear distinction from asthma is difficult using current imaging and physiological testing
TE
techniques, since the two conditions share common traits and clinical expressions.(337) Most other potential differential
U
IB
diagnoses are easier to distinguish from COPD (Figure 2.3).
TR
IS
D
T
MEDICAL HISTORY
O
N
O
-D
A detailed medical history of a new patient who is known, or suspected, to have COPD should include:
L
IA
ER
► Patient’s exposure to risk factors, such as smoking and environmental exposures (household/outdoor).
AT
► Past medical history, including early life events (prematurity, low birthweight, maternal smoking during
M
T
pregnancy, passive smoking exposure during infancy), asthma, allergy, sinusitis, or nasal polyps;
H
IG
respiratory infections in childhood; HIV; tuberculosis.

R
PY
► Family history of COPD or other chronic respiratory disease.

O
C
► Pattern of symptom development: COPD typically develops in adult life and most patients are conscious
of increased breathlessness, more frequent or prolonged “winter colds,” and some social restriction for
a number of years before seeking medical help.
► History of exacerbations or previous hospitalizations for respiratory disorder. Patients may be aware of
periodic worsening of symptoms even if these episodes have not been identified as exacerbations of
COPD.
► Presence of comorbidities, such as heart disease, osteoporosis, musculoskeletal disorders, anxiety and
depression, and malignancies that may also contribute to restriction of activity.
► Impact of disease on patient’s life, including limitation of activity, missed work and economic impact,
effect on family routines, feelings of depression or anxiety, wellbeing, and sexual activity.
► Social and family support available to the patient.
► Possibilities for reducing risk factors, especially smoking cessation.
TE
U
IB
TR
IS
D
T
O
N
O
-D
L
IA
ER
AT
M
T
H
IG
R
PY
O
C
PHYSICAL EXAMINATION
Although an important part of patient care, a physical examination is rarely (if ever) diagnostic in COPD. Physical signs
of airflow obstruction are usually not present until significant impairment of lung function has occurred,(338,339) and
detection based on physical examination has relatively low sensitivity and specificity. A number of physical signs (e.g.,
lung hyperinflation, cyanosis) may be present in COPD, but their absence does not exclude the diagnosis.
SPIROMETRY
Forced spirometry is the most reproducible and objective measurement of airflow obstruction. It is a noninvasive,
reproducible, cheap, and readily available test. Good quality spirometric measurement is possible in any healthcare
setting and all healthcare workers who care for people with COPD should have access to spirometry. Some of the
factors needed to achieve accurate test results are summarized in Figure 2.4.(340,341) Despite its good sensitivity, peak
expiratory flow measurement alone cannot be reliably used as the only diagnostic test because of its weak
specificity.(342,343)
TE
U
IB
TR
IS
D
T
O
N
O
-D
L
IA
ER
AT
M
T
H
IG
R
PY
O
C
As shown in Figure 2.5, forced spirometry measures: (1) the volume of air forcibly exhaled from the point of maximal
inspiration (forced vital capacity, FVC); (2) the volume of air exhaled during the first second of this maneuver (forced
expiratory volume in one second, FEV1); and (3) the ratio of these two measurements (FEV1/FVC). Spirometry
measurements are evaluated by comparison with reference values(341,344) based on age, height and sex.
Figure 2.5A shows a normal spirometry tracing and Figure 2.5B shows a tracing obtained in a person with COPD.
Patients with COPD typically show a decrease in both FEV1 (due to airflow obstruction) and (to a lesser degree) FVC
(due to gas trapping).
TE
U
IB
TR
IS
D
T
O
N
O
-D
L
IA
ER
AT
M
T
H
IG
R
PY
O
C
In line with other National and International guidelines, GOLD has recommended using post-bronchodilator values
when considering a diagnosis of COPD. Historically, post bronchodilator values were considered more appropriate for
confirming a diagnosis of fixed airflow obstruction as they were thought to be more reproducible, to be useful in
excluding asthma and could identify volume responders to bronchodilators in whom the obstruction was revealed by
bronchodilator-induced increase in FVC.(345) However, it is now recognised that the bronchodilator response has little
value in differentiating asthma from COPD,(346) that pre-bronchodilator values are reproducible(347) and obstruction
only found on post-bronchodilator measurements is uncommon.(348) Obtaining post-bronchodilator values is more
time consuming and this may deter clinicians from performing spirometry. GOLD states that pre-bronchodilator
spirometry can be used as an initial test to investigate whether symptomatic patients have airflow obstruction. If the
pre-bronchodilator spirometry does not show obstruction (see below for definition) performing post-bronchodilator
spirometry is not necessary unless there is a very high clinical suspicion of COPD, in which case an FVC volume response
may reveal FEV1/FVC < 0.7. Further tests to investigate the cause of the patient’s symptoms and follow-up, including
repeating the spirometry after an interval, may be required. If the pre-bronchodilator values show obstruction the
diagnosis of COPD should be confirmed using post-bronchodilator measurements. Individuals with a pre-
bronchodilator FEV1/FVC ratio < 0.7 that increases to ≥ 0.7 post-bronchodilator have been shown to have an increased
risk of future development of COPD, and should be followed closely.(349)
The spirometric criterion for airflow obstruction selected by GOLD for the diagnosis of COPD remains a post-
bronchodilator ratio of FEV1/FVC < 0.7. This criterion is simple and independent of reference values because it relates
to variables measured in the same individual, and has been used in all the clinical trials that form the evidence base
from which treatment recommendations are drawn. It should be noted that the use of a fixed FEV1/FVC ratio (< 0.7)
to define airflow obstruction may result in over-diagnosis of COPD in the elderly,(350,351) and under-diagnosis in
approximately 1% of young adults,(351-353) especially in mild disease, compared to using a cut-off based on the lower
limit of normal (LLN) values for FEV1/FVC. If COPD is suspected in younger adults (age < 50 years) who have a repeated
fixed ratio ≥ 0.7, comparing the ratio to a predicted LLN may help when deciding how to best manage this small number
of patients.
The LLN values are based on the normal distribution and classify the bottom 5% of the healthy population as abnormal.
From a scientific or clinical perspective, it is difficult to determine which of these criteria will result in optimal COPD
diagnostic accuracy. However, LLN values are highly dependent on the choice of valid reference equations using post-
bronchodilator FEV1, and there are no longitudinal studies available validating the use of the LLN, or studies using
TE
reference equations in populations where smoking is not the major cause of COPD. Using the fixed ratio is not inferior
U
to LLN regarding prognosis.(354)
IB
TR
IS
It is important to emphasize that airflow obstruction that is not fully reversible is not specific for COPD; the clinical
D
T
context and risk factors should also be considered. Airflow obstruction that is not fully reversible may also be found in
O
N
patients with asthma and other diseases.

O
-D
L
Normal spirometry may be defined by a new approach from the Global Lung Initiative (GLI).(355,356) Using GLI equations,
IA
ER
z scores (the number of standard deviations by which the value of a raw score (i.e., an observed value or data point)
AT
is above or below the mean value of what is being measured) were calculated for FEV1, FVC, and FEV1/FVC. The results
M
were compared to fixed ratio data. The findings suggest that among adults with GLI-defined normal spirometry, the
T
H
use of a fixed ratio may misclassify individuals as having respiratory impairment. It is important that these findings are
IG
reproduced in other cohorts.

R
PY
O
C
Importantly, the risk of misdiagnosis and over-treatment of individual patients using the fixed ratio as a diagnostic
criterion is limited, as spirometry is only one biologic measurement to establish the clinical diagnosis of COPD in the
appropriate clinical context (symptoms and risk factors). Diagnostic simplicity and consistency are crucial for the busy
clinician. Thus, GOLD favors the use of the fixed ratio over LLN.
Assessment of the presence or absence of airflow obstruction based on a single measurement of the post-
bronchodilator FEV1/FVC ratio should be confirmed by repeat spirometry on a separate occasion if the value is
between 0.60 and 0.80, as in some cases the ratio may change as a result of biological variation when measured at a
later interval.(357,358) If the initial post-bronchodilator FEV1/FVC ratio is less than 0.60 it is very unlikely to rise
spontaneously above 0.7.(357)
While post-bronchodilator spirometry is required for the diagnosis and assessment of COPD, assessing the degree of
reversibility of airflow obstruction (e.g., measuring FEV1 before and after bronchodilator or corticosteroids) to inform
therapeutic decisions is no longer recommended.(359) The degree of reversibility in a single patient varies over time
and has not been shown to differentiate the diagnosis from asthma, or to predict the response to long-term treatment
with bronchodilators or corticosteroids.(360) Accordingly, it is not necessary to stop inhaled medication before obtaining
spirometry measurements during follow-up of patients. Figure 2.6 shows the role of spirometry in patients with COPD.
Interpretation of the severity of lung function impairment is dependent on having appropriate reference values. The
TE
Prospective Urban and Rural Epidemiological (PURE) study analyzed pre-bronchodilator spirometry data from 153,996
U
IB
healthy people with less than 5 pack-year smoking histories in 17 countries and observed wide variation in lung
TR
function.(46) Compared with individuals living in North America or Europe, people living in Southeast Asia had FEV1
D
IS
values that were on average 31% lower, adjusted for age, height and sex. Similarly, those living in sub-Saharan Africa,
T
O
East Asia, Middle East and South America had FEV1 values that were on average 21%, 13%, 11%, and 6% lower than
N
individuals living in North America or Europe, respectively, independent of age, height, sex, and smoking status. (46)
O
-D
Unless relevant predicted values are used the severity of airflow obstruction will be overestimated. Even in high
L
IA
income countries, lung reference values change over time and require periodic revision.(361)
ER
AT
M
SCREENING AND CASE-FINDING

T
H
IG
R
PY
The role of screening spirometry for the diagnosis of COPD in the general population is controversial.(362,363) In
O
asymptomatic individuals without any significant exposures to tobacco or other risk factors, screening spirometry is
C
probably not indicated; whereas in those with symptoms or risk factors (e.g., > 20 pack-years of smoking, recurrent
chest infections, early life events), the diagnostic yield for COPD is relatively high and spirometry should be considered
as a method for early case finding.(364-366)
Both FEV1 and FVC predict all-cause mortality independent of tobacco smoking, and abnormal lung function identifies
a subgroup of smokers at increased risk for lung cancer. This has been the basis of an argument that spirometry should
be employed as a global health assessment tool.(367-369) A risk score based on routine data from electronic health
records in primary care may facilitate case-finding and be cost-effective.(370,371) However, data to support that
population-based screening spirometry is effective in directing management decisions or in improving COPD outcomes
in patients who are identified before the development of significant symptoms is weak.(363) This may reflect the design
and application of current case finding instruments that have not been utilized to identify patients with undiagnosed
COPD who are most likely to benefit from existing therapies.(372,373) Novel approaches to screening have been
developed that incorporate exposures, symptoms and health care utilization and simple peak flow measurement; one
of these has been developed for low- and middle-income countries and has shown discriminatory properties.(374,375)
GOLD advocates active case finding(364,376,377) i.e., performing spirometry in patients with symptoms and/or risk factors,
but not screening spirometry. Systematic active case-finding in a primary care setting via mail-out of a screening
questionnaire was also found to be an effective way to identify undiagnosed COPD patients.(378) The potential use of
spirometry in children, adolescents and young adults to identify individuals with poor lung development at risk of
COPD and other chronic conditions later in life merits future investigation.(41)
COPD case-finding tools have been created based on existing epidemiologic literature or expert opinion(373,379,380) or
with a multimodality approach.(374,375) Increasingly, it appears that the combination of questionnaires with simple
physiological measurements enhances the operating characteristics and performance of these approaches.(379,381,382)
In a variety of settings case-finding has been able to identify previously undiagnosed COPD.(378,381,383,384) In general,
these tools identify a high proportion of patients with mild or minimally symptomatic disease, exhibiting modest
sensitivity and specificity,(385) or higher specificity but low sensitivity.(386) COPD screening/case-finding in primary care
has been demonstrated to have a small but significant impact on increasing rates of diagnoses and physician’s clinical
actions but with limited data suggesting a significant impact on patient outcomes.(378,387-389) In the Veterans Affairs
system, the use of a clinical decision support system algorithm that incorporates case-finding for COPD and AATD,
improved COPD over- and under-diagnosis and screening rates of AATD in a primary care setting.(390) It remains vital
to critically assess how the introduction of case finding approaches can optimally improve clinician behavior, enhance
health care utilization, and improve patient outcomes while ensuring that patients identified with these techniques
have access to affordable and clinically and cost-effective interventions.(2,391,392) In a prospective study in China the
COPD Assessment in Primary Care to Identify Undiagnosed Respiratory Disease and Exacerbation Risk (CAPTURE) tool
TE
showed a good sensitivity to identify COPD patients who may require treatment because of elevated symptoms, risk
U
of exacerbations or hospitalization.(393)
IB
TR
Screening for COPD in targeted populations IS
D
T
O
The United States Preventative Service Task Force (USPSTF) recommended against screening for COPD in
N
O
asymptomatic adults.(394) This recommendation was based upon a systematic review of data from asymptomatic or
-D
mildly symptomatic COPD patients enrolled in pharmacological or non-pharmacological clinical trials. This
L
IA
recommendation is not applicable to populations at increased risk for COPD (e.g., those undergoing annual low dose
ER
chest computed tomography (LDCT) for lung cancer detection, particularly when airways or parenchymal
AT
abnormalities are found incidentally) or with radiologically identified structural abnormalities found on chest imaging
M
T
done for clinical respiratory complaints (e.g., emphysema, airway wall thickening, bronchiectasis, etc.).
H
IG
R
Leveraging lung cancer imaging for COPD screening

PY
O
Annual LDCT imaging of the chest is recommended by the USPSTF to diagnose lung cancer earlier among individuals
C
aged 50 to 80 years with a ≥ 20 pack-year smoking history. Clinical trials have shown annual LDCT significantly
improves survival.(395,396) Lung cancer and COPD share common risk factors, and COPD is also an independent risk factor
for lung cancer and represents the major comorbidity affecting survival in patients with lung cancer.(395,397-399)
Thoroughly assessing symptoms and performing spirometry in individuals undergoing LDCT for lung cancer screening
therefore represents a unique opportunity to simultaneously screen patients for both the presence of unrecognized
symptoms of COPD and airflow obstruction.
Studies that have evaluated patients for COPD symptoms and performed spirometry at lung cancer screening have
reported airflow obstruction in 34-57% of individuals, emphysema in 68-73% and no prior diagnosis of COPD in
67%.(398,400,401) Male sex, younger age, lower smoking duration and being asymptomatic were associated with
detection of airflow obstruction without a prior diagnosis of COPD.(401) Those without a prior diagnosis of COPD were
less symptomatic, however, the prevalence of symptoms was still high and found in over 50% of individuals. The
prevalence of the underdiagnosis of COPD in those undergoing lung cancer screening can approach 90% in some
reports.(368,402-407)
In a lung cancer screening cohort, over half of those with visually detected emphysema had airflow obstruction.(408)
Quantitative analysis of density can also be used to detect COPD with varying sensitivity and specificity depending on
the threshold chosen. In the National Lung Cancer Screening Trial (NLST), among individuals > 65 years, a threshold
of 1% quantitative emphysema was associated with a sensitivity of around 65% for women and 75% for men and a
specificity of over 70% and 65% respectively.(409) Deep learning approaches are also being investigated that could
diagnose COPD from lung cancer screening CT scans with results varying depending on the method and cohort
analyzed.(410)
Airflow obstruction or emphysema are markers of an increased risk for lung cancer. The severity of airflow obstruction
and the presence of emphysema are both independent risk factors and may be useful indicators for triaging patients
for more careful lung cancer surveillance.(368,395,396,403-407)
Leveraging incidental lung imaging abnormalities for COPD screening

Besides cigarette smoking other factors can increase the risk of COPD (e.g., developmental, genetic, environmental
exposures, childhood infections, etc.) and these individuals may undergo chest imaging for evaluation of respiratory
symptoms. These individuals have no or minimal exposure to cigarette smoking and are usually of younger age and
distinct from the population undergoing annual LDCT for lung cancer screening. The CT scans themselves can be used
to help identify individuals at increased risk for COPD in the non-lung cancer screened population and prompt
consideration for spirometry.(368,403-407)
TE
U
IB
Emphysema is a hallmark of COPD and easily detected on chest imaging, either through visual inspection via a
TR
radiologist or through quantitative lung density.(408-410) Lung imaging may also identify other abnormalities that may
IS
D
indicate the presence of COPD including air trapping, airway wall thickening and mucus plugging.(401,402,411-413) These
T
abnormalities may not only indicate the presence of airflow obstruction but indicate patients that might have a more
O
N
rapid decline in lung function and worse quality of life.(414-417)

O
-D
L
While quantitative analysis of LDCT data is often not available in clinical settings, the presence of emphysema and
IA
ER
other airway abnormalities should raise clinical suspicion for COPD and lead to a detailed assessment of symptoms
AT
and consideration for pulmonary function testing if not previously performed.

M
T
H
There is currently a missed opportunity to perform spirometry in people at high risk of having COPD during lung cancer
IG
R
screening programs or when incidental lung abnormalities are found on imaging that may indicate the presence of
PY
COPD. The use of spirometry in targeted patients undergoing lung cancer screening or when incidental imaging
O
C
abnormalities are found consistent with parenchymal or airway manifestations of airways disorders is recommended
by GOLD.(418)
INITIAL ASSESSMENT
Once the diagnosis of COPD has been confirmed by spirometry, in order to guide therapy COPD assessment must focus
on determining the following five fundamental aspects:
► Severity of airflow obstruction

► Nature and magnitude of current symptoms
► Previous history of moderate and severe exacerbations
► Blood eosinophil count
► Presence and type of other diseases (multimorbidity)
Severity of airflow obstruction
In the presence of FEV1/FVC ratio < 0.7 the assessment of airflow obstruction severity in COPD (note that this may be
different from severity of the disease) is based on the post-bronchodilator value of FEV1 (% reference). The specific
spirometric cut points are proposed for purposes of simplicity (Figure 2.7).
TE
U
IB
TR
IS
D
T
O
N
O
-D
L
IA
ER
AT
Symptoms
M
T
Because there is only a weak correlation between the severity of airflow obstruction (Figure 2.7) and the symptoms
H
IG
experienced by the patient or the impairment of their health status,(419,420) formal assessment of symptoms using
R
PY
validated questionnaires is required.

O
C
Dyspnea questionnaire: the modified Medical Research Council (mMRC) dyspnea scale
The mMRC scale was the first questionnaire developed to measure breathlessness, which is a key symptom in many
patients with COPD, although often unrecognized.(421) (Figure 2.8) Of note, the mMRC score relates well to other
multidimensional health status measures(422) and predicts future mortality risk.(423,424)
TE
U
IB
TR
IS
D
T
O
N
O
-D
Multidimensional questionnaires
L
It is now recognized that COPD impacts patients beyond dyspnea.(425) For this reason, multidimensional questionnaires
IA
ER
are recommended. The most comprehensive disease-specific health status questionnaires such as the Chronic
AT
Respiratory Questionnaire (CRQ)(426) and St. George’s Respiratory Questionnaire (SGRQ)(427) are important research
M
tools but they are too complex to use in routine practice. Shorter comprehensive measures, such as the COPD
T
H
Assessment Test (CAT™) and the Clinical COPD Questionnaire (CCQ©) have been developed and are suitable for use in
IG
R
the clinic. Below we discuss the CAT™ and the SGRQ.

PY
O
C
The CAT™* is an 8-item questionnaire that assesses health status in patients with COPD (Figure 2.9).(428) It was
developed to be applicable worldwide and validated translations are available in a wide range of languages. The score
ranges from 0 to 40, correlates very closely with the SGRQ, and has been extensively documented in numerous
publications.(429)
* The COPD Assessment Test was developed by a multi-disciplinary group of international experts in COPD supported by GSK. COPD Assessment Test and the CAT™ logo is a trademark of the
GlaxoSmithKline group of companies. © 2009 GlaxoSmithKline. All rights reserved. GSK activities with respect to the COPD Assessment Test™ are overseen by a governance board that includes
independent external experts, one of whom chairs the board.
TE
U
IB
TR
IS
D
T
O
N
O
-D
L
IA
ER
AT
M
T
H
IG
R
The SGRQ is the most widely documented comprehensive measure; scores < 25 are uncommon in diagnosed COPD
PY
patients(168) and scores ≥ 25 are very uncommon in healthy persons.(430,431) Therefore, it is recommended that a
O
C
symptom score equivalent to SGRQ score ≥ 25 should be used as the threshold for considering regular treatment for
symptoms including breathlessness, particularly since this corresponds to the range of severity seen in patients
recruited to the trials that have provided the evidence base for treatment recommendations. The equivalent cut-point
for the CAT™ is 10.(432) An equivalent mMRC score cannot be calculated because a simple breathlessness cut-point
cannot equate to a comprehensive symptom score cut-point. The great majority of patients with an SGRQ of ≥ 25 will
have an mMRC of ≥ 1; however patients with mMRC < 1 may also have a number of other COPD symptoms.(433) For
this reason, the use of a comprehensive symptom assessment is recommended. However, because use of the mMRC
is widespread, an mMRC of ≥ 2 is still included as a threshold for separating “less breathlessness” from “more
breathlessness.” Nevertheless, users are cautioned that assessment of other symptoms is required.(433)
Exacerbation risk
Exacerbations of COPD (ECOPD) are episodes of acute respiratory symptom worsening often associated with increased
local and systemic inflammation (see Chapter 4).(434-437) ECOPD are key events in the natural history of the disease
because they impact significantly on the health status of the patient (often for a prolonged period of time), enhance
the rate of lung function decline, worsen the prognosis of the patient and are associated with most of the healthcare
costs of COPD.(438) ECOPD rates vary greatly between patients(439) and during follow-up.(440) The best predictor of having
frequent exacerbations (defined as two or more exacerbations per year) is the previous history of exacerbations.(439)
Worsening of airflow obstruction is associated with an increasing prevalence of exacerbations, hospitalization(377,441)
and risk of death.(168,442)
Blood eosinophil count

A number of studies have shown that blood eosinophil counts predict the magnitude of the effect of ICS (added on
top of regular maintenance bronchodilator treatment) in preventing future exacerbations and blood eosinophil counts
are recommended by GOLD to guide the use of ICS as part of pharmacological management (see Chapter 3, Figure 3.7
& Figure 3.9).(443-448)
There is evidence that on average blood eosinophil counts are higher in COPD patients, although there is marked
overlap with controls.(449,450) Higher blood eosinophil counts in COPD patients are associated with increased lung
eosinophil numbers and the presence of higher levels of markers of type-2 inflammation in the airways, although the
concordance between blood and lung/airways T2 biomarkers is not strict.(451,452) These differences in airway
inflammation may explain the differential response to ICS treatment according to blood eosinophil counts.(453)
The repeatability of blood eosinophil counts in a large primary care population appears reasonable,(454) although
greater variability is observed at higher thresholds.(455) Better reproducibility is observed at the lower thresholds (e.g.,
TE
100 cells/µL).(456) Blood eosinophil counts can help clinicians estimate the likelihood of a beneficial preventive response
U
IB
to the addition of ICS to regular bronchodilator treatment, and thus can be used as a biomarker in conjunction with
TR
clinical assessment when making decisions regarding ICS use. D
IS
T
O
Cohort studies have produced differing results with regard to the ability of blood eosinophils to predict future
N
O
exacerbation outcomes, with either no relationship(457) or a positive relationship reported.(458,459) Differences between
-D
studies are likely to be related to different previous exacerbation histories and ICS use. There is insufficient evidence
L
IA
to recommend that blood eosinophils should be used to predict future exacerbation risk on an individual basis in COPD
ER
patients. Greater FEV1 decline was observed in mild to moderate COPD patients with higher blood eosinophil counts
AT
in a population where ICS use was low,(460) highlighting the possible usefulness of blood eosinophil counts as a
M
T
prognostic biomarker for lung function decline when not confounded by ICS use. In younger individuals without COPD,
H
IG
higher blood eosinophil counts are associated with increased risk of subsequent development of COPD.(461)
R
PY
Multimorbidity
O
C
People with COPD often suffer other concomitant chronic diseases (multimorbidity). This can occur in patients with
mild, moderate or severe airflow obstruction.(168) Multimorbidity influences mortality and hospitalizations
independently of the severity of airflow obstruction,(462) and deserves specific treatment. Therefore, comorbid
conditions should be looked for routinely, and treated appropriately if present, in any patient with COPD.
Recommendations for the diagnosis, assessment of severity, and management of individual comorbid diseases are the
same as for patients without COPD.
Frequent multimorbid diseases in COPD include cardiovascular disease,(42) metabolic syndrome, osteoporosis,
depression and anxiety, likely in relation to shared risk factors (e.g., aging, smoking, alcohol, diet and inactivity).(438,463-
465) Besides, COPD itself may increase the risk for other comorbid diseases (e.g., COPD (particularly emphysema) and
lung cancer).(466,467) Whether the association between COPD and lung cancer is due to common risk factors (e.g.,
smoking), involvement of shared susceptibility genes and/or impaired clearance of carcinogens is unclear. COPD can
also have significant extrapulmonary (systemic) effects including weight loss, nutritional abnormalities, and skeletal
muscle dysfunction. The latter is characterized by both sarcopenia (loss of muscle cells) and abnormal function of the
remaining cells.(468) Its causes are likely multifactorial (e.g., inactivity, poor diet, inflammation and/or hypoxia) and it
can contribute to exercise intolerance and poor health status in patients with COPD. Importantly, skeletal muscle
dysfunction is a modifiable source of exercise intolerance by rehabilitation.(469) A more detailed description of the
management of COPD and comorbidities is provided in Chapter 5.
Combined initial COPD assessment

In 2011, GOLD proposed to move from the simple spirometric grading system for disease severity assessment and
treatment to a combined assessment strategy based on the level of symptoms (mMRC or CAT™), the severity of airflow
obstruction (GOLD grades 1-4), and the frequency of previous exacerbations. This classification was proposed to guide
initial pharmacological treatment. The main step forward achieved by this combined assessment strategy was to
incorporate patient-reported outcomes and highlight the importance of exacerbation prevention in the management
of COPD. The initial version of the combined assessment relied on both the severity of airflow obstruction (GOLD
grades 1-4) and the frequency of previous exacerbations to assess exacerbation risk.
The severity of airflow obstruction was subsequently removed from this combined assessment scheme considering its
lower precision at the individual level (versus that at a population level) to predict outcomes and drive treatment
decisions, while complexifying the use of the classification by clinicians.(420,442,470,471)
In the 2023 GOLD report, GOLD proposed a further evolution of the ABCD combined assessment tool that recognized
the clinical relevance of exacerbations, independently of the level of symptoms of the patient. Figure 2.10 presents
TE
this proposal. The A and B groups remained unchanged, but the C and D groups were merged into a single group
U
IB
termed “E” to highlight the clinical relevance of exacerbations. It was acknowledged that this proposal would have to
TR
be validated by appropriate clinical research. D
IS
T
O
N
O
-D
L
IA
ER
AT
M
T
H
IG
R
PY
O
C
ADDITIONAL INVESTIGATIONS
In cases where there is a marked discordance between the level of airflow obstruction and the perceived symptoms,
a more detailed evaluation should be carried out to better understand lung mechanics (e.g., full lung function tests
and exercise testing), lung structure (e.g., computed tomography) and/or comorbidities (e.g., ischemic heart disease)
that might impact patient symptoms.
Physiological tests
Lung volumes
COPD patients exhibit gas trapping (a rise in residual volume) from the early stages of the disease, and as airflow
obstruction worsens, static hyperinflation (an increase in total lung capacity) occurs, particularly during exercise
(dynamic hyperinflation). These changes can be documented by body plethysmography, or less accurately by helium
dilution lung volume measurement. These measurements help characterize the severity of COPD but are not essential
to patient management.
Carbon monoxide diffusing capacity of the lungs (DLco)

The single breath DLco measurement (472) evaluates the gas transfer properties of the respiratory system. DLco is well-
TE
standardized and with valid predicted values of practical utility.(344,473-475) The advent of reliable portable systems
U
IB
capable of providing accurate determinations in the field, expands its potential use as a complement to the
TR
IS
information provided by spirometry.(476) DLco should be measured in any person with symptoms (dyspnea)
D
disproportionate to the degree of airflow obstruction since reduced DLco values < 60% predicted are associated with
T
O
increased symptoms, decreased exercise capacity, worse health status,(477-479) and increased risk of death,
N
O
independently of the severity of airflow obstruction and other clinical variables.(480-483) Additionally, in COPD patients,
-D
low DLco values help preclude surgical lung resection in patients with lung cancer(484) while in smokers without airflow
L
IA
obstruction, values < 80% predicted (as a marker of emphysema) signal an increased risk for developing COPD over
ER
time.(485)
AT
M
T
Over time people with COPD have an accelerated decline in DLco compared to smokers without the disease, and this
H
IG
decline is significantly greater in women than men.(486,487) However, DLco decline is slow, and years of follow up are
R
PY
often needed before a meaningful change in DLco is detected.

O
C
Oximetry and arterial blood gas measurement

Pulse oximetry can be used to evaluate a patient’s arterial oxygen saturation and need for supplemental oxygen
therapy at the point-of-care and should be used to assess all patients with clinical signs suggestive of respiratory failure
or right heart failure. If peripheral arterial oxygen saturation is ≤ 92%, arterial blood gases should be measured due to
the imperfect correlation between oxygen saturation detected via pulse oximetry as compared to arterial blood
gas.(488) Further, pulse oximetry does not provide information on PaCO2 or pH, which may have potential therapeutic
implications (e.g., non-invasive ventilation).
Exercise testing and assessment of physical activity

In some cases, patients may complain of minimal symptoms despite severe airflow obstruction. This may be due to
reduced dyspnea perception(489) and/or life-style adaptations (sedentarism) to reduce dyspnea generation. In these
cases, exercise tests such as the 6-minute walking distance may reveal that the patients are severely constrained and
do need more intense treatment (e.g., rehabilitation) than the initial evaluation would have suggested.
Further, objectively measured exercise impairment, assessed by a reduction in self-paced walking distance(490,491) or
during incremental exercise testing in a laboratory,(492) is a powerful indicator of health status impairment and
predictor of prognosis.(493) Laboratory testing using cycle or treadmill ergometry can assist in identifying co-existing or
alternative conditions e.g., cardiac diagnoses. Walking tests can be useful for assessing disability and risk of
mortality(494) and are used to assess the effectiveness of pulmonary rehabilitation. Both the paced shuttle walk test(495)
and the self-paced 6-minute walk test can be used.(496,497) As the course length has a substantial impact on the distance
walked, existing reference equations established for a 30 meter course cannot be applied to predict the distance
achieved on shorter courses.(498)
Monitoring of physical activity may be more relevant regarding prognosis than evaluating only exercise capacity.(499)
This can be conducted using accelerometers or multi-sensor instruments.
Imaging
Chest X-ray
A chest X-ray is not useful to establish a diagnosis in COPD, but it is valuable in excluding alternative diagnoses and
establishing the presence of significant comorbidities such as concomitant respiratory (pulmonary fibrosis,
bronchiectasis, pleural diseases), skeletal (e.g., kyphoscoliosis), and cardiac diseases (e.g., cardiomegaly). Radiological
changes associated with COPD may include signs of lung hyperinflation (flattened diaphragm and an increase in the
volume of the retrosternal air space), hyperlucency of the lungs, and rapid tapering of the vascular markings.
TE
U
Computed tomography (CT)
IB
TR
In recent years computed tomography (CT) has become increasingly available, both as a research tool and in clinical
IS
practice, providing additional insights into the structural and pathophysiologic abnormalities present in COPD. This
D
T
has led to enhanced understanding of disease phenotypes, severity, and outcomes.

O
N
O
From a clinical perspective, emphysema distribution and severity can be readily discerned and can assist with decision
-D
making for lung volume reduction surgery (LVRS) or endobronchial valve placement. While historically this has been
L
IA
performed based on expert radiologist visual analysis, particularly for LVRS, increasingly quantitative analysis for
ER
emphysema extent, location and fissure integrity is also being performed to assist with endobronchial valve therapy
AT
M
decision making. The presence of emphysema is also associated with more rapid progression of FEV1 decline and
T
mortality and increased likelihood of development of lung cancer.(483) Further, about 30% of COPD patients have
H
IG
bronchiectasis visible on CT, which is now the radiological examination of choice when this is suspected. Bronchiectasis
R
PY
is associated with increased exacerbation frequency and mortality,(500) although it is not yet known whether treatment
O
according to bronchiectasis guidelines influences these clinical outcomes.

C
Historically chest CT has not been considered a requirement for COPD diagnosis, but increasingly more COPD patients
do undergo CT as part of evaluation of pulmonary nodules detected on chest X-ray or assessment for concurrent lung
disease. Recently, the number of patients who would potentially benefit from chest CT has also expanded. First, this
is due to the recent lowering of the age for lung cancer screening to 50 years old. Second, the advent of endobronchial
valve therapy for emphysema has also expanded the pool of patients where CT evaluation may be helpful, in particular
patients with post-bronchodilator FEV1 between 15%-45% and evidence of marked hyperinflation on
plethysmography.(501) In such instances, quantification of emphysema on chest CT by lobe and ensuring fissure
integrity of the target lobe is required as part of the evaluation process.
More detailed computer assisted CT analysis enables quantification of airway abnormality as well, although these
methods are less well standardized than the methods used for emphysema quantification. Hence, historically airway
measures have been used more in the research setting. While segmental and subsegmental measures of wall thickness
can be made directly, measurements of small airways (< 2 mm diameter) must be inferred by comparing inspiratory
and expiratory to identify areas of non-emphysematous gas trapping. Validated algorithms are becoming increasingly
available, even in the clinical setting, that can identify small airway abnormality through this method. (502,503) Small
airway abnormality may also be present even among individuals without detectable spirometric obstruction and
identify individuals at increased risk for lung function decline.(504) It should also be noted that CT imaging of the chest
can also provide a wealth of information about COPD comorbidities including coronary artery calcium, pulmonary
artery enlargement, bone density and muscle mass. Such CT extracted features have been shown to be independently
associated with all-cause mortality.(505) As technology advances, such information is likely to become increasingly
available to clinicians to enhance patient management.
In summary, for COPD patients with persistent exacerbations, symptoms out of proportion to disease severity on lung
function testing, FEV1 less than 45% predicted with significant hyperinflation and gas trapping, or for those who meet
criteria for lung cancer screening, chest CT imaging should be considered (Figure 2.11).
TE
U
IB
TR
IS
D
T
O
N
O
-D
L
IA
ER
AT
M
T
H
IG
R
PY
O
C
Interstitial lung abnormalities (ILA)

Findings suggestive of parenchymal lung fibrosis or inflammation are common on chest CT imaging of both smokers
and nonsmokers, and have been termed interstitial lung abnormalities (ILA) when discovered incidentally in patients
without known interstitial lung disease (ILD).(506) The prevalence of ILA ranges from 4% to 9% among older (over 60
years) adults, and spans the spectrum from subclinical findings to clinical disease.(506) Among 4,360 COPDGene
participants, ILA was present in 8% of individuals, with half meeting criteria for suspected ILD, which was defined as
definite fibrosis on CT, FVC less than 80% predicted or DLCO less than 70% predicted.(255,507) Individuals with suspected
ILD had increased respiratory symptoms and mortality.(507) Fibrotic ILA (i.e., those with traction bronchiectasis,
architectural distortion and honeycombing) are more likely to progress and are associated with poor outcomes,
especially when combined with emphysema.(508,509) Given the clinical relevance of ILA, multiple studies support clinical
evaluation, risk stratification and follow up monitoring of individuals with these findings.
Alpha-1 antitrypsin deficiency (AATD)
The World Health Organization recommends that all patients with a diagnosis of COPD should be screened once for
AATD, especially in areas with high AATD prevalence.(510,511) Although the classical patient is young (< 45 years) with
panlobular basal emphysema, it has become recognized that delay in diagnosis has led to identification of some AATD
patients when they are older and have a more typical distribution of emphysema (centrilobular apical).(512) A low
concentration (< 20% normal) is highly suggestive of homozygous deficiency. Family members should be screened and,
together with the patient, referred to specialist centers for advice and management (see Chapter 3).
Composite scores
Several variables identify patients at increased risk for mortality including FEV1, exercise tolerance assessed by walking
distance or peak oxygen consumption, weight loss, and reduction of arterial oxygenation. The BODE (Body mass index,
Obstruction, Dyspnea, and Exercise) method gives a composite score that is a better predictor of subsequent survival
than any single component.(513,514) Simpler alternatives that do not include an exercise test have been suggested but
need validation across a wide range of disease severities and clinical settings to confirm that they are suitable for
routine clinical use.(515,516)
Biomarkers
TE
U
There is rapidly increasing interest in the use of biomarkers in COPD. Biomarkers are ‘characteristics (either clinical,
IB
functional, biologic and/or imaging) that are objectively measured and evaluated as an indicator of normal biological
TR
IS
or pathogenic processes or pharmacological responses to therapeutic interventions’. In general such data has proven
D
difficult to interpret, largely as a result of weak associations and lack of reproducibility between large patient
T
O
cohorts.(517)
N
O
-D
At present blood eosinophil counts (≥ 300 cells/µL) provide guidance to identify COPD patients at higher risk of
L
IA
exacerbations and more likely to benefit from preventive treatment with inhaled corticosteroids (see Chapter 3).(517)
ER
AT
Treatable traits
M
T
H
To address the heterogeneity and complexity of COPD in clinical practice, a strategy based on so-called ‘Treatable
IG
Traits’ (TTs) has been proposed.(518) TTs can be identified based on phenotypic recognition and/or on deep
R
PY
understanding of critical causal pathways (endotypes) through validated biomarkers (e.g., high circulating eosinophil
O
C
levels (a biomarker) identify COPD patients at risk of exacerbations (a TT) in whom treatment with inhaled
corticosteroid is most effective).(519) TTs can co-exist in the same patient(337) and change with time (spontaneously or
because of treatment). GOLD highlights the role of two key TTs (persistent dyspnea and exacerbations) in the follow
up algorithm of pharmacological treatment (Figure 3.9) but there are many more pulmonary and extra-pulmonary
traits, as well as behavioral/social risk factors, that merit individual attention and treatment if present.(337)
CHAPTER 3: PREVENTION & MANAGEMENT OF COPD
KEY POINTS:
 All individuals who smoke should be strongly encouraged and supported to quit. Nicotine
replacement and pharmacotherapy reliably increase long-term smoking abstinence rates.
Legislative smoking bans and counseling, delivered by healthcare professionals, improve quit rates.
There is no evidence to support the effectiveness and safety of e-cigarettes as a smoking cessation
aid at present.
 The main treatment goals are to reduce symptoms and future risk of exacerbations. The management
strategy of stable COPD should be predominantly based on the assessment of symptoms and the
history of exacerbations.
 Pharmacotherapy can reduce COPD symptoms, reduce the frequency and severity of
exacerbations, and improve health status and exercise tolerance. Data suggest beneficial effects on
rates of lung function decline and mortality.
TE
 Each pharmacological treatment regimen should be individualized and guided by the severity of
U
symptoms, risk of exacerbations, side-effects, comorbidities, drug availability and cost, and the
IB
patient’s response, preference, and ability to use various drug delivery devices.
TR
IS
 Inhaler technique needs to be assessed regularly.
D
T
O
N
 COVID-19 vaccines are highly effective against SARS-CoV-2 infection and people with COPD should
O
have the COVID-19 vaccination in line with national recommendations.

-D
L
IA
 Influenza vaccination and pneumococcal vaccination decrease the incidence of lower respiratory
ER
tract infections.
AT
M
 The CDC recommends: the Tdap vaccination (dTaP/dTPa; pertussis, tetanus and diptheria) for COPD
T
H
patients who were not vaccinated in adolescence; routine use of shingles vaccine in all COPD
IG
patients; the new respiratory syncytial virus (RSV) vaccine for individuals over 60 years and/or with
R
PY
chronic heart or lung disease.

O
C
 Pulmonary rehabilitation with its core components, including exercise training combined with
disease-specific education, improves exercise capacity, symptoms, and quality of life across all
grades of COPD severity.
 In patients with severe resting chronic hypoxemia (PaO2 ≤ 55 mmHg or < 60 mmHg if there is cor
pulmonale or secondary polycythemia), long-term oxygen therapy improves survival.
 In patients with stable COPD and resting or exercise-induced moderate desaturation, long-term
oxygen treatment should not be prescribed routinely. However, individual patient factors must be
considered when evaluating the patient’s need for supplemental oxygen.
 In patients with severe chronic hypercapnia and a history of hospitalization for acute respiratory
failure, long-term non-invasive ventilation may decrease mortality and prevent re-hospitalization.
 In select patients with advanced emphysema refractory to optimized medical care, surgical or
bronchoscopic interventional treatments may be beneficial.
 Palliative approaches are effective in controlling symptoms in advanced COPD.
INTRODUCTION
The aim of COPD management is to reduce symptoms and future risk (Figure 3.1). COPD patients should have an
assessment of the severity of their airflow obstruction, symptoms, history of exacerbations, exposure to risk factors
and comorbidities (see Chapter 2) to guide management.
TE
U
IB
TR
IS
D
T
O
N
O
-D
L
IA
Pharmacological and non-pharmacological therapy should be adjusted as necessary (see below) and further reviews
ER
undertaken (Figure 3.2). This chapter contains recommendations on how to manage patients with COPD in clinical
AT
practice and summarizes the evidence about the effectiveness and safety of maintenance and prevention strategies
M
T
in COPD on which the recommendations are based.

H
IG
R
PY
O
IDENTIFY AND REDUCE EXPOSURE TO RISK FACTORS

C
Identification and reduction of exposure to risk factors is important not only for the primary prevention of COPD but
also as part of the management of a COPD patient. Cigarette smoking is the most commonly encountered and easily
identifiable risk factor for COPD, and smoking cessation should be continually encouraged for all individuals who
smoke. Reduction of total personal exposure to occupational dusts, fumes, and gases, and to household and outdoor
air pollutants, should also be addressed (Figure 3.3).
TE
U
IB
TR
IS
D
T
O
N
O
-D
L
IA
ER
AT
M
T
H
IG
R
PY
O
C
Smoking cessation
Smoking cessation is a key intervention for all COPD patients who continue to smoke. Healthcare providers are pivotal
in delivering smoking cessation messages and interventions and should encourage patients to quit at every available
opportunity (Figure 3.4).
A significant proportion of people with COPD continue to smoke despite knowing they have the disease (approximately
40% of those with COPD are current smokers), and this behavior has a negative impact on prognosis and progression
of the disease.(520) Smoking cessation has the greatest capacity to influence the natural history of COPD, it also
improves daily symptoms,(521) and decreases the frequency of exacerbations.(522)
For smokers with COPD, the quitting may be more challenging than for smokers without COPD due to greater nicotine
dependence, lower self-efficacy and lower self-esteem.(523-525) In addition, it has been reported that depression is more
common in smokers with COPD(526) and this could contribute to failed attempts to quit.(526,527) Despite these adverse
conditions, if effective time and resources are dedicated to smoking cessation, long-term quit rates of 14% to 27%
have been reported.(527)
TE
U
IB
TR
IS
D
T
O
N
O
-D
L
IA
ER
AT
M
T
H
IG
R
PY
O
C
As for all smokers, smoking cessation treatment for people with COPD should be adapted to the individual’s needs and
according to the level of tobacco dependence. There is evidence that a combination of counseling and
pharmacotherapy is the most effective smoking cessation treatment for people with COPD.(527-529) The complexity of
the smoking cessation process is largely determined by nicotine addiction. An accurate assessment of nicotine
dependence should therefore be carried out for all patients. Some indicators of high nicotine dependence are: smoking
within 30 min of waking up, smoking at night, consuming ≥ 20 cigarettes per day, a score of 7 to 10 on the Fagerström
scale or 5 to 6 on the Heaviness of Smoking Index.(530,531)
In addition to individual approaches to smoking cessation, legislative smoking bans are effective in increasing quit
rates and reducing harm from second-hand smoke exposure.(532)
Advice and counseling interventions

A five-step program for intervention (Figure 3.4)(533-535) provides a helpful strategic framework to guide healthcare
providers interested in helping their patients stop smoking.(533,535,536) When possible, the patient should be referred to
a comprehensive smoking cessation program that incorporates behavior change techniques enhancing patient
motivation and confidence, patient education, and pharmacological and non-pharmacological interventions.
Recommendations for treating tobacco use and dependence are summarized in Figure 3.5.(533) Because tobacco
dependence is a chronic disease,(533,535) clinicians should recognize that relapse is common and reflects the chronic
TE
nature of dependence and addiction, and does not represent failure on the part of the patient or the clinician.
U
IB
TR
IS
D
T
O
N
O
-D
L
IA
ER
AT
M
T
H
IG
R
PY
O
C
Counseling delivered by physicians and other health professionals significantly increases quit rates over self-initiated
strategies.(537) Even brief (3-minute) periods of counseling urging a smoker to quit improve smoking cessation rates.(537)
In patients with COPD a network meta-analysis showed a trend for smoking cessation counseling alone to be superior
than usual care.(538) Another study reported a continuous one-year abstinence rate of 1.4% for usual care, 2.6% for
minimal counseling (< 90 min), 6% for intensive counseling (≥ 90 min), and 12.3% for intensive counseling plus
pharmacotherapy.(528) However, controversy remains as to whether more intensive individual counseling is more
effective when combined with pharmacotherapy.(538)
Household and outdoor air pollution

Reducing exposure to household and outdoor air pollution requires a combination of public policy, local and national
resources, cultural changes, and protective steps taken by individual patients. Reduction of exposure to smoke from
biomass fuel is a crucial goal to reduce the prevalence of COPD worldwide. Efficient ventilation, non-polluting cooking
stoves and similar interventions are feasible and should be recommended.(8,9)
TE
Occupational exposures
U
IB
TR
There are no studies that demonstrate whether interventions that reduce occupational exposures also reduce the
D
IS
burden of COPD, but it seems logical to advise patients to avoid ongoing exposures to potential irritants e.g., dusts,
T
O
fumes and gases, if possible.

N
O
-D
L
IA
ER
AT
M
T
H
IG
R
PY
O
C
Vaccinations
People with COPD should receive all recommended vaccinations in line with the relevant local guidelines (Figure 3.6).
Influenza vaccine
Influenza vaccination can reduce serious illness (such as lower respiratory tract infections requiring hospitalization)(539)
and death in people with COPD.(540-543) Only a few studies have evaluated exacerbations and they have shown
significant reduction in the total number of exacerbations per vaccinated subject compared with those who received
placebo.(540) Vaccines containing either killed or live inactivated viruses are recommended(544) as they are more
effective in elderly people with COPD.(545) Findings from a population-based study suggested that people with COPD,
particularly the elderly, had decreased risk of ischemic heart disease when they were vaccinated with influenza vaccine
over many years.(546) Occurrence of adverse reactions is generally mild and transient.
Pneumococcal vaccines
Pneumococcal vaccinations, pneumococcal conjugated vaccine (PCV20 or PCV15) and pneumococcal polysaccharide
vaccine (PPSV23), are approved for adults aged ≥ 65 years. They are also approved for adults aged 19-64 years if they
have an underlying medical condition such as chronic lung disease (including COPD, emphysema, and asthma),
TE
U
cigarette smoking, solid organ transplant etc. Pneumococcal vaccination is universally recommended for adults in
IB
TR
these age groups, if they have never received a pneumococcal conjugate vaccine previously, or if their previous
IS
pneumococcal vaccination history is unknown. The current recommendation is PCV15 followed by PPSV23 OR one
D
dose PCV20.(547) Adults who have only received PPSV23 may receive a PCV (either PCV20 or PCV15) ≥ 1 year after their
T
O
last PPSV23 dose (Figure 3.6).

N
O
-D
L
IA
ER
AT
M
T
H
IG
R
PY
O
C
Specific data on the effects of PPSV and PCV in people with COPD are limited.(548) A systematic review of injectable
vaccines in COPD patients identified twelve randomized studies for inclusion and observed injectable polyvalent
pneumococcal vaccination provides significant protection against community-acquired pneumonia, although no
evidence indicates that vaccination reduced the risk of confirmed pneumococcal pneumonia, which was a relatively
rare event. Vaccination reduced the likelihood of a COPD exacerbation, and moderate-quality evidence suggests the
benefits of pneumococcal vaccination in COPD patients. Evidence was insufficient for comparison of different
pneumococcal vaccine types.(549) PPSV23 has been shown to reduce the incidence of community-acquired pneumonia
in COPD patients < 65 years, with an FEV1 < 40% predicted, or comorbidities (especially cardiac comorbidities).(550) The
PCV13 has been shown to exhibit at least the same or greater immunogenicity than the PPSV23 up to two years after
vaccination in COPD patients.(551) In a large RCT PCV13 demonstrated significant efficacy for the prevention of vaccine-
type community-acquired pneumonia (45.6%) and vaccine-type invasive pneumococcal disease (75%) among adults ≥
65 years and the efficacy persisted for at least 4 years.(552)
A study compared the effectiveness of PPSV23 and PCV13 in COPD patients over a 5-year follow-up cohort study.
Although both vaccines have comparable clinical effects during the first year after vaccination, PCV13 showed
persistent clinical effectiveness during the 5-year follow-up period. Pneumonia by year 5 after vaccination was
registered in 47% of patients in the PPSV23 group, versus 3.3% of patients in the PCV13 group (p < 0.001). Similar
effects were shown in the reduction of COPD exacerbations.(553)
TE
U
IB
PCV15, PCV20, or PPSV23 can be co-administered with influenza vaccine in an adult immunization program, as
TR
concomitant administration (PCV15 or PPSV23 and QIV [Fluarix], PCV20 and adjuvanted QIV [Fluad]) has been
demonstrated to be immunogenic and safe.(554)
IS
D
T
O
N
Respiratory syncytial virus (RSV) vaccine

O
-D
The US Centers for Disease Control (CDC) Advisory Committee on Immunization Practices’ (ACIP) and the European
L
IA
Commission recommend use of the new respiratory syncytial virus (RSV) bivalent prefusion F protein-based vaccine(555)
ER
and prefusion F protein vaccine(556) for individuals 60 years and older. Adults at the highest risk for severe RSV illness
AT
include adults with chronic heart or lung disease, immune compromise, and those living in nursing homes or long-term
M
T
care facilities. The CDC estimates that every year, RSV causes approximately 60,000–160,000 hospitalizations and
H
IG
6,000–10,000 deaths among older adults.(557,558)

R
PY
Other vaccines
O
C
In adults with COPD the CDC recommends the Tdap vaccination (also called dTaP/dTPa) to protect against pertussis
(whooping cough), tetanus and diphtheria, in those who were not vaccinated in adolescence and also the routine use
of shingles vaccine.(559,560) People with COPD should have the COVID-19 vaccinations in line with national
recommendations.(561)
PHARMACOLOGICAL TREATMENT OF STABLE COPD

We propose a tailored approach to initiate treatment based on the level of symptoms and risk for exacerbations.
Treatment can be escalated/de-escalated based on the presence of the predominant symptoms (treatable traits) of
breathlessness and exercise limitation, and the continued occurrence of exacerbations whilst on maintenance therapy.
The basis for these recommendations, which propose an organized approach to treatment, was partly derived from
evidence generated from randomized controlled trials. However, as these recommendations are intended to support
clinician decision-making, they also incorporate expert advice based on clinical experience.
Initial pharmacotherapy should be based on the patient’s GOLD group (Figure 3.7). Patients should be offered
guidance and follow up on self-management of breathlessness, and stress management, and they should be given a
written action plan (Figure 3.13). Comorbidities should also be managed as per specific guidelines, irrespective of the
presence of COPD (Figure 3.2).
Patients should be reviewed after a suitable interval (shorter in more severe patients and longer in less severe patients)
and their current level of symptoms (using either the CAT or mMRC scores) and exacerbation frequency assessed. The
effect of treatment and possible adverse effects should be evaluated, and comorbidities reassessed.
Inhaler technique, adherence to prescribed therapy (both pharmacological and non-pharmacological), smoking status
and continued exposure to risk factors should be checked at each clinical visit. Physical activity should be encouraged
and referral for pulmonary rehabilitation considered in severe patients. The need for oxygen therapy, non-invasive
ventilatory support, lung volume reduction and palliative approaches should also be considered individually, and the
action plan should be updated accordingly. Spirometry should be repeated at least annually. If the patient is already
receiving bronchodilator treatment, the latter should not be interrupted for performing spirometry.
We no longer refer to asthma and COPD overlap (ACO), instead we emphasize that asthma and COPD are different
disorders, although they may share some common treatable traits and clinical features (e.g., eosinophilia, some degree
TE
of reversibility). Asthma and COPD may coexist in an individual patient. If a concurrent diagnosis of asthma is
U
IB
suspected, pharmacotherapy should primarily follow asthma guidelines.
TR
IS
D
T
O
N
O
-D
L
IA
ER
AT
M
T
H
IG
R
PY
O
C
Algorithms for the initiation and follow-up of
pharmacological treatment
Further information on the evidence that underpins these recommendations is given later in Chapter 3 in the section
entitled “Overview of the evidence: Pharmacotherapy”.
Initial pharmacological management

A proposal for the INITIATION of pharmacological management of COPD according to the individualized assessment
of symptoms and exacerbation risk following the ABE scheme, and also accounting for blood eosinophil count, is shown
in Figure 3.7. It is an attempt to provide clinical guidance. There is no high-quality evidence such as randomized
controlled trials to support initial pharmacological treatment strategies in newly diagnosed COPD patients.
Group A
► All Group A patients should be offered bronchodilator treatment based on its effect on breathlessness. This can be
either a short- or a long-acting bronchodilator. If available and affordable a long-acting bronchodilator is the preferred
choice except in patients with very occasional breathlessness.
TE
U
IB
► This should be continued if benefit is documented.
TR
IS
Group B
D
T
► Treatment should be initiated with a LABA+LAMA combination. It has been shown in a RCT that in patients with ≤ 1
O
N
moderate exacerbation in the year before the study and a CAT™ ≥ 10 LABA+LAMA is superior to a LAMA with regard
O
-D
to several endpoints.(562) Therefore, providing there are no issues regarding availability, cost and side-effects
L
LABA+LAMA is the recommended initial pharmacological choice.

IA
ER
AT
► If a LABA+LAMA combination is not considered appropriate, there is no evidence to recommend one class of long-
M
acting bronchodilators over another (LABA or LAMA) for initial relief of symptoms in this group of patients. In the
T
H
individual patient, the choice should depend on the patient’s perception of symptom relief.
IG
R
PY
► Group B patients are likely to have comorbidities that may add to their symptomatology and impact their prognosis,
O
C
and these possibilities should be investigated and treated, if present, by following national and international
guidelines.(563,564)
Group E
► A Cochrane systematic review and network meta-analysis comparing dual combination therapy versus mono long-
acting bronchodilators showed that the LABA+LAMA combination was the highest ranked treatment group to reduce
COPD exacerbations.(565) Therefore, provided there are no issues regarding availability, cost and side-effects
LABA+LAMA is the preferred choice for initial therapy in group E patients.
► Use of LABA+ICS in COPD is not encouraged. If there is an indication for an ICS, then LABA+LAMA+ICS has been
shown to be superior to LABA+ICS and is therefore the preferred choice.(448,566)
► Consider LABA+LAMA+ICS in group E if eos ≥ 300 cells/µL (practical recommendation). As detailed later in this
chapter, the effect of ICS on exacerbation prevention is correlated to blood eosinophil count. There are no direct data
in the literature concerning initiation of triple therapy in newly diagnosed patients. However, we think available studies
performed mostly in treated patients provide a rationale for considering this treatment option as initial therapy for
patients with a high eosinophil count (≥ 300 cells/μL).
► If patients with COPD have concomitant asthma they should be treated like patients with asthma. Under these
circumstances the use of an ICS is mandatory.
Rescue short-acting bronchodilators should be prescribed to all patients for immediate symptom relief.
Following implementation of therapy, patients should be reassessed for attainment of treatment goals and
identification of any barriers for successful treatment (Figure 3.8). Following review of the patient’s response to
treatment initiation, adjustments may be needed.
This is guided by the principles of first review and assess, then adjust if necessary (Figure 3.8):
► Review
 Review symptoms (dyspnea) and exacerbation risk (previous history, blood eosinophils).
► Assess
 Assess inhaler technique and adherence, and the role of non-pharmacological approaches (covered earlier
in this chapter).
TE
► Adjust
U
 Adjust pharmacological treatment, including escalation or de-escalation. Switching inhaler device or
IB
TR
molecules within the same class (e.g., using a different long-acting bronchodilator) may be considered as
IS
appropriate. Any change in treatment requires a subsequent review of the clinical response, including side
D
T
effects.
O
N
O
-D
L
IA
ER
AT
M
T
H
IG
R
PY
O
C
Follow-up pharmacological management
A separate algorithm is provided for FOLLOW-UP treatment, where the management is based on two key treatable
traits: persistence of dyspnea and occurrence of exacerbations (Figure 3.9). These follow-up recommendations are
designed to facilitate management of patients taking maintenance treatment(s), whether early after initial treatment
or after years of follow-up. These recommendations incorporate the evidence from clinical trials and the use of
peripheral blood eosinophil counts as a biomarker to guide the use of ICS therapy for exacerbation prevention (see
more detailed information regarding blood eosinophil counts as a predictor of ICS effects later in Chapter 3).
TE
U
IB
TR
IS
D
T
O
N
O
-D
L
IA
ER
AT
M
T
H
IG
R
PY
O
C
Figure 3.9 presents suggested escalation and de-escalation strategies based on available efficacy and safety data. The
response to treatment escalation should always be reviewed. Patients, in whom treatment modification is considered,
in particular de-escalation, should be under close medical supervision. We are fully aware that treatment escalation
has not been systematically tested; trials of de-escalation are also limited and only include ICS.
The follow-up pharmacological treatment algorithm (Figure 3.9) can be applied to any patient who is already taking
maintenance treatment(s) irrespective of the GOLD group allocated at treatment initiation. The need to target
primarily dyspnea/activity limitation or to prevent further exacerbations should be evaluated in each patient. If a
change in treatment is considered necessary, then select the corresponding algorithm for dyspnea (Figure 3.9 left
column) or exacerbations (Figure 3.9 right column); the exacerbation algorithm should also be used for patients who
require a change in treatment for both dyspnea and exacerbations. Identify which box corresponds to the patient’s
current treatment and follow the suggested algorithm.
Dyspnea
► For patients with persistent breathlessness or exercise limitation on bronchodilator monotherapy,(567) the use of
two long acting bronchodilators is recommended.
 If the addition of a second long acting bronchodilator does not improve symptoms, we suggest
considering switching inhaler device or molecules.
► At all stages, dyspnea due to other causes (not COPD) should be investigated and treated appropriately. Inhaler
technique and adherence should be considered as causes of inadequate treatment response. Rehabilitation should
also be considered.
TE
U
IB
Exacerbations
TR
IS
► For patients with persistent exacerbations on bronchodilator monotherapy, escalation to LABA+LAMA is
D
recommended.
T
O
N
O
► In patients who develop further exacerbations on LABA+LAMA therapy we suggest escalation to LABA+LAMA+ICS.
-D
A beneficial response after the addition of ICS may be observed at blood eosinophil counts ≥ 100 cells/µL, with a
L
IA
greater magnitude of response more likely with higher eosinophil counts.(448)

ER
AT
► If patients treated with LABA+LAMA+ICS (or those with eos < 100 cells/µL) still have exacerbations the following
M
T
options may be considered:

H
IG
 Add roflumilast. This may be considered in patients with an FEV1 < 50% predicted and chronic
R
PY
bronchitis,(568) particularly if they have experienced at least one hospitalization for an exacerbation in the
O
previous year.(569,570)
C
 Add a macrolide. The best available evidence exists for the use of azithromycin, especially in those who
are not current smokers.(571,572) Consideration to the development of resistant organisms should be
factored into decision-making.
 Withdrawing ICS can be considered if pneumonia or other considerable side-effects develop. If blood
eosinophils are ≥ 300 cells/µL de-escalation is more likely to be associated with the development of
exacerbations.(573,574) Carefully consider the dose of ICS used to reduce the potential of ICS related side
effects that are more frequent at higher doses.
Patients under treatment with LABA+ICS
► If a patient with COPD and no features of asthma has been treated – for whatever reason – with LABA+ICS and is
well controlled in terms of symptoms and exacerbations, continuation with LABA+ICS is an option. However, if the
patient has:
 Further exacerbations: treatment should be escalated to LABA+LAMA+ICS if the blood eosinophil count
is ≥ 100 cells/µL or switched to LABA+LAMA if it is < 100 cells/µL.
 Major symptoms: switching to LABA+LAMA should be considered.

Managing inhaled therapy
Most of the drugs used to treat COPD are inhaled. Thus, appropriate use of inhaler devices is crucial to optimize the
benefit-risk ratio of inhaled therapy. Achieving this goal requires choosing the appropriate device, providing education,
checking inhaler use regularly and, whenever necessary, adapting education and device (Figure 3.10).
TE
U
IB
TR
IS
D
T
O
There are currently at least 33 different inhaled therapies containing different bronchodilators (both short- and long-
N
O
acting) and inhaled corticosteroids (ICS) alone or in combinations (Figure 3.18). In addition, at least 22 different inhaler
-D
devices are available,(575) including nebulizers, metered-dose inhalers (MDIs) used with or without valved holding
L
IA
chamber (VHC)/spacers, breath-actuated MDIs (BAIs), soft mist inhalers (SMIs) and dry powder inhalers (DPIs)(576) In
ER
multi-dose DPIs, the powder is contained in a reservoir or in individual blisters.(576) More information about inhalation
AT
devices is available on the Asthma + Lung UK website.(577)

M
T
H
IG
Devices differ in their size and portability. They also differ in the number of steps required to prepare them,(578) in the
R
PY
force needed to load or actuate them,(579) in the time taken to deliver the drug, and in the need for cleaning and
O
maintenance, as well as in the inspiratory manoeuvre required to use them effectively.(576) Increased steps reduces
C
the ease of use and likelihood that patients use the inhaler correctly.(580) There may also be quite significant differences
in the carbon footprint of devices reflecting whether or not they contain a propellant gas, what they are made from,
how they are manufactured and transported, and whether they can be reused or recycled.(581) The proper use of an
inhaler has a positive environmental impact through the reduction of exacerbations and their CO2 footprint (especially
when hospitalization is required).(581) Smart inhalers incorporate sensors that detect the date and time of use, and for
some inspiratory flow and inspired volume. These allow the identification of problems and feedback in real time (582)
and can provide objective data on adherence and technique.(583,584)
Particles > 5 microns (µm) are most likely to be deposited in the oropharynx. For drug delivery to the lower respiratory
tract and lungs, particle size (mass-median aerodynamic diameter) can be fine (2-5 µm) or extra-fine (< 2 µm), which
influences the total respirable fraction (particles < 5 µm) and the amount and site of drug deposition (more peripheral
deposition with extra-fine particles).(576) Inspiratory flow, flow acceleration, and inhaled volume are important factors
for patients to successfully inhale drug particles from handheld devices into the lower respiratory tract.(576,585) MDIs
and SMIs require a slow and deep inspiration while DPIs require forceful inspiration. Each DPI has a unique internal
resistance and patients must create turbulent energy within the device during inhalation to disaggregate the powder
into fine particles. Prescribers should check visually that the patient can inhale forcefully through the device and, if
there is doubt, either check the inspiratory flow objectively(586,587) or switch to an MDI+/-spacer/VHC or SMI depending
on drug availability and patient’s characteristics. Suboptimal peak inspiratory flow and inhalation technique errors
were associated with higher COPD-related healthcare utilization and costs in patients on DPI maintenance therapy.(588)
Randomized controlled trials have not identified superiority of one device/formulation and there is no evidence for
superiority of nebulized therapy over hand-held devices in patients who are able to use these devices properly.(576)
However, patients included in these trials are usually those who master inhalation technique and receive proper
education and follow-up regarding this issue, and therefore may not be reflective of normal clinical practice. Fixed-
dose triple inhaled combination therapy in one inhaler may help improve health status compared to treatment using
multiple inhalers.(589)
Ability to use delivery system correctly

Specific instructions are available for each type of device.(576,577) On average more than two thirds of patients make at
least one error in using an inhalational device.(590-593) Observational studies in these patients show that, although the
type and frequency of inhalation errors vary between devices depending on their characteristics, there is no device
obviating the need to explain, demonstrate and regularly check inhalation technique.(594-600) The main errors in delivery
device use relate to problems with inspiratory flow, inhalation duration, coordination, dose preparation, exhalation
maneuver prior to inhalation and breath-holding following dose inhalation.(601)
TE
U
IB
Patients’ ability to use inhalers correctly is affected by their cognitive ability, manual dexterity and coordination skills,
TR
the inspiratory flow that they can achieve, the use of different types of device, and previous education on inhaler
IS
D
technique.(591,602) Poor inhaler technique and errors using devices are more common with advancing age,(603) but this
T
is likely to be mainly due to cofounders such as cognitive impairment or reduced manual dexterity.(604,605) pMDIs
O
N
require sufficient hand strength to actuate the inhaler, and although BAIs are triggered by inhalation they still require
O
-D
priming which needs a degree of strength.(579) Patients with poor dexterity may struggle to load a DPI, particularly if
L
capsules require extraction from foil, insertion into the device or puncturing prior to administration.(579) Tremor may
IA
ER
result in shaking of the device and loss of the dose.(606)

AT
M
If there is any doubt that the patient will not be able to use a pMDI correctly they should be prescribed a VHC/spacer;
T
H
however, these are not a panacea and there is evidence that incorrect use of pMDIs is more common in older patients
IG
R
if they use a VHC.(607) Currently available VHCs range in volume from < 50 to 750 mL(608) but VHC with volumes from
PY
150 to 250 mL have been shown to be as effective as those with larger volumes(609) and are more portable. As well as
O
C
reducing difficulties caused by poor co-ordination and inspiratory maneuvers with pMDIs, VHCs increase pulmonary
and reduce oropharyngeal deposition, which is particularly important to minimize the risk of oropharyngeal candidiasis
with corticosteroid containing pMDIs.(576)
Leaflets included in device packages are insufficient to provide proper education of patients regarding inhaler use.
Other strategies and tools including physical training and use of video or web-based education have proven effective
to improve inhaler technique in some but not all patients on the short-term, but effects appear to wane over time.(580)
Using the “teach-back” approach (patients being asked to show how the device has to be used) appears to be
particularly effective.(610) Pharmacist-, physician-, physiotherapist- and nurse-led interventions(611) as well as lay health
coaching(612) can improve inhalation technique and adherence in COPD patients. As in asthma, digital inhalers could
contribute to improved adherence and inhaler technique in patients with COPD.(613)
Choice of inhaler device

If a patient is currently taking inhaled therapy and able to use their current device correctly, new therapy is best
prescribed in the same device. If a new device is required, either because the patient is not using their current device
correctly or the drug is not available in the same device, a systematic iterative process should be used to select a
delivery system and ensure the patient can use it.
The choice of an inhaler device depends on drug availability, characteristics of the device, the patient’s abilities and
preferences, and the knowledge of healthcare professionals caring for the patient about devices and their correct
usage. The final choice should be made jointly by the prescriber and the patient using a shared decision-making
approach. Figure 3.11 summarises the main principles that should be considered to guide the individualized selection
of the appropriate device for a given patient.
TE
U
IB
TR
IS
D
T
O
N
O
-D
L
IA
ER
AT
M
T
H
IG
R
PY
O
C
Appropriate education must be provided by health care professionals, including physical, video- or be-based
demonstration of the proper technique and live verification that the patient masters this technique. It is crucial to
check regularly (ideally, at each visit) that patients continue to use their device correctly. Lack of placebo devices within
clinical areas is often a limitation and barrier to providing quality inhaler technique instruction to patients. Encouraging
a patient to bring their own devices to clinic is a useful alternative.
NON-PHARMACOLOGICAL TREATMENT OF STABLE COPD
Non-pharmacological treatment is complementary to pharmacological treatment and should form part of the
comprehensive management of COPD.
After receiving a diagnosis of COPD a patient should be given further information about the condition. Physicians
should emphasize the importance of a smoke free environment, empower adherence to prescribed medication,
ensure proper inhaler technique, promote physical activity, prescribe vaccinations, and refer patients to pulmonary
rehabilitation.
Algorithms for the initiation and follow-up of non-

pharmacological treatment
Some relevant non-pharmacological measures based on the patient’s GOLD A,B,E group AT DIAGNOSIS are
summarized in Figure 3.12.
TE
U
IB
TR
IS
D
T
O
N
O
-D
L
IA
ER
AT
M
T
H
IG
R
PY
O
C
Recommendations for FOLLOW UP non-pharmacological treatments are based on a patient’s treatable traits e.g.,
symptoms and exacerbations (Figure 3.13).
TE
U
IB
TR
IS
D
T
O
N
O
-D
L
IA
ER
AT
M
T
H
IG
R
PY
O
C
Rehabilitation, Education & Self-Management

Pulmonary rehabilitation
Pulmonary rehabilitation is defined as “a comprehensive intervention based on thorough patient assessment followed
by patient-tailored therapies that include, but are not limited to, exercise training, education, self-management
intervention aiming at behavior change, designed to improve the physical and psychological condition of people with
chronic respiratory disease and to promote the long-term adherence to health-enhancing behaviors.”(614)
Patients with high symptom burden and risk of exacerbations (Groups B and E), should be encouraged to take part in
a formal rehabilitation program that includes setting patient goals and is designed and delivered in a structured
manner, taking into account the individual’s COPD characteristics and comorbidities.(614-616) This includes patients who
are older, female, more deprived, or have a comorbidity of diabetes, asthma, or painful condition and currently appear
less likely to be referred for pulmonary rehabilitation.(617)
Pulmonary rehabilitation should be considered as part of integrated patient management, and usually includes a range
of healthcare professionals to ensure optimum coverage of the many aspects involved.(615) Optimum benefits are
achieved from programs lasting 6 to 8 weeks. Available evidence indicates that there are no additional benefits from
extending pulmonary rehabilitation to 12 weeks.(618) Supervised exercise training at least twice weekly is
recommended, and this can include any regimen from endurance training, interval training, resistance/strength
training; upper and lower limbs ideally should be included as well as walking exercise; flexibility, inspiratory muscle
training and neuromuscular electrical stimulation can also be incorporated. In all cases the rehabilitation intervention
(content, scope, frequency, and intensity) should be individualized to maximize personal functional gains.(618) When
the intervention includes ongoing feedback (telephone calls, biofeedback provided via pedometer and progressive
goal setting) but the program is not supervised, it is no more effective in improving physical activity than a walking
program with no feedback.(619) The importance of long-term behavior change to improve physical functionality, and
reduce the psychological impact of COPD, should be emphasized to the patient.
Assessment and follow-up of pulmonary rehabilitation

Baseline and outcome assessments of each participant in a pulmonary rehabilitation program should be made to
specify individual maladaptive behaviors (including motivation), physical and mental health impediments to training,
goals, barriers and capabilities and to quantify gains and to target areas for improvement.
TE
Assessments should include:
U
IB
TR
► Detailed history and physical examination
IS
►
D
Measurement of post-bronchodilator spirometry
T
► Assessment of exercise capacity

O
N
► Measurement of health status and impact of breathlessness

O
-D
► Assessment of inspiratory and expiratory muscle strength and lower limb strength in patients who suffer
L
from muscle wasting

IA
ER
► Discussion about individual patient goals and expectations

AT
M
The first two assessments are important for establishing entry suitability and baseline status but are not used in
T
H
outcome assessment.
IG
R
PY
Exercise tolerance can be assessed by cycle ergometry or treadmill exercise with the measurement of a number of
O
C
physiological variables, including maximum oxygen consumption, maximum heart rate, and maximum work
performed. Standardized self-paced, timed walking tests (e.g., 6-minute walking distance) are useful in clinical practice
as they require minimal facilities and are relevant to routine functioning. Shuttle walking tests provide more complete
information than an entirely self-paced test, and are simpler to perform than a treadmill test.(620) Walking tests do
require at least one practice session before data can be interpreted.
It is important not to limit assessment only to these outcome measures but gather information on each patient’s
ultimate goal (relevant or valued outcomes), such as their desired achievements in work, home and leisure by the end
of the program.
Several detailed questionnaires for assessing health status are available, including some specifically designed for
patients with respiratory disease. Health status can also be assessed by generic instruments, although these are less
sensitive to change than the disease specific questionnaires such as the CAT™, CRQ or SGRQ. The Hospital Anxiety and
Depression Scale (HADS)(621) and the Primary Care Evaluation of Mental Disorders (PRIME-MD) Patient
Questionnaire(622) have been used to improve identification and treatment of anxious and depressed patients.
Education, self-management and integrative care
Patient “education” often takes the form of providers giving information and advice, and assumes that knowledge will
lead to behavior change. Although enhancing patient knowledge is an important step towards behavior change,
didactic group sessions are insufficient for promoting self-management skills. Topics such as smoking cessation,
correct use of inhaler devices, early recognition of exacerbation, decision-making and taking action, and when to seek
help, surgical interventions, considering advance directives, and others will be better dealt with using self-
management interventions. Personalized education and training that considers specific issues relating to the individual
patients, and that aims to enhance long-term functionality and appropriate health behaviors, is likely to benefit
patients more. These are addressed under self-management.
Education
Patients may have individual and/or group education sessions. During group sessions, patients engage in active,
participatory-based learning of program content. During one-on-one interactions, a motivational communication style
should be used, as this approach empowers patients to take greater responsibility for their health and wellbeing,
where physicians and other healthcare professionals only serve as guides in the behavior change process.
Topics considered appropriate for an education program include: smoking cessation; basic information about COPD;
TE
general approach to therapy and specific aspects of medical treatment (respiratory medications and inhalation
U
devices); strategies to help minimize dyspnea; advice about when to seek help; decision-making during exacerbations;
IB
TR
and advance directives and end-of-life issues. The intensity and content of these educational messages will vary
IS
depending on the severity of the patient’s disease, although the specific contributions of education to the
D
T
improvements seen after pulmonary rehabilitation remain unclear.(623) Implicit in this description is the provision of
O
N
“self-management support/coaching”, which refers to the strategies, techniques and skills used by healthcare
O
providers to arm patients with the knowledge, confidence and skills required to self-manage their disease effectively.
-D
However, the individual patient’s evaluation and risk assessment with respect to exacerbations, patient’s needs,
L
IA
preferences, and personal goals should inform the personalized design of the self-management education plan.
ER
AT
M
Self-management
T
H
Self-management education and coaching by healthcare professionals should be a major component of the “Chronic
IG
R
Care Model” within the context of the healthcare delivery system.

PY
O
C
The aim of self-management interventions is to motivate, engage and coach patients to positively adapt their health
behavior(s) and develop skills to better manage their COPD on a day-to-day basis.(624) Physicians and healthcare
providers need to go beyond pure education/advice-giving (didactic) approaches to help patients learn and adopt
sustainable self-management skills. The basis of enabling patients to become active partners in their ongoing care is
to build knowledge and skills. It is important to recognize that patient education alone does not itself change behavior
or even motivate patients, and it has had no impact on improving exercise performance or lung function,(625,626) but it
can play a role in improving skills, ability to cope with illness, and health status.(614)
Integrative care
COPD is a complex disease that requires the input of multiple care providers who need to work together closely. In
principle, use of a formal structured program that determines how each component is delivered should make care
more efficient and effective, but the evidence for this is divided.
Oxygen therapy and ventilatory support
Oxygen therapy
The long-term administration of oxygen (> 15 hours per day) to patients with chronic respiratory failure has been
shown to increase survival in patients with severe resting hypoxemia.(627) Long-term oxygen therapy does not lengthen
time to death or first hospitalization or provide sustained benefit for any of the measured outcomes in patients with
stable COPD and resting or exercise-induced moderate arterial oxygen desaturation.(628) Breathlessness may be
relieved in COPD patients who are either mildly hypoxemic, or non-hypoxemic but do not otherwise qualify for home
oxygen therapy, when oxygen is given during exercise training; however, studies have shown no improvement of
breathlessness in daily life and no benefit on health related quality of life (Figure 3.14).(628-630) There are contradictory
studies although the majority do not demonstrate changes.(631)
TE
U
IB
TR
IS
D
T
O
N
O
-D
L
IA
ER
AT
M
T
H
IG
R
PY
O
C
Although air travel is safe for most patients with chronic respiratory failure who are on long-term oxygen therapy,(632)
patients should ideally maintain an in-flight PaO2 of at least 6.7 kPa (50 mmHg). Studies indicate that this can be
achieved in those with moderate to severe hypoxemia at sea level by supplementary oxygen at 3 liters/min by nasal
cannula or 31% by Venturi facemask.(633) Those with a resting oxygen saturation > 95% and 6-minute walk oxygen
saturation > 84% may travel without further assessment,(634) although it is important to emphasize that resting
oxygenation at sea level does not exclude the development of severe hypoxemia when travelling by air.(632) Careful
consideration should be given to any comorbidity that may impair oxygen delivery to tissues (e.g., cardiac impairment,
anemia). Also, walking along the aisle may profoundly aggravate hypoxemia.(635)
Long-term oxygen therapy (LTOT) is indicated for stable patients who have:
► PaO2 at or below 55 mmHg (7.3 kPa) or SaO2 at or below 88%, with or without hypercapnia confirmed
twice over a three-week period; or
► PaO2 between 55 mmHg (7.3 kPa) and 60 mmHg (8.0 kPa), or SaO2 of 88%, if there is evidence of pulmonary
hypertension, peripheral edema suggesting congestive cardiac failure, or polycythemia (hematocrit >
55%).
Once placed on LTOT the patient should be re-evaluated after 60 to 90 days with repeat arterial blood gas (ABG) or
oxygen saturation measurements while inspiring room air and the level of oxygen flow that had been prescribed to
determine if oxygen is still indicated and if so, therapeutic. An appropriate algorithm for the prescription of oxygen to
COPD patients is shown in Figure 3.15.
TE
U
IB
TR
IS
D
T
O
N
O
-D
L
IA
ER
AT
M
T
H
IG
R
PY
O
C
Ventilatory support
Noninvasive ventilation (NIV) is occasionally used in patients with stable very severe COPD.(636) NIV may be considered
of some use in a selected group of patients, particularly in those with pronounced daytime hypercapnia and recent
hospitalization, although a systematic review was unable to support or refute this.(637) In contrast, in patients with both
COPD and obstructive sleep apnea there are clear indications for continuous positive airway pressure (CPAP).(638,639)
During exacerbations of COPD
NIV in the form of noninvasive positive pressure ventilation (NPPV) is the standard of care for decreasing morbidity
and mortality in patients hospitalized with an exacerbation of COPD and acute respiratory failure(640-643) (see also
Chapter 4).
Stable patient
In patients with both COPD and obstructive sleep apnea there are clear benefits associated with the use of continuous
positive airway pressure (CPAP) to improve both survival and the risk of hospital admissions.(638,639)
Whether to use NPPV chronically at home to treat patients with acute on chronic respiratory failure following
hospitalization remains undetermined and outcome may be affected by persistent hypercapnia.(644) A multicenter
prospective RCT of COPD patients with persistent hypercapnia (PaCO2 > 53 mmHg) after 2-4 weeks of hospital
discharge because an acute episode of exacerbation, compared the effects of home NIV plus oxygen compared to
home oxygen alone on time to readmission or death.(644) Results showed that adding home NIV to oxygen therapy
significantly prolonged the time to readmission or death within 12 months.(644) A systematic review and meta-analysis
of these studies confirms that NIV decreases mortality and risk of hospitalization. The best candidate subgroups (by
recent hospitalization history or PaCO2) remain unclear.(643)
TE
Two previous retrospective studies(645,646) and two of three RCTs(644,647-650) reported reductions in re-hospitalization and
U
IB
improved survival with using NPPV post-hospitalization. Two studies reported decreases in mortality and
TR
hospitalization rates while another showed no benefit of NPPV for survival.(648) Several factors may account for
D
IS
discrepancies: differences in patient selection, underpowered studies, NPPV settings incapable of achieving adequate
T
O
ventilation, and poor adherence with NPPV therapy.(651) NPPV when indicated should be instituted and monitored
N
under the direction of personnel familiar with the process and the devices utilized.(652,653)
O
-D
L
IA
ER
MONITORING AND FOLLOW-UP

AT
M
T
Routine follow-up of COPD patients is essential. Lung function may worsen over time, even with the best available
H
IG
care. Symptoms, exacerbations and objective measures of airflow obstruction should be monitored to determine
R
PY
when to modify management and to identify any complications and/or comorbidities that may develop.
O
C
Symptoms
At each visit, information on symptoms since the last visit should be collected, including cough and sputum,
breathlessness, fatigue, activity limitation, and sleep disturbances, including insomnia. Questionnaires such as the
COPD Assessment Test (CAT™)(428) can be used; trends and changes are more valuable than single measurements.
Exacerbations
The frequency, severity, type and likely causes of all exacerbations(654) should be monitored. Sputum volume and
presence or absence of sputum purulence should be noted. Specific inquiry into response to previous treatment,
unscheduled visits to providers, telephone calls for assistance, and use of urgent or emergency care facilities is
important. Hospitalizations should be documented, including the facility, duration of stay, and any use of critical care
or mechanical ventilatory support.
Adherence and appropriate use of prescribed treatments

This is a key action in the chronic management of COPD patients that should be mandatory in each clinical visit. The
following aspects need careful and personalized attention:
► Dosages of prescribed medications
► Adherence to the regimen
► Inhaler technique
► Effectiveness of the current regime
► Side effects
Treatment modifications should be recommended (Figure 3.7).
Smoking status
At each visit, the current smoking status and smoke exposure should be determined followed by appropriate action.
Measurements
Decline in FEV1 can be tracked by spirometry performed at regular intervals (e.g., yearly) to identify patients who are
declining quickly, although other lung function parameters reflecting hyperinflation and gas transfer may also be
informative.
A timed walking test (6-minute walking distance or shuttle-walking test) provides additional information regarding
prognosis.(655,656) Measurement of oxygenation at rest in an arterial blood gas sample may help identify patients who
TE
will benefit from supplemental oxygen to improve both symptoms and survival in those with severe resting hypoxemia.
U
IB
TR
Imaging D
IS
If there is a clear worsening of symptoms, imaging may be indicated. When exacerbations are repeatedly characterized
T
O
by purulent sputum, patients should be investigated for bronchiectasis.

N
O
-D
Comorbidities
L
IA
Symptoms that may indicate the development or worsening of a comorbid condition such as lung cancer, obstructive
ER
sleep apnea, congestive heart failure, ischemic heart disease, osteoporosis or depression/anxiety etc. should be
AT
M
recorded. If present, an appropriate diagnostic work-up should follow (see also Chapter 5).
T
H
IG
Telehealth and remote monitoring

R
PY
The COVID-19 pandemic has dramatically changed how outpatient care is delivered in health care practices. Telehealth
O
C
may offer a bridge to care, and now offers a chance to consider virtual and hybrid virtual/in-person care models, with
a goal of improved healthcare access, outcomes, and affordability. However, incorporation of virtual care into
ambulatory care should be based on evidence.
From a recent Cochrane review(657) on telehealth for remote monitoring and consultations for patients with COPD,
different models have been reviewed based on RCTs:
► Remote monitoring (linked to a healthcare professional) plus usual care versus usual care alone (as
reported by trialists).
► Remote consultation (e.g., real-time contact with a health professional) plus usual care versus usual care
alone (e.g., face-to- face visit for a check-up in a health service with a health professional, or as reported
by trialists).
► Remote monitoring or remote consultation versus usual care (e.g., where tele healthcare has replaced an
element of usual face-to-face care).
For most of the studies included in the review (24 RCTs) remote monitoring interventions required participants to
transfer measurements using a remote device for subsequent health professional review (asynchronous) as opposed
to only 5 RCTs that transferred data and allowed review by health professionals in real time (synchronous). (657) The
results of this systematic review demonstrate the paucity of evidence of superiority of these models compared to
usual care, i.e., exacerbations, hospitalization, health status and mortality. While there was no evidence of harm, it is
still unclear which COPD severity subgroups would benefit, or possibly be harmed, by telehealth interventions.
Telehealth interventions may be beneficial as an additional health resource based on professional assessment, and
depending on individual needs, although the long-term effects remain unknown.
SUPPORTIVE, PALLIATIVE, END-OF-LIFE & HOSPICE CARE

Symptom control and palliative care
Palliative care is a broad term that encompasses approaches to symptom control as well as management of terminal
patients close to death. The goal of palliative care is to prevent and relieve suffering, and to support the best possible
quality of life for patients and their families, regardless of the stage of disease or the need for other therapies.(658)
COPD is a highly symptomatic disease and has many elements such as fatigue, dyspnea, depression, anxiety, insomnia
that require symptom-based palliative treatments. There is evidence that people with COPD are less likely to receive
TE
such services compared to patients with lung cancer.(659,660) Palliative care expands traditional disease-model medical
U
IB
treatment to increase the focus on the goals of enhancing quality of life, optimizing function, helping with decision-
TR
making about end-of-life care, and providing emotional and spiritual support to patients and their families.(658)
IS
D
Palliative approaches are essential in the context of end-of-life care as well as hospice care (a model for delivery of
T
end-of-life care for patients who are terminally ill and predicted to have less than 6 months to live). Increasingly,
O
N
palliative care teams are available for consultation for hospitalized patients.(661) Availability for outpatient palliative
O
-D
care consultation is less common, and has been shown to improve quality of life, reduce symptoms and even prolong
L
survival for patients with advanced lung cancer.(660) Key points for palliative, end-of-life and hospice care in COPD are
IA
ER
summarized in Figure 3.16.

AT
M
T
H
IG
R
PY
O
C
Therapy relevant to all people with COPD
Even when receiving optimal medical therapy many people with COPD continue to experience distressing
breathlessness, impaired exercise capacity, fatigue, and suffer panic, anxiety and depression.(662) Some of these
symptoms can be improved by wider use of palliative therapies that in the past have often been restricted to end-of-
life situations.
Palliative treatment of dyspnea

Relieving dyspnea during daily life activities to limit disability, improve quality of life, and reduce medical resource use
is a major goal of COPD care. Multiple therapeutic approaches can be considered to target the variety of involved
mechanisms; they are dominated by inhaled bronchodilators, self-management education (where patients learn
breathing techniques) and pulmonary rehabilitation that includes exercise training. The roles of oxygen therapy, high-
flow nasal therapy (HFNT) and non-invasive ventilation (NIV) for palliation of dyspnea are debated.(663)
Opiates,(664-666) neuromuscular electrical stimulation (NMES),(666,667) chest wall vibration (CWV)(666) and fans blowing air
onto the face(666,668,669) can relieve breathlessness. Morphine may improve health status in COPD patients.(317)
Immediate-release morphine extended exercise endurance time in over half of the patients with advanced COPD in
one study.(317) However, in another RCT oral extended-release morphine (8 mg/day or 16 mg/day for one week) did
TE
not improve dyspnea compared with placebo in patients with mMRC breathlessness scale scores of 3 or 4.(670) Further
U
research is required to determine what patient characteristics predict response to opioid therapy.(671) The optimal
IB
TR
formulation and administration route remain under discussion.(666,672)
IS
D
T
Oxygen may offer some benefit even if the patient is not hypoxemic (Sp02 > 92%) (Figure 3.14).(673) Pulmonary
O
N
rehabilitation is effective and in severe cases NIV can also reduce daytime breathlessness. Acupuncture and
O
acupressure are other non-pharmacological approaches in patients with advanced COPD that may improve
-D
breathlessness and quality of life.(674) Refractory dyspnea may be more effectively managed with a multidisciplinary
L
IA
integrated palliative and respiratory care service.(675)

ER
AT
M
There is no evidence for a beneficial effect of benzodiazepines(676) and there is not enough data to recommend
T
H
distractive auditory stimuli (music), relaxation, counseling and support, with or without breathing relaxation training,
IG
or psychotherapy.(677)
R
PY
O
Nutritional support
C
Low BMI and particularly low fat-free mass is associated with worse outcomes in people with COPD.(678) In
malnourished people with COPD, nutritional supplementation promotes significant weight gain and leads to significant
improvements in respiratory muscle strength and overall health-related quality of life.(679) Nutritional antioxidant
supplementation (vitamin C and E, zinc, and selenium) has been shown to improve antioxidant deficits, quadriceps
strength, and serum total protein, without further improvement in quadriceps endurance. Only in malnourished
patients has nutritional supplementation demonstrated significant improvements for 6-minute walk test, respiratory
muscle strength and health status.(680) A 12-month nutritional intervention in muscle wasted patients had no effect on
physical capacity but physical activity was significantly higher.(681)
Panic, anxiety & depression

The causes of depression and anxiety symptoms in people with COPD are multifactorial and include behavioral, social
and biological factors.(682) Pulmonary rehabilitation may help reduce anxiety symptoms. The efficacy of
antidepressants in people with COPD has been inconclusive, possibly as a result of methodological issues in the
published trials. Cognitive behavioral therapy and mind-body interventions (e.g., mindfulness-based therapy, yoga,
and relaxation) can reduce anxiety and depression; mind-body interventions also improve physical outcomes such as
lung function, dyspnea, exercise capacity and fatigue in people with COPD and psychological problems.(683)
Fatigue
Fatigue in people with COPD can be improved by self-management education, pulmonary rehabilitation, nutritional
support and mind-body interventions.(684)
End-of-life and hospice care

In many patients, the disease trajectory in COPD is marked by a gradual decline in health status and increasing
symptoms, punctuated by acute exacerbations that are associated with an increased risk of dying.(685) Although
mortality rates following hospitalization for an acute exacerbation of COPD are declining,(686) reported rates still vary
from 23%(687) to 80%.(688) Progressive respiratory failure, cardiovascular diseases, malignancies and other diseases are
the primary cause of death in people with COPD hospitalized for an exacerbation.(688) In qualitative studies, as well as
describing the high symptom burden, people with COPD and their families describe a need for a better understanding
of their condition and the psychological impact of living and dying with COPD.(689) Palliative care is a broad term that
includes approaches to symptom control as well as management of terminal patients close to death. Palliative care,
end-of-life care, and hospice care are important components of the care of patients with advanced COPD.
End-of-life care should also include discussions with patients and their families about their views on resuscitation,
TE
U
advance directives and place of death preferences.(690) At an individual level, prediction of 6-month survival in people
IB
with COPD is unreliable and therefore early discussion of these issues is important together with phased introduction
TR
IS
of supportive care.(691) Hospitalization may be a trigger to initiate discussion of advance care planning. Patients and
D
their families live with uncertainty about the timing of death and fear of death will result from worsening dyspnea and
T
O
suffocation.(692) Good advance care planning can reduce anxiety for patients and their families by talking about death
N
O
and dying and offering emotional support. It can also ensure that care is consistent with their wishes and avoids
-D
unnecessary, unwanted and costly invasive approaches.(693,694)

L
IA
ER
For patients with very advanced or terminal illness, hospice services may provide additional benefit. Hospice services
AT
often focus on patients with severe disability or symptom burden and may provide these services within the patient’s
M
T
home or in hospice beds in dedicated hospice units or other institutions such as hospitals or nursing homes.
H
IG
Organizations such as the National Hospice and Palliative Care Organization(695) provide guidance for selecting patients
R
PY
with non-cancer diseases like COPD for access to hospice services (for example, disabling dyspnea at rest that is poorly
O
responsive to bronchodilators and progression of advanced disease demonstrated by increasing hospitalizations or

C
emergency department visits).(659,660) These guidelines discuss the difficulties in accurately predicting the prognosis of
patients with advanced COPD, but recognize the appropriateness of providing hospice services for some of these
patients.(658)
Therapeutic interventions that reduce COPD mortality

COPD is the third leading cause of death worldwide, causing 3.23 million deaths in 2019. As we move towards targeting
subgroups of COPD patients for specific therapy, it is important to know which modifiable factors (treatable traits) are
associated with mortality. A large clinical database study of COPD in primary care has demonstrated that the highest
magnitude of risk of all-cause mortality, COPD- and CVD-related mortality, was in individuals with increased severity
and frequency of COPD exacerbations, GOLD groups B and D, and those with lower FEV1 (particularly GOLD 3 and
4).(696) We are still learning about the mechanisms that cause death in patients with COPD. Demonstrating benefits of
therapeutic modalities on mortality in RCTs has been difficult, requiring large populations and/or long follow-up
duration and/or highly selected populations with a high but preventable risk of death during follow-up. In addition,
the low number of events makes the analysis of disease specific mortality (e.g., respiratory or cardiovascular) in most
trials difficult. Figure 3.17 presents a summary of pharmacological and non-pharmacological therapies with evidence
of efficacy in reducing the mortality of COPD patients.
Pharmacological therapy
Previous studies such as the TORCH clinical trial(697) and the SUMMIT trial(698) failed to provide evidence for the efficacy
of a LABA+ICS combination compared to placebo in reducing mortality (primary outcome) in COPD patients. These
trials had no requirement for a history of previous exacerbations. In the largest LAMA treatment trial UPLIFT, the
intention to treat analysis, i.e., 30 days after completion of the study period, did not demonstrate a reduction in
mortality (secondary outcome) compared to placebo. The majority of patients included in this study utilized an ICS.
Recently, evidence has emerged from two large randomized clinical trials, IMPACT(448) and ETHOS,(566) that fixed-dose
inhaled triple combinations (LABA+LAMA+ICS), reduce all-cause mortality compared to dual inhaled long-acting
bronchodilation therapy. These trials were enriched for symptomatic patients (CAT ≥ 10) with a history of frequent (≥
2 moderate exacerbations) and/or severe exacerbations (≥ 1 exacerbation requiring a hospital admission) (Figure
3.17).
TE
U
IB
TR
IS
D
T
O
N
O
-D
L
IA
ER
AT
M
T
H
IG
R
PY
O
C
Non-pharmacological therapy
Smoking cessation. From the Lung Health Study, a randomized clinical trial (RCT) that included asymptomatic or mildly
symptomatic COPD patients treated with a 10-week smoking cessation intervention program and followed up to 14.5
years, the overall mortality rate was reduced in the smoking cessation intervention group compared to the usual care
group.(699)
Pulmonary rehabilitation (PR). A systematic review of RCTs reported a reduction in mortality for patients who had PR
initiated during hospitalization or 4 weeks after discharge compared to those who did not have PR.(700-703) These results
have been corroborated by real-world evidence, from a large population-based cohort of 190,000 patients hospitalized
for COPD, in whom initiation of PR within 90 days of discharge, while rare, was associated with a statistically significant
reduced mortality.(704)
Long term oxygen therapy (LTOT). Survival benefit of LTOT in COPD demonstrated in two studies in the early 1980s
laid the foundation for long-term domiciliary management of hypoxemia. The Nocturnal Oxygen Therapy Trial
(NOTT)(≥ 19 hours of continuous oxygen compared to ≤ 13 hours)(705) and the Medical Research Council (MRC)(≥ 15
hours compared to no oxygen),(706) two RCTs in COPD patients with resting PaO2 ≤ 55 mmHg or < 60 mmHg with cor
pulmonale or secondary polycythemia showed a survival benefit. No significant benefit of LTOT was found in patients
with moderate desaturation.(707)
TE
U
IB
Non-invasive positive pressure ventilation (NPPV). Recent meta-analyses(643,708) have shown positive results of long-
TR
term NPPV in patients with stable COPD. Although RCT results have being inconsistent on survival, larger trials with
IS
D
mortality as the primary outcome, enrolling patients with marked hypercapnia and applying higher IPAP levels
T
demonstrated a reduction of mortality.(648,709)

O
N
O
-D
Lung transplantation and lung volume reduction surgery (LVRS). Because of the absence of randomized trials,
L
observational data has been used to estimate the survival benefit of lung transplantation, relative to remaining
IA
ER
“untransplanted.” The survival benefit of transplantation varied by disease group, with a 2-year expected benefit in
AT
2/5 of transplanted COPD patients.(710)

M
T
H
LVRS has been shown to prolong survival compared to medical therapy in a very select group of patients with severe
IG
R
COPD, predominantly upper lobe emphysema, and low exercise capacity.(289) Among patients with non-upper-lobe
PY
emphysema and high exercise capacity, mortality was higher in the surgery group than in the medical-therapy group.
O
C
In summary, available data suggest that several pharmacological and non-pharmacological treatments may reduce
mortality. Further analyses or studies may help to determine whether specific patient subgroups demonstrate a
greater survival benefit.
Overview of the evidence: Pharmacotherapy

Pharmacotherapies for smoking cessation
Pharmacological treatments for smoking cessation include controller medications aimed at achieving long-term
abstinence (nicotine patch, bupropion, and varenicline) and those that rapidly relieve acute withdrawal symptoms
(short-acting nicotine).
Nicotine replacement products

Nicotine replacement therapy (nicotine gum, inhaler, nasal spray, transdermal patch, sublingual tablet, or lozenge)
reliably increases long-term smoking abstinence rates(533,535,537,711,712) and is significantly more effective than placebo.
Nicotine replacement therapy often causes irritation at the site through which it is administered, and can cause non-
ischemic chest pain and palpitations, therefore medical contraindications to nicotine replacement therapy include
recent myocardial infarction or stroke.(537,713,714) The contraindication to nicotine replacement therapy after acute
coronary syndrome remains unclear and the evidence suggests that this treatment can and should be started > 2
weeks after a cardiovascular event.(715) Continuous chewing of nicotine gum produces secretions that are swallowed
rather than absorbed through the buccal mucosa resulting in little absorption and potentially causing nausea.
Vaping/E-cigarettes
There is a perception that vaping with electronic cigarettes (e-cigarettes, vapes) is safer than smoking and therefore
an effective nicotine replacement therapy for smoking cessation. The efficacy of vaping with regard to smoking
cessation remains controversial.(716-720) E-cigarettes provide a vaporized and doseable method of nicotine inhalation
and have increased in usage as an alternative to cigarettes for those wishing to quit, but also as a rising trend in
younger individuals who have never smoked. E-cigarettes may contain not only nicotine but also other chemicals, such
as vegetable glycine, propylene glycol, various flavoring agents, volatile carbonyls, diacetyl, reactive oxygen species,
furones and metals. The long-term health effects in general smokers, but more importantly in high-risk populations
such as COPD, are largely unknown.
What is known has been reported mainly as individual, or series of, case reports of the acute effects of e-cigarettes,
TE
including vaping-associated lung injury. Severe acute lung injury, eosinophilic pneumonia, alveolar hemorrhage,
U
IB
respiratory bronchiolitis and other forms of lung abnormalities have been reportedly linked to e-cigarette use, and
TR
occasionally death.(721-724) The U.S. Centers for Disease Control (CDC), the U.S. Food and Drug Administration (FDA),
IS
D
state and other clinical and public health partners investigated an outbreak of e-cigarette, or vaping, product use-
T
associated lung injury (EVALI). By February 2020, a total of 2,807 cases of lung illness and 68 deaths had been
O
N
associated with using e-cigarette products (devices, liquids, refill pods, and/or cartridges).(724) Patients were reported
O
-D
to have had clinical improvement with systemic glucocorticoid therapy and the majority received prolonged
L
courses.(723) Laboratory data showed that vitamin E acetate, an additive in some THC-containing e-cigarettes, was
IA
ER
strongly linked to the EVALI outbreak.(725) Following the identification of vitamin E acetate as a primary cause of EVALI
AT
there was a decline in new cases.

M
T
H
Neutrophilic inflammation of the airways, airways irritability, ciliary paresis and increased mucus hypersecretion are
IG
R
seen in animal models and in vitro human airway studies and are similar to changes induced by cigarette smoke and
PY
recognised features of COPD.(726-730) These data are summarized in a review by Gotts and colleagues,(731) although it is
O
C
likely to be many years before the long-term risks of vaping, including risks of cancer, are clarified, particularly in
people with COPD and/or whether vaping is an independent risk factor for developing COPD.(721-724) In a large
prospective cohort study, an increased risk of respiratory disease among former and current e-cigarette users was
observed even when adjusted for cigarette and other combustible tobacco product use, demographic characteristics,
and chronic health conditions.(732) There is additional evidence that in older adults at risk of or with COPD, e-cigarette
users have greater nicotine dependence, poorer lung-related health outcomes (more chronic bronchitis and
exacerbations), and are less likely to reduce or quit smoking conventional cigarettes.(733)
A meta-analysis of five RCTs has suggested that e-cigarettes are superior to nicotine replacement therapy for achieving
6 months continuous abstinence from smoking tobacco.(734) Nevertheless, based on the available evidence and the
lack of knowledge about the long-term effects of e-cigarettes on respiratory health, it is not possible to recommend
this intervention for smoking cessation in patients with COPD.
Pharmacological products
Results of a meta-analysis comparing simple controller pharmacotherapy (nicotine replacement therapy, bupropion,
nortriptyline and varenicline) with placebo in smokers with COPD showed that all pharmacotherapy groups (except
nortriptyline) increased the chances of smoking cessation compared with placebo.(527) Prolonged abstinence rates in
the pharmacotherapy groups ranged from 14% to 27%, and in the placebo group from 5% to 9%.(527)
A study in patients with COPD showed higher continuous abstinence rates during weeks 9 to 24 with varenicline
(58.3%) and bupropion (55.6%) compared with nicotine patch (38.2%).(735) Varenicline and bupropion showed similar
efficacy, however, the group receiving varenicline compared with bupropion smoked more cigarettes per day.(735)
Pharmacotherapy to treat stable COPD

Pharmacotherapy for COPD is currently focused on symptoms and exacerbations. FEV1 decline has been considered a
surrogate for the natural course of the disease. In this context, studies have been performed to evaluate if
pharmacotherapy may have an impact on the change of FEV1 over time. Individual clinical trials have not been
sufficiently conclusive to show that pharmacotherapy can reduce the rate of FEV1 decline.(736-740) However, a
systematic review combining data from 9 studies demonstrated a reduction in the rate of FEV1 decline of 5.0 mL/year
in active treatment arms compared with placebo arms.(741) The difference between long-acting bronchodilator
containing treatment arms and placebo arms was 4.9 mL/year. The difference between inhaled corticosteroid
containing treatment arms and placebo arms was 7.3 mL/year. Although we need to be aware of the potential benefit
of pharmacotherapy in reducing the rate of lung function decline, further research is needed to know which patients
are likely to benefit.
TE
U
IB
The classes of medications commonly used to treat COPD are shown in Figure 3.18. The choice within each class
TR
depends on the availability and cost of medication, and the clinical response balanced against side effects. Each
D
IS
treatment regimen needs to be individualized as the relationship between severity of symptoms, airflow obstruction,
T
O
and severity of exacerbations can differ between patients. The WHO has defined a minimum set of interventions for
N
O
the management of stable COPD in primary care.(742)

-D
L
Bronchodilators
IA
ER
AT
Bronchodilators are medications that increase FEV1 and/or change other spirometric variables (Figure 3.19). They act
M
by altering airway smooth muscle tone and the improvements in expiratory flow reflect widening of the airways rather
T
H
than changes in lung elastic recoil. Bronchodilators tend to reduce dynamic hyperinflation at rest and during
IG
exercise,(282,743) and improve exercise performance. The extent of these changes, especially in patients with severe and
R
PY
very severe COPD, is not easy to predict from the improvement in FEV1 measured at rest.(744,745)
O
C
Bronchodilator dose-response (FEV1 change) curves are relatively flat with all classes of bronchodilators.(746-752)
Increasing the dose of either a beta2-agonist or an anticholinergic by an order of magnitude, especially when given by
a nebulizer, appears to provide subjective benefit in acute episodes(753) but is not necessarily helpful in stable
disease.(754) Bronchodilator medications in COPD are most often given on a regular basis to prevent or reduce
symptoms. Toxicity is also dose-related (Figure 3.18). Use of short acting bronchodilators on a regular basis is not
generally recommended.
TE
U
IB
TR
IS
D
T
O
N
O
-D
L
IA
ER
AT
M
T
H
IG
R
PY
O
C
TE
U
IB
TR
IS
D
T
O
N
O
-D
L
IA
ER
AT
M
T
H
IG
R
PY
O
C
Beta2-agonists
The principal action of beta2-agonists is to relax airway smooth muscle by stimulating beta2-adrenergic receptors,
which increases cyclic AMP and produces functional antagonism to bronchoconstriction. There are short-acting (SABA)
and long-acting (LABA) beta2-agonists. The effect of SABAs usually wears off within 4 to 6 hours.(748,749) Regular and as-
needed use of SABAs improve FEV1 and symptoms.(755) LABAs show duration of action of 12 or more hours and do not
preclude additional benefit from as-needed SABA therapy.(756)
Formoterol and salmeterol are twice-daily LABAs that significantly improve FEV1 and lung volumes, dyspnea, health
status, exacerbation rate and number of hospitalizations,(757) but have no effect on mortality or rate of decline of lung
function. Indacaterol is a once daily LABA that improves breathlessness,(758,759) health status(759) and exacerbation
rate.(759) Some patients experience cough following the inhalation of indacaterol. Oladaterol and vilanterol are
additional once daily LABAs that improve lung function and symptoms.(760,761)
Adverse effects
Stimulation of beta2-adrenergic receptors can produce resting sinus tachycardia and has the potential to precipitate
cardiac rhythm disturbances in susceptible patients. Exaggerated somatic tremor is troublesome in some older
patients treated with higher doses of beta2-agonists, regardless of route of administration. Although hypokalemia can
occur, especially when treatment is combined with thiazide diuretics,(762) and oxygen consumption can be increased
under resting conditions in patients with chronic heart failure,(763) these metabolic effects decrease over time (i.e.,
show tachyphylaxis). Mild falls in partial pressure of oxygen (PaO2) can occur after administration of both SABAs and
LABAs(764) but the clinical significance of these changes is uncertain. Despite prior concerns related to the use of beta2-
agonists in the management of asthma, no association between beta2-agonist use and loss of lung function or
increased mortality has been reported in COPD.(757,765,766)
Antimuscarinic drugs
Antimuscarinic drugs block the bronchoconstrictor effects of acetylcholine on M3 muscarinic receptors expressed in
airway smooth muscle.(767) Short-acting antimuscarinics (SAMAs), namely ipratropium and oxitropium, also block the
inhibitory neuronal receptor M2, which potentially can cause vagally induced bronchoconstriction.(768) Long-acting
muscarinic antagonists (LAMAs), such as tiotropium, aclidinium, glycopyrronium bromide (also known as
glycopyrrolate), umeclidinium and revefenacin have prolonged binding to M3 muscarinic receptors, with faster
dissociation from M2 muscarinic receptors, thus prolonging the duration of bronchodilator effect.(767)
TE
U
IB
A systematic review of RCTs concluded that ipratropium, a short acting muscarinic antagonist, alone provided small
TR
benefits over short-acting beta2-agonist in terms of lung function, health status and requirement for oral steroids.(769)
D
IS
Among LAMAs, some are administered once a day (tiotropium, umeclidinium, revefenacin), others twice a day
T
O
(aclidinium), and some are approved for once daily dosing in some countries and twice daily dosing in others
N
(glycopyrrolate).(767,770) LAMA treatments improve symptoms, including cough and sputum and health status.(767,771,772)
O
-D
They also improve the effectiveness of pulmonary rehabilitation(773,774) and reduce exacerbations and related
L
IA
hospitalizations.(771) Clinical trials have shown a greater effect on exacerbation rates for LAMA treatment (tiotropium)
ER
versus LABA treatment.(775,776)

AT
M
Adverse effects
T
H
IG
Inhaled anticholinergic drugs are poorly absorbed which limits the troublesome systemic effects observed with
R
PY
atropine.(767,777) Extensive use of this class of agents in a wide range of doses and clinical settings has shown them to
O
be very safe. The main side effect is dryness of mouth.(768,778) Although occasional urinary symptoms have been
C
reported, there are no data to prove a true causal relationship.(779) Some patients using ipratropium report a bitter,
metallic taste. An unexpected small increase in cardiovascular events in COPD patients regularly treated with
ipratropium bromide has been reported.(780,781) In a large, long-term clinical trial in COPD patients, tiotropium added
to other standard therapies had no effect on cardiovascular risk.(740) Although there were some initial concerns
regarding the safety of tiotropium delivery via the Respimat®(782) inhaler, the findings of a large trial observed no
difference in mortality or exacerbation rates when comparing tiotropium in a dry-powder inhaler and the Respimat®
inhaler.(783) There are less safety data available for the other LAMAs, but the rate of anti-cholinergic side effects for
drugs in this class appears to be low and generally similar. Use of solutions with a facemask can precipitate acute
glaucoma, probably as a direct result of the contact between the solution and the eye.(784-786)
Methylxanthines
Controversy remains about the exact effects of xanthine derivatives. They may act as non-selective phosphodiesterase
inhibitors, but have also been reported to have a range of non-bronchodilator actions, the significance of which is
disputed.(787-789) Data on duration of action for conventional, or even slow-release, xanthine preparations are lacking
in COPD.
Theophylline, the most commonly used methylxanthine, is metabolized by cytochrome P450 mixed function oxidases.
Clearance of the drug declines with age. Many other physiological variables and drugs modify theophylline
metabolism. Enhanced inspiratory muscle function has been reported in patients treated with methylxanthines,(787)
but whether this reflects a reduction in gas trapping or a primary effect on the respiratory skeletal muscles is not clear.
All studies that have shown efficacy of theophylline in COPD were performed with sustained-release preparations.
There is evidence for a modest bronchodilator effect compared with placebo in stable COPD.(790) Addition of
theophylline to salmeterol produces a greater improvement in FEV1 and breathlessness than salmeterol alone.(791,792)
Earlier studies reported contradictory evidence regarding the effect of low-dose theophylline on exacerbation
rates.(793,794) A study that investigated the effectiveness of adding low-dose theophylline to ICS in COPD patients at
increased risk of exacerbation showed no difference compared with placebo in the number of COPD exacerbations
over a one-year period.(795) A large placebo-controlled trial showed no effect of oral theophylline alone or in
combination with prednisolone 5 mg daily on exacerbations of severe COPD.(796)
Adverse effects
Toxicity is dose-related, which is a particular problem with xanthine derivatives because their therapeutic ratio is small
and most of the benefit occurs only when near-toxic doses are given.(788,790) Methylxanthines are non-specific inhibitors
of all phosphodiesterase enzyme subsets, which explains their wide range of toxic effects. Problems include atrial and
TE
ventricular arrhythmias (which can prove fatal) and grand mal convulsions (which can occur irrespective of prior
U
IB
epileptic history). Other side effects include headaches, insomnia, nausea, and heartburn, and these may occur within
TR
the therapeutic range of serum levels of theophylline. These medications have significant interactions with commonly
D
IS
used medications such as erythromycin (but not azithromycin), certain quinolone antibiotics (ciprofloxacin, but not
T
O
ofloxacin), allopurinol, cimetidine (but not ranitidine), serotonin uptake inhibitors (fluvoxamine) and the 5-
N
lipoxygenase inhibitor zileuton.

O
-D
L
Combination bronchodilator therapy

IA
ER
Combining bronchodilators with different mechanisms and durations of action may increase the degree of
AT
M
bronchodilation with a lower risk of side-effects compared to increasing the dose of a single bronchodilator.(797,798)
T
Combinations of SABAs and SAMAs are superior compared to either medication alone in improving FEV1 and
H
IG
symptoms.(799) Treatment with formoterol and tiotropium in separate inhalers has a bigger impact on FEV1 than either
R
PY
component alone.(800) There are numerous combinations of a LABA and LAMA in a single inhaler available (Figure 3.18).
O
These combinations improve lung function compared to placebo;(797) this improvement is consistently greater than
C
long acting bronchodilator monotherapy effects although the magnitude of improvement is less than the fully additive
effect predicted by the individual component responses.(801) Single inhalers improve adherence to treatment.(802) In
studies where patient reported outcomes (PROs) are the primary endpoint or in pooled analyses, combination
bronchodilators have a greater impact on PROs compared to monotherapies.(803-806) In one clinical trial, combination
LABA+LAMA treatment had the greatest improvement in quality of life compared to placebo or its individual
bronchodilator components in patients with a greater baseline symptom burden.(807) A clinical trial showed that
LABA+LAMA improved lung function and symptoms versus long-acting bronchodilator monotherapy in symptomatic
patients with low exacerbation risk and not receiving inhaled corticosteroids.(562) The LABA+LAMA combination
demonstrated favorable improvements compared with the monotherapies for the majority of outcomes irrespective
of baseline HRQoL.(808) These clinical trials deal with group mean data, but symptom responses to LABA+LAMA
combinations are best evaluated on an individual patient basis. A lower dose, twice daily regimen for a LABA+LAMA
has also been shown to improve symptoms and health status in COPD patients(809) (Figure 3.19). These findings have
been shown in people across different ethnic groups (Asian as well as European).(810)
Most studies with LABA+LAMA combinations have been performed in patients with a low rate of exacerbations. One
study in patients with a history of exacerbations indicated that a combination of long-acting bronchodilators is more
effective than long-acting bronchodilator monotherapy for preventing exacerbations.(811) Another large study found
that combining a LABA with a LAMA did not reduce exacerbation rate as much as expected compared with a LAMA
alone.(812) Another study in patients with a history of exacerbations showed that a combination LABA+LAMA decreased
exacerbations to a greater extent than an LABA+ICS combination.(813) However, another study in a population with
high exacerbation risk (≥ 2 exacerbations and/or 1 hospitalization in the previous year) reported that LABA+ICS
decreased exacerbations to a greater extent than a LABA+LAMA combination at higher blood eosinophil
concentrations.(448) A large observational pharmaco-epidemiological study found similar effectiveness of LABA+LAMA
and LABA+ICS but a significantly higher risk of pneumonia in those treated with LABA+ICS.(814)
Anti-inflammatory agents
To date, exacerbations (e.g., exacerbation rate, patients with at least one exacerbation, time-to-first exacerbation)
represent the main clinically relevant end-point used for efficacy assessment of drugs with anti-inflammatory effects
(Figure 3.20).
TE
U
IB
TR
IS
D
T
O
N
O
-D
L
IA
ER
AT
M
T
H
IG
R
PY
O
C
TE
U
IB
TR
IS
D
T
O
N
O
-D
L
IA
ER
AT
M
T
H
IG
R
PY
O
C
Inhaled corticosteroids (ICS)
General considerations
In vitro evidence suggests that COPD-associated inflammation has limited responsiveness to corticosteroids.
Moreover, some drugs including beta2-agonists, theophylline or macrolides may partially facilitate corticosteroid
sensitivity in COPD.(815,816) The clinical relevance of this effect has not yet been fully established.
In vivo data suggest that the dose-response relationships and long-term (> 3 years) safety of ICS in people with COPD
are unclear and require further investigation.(813) Because the effects of ICS in COPD can be modulated by the
concomitant use of long-acting bronchodilators, these two therapeutic options are discussed separately.
Both current and ex-smokers with COPD benefit from ICS use in terms of lung function and exacerbation rates,
although the magnitude of the effect is lower in heavy or current smokers compared to light or ex-smokers. (448,817)
Efficacy of ICS (alone)

Most studies have found that regular treatment with ICS alone does not modify the long-term decline of FEV1 nor
mortality in people with COPD.(818) Studies and meta-analyses assessing the effect of regular treatment with ICS alone
on mortality in people with COPD have not provided conclusive evidence of benefit.(818) In the TORCH trial, a trend
TE
toward higher mortality was observed for patients treated with fluticasone propionate alone compared to those
U
IB
receiving placebo or salmeterol plus fluticasone propionate combination.(697) However, an increase in mortality was
TR
not observed in COPD patients treated with fluticasone furoate in the Survival in Chronic Obstructive Pulmonary
IS
Disease with Heightened Cardiovascular Risk (SUMMIT) trial.(819) In moderate COPD, fluticasone furoate alone or in
D
T
combination with vilanterol was associated with slower decline in FEV1 compared with placebo or vilanterol alone by
O
N
on average 9 mL/year.(820) A number of studies have investigated whether there is a relationship between ICS
O
-D
treatment and risk of lung cancer with conflicting results.(821)

L
IA
ER
ICS in combination with long-acting bronchodilator therapy

AT
In patients with moderate to very severe COPD and exacerbations, an ICS combined with a LABA is more effective than
M
either component alone in improving lung function, health status and reducing exacerbations.(822,823) Clinical trials
T
H
powered on all-cause mortality as the primary outcome failed to demonstrate a statistically significant effect of
IG
R
combination therapy on survival.(697,819)

PY
O
C
Most studies that found a beneficial effect of a LABA+ICS fixed dose combination (FDC) over a LABA alone on
exacerbation rate, recruited patients with a history of at least one exacerbation in the previous year.(822) A pragmatic
RCT conducted in a primary healthcare setting in the United Kingdom compared a LABA+ICS combination with usual
care. Findings showed an 8.4% reduction in moderate-to-severe exacerbations (primary outcome) and a significant
improvement in CAT™ score, with no difference in the rate of healthcare contacts or pneumonias. However, basing
recommendations on these results is difficult because of the heterogeneity of treatments reported in the usual care
group, the higher rate of treatment changes in the group receiving the LABA+ICS combination of interest, and the
medical practice patterns unique to the UK region where the study was conducted.(824)
TE
U
IB
TR
IS
D
T
O
N
O
-D
L
IA
ER
AT
M
T
Blood eosinophil count

H
IG
A number of studies have shown that blood eosinophil counts predict the magnitude of the effect of ICS (added on
R
PY
top of regular maintenance bronchodilator treatment) in preventing future exacerbations.(443-448) There is a continuous
O
relationship between blood eosinophil counts and ICS effects; no and/or small effects are observed at lower eosinophil
C
counts, with incrementally increasing effects observed at higher eosinophil counts.(453) Data modeling indicates that
ICS containing regimens have little or no effect at a blood eosinophil count < 100 cells/µL,(443) therefore this threshold
can be used to identify patients with a low likelihood of treatment benefit with ICS. In addition, lower blood and
sputum eosinophils are associated with greater presence of proteobacteria,(825-827) notably haemophilus, and increased
bacterial infections and pneumonia.(828) Lower blood eosinophil counts therefore may identify individuals with
microbiome profiles associated with increased risk of clinical worsenings due to pathogenic bacterial species. The
threshold of a blood eosinophil count ≥ 300 cells/µL identifies the top of the continuous relationship between
eosinophils and ICS, and can be used to identify patients with the greatest likelihood of treatment benefit with ICS.
Sources of evidence include: 1) Post-hoc analyses comparing LABA+ICS versus LABA(443,444,446); 2) Pre-specified analyses
comparing triple therapy versus LABA+LAMA or LAMA(445,447,448); and 3) other analyses comparing LABA+ICS versus
LABA+LAMA(829) or studying ICS withdrawal.(573,574,830)
The treatment effect of ICS containing regimens (LABA+LAMA+ICS and LABA+ICS vs LABA+LAMA) is higher in patients
with high exacerbation risk (≥ 2 exacerbations and / or 1 hospitalization in the previous year). (445,448,813) Thus, the use
of blood eosinophil counts to predict ICS effects should always be combined with clinical assessment of exacerbation
risk (as indicated by the previous history of exacerbations). Other factors (smoking status, ethnicity, geographical
location) could influence the relationship between ICS effect and blood eosinophil count but remains to be further
explored.
Factors to consider when initiating ICS treatment in combination with one or two long-acting bronchodilators are
shown in Figure 3.21.(519)
Adverse effects
There is high quality evidence from RCTs that ICS use modifies the airway microbiome(831) and is associated with higher
prevalence of oral candidiasis, hoarse voice, skin bruising and pneumonia.(818) This excess risk has been confirmed in
ICS studies using fluticasone furoate, even at low doses.(832) Patients at higher risk of pneumonia include those who
currently smoke, are aged ≥ 55 years, have a history of prior exacerbations or pneumonia, a body mass index (BMI) <
25 kg/m2, a poor MRC dyspnea grade and/or severe airflow obstruction.(833,834) Independent of ICS use, there is
evidence that a blood eosinophil count < 2% increases the risk of developing pneumonia.(835) In studies of patients with
moderate COPD, ICS by itself or in combination with a LABA did not increase the risk of pneumonia.(819,834)
Results from RCTs have yielded varied results regarding the risk of decreased bone density and fractures with ICS
treatment, which may be due to differences in study designs and/or differences between ICS compounds.(738,832,836-838)
TE
Results of observational studies suggest that ICS treatment could also be associated with increased risk of
U
IB
diabetes/poor control of diabetes,(839) cataracts,(840) and mycobacterial infection.(841) An increased risk of tuberculosis
TR
has been found in both observational studies and a meta-analysis of RCTs.(842-844) In the absence of RCT data on these
IS
D
issues, it is not possible to draw firm conclusions.(845) ICS and lung cancer incidence is discussed in Chapter 5.
T
O
N
Withdrawal of ICS
O
-D
Results from withdrawal studies provide equivocal results regarding consequences of withdrawal on lung function,
L
IA
symptoms and exacerbations.(846-850) Some studies have shown an increase in exacerbations and/or symptoms
ER
following ICS withdrawal, while others have not. There has been evidence for a modest decrease in FEV1
AT
(approximately 40 mL) with ICS withdrawal,(850) which could be associated with increased baseline circulating
M
eosinophil numbers.(830) A study examining ICS withdrawal on a background of dual bronchodilator therapy
T
H
IG
demonstrated that both FEV1 loss and an increase in exacerbation frequency associated with ICS withdrawal was
R
greatest among patients with a blood eosinophil count ≥ 300 cells/µL at baseline.(573) Differences between studies may
PY
relate to differences in methodology, including the use of background long-acting bronchodilator medication(s) which
O
C
may minimize any effect of ICS withdrawal.
Triple therapy (LABA+LAMA+ICS)

The step up in inhaled treatment to LABA plus LAMA plus ICS (triple therapy) can occur by various approaches(851) and
has been shown to improve lung function, patient reported outcomes and reduce exacerbations when compared to
LAMA alone, LABA+LAMA and LABA+ICS.(445,447,448,852-859) A post-hoc analysis of one of the RCTs that evaluated the
effects of LABA+LAMA+ICS showed that triple therapy improved clinical outcomes versus dual therapy regardless of
smoking status.(860)
A post-hoc pooled analysis of three triple therapy clinical trials in COPD patients with severe airflow obstruction and a
history of exacerbations showed a non-significant trend for lower mortality (assessed as a safety outcome) with triple
inhaled therapy compared to non-ICS based treatments.(861) Two large one-year randomized controlled trials (named
IMPACT and ETHOS) were reviewed earlier in Chapter 3 (see ‘Therapeutic interventions that reduce COPD mortality’)
and provide new evidence on mortality reduction with fixed-dose inhaled triple combinations compared to dual
bronchodilation.(566,862)
Oral glucocorticoids
Oral glucocorticoids have numerous side effects, including steroid myopathy(863) which can contribute to muscle
weakness, decreased functionality, and respiratory failure in people with very severe COPD. Systemic glucocorticoids
for treating acute exacerbations in hospitalized patients, or during emergency department visits, have been shown to
reduce the rate of treatment failure, the rate of relapse and to improve lung function and breathlessness.(864)
Conversely, prospective studies on the long-term effects of oral glucocorticoids in stable COPD are limited.(865,866)
Therefore, while oral glucocorticoids play a role in the acute management of exacerbations, they have no role in the
chronic daily treatment in COPD because of a lack of benefit balanced against a high rate of systemic complications.
Phosphodiesterase-4 (PDE4) inhibitor

The principal action of PDE4 inhibitors is to reduce inflammation by inhibiting the breakdown of intracellular cyclic
AMP.(867) Roflumilast is a once daily oral medication with no direct bronchodilator activity. Roflumilast reduces
moderate and severe exacerbations treated with systemic corticosteroids in patients with chronic bronchitis, severe
to very severe COPD, and a history of exacerbations.(868) The effects on lung function are also seen when roflumilast is
added to long-acting bronchodilators,(869) and in patients who are not controlled on fixed-dose LABA+ICS
combinations.(568) The beneficial effects of roflumilast have been reported to be greater in patients with a prior history
of hospitalization for an acute exacerbation.(570,572) There has been no study directly comparing roflumilast with an
TE
inhaled corticosteroid.
U
IB
TR
Adverse effects D
IS
Roflumilast has more adverse effects than inhaled medications for COPD.(870) The most frequent are diarrhea, nausea,
T
O
reduced appetite, weight loss, abdominal pain, sleep disturbance, and headache. Adverse effects have led to increased
N
withdrawal rates from clinical trials. Adverse effects seem to occur early during treatment, are reversible, and diminish
O
-D
over time with continued treatment. In controlled studies an average unexplained weight loss of 2 kg has been seen
L
and weight monitoring during treatment is advised, in addition to avoiding roflumilast treatment in underweight
IA
ER
patients. Roflumilast should also be used with caution in patients with depression.
AT
M
Antibiotics
T
H
IG
In older studies prophylactic, continuous use of antibiotics had no effect on the frequency of exacerbations in
R
PY
COPD(871,872) and a study that examined the efficacy of chemoprophylaxis undertaken in winter months over a period
O
of 5 years concluded that there was no benefit.(873) Later studies have shown that regular use of some antibiotics may
C
reduce exacerbation rate.(874,875)
Azithromycin (250 mg/day or 500 mg three times per week) or erythromycin (250 mg two times per day) for one year
in patients prone to exacerbations reduced the risk of exacerbations compared to usual care.(571,876,877) Azithromycin
use was associated with an increased incidence of bacterial resistance, prolongation of QTc interval, and impaired
hearing tests.(571) A post-hoc analysis suggests lesser benefit in active smokers.(572) There are no data showing the
efficacy or safety of chronic azithromycin treatment to prevent COPD exacerbations beyond one-year of treatment.
Pulse therapy with moxifloxacin (400 mg/day for 5 days every 8 weeks) in patients with chronic bronchitis and frequent
exacerbations had no beneficial effect on the exacerbation rate overall.(878) Long-term doxycycline did not reduce
exacerbations, although there may be responder subgroups.(879)
Mucolytic (mucokinetics, mucoregulators) and antioxidant agents (N-acetylcysteine,

carbocysteine, erdosteine)
In COPD patients not receiving ICS, regular treatment with mucolytics such as carbocysteine and N-acetylcysteine
(NAC) may reduce exacerbations and modestly improve health status.(880-883) In contrast, it has been shown that
erdosteine may have a significant effect on (mild) exacerbations irrespective of concurrent treatment with ICS. Due to
the heterogeneity of studied populations, treatment dosing and concomitant treatments, currently available data do
not allow precise identification of the potential target population for antioxidant agents in COPD.(884)
Other drugs with potential to reduce exacerbations

Four large phase 3 studies have investigated the efficacy of the anti-IL-5 monoclonal antibody mepolizumab(885) and
the anti-IL-5 receptor- antibody benralizumab(886) in patients with severe COPD, recurrent exacerbations and
peripheral blood evidence of eosinophilic inflammation despite high intensity inhaled therapy. The studies showed a
15% to 20% reduction in the rate of severe exacerbations but the effect was not always statistically significant, and it
was variable between studies and doses. There was no effect on FEV1 or quality of life scores and no consistent
relationship between the response to treatment and the peripheral blood eosinophil count. A post-hoc analysis of the
mepolizumab trial showed greater benefit and more clear evidence of a blood eosinophil related treatment effect
against oral corticosteroid treated exacerbations raising the possibility that this treatment might find a role in a highly
selected subgroup of patients with eosinophilic COPD and frequent requirement for oral corticosteroids. Further
studies are required to investigate this possibility.
A RCT showed that treatment with the humanized anti-IL-4 receptor alpha monoclonal antibody dupilumab reduced
TE
exacerbations and improved FEV1 as well as symptoms and health-related quality of life in patients with COPD, chronic
U
IB
bronchitis, a baseline blood eosinophil count ≥ 300 cells/µL, and a relevant exacerbation history. These findings are
TR
potentially important and clinical practice changing but require confirmation in further studies.(887)
IS
D
T
O
Nedocromil and leukotriene modifiers have not been tested adequately in COPD patients and the available evidence
N
O
does not support their use. (888,889)

-D
L
IA
There was no evidence of benefit, and some evidence of harm, including malignancy and pneumonia, following
ER
treatment with an anti-TNF-alpha antibody (infliximab) in moderate to severe COPD.(890)

AT
M
T
A recent Cochrane meta-analysis did not show sufficient evidence to support the use of immunostimulants.(891)
H
IG
R
An RCT of the selective β1 receptor blocker metoprolol in patients with moderate or severe COPD, who did not have
PY
O
an established indication for beta-blocker use, showed it did not delay the time until the first COPD exacerbation
C
compared to the placebo group and hospitalization for exacerbation was more common among the patients treated
with metoprolol.(892) There is no evidence that beta-blockers should be used in people with COPD who do not have a
cardiovascular indication for their use.
Simvastatin did not prevent exacerbations in people with COPD who had no metabolic or cardiovascular indication for
statin treatment.(893) An association between statin use and improved outcomes (including decreased exacerbations
and mortality) has been reported in observational studies of people with COPD who received them for cardiovascular
and metabolic indications.(894)
There is no evidence that supplementation with vitamin D has a positive impact on exacerbations in unselected
patients.(895) In a meta-analysis vitamin D supplementation reduced exacerbation rates in patients with low baseline
vitamin D levels,(896) but a more recent study has shown no effect.(897)
Adherence to inhaled COPD medications
Adherence is defined as the process by which a person takes their medication as prescribed by a healthcare
provider.(898) Adherence to therapy is a challenging issue in any chronic condition including COPD.
Non-adherence to COPD medication has been associated with poor symptom control, increased risk of exacerbation,
increased healthcare utilization and costs, decreased health-related quality of life and higher mortality risk.(899-909)
Although inhaled therapy is a key component in the management of COPD, the adherence to inhaled medication is
generally low, even in very severe disease. One systematic review(910) reported non-adherence rates to COPD
medication of 22% to 93%, with over half of the included studies reporting non-adherence in > 50% of subjects.(910)
Most studies included were conducted in high-income countries and many used pharmacy claims data to assess
adherence.(910) Self-reported non-adherence to COPD medication varies between 28% and 74% (mean 50.9%) in high
income countries(901,910,911) and between 46% and 93% (mean 61.7%) in low- and middle-income countries (LMICs).(912-
915) However, when compared with data obtained through electronic monitoring, studies have consistently
demonstrated that self-reports are inaccurate as people generally over-report medication use.(916,917)
TE
Adherence is a complex concept, influenced by multiple factors including social/environmental, person-related and
U
treatment-related factors.(918) Several studies have explored the variables associated with medication adherence in
IB
TR
people with COPD.(910,912) Factors such as the presence of co-morbidities, in particular depression, smoking status,
IS
schooling level, disease severity, and drug regimen factors such as dosage complexity, polypharmacy and side effects
D
of therapy, are the main factors associated with low adherence.(909,910,912,913,919,920) In addition, socioeconomic factors,
T
O
N
including unemployment, low-income status, immigration status, living alone and poor medication availability(60) have
O
been shown to negatively influence inhaled medication adherence and to be related to the non-use of
-D
medication.(919,921,922)
L
IA
ER
Although patient preferences may vary, prescribing strategies that could help improve adherence often include
AT
M
selecting devices with a similar inhalation technique (in the case of multiple inhalers) and combination therapy. (589,923)
T
H
IG
Healthcare provider and caregiver factors can also contribute to perception of disease, healthcare, medication and
R
PY
ultimately adherence. A better understanding of the disease and drug therapy, as well as greater trust in healthcare
O
professionals and pharmacist-led interventions have been shown to improve COPD medication adherence.(611,910) Self-
C
management education can help a person understand their disease and the benefits of proper use of medication.
Prescribing behavioral components that are tailored to the individual barriers of each person (e.g., keeping
medications in one place, self-monitoring of symptoms, medication reminders, etc) is more effective in changing
behavior than offering general suggestions. A study assessing interventions intended to improve adherence to
pharmacological therapy showed that multi-component interventions with education, motivational or behavioral
components delivered by health professionals may improve adherence.(657) Involving a person in establishing an
individually tailored treatment plan has been shown to improve adherence.(924) Further research on medication
adherence in COPD is needed to gain insight into the effectiveness of different self-management education and health
behavior change strategies.
Other pharmacological treatments
Other pharmacological treatments for COPD are summarized in Figure 3.22.
TE
U
IB
TR
IS
D
T
O
N
O
-D
L
IA
ER
AT
M
T
H
IG
Alpha-1 antitrypsin augmentation therapy

R
PY
The logical approach to minimize the development and progression of lung disease in alpha-1 antitrypsin deficiency
O
(AATD) patients is alpha-1-antitrypsin augmentation. Such therapy has been available in many, though not all,
C
countries since the 1980s. Because AATD is rare, few clinical trials to assess efficacy with conventional spirometric
outcome have been undertaken. However, a wealth of observational studies suggest a reduction in spirometric
progression in treated versus non-treated patients(925) and that this reduction is most effective for patients with FEV1
35% to 49% predicted.(926) Never or ex-smokers with an FEV1 of 35% to 60% predicted have been suggested as those
most suitable for AATD augmentation therapy (Evidence B).
The available clinical trial and registry data have almost exclusively been focussed on patients with the ZZ (ZZ-
AATD/PiZZ) genotype. Risks to other genotypes have not been explored in clinical trials although people with the Z/null
or null/null genotypes have even lower levels of plasma AAT and are usually assessed for augmentation therapy. Other
genotypes are not considered at risk or likely to benefit from augmentation therapy. Recent studies have suggested
an increased risk of developing mild COPD in heterozygotes for the Z gene(106,107) although unlike ZZ neither develop
COPD in the absence of smoking, so smoking cessation is thought to prevent progression and hence augmentation is
not necessary or appropriate.
Studies using sensitive parameters of emphysema progression determined by CT scans have provided evidence for an
effect on preserving lung tissue compared to placebo.(927-929) Based on the last trial the indications for therapy have
been extended to include "those patients with evidence of progressive lung disease despite other optimal therapy."
However, not all patients with AATD develop or persist with rapid spirometric progression especially following smoking
cessation.(930) Since the purpose of augmentation therapy is to preserve lung function and structure it seems logical to
reserve such expensive therapy for those with evidence of continued and rapid progression following smoking
cessation.(930)
The indication for AAT augmentation is emphysema although there are no fixed criteria for diagnosis or confirmation.
The evidence for augmentation therapy efficacy varies according to the outcome studied.(931) Intravenous
augmentation therapy has been recommended for individuals with AATD and an FEV1 ≤ 65% predicted based on
previous observational studies. However, the last study powered on CT scan as an outcome has recommended that all
patients with evidence of progressive lung disease should be considered for those with lung disease related to AATD,
and an FEV1 > 65%. Individual discussion is recommended with consideration of the cost of therapy and lack of
evidence for much benefit.(932) The main limitation for this therapy is the very high cost and lack of availability in many
countries.
Antitussives
The role of antitussives in people with COPD is inconclusive.(933)
TE
Vasodilators
U
IB
Vasodilators have not been properly assessed in COPD patients with severe/disproportionate pulmonary
TR
hypertension. Inhaled nitric oxide can worsen gas exchange because of altered hypoxic regulation of ventilation-
D
IS
perfusion balance and is contraindicated in stable COPD.(934) Studies have shown that sildenafil does not improve the
T
O
results of rehabilitation in people with COPD and moderately increases pulmonary artery pressure.(935) Tadalafil does
N
not appear improve exercise capacity or health status in COPD patients with mild pulmonary hypertension.(936)
O
-D
L
Management of mucus hypersecretion

IA
ER
Treatment goals for patient with chronic bronchitis (CB) include: 1) reducing the overproduction of mucus; 2)
AT
M
decreasing mucus hypersecretion by reducing inflammation; 3) facilitating elimination of mucus by increasing ciliary
T
transport; 4) decreasing mucus viscosity; and 5) facilitating cough mechanisms. Smoking cessation can improve cough
H
IG
by improving mucociliary function and decreasing goblet cell hyperplasia.(937) Smoking cessation may decrease airway
R
PY
injury by limiting immune mechanisms that cause persistent inflammation and abnormal epithelial cell gene
O
expression.(938)
C
Mucus clearance treatments that promote mechanical movement through the airway such as oscillating positive
expiratory pressure (OPEP) therapy may improve mucus mobilization, symptoms and quality of life in people with
COPD who produce sputum daily or most days.(939,940) The use of nebulized hypertonic saline for copious mucus has
been used in obstructive lung disease and cystic fibrosis with beneficial effects. However, in patients with COPD,
current studies are limited, and results are inconsistent (941-945)
Long-acting muscarinic antagonists, predominantly tiotropium and aclidinium, can improve sputum production and
decrease cough in patients with moderate to severe COPD.(946-949) Triple therapy with dual long acting bronchodilators
combined with inhaled steroids may be effective in reducing exacerbations and improving lung function and quality of
life regardless of the presence of mucus hypersecretion.
Use of mucolytics was associated with a reduction of 0.03 exacerbations per participant per month compared with
placebo, that is, about 0.36 per year, or one exacerbation every three years. Very high heterogeneity was noted for
this outcome, so results need to be interpreted with caution.(881) Nevertheless, in participants with chronic bronchitis
or COPD, we are moderately confident that treatment with mucolytics may produce a small reduction in acute
exacerbations and a small effect on overall quality of life.(881) Recombinant human DNase has similarly shown lack of
benefit in mucopurulent patients with COPD.(950,951) New classes of mucolytics agents are being developed.(952) In a
small double-blind placebo-controlled study, patients randomized to receive a CFTR potentiator icenticaftor had
improvements in FEV1 and sputum bacterial colonization compared to placebo.(953) New bronchoscopic interventions
have been proposed to reduce mucus hypersecretion by eliminating airway goblet cell hyperplasia and submucosal
glands. Liquid nitrogen metered cryospray, rheoplasty, and targeted lung denervation are currently under
evaluation.(954-957)
Overview of the evidence: Non-pharmacological therapy

Self-management
A Delphi process has resulted in a conceptual definition for COPD self-management interventions: “A COPD self-
management intervention is structured but personalized and often multi-component, with goals of motivating,
engaging and supporting the patients to positively adapt their health behavior(s) and develop skills to better manage
their disease.”(624) The process requires iterative interactions between patients and healthcare professionals who are
competent in delivering self-management interventions. Behavior change techniques are used to elicit patient
TE
motivation, confidence and competence. Literacy sensitive approaches are used to enhance comprehensibility.(624)
U
IB
TR
Systematic reviews have provided evidence that self-management interventions improve outcomes in COPD. A 2022
IS
D
Cochrane review reported that interventions for people with COPD are associated with improvements in HRQoL, a
T
lower probability of respiratory-related hospital admissions, and no excess respiratory-related and all-cause mortality
O
N
risks.(958) This strengthens the view that self-management interventions are unlikely to cause harm. There had
O
-D
previously been concerns that health benefits from self-management programs in COPD could be counterbalanced by
L
increased mortality.(959,960) However, a previous Cochrane review and another meta-analysis reported no impact of
IA
ER
self-management interventions on overall mortality, and while the Cochrane review did find a small, but statistically
AT
significant, higher respiratory-related mortality rate in the self-management invention group as compared to usual
M
care, the authors of the review stated the results should be interpreted with caution as misclassification in cause of
T
H
death is common, the overall effect was dominated by two studies, and no effect on all-cause mortality was seen in
IG
R
the overall analysis. Furthermore, two independent, well designed studies, the COMET(961) and the PIC-COPD,(962) have
PY
shown the potential for reduction in mortality from integrated case management with self-management interventions.
O
C
The program in these two studies may have promoted earlier appropriate treatment for exacerbations, which could
have prevented some fatal complications. These data, in conjunction with the most recently published Cochrane
review, once again strengthens the view that self-management interventions are unlikely to cause harm.(958)
An RCT has shown that implementation of a comprehensive 3-month program to improve long-term self-management
of patients recently discharged from hospital with COPD exacerbation resulted in nearly two-fold higher rates of COPD-
related hospitalizations and emergency visits over 6 months. These data suggest that self-management strategies in
recently hospitalized patients may lead to increased health care service utilization compared with usual care.(963)
There remain problems with heterogeneity among interventions, consistency of their application, specifics of the
intervention, patient populations, follow-up times and outcome measures that make generalization difficult in real
life. It is also challenging to formulate clear recommendations regarding the most effective form and content of a self-
management intervention in COPD given the range of heterogeneity across studies, and lack of precise definitions of
self-management components (e.g., skills taught) and fidelity measures. The recent conceptual definition should help
redress these deficiencies. For example, in the definition it is mentioned that: “The process requires iterative
interactions between patients and healthcare professionals who are competent in delivering self-management
interventions.” Having proper health coaching is important to improve self-management abilities. In people with
COPD admitted for an exacerbation, a study has reported the positive effect of health coaching, commencing at the
time of hospital discharge, on reducing risk of re-hospitalization and emergency department visits.(964) Furthermore,
this randomized study indicated that health coaching delivered by a respiratory therapist or nurse may improve self-
management abilities as demonstrated by meaningful improvements in Chronic Respiratory Disease Questionnaire
mastery scores.(965)
Integrated care programs

COPD is a complex disease that requires the input of multiple care providers who need to work together closely. In
principle, use of a formal structured program that determines how each component is delivered should make care
more efficient and effective, but the evidence for this is divided. A meta-analysis of 52 studies shows that integrated
disease management probably results in improvement in disease-specific quality of life, exercise capacity, hospital
admissions, and hospital days, although not mortality.(966) In contrast, a large multicenter study in primary care within
an existing well-organized system of care did not confirm this.(967) Besides, delivering integrated interventions by
telemedicine did not show a significant effect.(968,969) The pragmatic conclusion is that well organized care is important,
but there may be no advantage in structuring it tightly into a formalized program. Furthermore, integrated care needs
to be individualized to the stage of the person’s illness and health literacy.
TE
Physical activity
U
IB
TR
Pulmonary rehabilitation, including community and home-based, is an approach with clear evidence of benefits.
IS
However, the challenge is promoting physical activity and maintaining it. There is evidence that physical activity is
D
T
decreased in COPD patients.(970) This leads to a downward spiral of inactivity which predisposes patients to reduced
O
N
quality of life, increased rates of hospitalization and mortality.(971-973) As such, there has been tremendous interest in
O
implementing behavior-targeted interventions with the aim of improving physical activity(974) and these should be
-D
encouraged.(971) Technology-based interventions have the potential to provide convenient and accessible means to
L
IA
enhance exercise self-efficacy, and to educate and motivate people in their efforts to make healthy lifestyle
ER
changes.(975) The use of an internet-mediated intervention may benefit people with COPD with low baseline self-
AT
M
efficacy to increase physical activity.(976) However, most published studies to date provide little guidance, being
T
H
inconsistent in the techniques, and lacking the necessary details (e.g., type, quantity, timing and method of delivery;
IG
tools used; quality-assurance methods) to replicate the study or adapt the interventions for clinical care. One RCT that
R
PY
evaluated the long-term effectiveness of a community-based physical activity coaching intervention in people with
O
COPD exacerbation history showed no benefits in acute care use or survival.(977) Another pedometer-based physical
C
activity interventional study (pedometer alone or pedometer plus a website with feedback) showed an association
between the intervention and reduced risk for acute exacerbations over 12-15 months of follow-up.(978) Non-
pharmacological interventions such as pursed lip breathing and diaphragmatic breathing have also been shown to
improve pulmonary function and increased exercise capacity in patients with COPD.(979)
Exercise training
A meta-analysis of RCTs found that exercise training alone, or with the addition of activity counseling, significantly
improved physical activity levels in COPD patients.(980) A combination of constant load or interval training with strength
training provides better outcomes than either method alone.(981)
Where possible, endurance exercise training to 60-80% of the symptom-limited maximum work or heart rate is
preferred,(982) or to a Borg-rated dyspnea or fatigue score of 4 to 6 (moderate to severe).(983) Endurance training can be
accomplished through either continuous or interval exercise programs. The latter involves the patient doing the same
total work but divided into briefer periods of high-intensity exercise, a useful strategy when performance is limited by
other comorbidities.(984,985)
In some cultures, other alternatives such as Tai Chi practice, emphasizing the use of ‘mind’ or concentration for control
of breathing and circular body movement, has been shown to improve exercise capacity in comparison to usual care
in COPD patients.(986) However from this meta-analysis, the effects of Tai Chi in reducing dyspnea level and improving
quality of life remain inconclusive. Future studies addressing these topics and the most beneficial protocols for Tai Chi
practice are warranted.
Exercise training can be enhanced by optimizing bronchodilators,(774) since both LAMA and LABA have shown reduced
resting and dynamic hyperinflation. These changes contribute to better training effects.(282,987) Adding strength training
to aerobic training is effective in improving strength, but does not improve health status or exercise tolerance. (988)
Upper extremities exercise training improves arm strength and endurance, and results in improved functional capacity
for upper extremity activities.(989) Exercise capacity may also be improved by whole-body vibration training.(990)
Inspiratory muscle training increases strength of inspiratory muscles,(991) but this not consistently translate to better
performance, reduced dyspnea or improved health related quality of life when added to a comprehensive pulmonary
rehabilitation program.(992-994)
Pulmonary rehabilitation
The benefits to COPD patients from pulmonary rehabilitation are considerable (Figure 3.23), and rehabilitation has
TE
been shown to be the most effective therapeutic strategy to improve shortness of breath, health status and exercise
U
IB
tolerance.(995) Pulmonary rehabilitation is appropriate for most people with COPD; improved functional exercise
TR
capacity and health related quality of life have been demonstrated across all grades of COPD severity, although the
D
IS
evidence is especially strong in patients with moderate to severe disease. Even patients with chronic hypercapnic
T
O
failure show benefit.(996,997)

N
O
-D
Exercise-induced oxygen desaturation can be seen in a significant minority of COPD patients and has been associated
L
IA
with impaired quality of life, exacerbation risk, and mortality.(998) A large RCT did not suggest clinical improvement
ER
with long term oxygen therapy for patients without resting hypoxemia but exertional desaturation.(999) During
AT
pulmonary rehabilitation it is common practice to supplement oxygen during exercise training with the aim of
M
T
facilitating higher exercise intensity. There was little support for oxygen supplementation during exercise training for
H
IG
individuals with COPD from a 2007 systematic review,(1000) but most evidence was limited by low study quality. A large
R
RCT,(631) with blinding of participants, trainers and assessors, demonstrated that COPD patients training with either
PY
O
supplemental oxygen or medical air had significantly improved exercise capacity and health-related quality of life; no
C
greater benefit with oxygen was observed. The incidence and severity of adverse events were similar in both groups.
In patients with severe COPD on long-term oxygen therapy (LTOT) in whom exercise training is done with oxygenation
systems, there has been increased interest in using an alternative tool, namely nasally administered mixtures of
humidified air-oxygen blends at flow rates of 20-60 L/min (HFNT). HFNT may reduce respiratory muscle load and
respiratory rate, while increasing expiratory time.(1001) In an RCT, the delivery of HFNT during training sessions, as
compared with usual oxygen, was not associated with a greater improvement in endurance time, the primary
outcome, or in health status.(1002) However, a greater improvement in 6-minute walking distance (6MWD) test was
observed with HFNT. A similar small trial suggested an improved walking distance.(1003) The proportion of patients
reaching the minimal clinically important difference (MCID) in endurance time and 6MWD was also significantly higher
with HFNT. Finally, there was no significant difference between the two therapies in patients’ satisfaction. Further
studies are needed to evaluate the efficacy of this treatment.
TE
U
IB
TR
IS
D
T
O
N
O
-D
L
IA
ER
AT
M
T
H
IG
R
There are data from large RCTs regarding the effectiveness of pulmonary rehabilitation after hospitalization for an
PY
O
acute exacerbation of COPD. A systematic review that included 13 RCTs reported reduced mortality, and number of
C
readmissions among patients who had pulmonary rehabilitation initiated during hospitalization or within 4 weeks of
discharge.(701) Long-term effects on mortality were not statistically significant, but improvements in health-related
quality of life and exercise capacity appeared to be maintained for at least 12 months. These results have been
corroborated by real world evidence, from a large population-based cohort of more than 190,000 patients hospitalized
for COPD in the US, in whom initiation of pulmonary rehabilitation within 90 days of discharge, while rare, was
significantly associated with lower risk of mortality(704) and fewer rehospitalizations at one year.(1004) One study has
reported that initiating pulmonary rehabilitation before the patient’s discharge may compromise survival through
unknown mechanisms.(1005) Pulmonary rehabilitation ranks as one of the most cost-effective treatment strategies.(615)
There are many challenges with pulmonary rehabilitation. Referral of patients who might benefit, uptake and
completion of pulmonary rehabilitation is frequently limited, partly through provider ignorance as well as patients’
lack of awareness of availability or benefits. The recommended length of pulmonary rehabilitation (minimum of 6
weeks) could also be a limitation in many countries due to funding constraints of insurance companies and/or national
health funds. Virtual reality pulmonary rehabilitation could be an alternative combined or not with traditional exercise
training; this may be of particular interest in countries where the length of pulmonary rehabilitation programs is
limited to less than 4 weeks.(1006) Another challenge is encouraging sustained long-term physical activity. Although the
approach may need to be personalized, behavioral lifestyle physical activity intervention has shown promising results
i.e., the potential to decrease sedentarity and increase physical activity in patients with moderate to severe COPD.(1007)
A major barrier to full participation is access, which is particularly limited by geography, culture, finances, transport
and other logistics.(614,656,662,1008)
Pulmonary rehabilitation can be conducted at a range of sites.(614) Community-based and home-based programs have
been shown to be as effective as hospital-based programs in randomized controlled trials,(1009,1010) as long as the
frequency and intensity are equivalent.(1011) In countries where there is economic limitation or those with challenges
because patients live in rural or remote regions, home-based programs that deliver exercise training using a stationary
bicycle(1009) or a walking program(1010) could be considered as alternative to traditional hospital rehabilitation training
programs. There is also evidence that standardized home-based pulmonary rehabilitation programs improve dyspnea
in COPD patients.(1012) However, in real life, traditional pulmonary rehabilitation with supervision remains the standard
of care and first-line option, with home-based exercise likely to be a less effective alternative for people with COPD
who are unable to attend pulmonary rehabilitation.(1013) Another challenge is that the benefits of rehabilitation tend
to wane over time. There is insufficient evidence, with conflicting research findings in the 11 available RCTs, to
recommend continuation of lower intensity or lower frequency exercise programs with the aim of maintaining benefit
long-term. However, if such programs are available they should target health behavior taking into account the
patient’s own preferences, needs and personal goals.(618,1014) Pulmonary rehabilitation may help reduce anxiety and
TE
depression symptoms.(1015)
U
IB
TR
Tele-rehabilitation
IS
D
In- or out-patient pulmonary rehabilitation (PR) in COPD is effective in improving several clinically relevant
T
O
outcomes.(995,1016) There is clear evidence that core components of PR including exercise training combined with
N
O
disease-specific education and self-management interventions(614,995) can benefit almost every COPD patient.(1017-1019)
-D
L
IA
However, there are many challenges encountered in the delivery of PR, which include systemic barriers integral to
ER
some health care systems leading to a scarcity of in-person PR programs and facilities. In many regions, the programs
AT
that do exist tend to be located in urban areas. Hence attending PR is challenging for many COPD patients. Even for
M
T
those patients residing in urban areas, availability of frequent transportation that is required for out-patient PR may
H
IG
still be a challenge.
R
PY
O
Tele-rehabilitation has been proposed as an alternative to the traditional approaches. This has become even more
C
relevant in the COVID-19 pandemic era where in-person PR has not been feasible, and models of delivery had to be
adapted. However, it is important to distinguish between evidence-based tele-rehabilitation models and pandemic-
adapted models. Most of the available evidence regarding tele-rehabilitation has been analyzed in a recent Cochrane
review.(1020)
Across multiple trials performed in groups and individuals with a large variety of tele-rehabilitation delivery platforms
(videoconferencing, telephone only, website with telephone support, mobile application with feedback, centralized
“hub” for people to come together), the reported results suggest that tele-rehabilitation is safe and has similar benefits
to those of center-based PR across a range of outcomes. The evidence-based models from the Cochrane review were
published before the COVID-19 pandemic, and have all included an in-person exercise test at the center prior to
commencement, for the purposes of assessing the full extent of desaturation during exercise training(1021) and
accurately prescribing exercise capacity.(1022)
Promoting physical activity is also central to the recommendations that should be given to every COPD patient
regardless of disease severity. Promoting physical activity using smartphone apps is gaining popularity although at
present data on effectiveness are lacking.(1023)
In the field of tele-rehabilitation, the evidence base is still evolving and best practices are not yet established at this
time due to a lack of: i) standardization of delivery platform, e.g., no one single best mode of tele-rehabilitation
delivery; ii) tests performed remotely allowing for accurate exercise prescription; iii) information on suitable variations
in components and timing of interventions (e.g., no data are available regarding post-exacerbation rehabilitation); and
iv) evidence about duration of benefit (beyond immediate post PR). Furthermore, it is unclear what types of patients
were recruited to these studies or their level of familiarity with the technology used. In order to ensure that PR is
accessible to all, we must understand the barriers that might be unique to tele-rehabilitation.
Nutritional support
In people with COPD, weight loss and malnutrition develop as disease severity progresses and indicates a poor
prognosis. Malnutrition in COPD is associated with impaired lung function, increased hospitalizations, poor exercise
tolerance, worsened quality of life and increased mortality.(334,1024-1028) Malnutrition has been reported in 30-60% of
patients hospitalized with COPD;(1029) up to 50% of people with COPD weigh less than 90% of ideal body weight.(1030)
Weight loss occurs when energy expenditure exceeds energy supply; in people with COPD decreases in appetite and
oral intake often coincide with elevated systemic levels of pro-inflammatory cytokines and the appetite suppressant
hormone, leptin.(1031,1032) The severity of airflow obstruction correlates with the presence of malnutrition(1033) since
ventilator inefficiency increases daily energy requirements.(1034) The imbalance of decreased oral intake and increased
energy expenditure can lead to a negative nitrogen balance and decreases in skeletal muscle mass and function.(1035-
TE
1037)
U
IB
TR
Nutritional repletion in people with COPD should be coupled with optimization of lung function, regular exercise, and
D
IS
improvement of tissue oxygenation. Dietary advice and oral supplementation have been reported to improve body
T
O
weight, quality of life, respiratory muscle strength and 6-minute walk distance.(679,1029) However, nutritional support
N
has not been consistently shown to improve lung function.(679,1038-1040) Multimodality treatment that incorporates
O
-D
rehabilitation with nutritional support and protein supplementation may improve fat free mass, BMI and exercise
L
performance.(1041) Among malnourished, hospitalized people with COPD, a protein enriched supplementation
IA
ER
decreased mortality and improved handgrip strength, body weight and nutritional biomarkers 90 days post hospital
AT
discharge.(1042)
M
T
H
IG
R
PY
O
C
INTERVENTIONAL & SURGICAL THERAPIES FOR COPD
COPD is associated with airway and lung parenchyma structural changes that provide potential targets for
interventional and surgical treatments to alleviate dyspnea, reduce cough and mucous production, and improve
quality of life (Figure 3.24).
TE
U
IB
TR
IS
D
T
O
N
O
-D
L
IA
ER
AT
M
T
H
IG
R
PY
O
C
Lung structural related therapies for COPD include airway and emphysematous predominant treatments. Phenotyping
patients with clinical, physiological, and imaging tests is critical to select appropriate candidates and in assessing the
benefits, timing, and type of intervention to be performed. Multidisciplinary collaboration of pulmonology, thoracic
surgery and imaging disciplines are necessary to ensure quality outcomes.
Airway predominant treatments are currently the subject of Phase III clinical trials; emphysematous based treatments
include bullectomy, lung volume reduction surgery, bronchoscopic lung reduction and in select cases, lung
transplantation. Each of these therapies are reviewed below.
Surgical and interventional treatments for patients with emphysema depends upon the severity of patient symptoms
despite optimized medical treatment, the specific structural abnormalities and features of the lung seen on CT imaging,
the presence of pulmonary and non-pulmonary comorbid conditions, physiological assessment, and the balance of
benefits and risks for the individual patient.
Lung surgical treatments for patients with emphysema
Bullectomy
Giant bullectomy is a rare, but effective procedure for surgical resection of bulla that occupies > one-third of a
hemithorax and compresses adjacent viable lung tissue. Reductions in dyspnea, and improvements in lung, respiratory
muscle, and cardiac performance, as well as exercise tolerance have been reported.(1043-1045) Blood or thrombin
instillation may be effective in those unfit for resection.(1046-1048)
Lung volume reduction surgery (LVRS)

Lung hyperinflation is a major contributor to impaired respiratory function and is associated with increased
hospitalization and mortality. Hyperinflation increases the sensation of breathlessness and causes a reduction in
exercise due to increased chest wall elastance and reduced respiratory muscle and cardiac mechanics. Hyperinflation
is most pronounced in those patients with COPD that have an emphysematous predominant phenotype.
With LVRS, the most emphysematous portions of the lungs are resected to reduce hyperinflation, (1049) and increase
lung elastic recoil pressure and density.(1050) The structural changes that result from LVRS can significantly improve
expiratory flow and chest wall, respiratory muscle and cardiac mechanics.(1051,1052) that results in improvements in
FEV1, walking distance and quality of life.(1053-1056) LVRS can be performed unilaterally or bilaterally. In the National
TE
Emphysema Treatment Trial (NETT), a RCT that included severe emphysema patients, bilateral LVRS improved survival
U
in patients with upper-lobe emphysema and low post-rehabilitation exercise capacity.(289) In similar patients with high
IB
TR
post-pulmonary rehabilitation exercise capacity, no difference in survival was noted after LVRS, although health status
IS
and exercise capacity improved. A reinterpretation of the NETT data at 5 years post treatment showed sustained
D
T
improvements in lung function, exercise, shortness of breath and quality of life.(1057)

O
N
O
-D
LVRS has been demonstrated to result in higher mortality than medical management in severe emphysema patients
L
with FEV1 ≤ 20% predicted and either homogeneous emphysema on high resolution computed tomography or a DLco
IA
ER
≤ 20% of predicted.(1058) In addition to a lower DLco, a lower FEV1 and BMI have also been reported to increase
AT
mortality.(1059) Postoperative BODE (body mass index, degree of airflow obstruction, level of dyspnea and exercise
M
capacity) is a predictor of survival following LVRS.(1060) Successful outcomes with LVRS have been reported in select
T
H
patients with severely impaired DLco when hyperinflation is severe, and associated with approachable
IG
emphysematous targets for resection.(1061) Identification of target zones using three-dimensional computed
R
PY
tomographic imaging is beneficial in selecting resectable target zones.(1062) A prospective economic analysis in NETT
O
C
indicated that LVRS is costly relative to healthcare programs that do not include surgery.(1063)
Post NETT, experienced centers have reported substantial physiological and functional improvements with LVRS with
reduced morbidity and mortality.(1064,1065) However, the numbers of patients undergoing LVRS remain low
worldwide.(1065,1066) Several patient factors such as difficulty in obtaining referrals, the perception of increased surgical
complications, and limited continuity of care are reasons why the numbers of patients undergoing LVRS remain low
despite its reported benefits.(1067) Additionally, respiratory physicians are reluctant to refer patients for LVRS because
of the uncertainty about the associated complications, or lack of access to a multidisciplinary team to discuss patient
candidates.(1068) To achieve successful outcomes, a multidisciplinary team is key to select potential LVRS patients and
coordinate postoperative care.(1069)
Lung transplantation
Over 1,000 patients with COPD undergo lung transplantation on an annual basis, about 30.6% of all patients that
undergo transplantation.(1070) Since implementation of the lung allocation severity (LAS) scoring system, the numbers
of patients undergoing lung transplantation for COPD is exceeded by the numbers of patients receiving transplantation
for interstitial lung diseases. Patients with COPD should be referred for consideration of lung transplantation when
they have progressive disease despite maximal medical treatment, are not candidates for lung volume reduction
surgery, have a BODE index of 5 to 6, a PaCO2 > 50 mmHg (6.6 kPa) and/or PaO2 < 60 mmHg (8 kPa) and FEV1 < 25%.(1071)
They should be considered for listing for lung transplantation when the BODE index is > 7, FEV1 is < 15% to 20%, and
they have had three or more severe exacerbations during the previous year, one severe exacerbation with hypercapnic
respiratory failure, or have moderate to severe pulmonary hypertension.(1071) In the last decade, lung transplant has
been increasingly performed in patients of older age, higher BMI, prior chest surgery, poor nutritional status, prior
evidence of chronic infection, cardiovascular disease, or extrapulmonary comorbid conditions.(1072)
Lung transplantation in patients with COPD has been predominately associated with an improvement in quality of life,
not an increase in survival except for COPD patients with severe AATD or those severely impaired with high BODE
scores.(1043,1073-1079) The median survival post lung transplantation for COPD is 5.9 years.(1070) Over 70% of lung
transplants conducted in COPD patients are double lung transplants; the remainder are single lung transplants. (1080)
Bilateral lung transplantation leads to longer survival in patients with COPD especially in those < 60 years of
age.(1081,1082)
Two unique native lung complications have been proposed to account for the superiority of double lung
transplantation in patients with COPD, native lung hyperinflation and lung cancer occurrence in the native
lung.(1083,1084) Lung cancer has been reported to occur in the native lung following single lung transplantation with an
TE
incidence of 5.2-6.1%.(1083,1085) Native lung hyperinflation following single lung transplantation for COPD has been
U
reported to occur 15-30% of the time.(1086,1087) Positive pressure ventilation in a patient with COPD with an overly
IB
TR
compliant native lung coupled with reduced compliance in an edematous allograft may result in native lung
IS
hyperinflation. However, some studies have shown no impact of single lung transplant on post-transplant morbidity,
D
T
and even improved survival following single lung transplantation in patients with COPD.(1086,1088,1089)
O
N
O
-D
In general, lung transplantation has limited availability due to the shortage of donor organs and cost, thus single vs.
L
double lung transplantation is balanced between individual patient factors vs. societal demands to increase the donor
IA
ER
pool for eligible recipients.(1090) The complications most seen in COPD patients after lung transplantation are acute
AT
rejection, bronchiolitis obliterans, opportunistic infections and lymphoproliferative disease.(1091)

M
T
Bronchoscopic interventions in COPD

H
IG
R
► In selected patients with heterogeneous or homogenous emphysema and significant hyperinflation refractory
PY
O
to optimized medical care, surgical or bronchoscopic modes of lung volume reduction (e.g., endobronchial
C
one-way valves, lung coils or thermal ablation) may be considered.(1092) Some of these therapies (vapor
ablation and lung coils) are not widely available for clinical care in many countries.
► In selected patients with a large bulla, surgical bullectomy may be considered.
► In selected patients with very severe COPD and without relevant contraindications, lung transplantation may
be considered.
Bronchoscopic Interventions to reduce hyperinflation in severe emphysema

Due to the morbidity and mortality associated with LVRS, less invasive bronchoscopic approaches to lung reduction
have been examined.(1093) These include a variety of different bronchoscopic procedures to perform lung volume
reduction (i.e., endoscopic lung volume reduction, ELVR) including airway bypass stents, endobronchial one-way
valves (EBV) , self-activating coils, sealants and thermal ablative techniques.(1093) Although these techniques differ
markedly from one another they are similar in their objective to decrease thoracic volume to improve lung, chest wall
and respiratory muscle mechanics.
Choosing bronchoscopic lung reduction (endobronchial valve, coil placement or thermal ablation) or surgical resection
(lung volume reduction surgery, LVRS) to treat hyperinflation in an emphysematous patient depends on a number of
factors. These include: the extent and pattern of emphysema identified on HRCT; the presence of interlobar collateral
ventilation measured by fissure integrity on HRCT or physiological assessment (endoscopic balloon occlusion and flow
assessment); regional availability of the various therapies for clinical care, local proficiency in the performance of the
procedures; and patient and provider preferences. Bronchoscopic techniques depend upon the presence of an intact
fissure between the treated and non-treated lobe for EBV to be successful, but not for the other techniques. Vapor
ablation therapy is the only lung reduction therapy that has been reported to be successfully performed at the
segmental rather than lobar level.(1094) Figure 3.25 provides an overview of the various interventional and surgical
options for patients with emphysema.
TE
U
IB
TR
IS
D
T
O
N
O
-D
L
IA
ER
AT
M
T
H
IG
R
PY
O
C
Endobronchial one-way valves (EBV)

EBV are the most well studied therapy of all the ELVR techniques. RCTs showed significant increases in FEV1 and 6-
minute walk distance as well as health status in subjects selected for the absence of interlobar collateral ventilation
compared to the control group at 6 and 12 months.(291,501) Adverse effects in the endobronchial valve treatment group
in both studies included pneumothorax, valve removal or valve replacement.(501) Pneumothorax was seen in 26.6% of
subjects treated with the endobronchial valve usually within the first 72 hours of the procedure (76%).(291,1095,1096) But
benefits have also been shown in patients with heterogeneous compared to those with homogenous emphysema in
one study.(501)
Early-onset pneumothorax in the EBV treated group likely results from lung structural changes due to acute volume
reduction in the emphysematous targeted lobe by valve therapy that triggers rapid ipsilateral non-targeted lobe
expansion, a recognized indicator of successful target lobe occlusion in patients with intact fissures or absence of
collateral ventilation.(290) Pleural adhesions may also be a contributing factor to the development of a
pneumothorax.(1097) The occurrence of pneumothorax highlights the need for physicians performing this procedure to
have expertise in the management of procedural complications.(290)
After the post-procedural period however, patients treated with EBV compared to usual care tend to have a lower
number of exacerbations and episodes of respiratory failure. A comparison of treatment benefits and complications
associated with EBV compared to LVRS show comparable benefits with endobronchial valve treatment but with fewer
complications.(291) Additionally, ELVR has similar beneficial effects whether it is performed in the upper or lower
lobes.(290,291)
Improved survival has been associated with post procedural atelectasis of the treated lobe post EBV.(1098-1100) Improved
survival has also been reported in patients with severe hyperinflation undergoing EBV compared to a matched
population not undergoing ELVR.(1101)
When preferences for medical treatment for patients with severe emphysema are elicited, the majority chose
treatments with EBV over LVRS or continued medial therapy.(1102) ELVR with EBV is clinically available and approved
for treatment in many countries in the treatment of patients who have intact fissures or lack collateral
TE
ventilation.(291,1103,1104)
U
IB
TR
The following bronchoscopic lung volume reduction techniques do not depend upon the presence of intact fissures or
absence of collateral ventilation.
IS
D
T
O
N
Airway bypass stents

O
-D
Airway bypass stents are transbronchial passages that are created through the walls of the central airways into the
L
emphysematous parenchyma to facilitate the emptying of trapped gas. In a prospective randomized controlled clinical
IA
ER
trial, patients had short term improvements, but no durable improvements were found in lung function, 6 MWD or
AT
quality of life.(1105)
M
T
H
Sealants
IG
R
A multicenter study examining the effects of a lung sealant to create lung reduction was discontinued prematurely;
PY
while the study reported significant benefits in some physiologic parameters, the intervention was associated with
O
C
significant morbidity and mortality.(1106)
Vapor ablation
In a prospective RCT, targeted thermal vapour ablation of more diseased emphysematous segments to produce
fibrosis and atelectasis resulted in clinically meaningful and statistically significant improvements in lung function and
health status at 6 months. COPD exacerbation was the most common serious adverse event. Durability of these
changes was subsequently reported at 12 months follow-up.(1094,1107) This therapy has limited clinical availability.
Self-activating coils
Multicenter trials have examined nitinol coils implanted into the lung compared to usual care on changes in 6-minute
walk distance, lung function and health status in patients with advanced homogenous and heterogeneous
emphysema. Studies reported an increase in 6-minute walk distance with coil treatment compared to control and
smaller improvements in FEV1, and quality of life measured by St George’s Respiratory Questionnaire.(1108-1110) Patients
with baseline residual volume > 200% predicted, emphysema score > 20% low attenuation area, and absence of airway
disease are more likely to have clinically meaningful improvements in lung function and quality of life.(1111)
Major complications included pneumonia, pneumothorax, hemoptysis and COPD exacerbations occurring more
frequently in the coil group.(1109) This therapy has limited clinical availability.
Additional data are needed to define the optimal bronchoscopic lung volume technique to produce bronchoscopic
lung volume reduction in patients who lack fissure integrity, or exhibit collateral ventilation, and to refine the
procedure to reduce complications and improve longer term clinical outcomes.(1109)
Sequential performance of LVRS or ELVR prior to or following lung transplantation

Because COPD is a progressive disease, LVRS or ELVR may be followed by lung transplantation. Conversely, patients
who undergo single lung transplantation may subsequently undergo LVRS or ELVR to treat the hyperinflated native
lung. In hyperinflated patients with advanced emphysema, LVRS or ELVR might be effective treatments to either delay
the need for lung transplantation or optimize the condition of patients who may eventually require lung
transplantation.(1112-1114) In some patients following single lung transplantation, the performance of LVRS or ELVR to
decrease native lung hyperinflation may improve lung function and performance status.(1115-1120) The incidence of
postoperative bleeding requiring re-exploration and renal dysfunction requiring dialysis or the use of extracorporeal
membrane oxygenation (ECMO) may be higher in patients undergoing lung transplantation following LVRS.(1121,1122)
Previous ELVR has been reported to have no impact on morbidity or survival post subsequent lung transplantation but
may affect microbial colonization.(1122,1123)
TE
U
IB
Airway predominant treatments
TR
Abnormalities that predominantly involve the airways, such as excessive dynamic collapse of the large airways
D
IS
(tracheobronchomalacia) chronic bronchitis and frequent and severe exacerbations not responsive to optimal medical
T
O
treatment pose significant clinical challenges.

N
O
-D
Excessive dynamic airway collapse (EDAC)

L
IA
EDAC or tracheobronchomalacia (TBM) is a disorder of the large airways where abnormal collapsibility occurs with
ER
expiration. Commons symptoms are dyspnea, cough and wheezing with inability to expectorate phlegm. In a cross-
AT
sectional analysis of smokers the presence of excessive dynamic airway collapse observed on CT imaging was 5% and
M
associated with worsened quality of life and more frequent and severe exacerbations.(1124) Airway stenting and
T
H
IG
tracheoplasty may be beneficial in select patients.(1125,1126)

R
PY
O
Chronic bronchitis is a common and significant contributor to a worsening of patient’s symptoms of cough and sputum
C
production and cause worsened quality of life and increased mortality. No specific medical intervention significantly
and consistently alleviates chronic bronchitis. Newer interventions have been proposed to reduce mucous
hypersecretion by eliminating airway goblet cell hyperplasia and submucosal glands.
Nitrogen cryospray
Liquid nitrogen metered cryospray is delivered to the central airways and ablates the epithelium to a depth of 0.1 to
0.5 mm.(954) After treatment, rapid regeneration of normal epithelium occurs without scarring and may potentially
treat chronic bronchitis.(1127)
Another novel treatment for chronic bronchitis is rheoplasty.(1128) Rheoplasty delivers short bursts of high frequency
electrical energy to the airway epithelium targeting submucosal tissues and goblet cells to facilitate their replacement
with healthier tissue. Ongoing phase III randomized clinical trials are evaluating the efficacy of these therapies.(1129,1130)
Lung denervation
Targeted lung denervation is another therapy currently undergoing phase III clinical trial study to determine its impact
of frequent moderate or severe exacerbations in patients with COPD already on maximal inhaled respiratory
treatment.(1131,1132) The therapy intends to disrupt the parasympathetic nerve transmission to and from the lungs. In
patients with COPD, basal parasympathetic tone is elevated and increases acetylcholine levels and mucus production
and airway contraction. The treatment uses a water-cooled catheter with radiofrequency energy to disrupt
parasympathetic nerve transmission while protecting the airway surface.(956,957,1132,1133)
Key points for interventional therapy in stable COPD are summarized in Figure 3.26.
TE
U
IB
TR
IS
D
T
O
N
O
-D
L
IA
ER
AT
M
T
H
IG
R
PY
O
C
Surgery in the COPD patient

General surgery
Postoperative pulmonary complications are as important and common as postoperative cardiac complications and,
consequently, are a key component of the increased risk posed by general surgery in COPD patients.(1134) The key
factors that can contribute to the risk include smoking, poor general health status, age, obesity, and COPD severity. A
comprehensive definition of postoperative pulmonary complications should include only major pulmonary respiratory
complications, namely lung infections, atelectasis and/or increased airflow obstruction, which all potentially result in
acute respiratory failure and aggravation of COPD.(1135-1137)
Increased risk of postoperative pulmonary complications in COPD patients may vary with the severity of COPD,
although the surgical site is the most important predictor and risk increases as the incision approaches the
diaphragm.(1137) Most reports conclude that epidural or spinal anesthesia have a lower risk than general anesthesia,
although the results are not totally uniform. Some studies conducted in patients undergoing sham bronchoscopic
procedures have reported acute exacerbation rates as high as 8.4%.(1105) These data suggest that intubation and/or
simple airway manipulation may increase the risk of exacerbation in select COPD patients.
To prevent postoperative pulmonary complications, stable COPD patients clinically symptomatic and/or with limited
exercise capacity should be treated medically intensively before surgery, with all the measures already well established
for stable COPD patients who are not about to have surgery. The presence of comorbid conditions, especially cardiac
abnormalities, should be systemically assessed and treated before any major surgical intervention.
Lung resection
For lung resection, the individual patient’s risk factors should be identified by careful history taking including physical
examination, chest radiography, and pulmonary function tests. Although the value of pulmonary function tests
remains contentious, there is consensus that all COPD candidates for lung resection should undergo a complete
battery of tests, including spirometry with bronchodilator response, static lung volumes, diffusing capacity, and arterial
TE
blood gases at rest.(1138,1139) COPD patients at high risk for surgical complications due to poor lung function should
U
IB
undergo further assessment, for example, tests of regional distribution of perfusion and exercise capacity.(1138,1139)
TR
IS
D
The risk of postoperative complications from lung resection appears to be increased in patients with decreased
T
predicted postoperative pulmonary function (FEV1 or DLco < 30-40% predicted) or exercise capacity (peak VO2 < 10
O
N
ml/kg/min or 35% predicted). The final decision to pursue surgery should be made after discussion with the surgeon,
O
-D
pulmonary specialist, primary clinician, and the patient. Surgery should be postponed if an exacerbation is present.
L
IA
ER
AT
M
T
H
IG
R
PY
O
C
CHAPTER 4: MANAGEMENT OF EXACERBATIONS
KEY POINTS:
 An exacerbation of COPD is defined as an event characterized by dyspnea and/or cough
and sputum that worsen over < 14 days. Exacerbations of COPD are often associated with
increased local and systemic inflammation caused by airway infection, pollution, or other
insults to the lungs.
 As the symptoms are not specific to COPD relevant differential diagnoses should be
considered, particularly pneumonia, congestive heart failure and pulmonary embolism.
 The goals for treatment of COPD exacerbations are to minimize the negative impact of the
current exacerbation and to prevent subsequent events.
 Short-acting inhaled beta2-agonists, with or without short-acting anticholinergics, are

recommended as the initial bronchodilators to treat an exacerbation.
 Maintenance therapy with long-acting bronchodilators should be initiated as soon as
TE
possible. In patients with frequent exacerbations and elevated blood eosinophil levels
U
IB
addition of inhaled corticosteroids to the double bronchodilator regimen should be
TR
considered.
IS
D

T
In patients with severe exacerbations, systemic corticosteroids can improve lung function
O
N
(FEV1), oxygenation and shorten recovery time including hospitalization duration.

O
Duration of therapy should not normally be more than 5 days.

-D
L
 Antibiotics, when indicated, can shorten recovery time, reduce the risk of early relapse,
IA
ER
treatment failure, and hospitalization duration. Duration of therapy should be 5 days.

AT

M
Methylxanthines are not recommended due to increased side effect profiles.

T
H
IG
 Non-invasive mechanical ventilation should be the first mode of ventilation used in COPD
R
patients with acute respiratory failure who have no absolute contraindication because it
PY
improves gas exchange, reduces work of breathing and the need for intubation, decreases
O
C
hospitalization duration and improves survival.
 Exacerbation recovery time varies, taking up to 4-6 weeks to recover, with some patients
failing to return to the pre-exacerbation functional state. Following an exacerbation,
appropriate measures for exacerbation prevention should be initiated (see Chapter 3).
DEFINITION
An exacerbation of chronic obstructive pulmonary disease (ECOPD) is defined as an event characterized by increased
dyspnea and/or cough and sputum that worsens in < 14 days which may be accompanied by tachypnea and/or
tachycardia and is often associated with increased local and systemic inflammation caused by infection, pollution, or
other insult to the airways.(304)
Considerations
Exacerbations of COPD are important events in the management of COPD because they negatively impact health
status, rates of hospitalization and readmission, and disease progression.(435,436) COPD exacerbations are usually
associated with increased airway inflammation, increased mucus production and marked gas trapping. These changes
contribute to increased dyspnea that is the key symptom of an exacerbation. Other symptoms include increased
sputum purulence and volume, together with increased cough and wheeze.(1140,1141) Patients with COPD are at
increased risk of other acute events, particularly decompensated heart failure,(1142,1143) pneumonia,(1144,1145) pulmonary
embolism(1146,1147) that may also mimic or aggravate an ECOPD. Thus, while worsening of dyspnea, particularly if
associated with cough and, purulent sputum, and no other symptoms or signs in a patient with COPD may be diagnosed
as an ECOPD, other patients may have worsening of respiratory symptoms, particularly dyspnea without the classic
characteristics of ECOPD, that should prompt careful consideration and/or search of those potential confounders, or
contributors. In some patients one or more of these diagnoses may contribute to the clinical presentations and should
be addressed appropriately (Figure 4.1).
TE
U
IB
TR
IS
D
T
O
N
O
-D
L
IA
ER
AT
M
T
H
IG
R
PY
O
C
Currently, exacerbations are classified after the event has occurred as:
► Mild (treated with short acting bronchodilators only, SABDs)

► Moderate (treated with SABDs and oral corticosteroids ± antibiotics) or
► Severe (patient requires hospitalization or visits the emergency room). Severe exacerbations may also be
associated with acute respiratory failure.
The current grading of the severity of an ECOPD, based on post facto use of healthcare resources, is a major limitation
of the current definition. Because of global variability in the available resources to treat patients and local customs
affecting the criteria for hospital visits and admissions, there is substantial variability in reported ECOPD outcomes.(1148)
Figure 4.2 shows a proposed clinical approach based on the current best available evidence.(304)
TE
U
IB
TR
IS
D
T
O
N
O
-D
L
IA
ER
AT
M
T
H
IG
R
PY
O
C
It has been proposed that these easy to obtain clinical variables can help define the severity of exacerbations on point
of contact (The ROME Proposal).(304) Using The ROME Proposal for exacerbations, hospitalized patients with acute
exacerbations can be further subclassified into mild, moderate and severe events with differences in mortality.(1149,1150)
Based on a thorough review of the available literature and using a Delphi approach to agree on the variable thresholds,
the severity classification is summarized in Figure 4.3.
In the primary care setting, where laboratories may not be available, severity can be determined with the easily
obtainable dyspnea intensity (using a VAS 0 to 10 dyspnea scale with zero being not short of breath at all and 10 the
worst shortness of breath you have ever experienced), respiratory rate, heart rate and oxygen saturation level. Where
available, blood C-reactive protein (CRP) level is recommended. To determine the need for ventilator support (usually
in the emergency room or hospital setting) arterial blood gases or equivalent should be measured. To move from a
mild to a moderate level, three of the variables need to exceed the established thresholds. It is hoped that prospective
validation will help better define exacerbations and their severity at point of contact, and that documented validation
may confirm or help modify the proposed thresholds of the variables now included. It is proposed that prospective
research can help determine a more specific marker of lung injury than the more generic CRP, as has been true for
other organs acute events.
TE
U
IB
TR
IS
D
T
O
N
O
-D
L
IA
ER
AT
M
T
H
IG
R
PY
O
C
It is now recognized that many exacerbations are not reported to healthcare professionals for therapy and yet these
events, although often shorter in duration, also have a significant impact on health status.(1151,1152) Thus COPD patients
need to receive education about the importance of understanding exacerbation symptoms and when to seek
professional healthcare. The WHO has defined a minimum set of interventions for the management of
exacerbations.(742)
Exacerbations are mainly triggered by respiratory viral infections although bacterial infections and environmental
factors such as ambient air pollution and excess heat may also initiate and/or amplify these events.(1153,1154) Short-term
exposure to fine (PM2.5) and coarse (PM10) particulate matter is associated with increased hospitalizations, ER visits,
and outpatient visits,(1154) as well as increased mortality of COPD exacerbations.(1153,1155,1156) Another study also showed
that short-term exposure to ambient nitrogen dioxide and PM2.5 was associated with exacerbations in mild to
moderate COPD patients.(101) The most common viruses isolated are human rhinovirus (the cause of the common cold),
influenza, para-influenza and metapneumovirus which can be detected for up to a week after an exacerbation
onset.(1157,1158) When associated with viral infections, exacerbations are often more severe, last longer and precipitate
more hospitalizations, as seen during winter. Filamentous fungi, particularly Aspergillus species, may be identified in
sputum samples of patients during moderate or severe exacerbations(1159-1161) although their clinical relevance remains
unclear. Invasive pulmonary aspergillosis is rare (1.3%-3.9%)(1162) and more frequent in patients with more severe
baseline airflow obstruction, recent use of broad spectrum antibiotics or parenteral steroids, and
TE
hypoalbuminemia.(1163) Aspergillus sensitization is also a marker of increased risk of exacerbations.(1164) The diagnostic
U
approach to invasive aspergillosis in this setting remains challenging.(1165)
IB
TR
IS
Exacerbations can be associated with increased sputum production and, if purulent, they are most likely due to
D
T
bacterial infection(1141,1157,1166) There is reasonable evidence to support the concept that eosinophils are increased in
O
N
the airways, lung, and blood in a significant proportion of people with COPD.(1167-1169) The presence of sputum
O
-D
eosinophilia has been related to susceptibility to viral infection.(1166) It has been suggested that exacerbations
L
associated with an increase in sputum or blood eosinophils may be more responsive to systemic steroids(1170) although
IA
ER
more prospective trials are needed to test this hypothesis.(1170)

AT
M
During a COPD exacerbation, increased symptoms are usually present for 7 to 10 days, but some events may last
T
H
longer. At 8 weeks up to 20% of patients will not have recovered to their pre-exacerbation state.(1171) COPD
IG
exacerbations contribute to disease progression,(1172) which is more likely if recovery from exacerbations is slow.(1173)
R
PY
Exacerbations can also cluster in time and once they occur there is increased likelihood of another event(439,1174) (see
O
C
Chapter 2).
Some patients are susceptible to frequent exacerbations (defined as two or more exacerbations per year), and these
patients have worse health status and morbidity than patients with less frequent exacerbations.(436) The exact reason
for an individual’s increased susceptibility to exacerbation symptoms remains largely unknown. However, the
perception of breathlessness is greater in frequent exacerbators than infrequent exacerbators,(489) suggesting that a
perception of breathing difficulty may contribute to precipitating the respiratory symptoms rather than solely
physiological, or causative factors. The strongest predictor of a patient’s future exacerbation frequency remains the
number of exacerbations they have had in the prior year.(439) It is recognized that these patients form a moderately
stable phenotype, although some studies have shown that a significant proportion of patients change their
exacerbation frequency especially with worsening FEV1.(1175)
Other factors that have been associated with an increased risk of acute exacerbations and/or severity of exacerbations
include an increase in the ratio of the pulmonary artery to aorta cross sectional dimension (i.e., ratio > 1),(301) a greater
percentage of emphysema or airway wall thickness(1176) measured by chest CT imaging and the presence of chronic
bronchitis.(169,1177)
Vitamin D has an immune-modulating role and has been implicated in the pathophysiology of exacerbations. As with
many chronic diseases vitamin D levels are lower in COPD than in health. Some, but not all studies have shown that
supplementation in people with severe deficiency results in a 50% reduction in episodes and hospital
admission.(896,1178) Therefore it is recommended that all patients hospitalized for exacerbations should be assessed and
investigated for severe deficiency (< 10 ng/ml or < 25 nM) followed by supplementation if required.
TREATMENT OPTIONS
Treatment setting
The goals of treatment for COPD exacerbations are to minimize the negative impact of the current exacerbation and
prevent the development of subsequent events.(1179) Depending on the severity of an exacerbation and/or the severity
of the underlying disease, an exacerbation can be managed in either the outpatient or inpatient setting. More than
80% of exacerbations are managed on an outpatient basis with pharmacological therapies including bronchodilators,
corticosteroids, and antibiotics.(439,740,1180)
TE
U
IB
TR
IS
D
T
O
N
O
-D
L
IA
ER
AT
M
T
H
IG
R
PY
O
C
The indications for assessing the need for hospitalization during a COPD exacerbation are shown in Figure 4.4. When
patients with a COPD exacerbation come to the emergency department, if hypoxemic they should be provided with
supplemental oxygen and undergo assessment to determine whether the exacerbation is life-threatening and if
increased work of breathing or impaired gas exchange requires consideration for non-invasive ventilation. If so,
healthcare providers should consider admission to an area where proper monitoring and care can be provided. In less
severe cases, the patient may be managed in the emergency department or hospital ward unit. In addition to
pharmacological therapy, hospital management of exacerbations includes respiratory support (oxygen therapy,
ventilation). The management of severe, but not life threatening, exacerbations is outlined in Figure 4.5.
The clinical presentation of COPD exacerbation is heterogeneous, thus we recommend that in hospitalized patients
the severity of the exacerbation should be based on the patient’s clinical signs and recommend the following
classification:(1181)
No respiratory failure: Respiratory rate: ≤ 24 breaths per minute; heart rate < 95 beats per minute, no use of
accessory respiratory muscles; no changes in mental status; hypoxemia improved with supplemental oxygen given via
Venturi mask 24-35% inspired oxygen (FiO2); no increase in PaCO2.
Acute respiratory failure – non-life-threatening: Respiratory rate: > 24 breaths per minute; using accessory
respiratory muscles; no change in mental status; hypoxemia improved with supplemental oxygen via Venturi mask
> 35% FiO2; hypercarbia i.e., PaCO2 increased compared with baseline or elevated 50-60 mmHg.
Acute respiratory failure – life-threatening: Respiratory rate: > 24 breaths per minute; using accessory
respiratory muscles; acute changes in mental status; hypoxemia not improved with supplemental oxygen via Venturi
mask or requiring FiO2 > 40%; hypercarbia i.e., PaCO2 increased compared with baseline or elevated > 60 mmHg or the
presence of acidosis (pH ≤ 7.25).
TE
U
IB
TR
IS
D
T
O
N
O
-D
L
IA
ER
AT
M
T
H
IG
R
PY
O
C
Long-term prognosis following hospitalization for COPD exacerbation is poor, with a five-year mortality rate of about
50%.(1182) Factors independently associated with poor outcome include older age, lower BMI, comorbidities (e.g.,
cardiovascular disease or lung cancer), previous hospitalizations for COPD exacerbations, clinical severity of the index
exacerbation and need for long-term oxygen therapy at discharge.(1183-1185) Patients characterized by a higher
prevalence and severity of respiratory symptoms, poorer quality of life, worse lung function, lower exercise capacity,
lower lung density and thickened bronchial walls on CT-scan are also at increased risk for a higher mortality following
an acute COPD exacerbation.(1186) Mortality risk may be heightened during spells of cold weather.(1187)
An updated Cochrane review concluded that the use of COPD exacerbation action plans with a single short educational
component, in conjunction with ongoing support, reduced in-hospital healthcare utilization. Such educational
interventions were also found to increase the treatment of COPD exacerbations with corticosteroids and
antibiotics.(1188)
Key points for the management of all exacerbations are given in Figure 4.6.
TE
U
IB
TR
IS
D
T
O
N
O
-D
L
IA
ER
AT
M
Pharmacological treatment
T
H
IG
The three classes of medications most commonly used for COPD exacerbations are bronchodilators, corticosteroids,
R
PY
and antibiotics.
O
C
Bronchodilators
Although there is no high-quality evidence from RCTs, it is recommended that short-acting inhaled beta2-agonists, with
or without short-acting anticholinergics, are the initial bronchodilators for acute treatment of a COPD
exacerbation.(1135,1189) A systematic review of the route of delivery of short-acting bronchodilators found no significant
differences in FEV1 between using metered dose inhalers (MDI) (with or without a spacer device) or nebulizers to
deliver the agent,(527,1190) although the latter may be an easier delivery method for sicker patients. It is recommended
that patients do not receive continuous nebulization but use the MDI inhaler one or two puffs every one hour for two
or three doses and then every 2-4 hours based on the patient’s response. Although, there are no clinical studies that
have evaluated the use of inhaled long-acting bronchodilators (either beta2-agonists or anticholinergics or
combinations) with or without ICS during an exacerbation, we recommend continuing these treatments during the
exacerbation or to start these medications as soon as possible before hospital discharge. Intravenous methylxanthines
(theophylline or aminophylline) are not recommended to use in these patients due to significant side effects. (1191,1192)
If a nebulizer is chosen to deliver the bronchodilator agent, air-driven bronchodilator nebulization is preferable to
oxygen-driven in acute exacerbations of COPD in order to avoid the potential risk of increasing the PaCO2 associated
with oxygen-driven bronchodilator administration.(1193)
Glucocorticoids
Data from studies (mostly hospital based) indicate that systemic glucocorticoids in COPD exacerbations shorten
recovery time and improve lung function (FEV1). They also improve oxygenation,(1194-1197) the risk of early relapse,
treatment failure,(1198) and the length of hospitalization.(1194,1196,1199) A dose of 40 mg prednisone-equivalent per day
for 5 days is recommended.(1200) One observational study suggests that longer courses of oral corticosteroids for COPD
exacerbations are associated with an increased risk of pneumonia and mortality.(1201) Therapy with oral prednisolone
is equally effective to intravenous administration.(1202) Nebulized budesonide alone may be a suitable alternative for
treatment of exacerbations in some patients,(1195,1203,1204) and provides similar benefits to intravenous
methylprednisolone, although the choice between these options may depend on local cost issues.(1205,1206) Even short
bursts of corticosteroids are associated with subsequent increased risk of pneumonia, sepsis and death(1207) and use
should be confined to patients with significant exacerbations. Recent studies suggest that glucocorticoids may be less
efficacious to treat acute COPD exacerbations in patients with lower levels of blood eosinophils(439,1167,1170,1208) and
more trials of steroid-sparing treatment regimens are required.
Antibiotics
Although the infectious agents in COPD exacerbations can be viral or bacterial,(1158,1209) the use of antibiotics in
exacerbations remains controversial.(326,1210,1211) The uncertainties originate from studies that did not differentiate
between bronchitis (acute or chronic) and COPD exacerbations, studies without placebo-control, and/or studies
TE
without chest X-rays that do not exclude that patients may have had underlying pneumonia. There is evidence
U
IB
supporting the use of antibiotics in exacerbations when patients have clinical signs of a bacterial infection e.g.,
TR
increased sputum purulence.(326,1211) Indeed the use of observed sputum color can safely modulate antibiotic therapy
D
IS
with no adverse effects if sputum is white or clear in color. On the other hand observed sputum purulence has 94.4%
T
O
sensitivity and 52% specificity for high bacterial load, indicative of a causative relationship.(326)
N
O
-D
A systematic review of placebo-controlled studies has shown that antibiotics reduce the risk of short-term mortality
L
IA
by 77%, treatment failure by 53% and sputum purulence by 44%.(1212) The review provides evidence to treat
ER
moderately or severely ill patients with COPD exacerbations and increased cough and sputum purulence with
AT
antibiotics.(1212,1213) These data are supported by more RCTs in patients with diagnoses of moderate COPD.(1214) In an
M
RCT, the addition of doxycycline to oral corticosteroid an outpatient setting did not prolong time to next
T
H
IG
exacerbation.(1215) In the outpatient setting, sputum cultures are not feasible as they take at least two days and
R
frequently do not give reliable results for technical reasons. Several biomarkers of airway infection are being studied
PY
in exacerbations of COPD that have a better diagnostic profile. Earlier studies of C-reactive protein (CRP) have reported
O
C
contradictory findings.(1216,1217) A randomized trial found a marked reduction in antibiotic prescriptions without
impaired outcomes in UK primary care outpatients with ECOPD in whom antibiotics prescriptions were guided by
point-of-care CRP testing.(1218) Another trial in patients hospitalized for exacerbations of COPD in The Netherlands
found similar results (reduced antibiotic use with no increase in treatment failure). These findings need confirmation
in other settings before a recommendation to generalize this approach. However, data has indicated that antibiotic
usage can be safely reduced from 77.4% to 47.7% when CRP is low.(1219)
Procalcitonin is an acute phase reactant that increases in response to inflammation and infection and has been studied
to determine the use of antibiotics in COPD exacerbations.(1220) The efficacy of this biomarker is controversial. Several
studies, mainly done in the outpatient setting, suggested that procalcitonin-guided antibiotic treatment reduces
antibiotic exposure and side effects with the same clinical efficacy.(1221-1223) A systematic review and meta-analysis on
the use of procalcitonin in hospitalized patients with a COPD exacerbation found no significant reduction in overall
antibiotic exposure.(1224) In patients with COPD exacerbations treated in an ICU setting, the use of a procalcitonin-
based algorithm for initiating or stopping antibiotics was associated with a higher mortality rate when compared to
those receiving standard antibiotic regimens.(1225) Based on these conflicting results we cannot recommend at this
time the use of procalcitonin-based protocols to make the decision on using antibiotics in patient with COPD
exacerbations; however, confirmatory trials with rigorous methodology are required.
In summary, antibiotics should be given to patients with exacerbations of COPD who have three cardinal symptoms:
increase in dyspnea, sputum volume, and sputum purulence; have two of the cardinal symptoms, if increased
purulence of sputum is one of the two symptoms; or require mechanical ventilation (invasive or noninvasive).(1141,1158)
A metanalysis demonstrated that ≤ 5 days of antibiotic treatment had the same clinical and bacteriological efficacy to
longer conventional treatment in outpatients with COPD exacerbations. Furthermore, shorter exposure to antibiotics
may decrease the risk developing antimicrobial resistance and complications associated with this therapy. The
recommended length of antibiotic therapy is 5-7 days.(1226) We recommend a duration of ≤ 5 days of antibiotic
treatment for outpatient treatment of COPD exacerbations.(1225,1227)
The choice of the antibiotic should be based on the local bacterial resistance pattern. Usually, initial empirical
treatment is an aminopenicillin with clavulanic acid, macrolide, tetracycline or, in selected patients, quinolone. In
patients with frequent exacerbations, severe airflow obstruction,(1228,1229) and/or exacerbations requiring mechanical
ventilation,(1230) cultures from sputum or other materials from the lung should be performed, as gram-negative
bacteria (e.g., Pseudomonas species) or resistant pathogens that are not sensitive to the above-mentioned antibiotics
may be present. The route of administration (oral or intravenous) depends on the patient’s ability to eat and the
pharmacokinetics of the antibiotic, although it is preferable that antibiotics be given orally. Improvements in dyspnea
TE
and sputum purulence suggest clinical success.
U
IB
TR
Adjunct therapies
IS
D
Depending on the clinical condition of the patient, an appropriate fluid balance, use of diuretics when clinically
T
indicated, anticoagulants, treatment of comorbidities and nutritional aspects should be considered. Among COPD
O
N
patients hospitalized with a suspected exacerbation, up to 5.9% were found to have pulmonary embolism.(1146)
O
-D
Hospitalized patients with COPD are at an increased risk of deep vein thrombosis and pulmonary embolism(1231,1232)
L
and prophylactic measures for thromboembolism should be instituted.(1233,1234) At all times, healthcare providers
IA
ER
should strongly enforce the need for smoking cessation.

AT
M
Respiratory support
T
H
IG
Oxygen therapy
R
PY
This is a key component of hospital treatment of an exacerbation. Supplemental oxygen should be titrated to improve
O
the patient’s hypoxemia with a target saturation of 88-92%.(1235) Once oxygen is started, blood gases should be checked
C
frequently, or as clinically indicated, to ensure satisfactory oxygenation without carbon dioxide retention and/or
worsening acidosis. Pulse oximetry is not as accurate as arterial blood gas(488) and in particular, may overestimate
blood oxygen content among individuals with darker skin tones.(1236) A study demonstrated that venous blood gas to
assess bicarbonate levels and pH is accurate when compared with arterial blood gas assessment.(1237) Additional data
are needed to clarify the utility of venous blood gas sampling to make clinical decisions in scenarios of acute respiratory
failure; most patients included had a pH > 7.30 on presentation, PCO2 levels were dissimilar when measured by venous
compared to arterial blood samples and the severity of airflow obstruction was not reported.(1237) Venturi masks offer
more accurate and controlled delivery of oxygen than do nasal prongs.(1135)
High-flow nasal therapy

High-flow nasal therapy (HFNT) delivers heated and humidified air-oxygen blends via special devices (e.g.,
Vapotherm®, Comfort Flo®, or Optiflow®) at rates up to 8 L/min in infants and up to 60 L/min in adults.(1238) HFNT has
been associated with decreased respiratory rate and effort, decreased work of breathing, improved gas exchange,
improved lung volume and dynamic compliance, transpulmonary pressures and homogeneity.(1239,1240) These
physiologic benefits positively improve oxygenation and clinical outcomes in patients with acute hypoxemic
respiratory failure.(1239-1242) HFNT has been reported to improve oxygenation and ventilation, decrease hypercarbia and
improve health-related quality of life in patients with acute hypercapnia during an acute exacerbation, and also in
select patients with stable hypercapnic COPD.(1239,1243-1245) However, the small sample sizes, heterogeneity of the
patient populations and short duration of follow-up are current limitations in the interpretation of the value of HFNT
for the COPD patient population at large.(1246) A meta-analysis, based on poor quality studies, showed no clear
benefit.(1247) HFNT has been reported to improve oxygenation and ventilation, decrease hypercarbia, prolong the time
to next moderate exacerbation and improve health-related quality of life scores in patients with acute hypercapnia
during an exacerbation or in select patients with stable hypercapnic COPD receiving long term oxygen therapy.(1248)
HFNT did not prevent intubation in a RCT conducted in patients hospitalized with an acute exacerbation.(1249) It should
be noted that European Respiratory Society (ERS) Clinical Practice Guidelines recommend trialling NIV prior to use of
HFNT in patients with COPD and hypercapnic ARF.(1250) There is a need for well-designed, prospective, randomized and
controlled multicenter trials to study the effects of HFNT in people with COPD experiencing episodes of either acute
or chronic hypercapnic respiratory failure.
Ventilatory support
Some patients need immediate admission to the respiratory care or intensive care unit (ICU) (Figure 4.7). Admission
of patients with severe exacerbations to intermediate or special respiratory care units may be appropriate if adequate
personnel skills and equipment exist to identify and manage acute respiratory failure. Ventilatory support in an
exacerbation can be provided by either noninvasive (nasal or facial mask) or invasive (oro-tracheal tube or
TE
tracheostomy) ventilation. Respiratory stimulants are not recommended for acute respiratory failure.(1189)
U
IB
TR
IS
D
T
O
N
O
-D
L
IA
ER
AT
M
T
H
IG
R
PY
O
C
TE
U
IB
TR
IS
D
T
O
N
O
-D
L
IA
ER
AT
M
T
H
IG
R
PY
Noninvasive mechanical ventilation

O
C
The use of noninvasive mechanical ventilation (NIV) is preferred over invasive ventilation (intubation and positive
pressure ventilation) as the initial mode of ventilation to treat acute respiratory failure in patients hospitalized for
acute exacerbations of COPD. NIV has been studied in RCTs showing a success rate of 80-85%.(641,1251-1254) NIV has been
shown to improve oxygenation and acute respiratory acidosis i.e., NIV increases pH and decreases PaCO2. NIV also
decreases respiratory rate, work of breathing and the severity of breathlessness but also decreases complications such
as ventilator associated pneumonia, and length of hospital stay. More importantly, mortality and intubation rates are
reduced by this intervention.(1252,1255-1257) Once patients improve and can tolerate at least 4 hours of unassisted
breathing, NIV can be directly discontinued without any need for a “weaning” period.(1258) The indications for NIV(1254)
are summarized in Figure 4.8.
Invasive mechanical ventilation

The indications for initiating invasive mechanical ventilation during an exacerbation are shown in Figure 4.9, and
include failure of an initial trial of NIV.(1259) As experience is gained with the generalized clinical use of NIV in COPD, a
number of indications for invasive mechanical ventilation are being successfully treated with NIV, thus eliminating
invasive mechanical ventilation as first line treatment of acute respiratory failure during hospitalization for COPD
exacerbation.(1259) In patients who fail non-invasive ventilation as initial therapy and receive invasive ventilation as
subsequent rescue therapy, morbidity, hospital length of stay and mortality are greater.(641) The use of invasive
ventilation in patients with very severe COPD is influenced by the likely reversibility of the precipitating event, the
patient’s wishes, and the availability of intensive care facilities.(641) When possible, a clear statement of the patient’s
own treatment wishes, such as an advance directive or “living will”, makes these difficult decisions easier to resolve.
Major hazards include the risk of ventilator-acquired pneumonia (especially when multi-resistant organisms are
prevalent), barotrauma and volutrauma, and the risk of tracheostomy and consequential prolonged ventilation.
Acute mortality among COPD patients with respiratory failure is lower than mortality among patients ventilated for
non-COPD causes.(1260) Despite this, there is evidence that patients who might otherwise survive are frequently denied
admission to intensive care for intubation because of unwarranted prognostic pessimism.(1261) A large study of COPD
patients with acute respiratory failure reported in-hospital mortality of 17-49%.(1262) Further deaths were reported
over the next 12 months, particularly among those patients who had poor lung function before invasive ventilation
(FEV1 < 30% predicted), had a non-respiratory comorbidity, or were housebound. Patients who did not have a
previously diagnosed comorbidity, had respiratory failure due to a potentially reversible cause (such as an infection),
or were relatively mobile and not using long-term oxygen, did well after ventilator support.
Hospital discharge and follow-up

The cause, severity, impact, treatment and time course of exacerbations varies from patient to patient and facilities in
TE
the community, and healthcare systems, differ from country to country. Accordingly, there are no standards that can
U
IB
be applied to the timing and nature of discharge. However, it is recognized that recurrent exacerbations leading to
TR
short-term readmission and increased all-cause mortality are associated with the initial hospitalization for an acute
D
IS
episode of deterioration.(1263)
T
O
N
O
When features related to re-hospitalization and mortality have been studied, defects in perceived optimal
-D
management have been identified including spirometric assessment and arterial blood gas analysis.(1264) A systematic
L
IA
review has shown that comorbidities, previous exacerbations and hospitalization, and increased length of stay were
ER
significant risk factors for 30- and 90-day all-cause readmission after an index hospitalization with an exacerbation of
AT
COPD.(1265) Mortality relates to patient age, the presence of acidotic respiratory failure, the need for ventilatory
M
support and comorbidities including anxiety and depression.(1266)

T
H
IG
R
The introduction of care bundles at hospital discharge to include education, optimization of medication, supervision
PY
O
and correction of inhaler technique, assessment and optimal management of comorbidities, early rehabilitation,
C
telemonitoring and continued patient contact have all been investigated to address these issues (Figure 4.10).(1267)
While these measures all seem sensible there is insufficient data that they influence either readmission rates or short-
term mortality(1264,1266,1268,1269) and there is little evidence of cost-effectiveness.(1266) One RCT showed that
telemonitoring did not change hospitalization or exacerbation rates in people with COPD.(1270) Nevertheless, it remains
good clinical practice to cover these issues before discharge and their effectiveness on health status and readmission
rates may be increased if they are delivered with an approach that includes motivational interview-based health
coaching.(964)
TE
U
IB
TR
IS
D
T
O
N
O
-D
L
IA
ER
AT
M
T
The only possible exception is early rehabilitation as there is some evidence that this factor is associated with increased
H
IG
mortality, although the reasons remain unknown.(1269) However, other data suggest that early rehabilitation post
R
PY
hospital discharge (i.e., < 4 weeks) may be associated with improved survival.(702)
O
C
Early follow-up (within one month) following discharge should be undertaken when possible and has been related to
less exacerbation-related readmissions.(1271) There are many patient issues that prevent early follow-up; those not
attending early follow-up have increased 90-day mortality. This may reflect both patient compliance, limited access to
medical care, poor social support, and/or the presence of more severe disease. Nevertheless, early follow-up permits
a careful review of discharge therapy and an opportunity to make any needed changes in therapy.
Additional follow-up at three months is recommended to ensure return to a stable clinical state and permit a review
of the patient’s symptoms, lung function (by spirometry), and where possible the assessment of prognosis using
multiple scoring systems such as BODE.(1272) In addition, arterial oxygen saturation and blood gas assessment will
determine the need for long-term oxygen therapy more accurately at prolonged follow-up compared to shortly after
discharge.(1273)
CT assessment to determine the presence of bronchiectasis and emphysema should be done in patients with recurrent
exacerbations and/or hospitalizations.(483,1274) A further detailed assessment of the presence and management of
comorbidities should also be undertaken (Figure 4.10).(1274)
Prevention of exacerbations
After an acute exacerbation, appropriate measures for prevention of further exacerbations should be initiated (Figure
4.6 and Figure 4.11). For the following treatment modalities significant effects on exacerbation risk/frequency could
be shown in clinical trials. For details refer to Chapter 3.
Based on findings from observational studies in various countries(1275-1278) there was a major decrease in hospital
admissions for COPD exacerbations during the COVID-19 epidemic. It was hypothesized that this phenomenon may be
a consequence of shielding measures (e.g., wearing masks, avoiding social contact, regular hand washing etc). An
alternative explanation is that patients may not have been seeking medical assistance during an exacerbation due to
concern about becoming infected with the SARS-CoV-2 virus. If this was the case, then a corresponding increase in
COPD related mortality would be expected. However, two major studies from the US and the UK(1275,1279) did not report
increased COPD associated mortality during the pandemic. Accordingly, shielding measures could be considered
during the winter months (on top of established pharmacological and non-pharmacological measures) in patients at
risk of exacerbation.
TE
U
IB
TR
IS
D
T
O
N
O
-D
L
IA
ER
AT
M
T
H
IG
R
PY
O
C
CHAPTER 5: COPD AND COMORBIDITIES
KEY POINTS:
 COPD often coexists with other diseases (comorbidities) that may have a significant
impact on disease course.
 In general, the presence of comorbidities should not alter COPD treatment and
comorbidities should be treated per usual standards regardless of the presence of COPD.
 Cardiovascular diseases are common and important comorbidities in COPD.
 Lung cancer is frequently seen in people with COPD and is a major cause of death.
o Annual low-dose CT scan (LDCT) is recommended for lung cancer screening in

people with COPD due to smoking according to recommendations for the general
population
o Annual LDCT is not recommended for lung cancer screening in people with COPD
TE
not due to smoking due to insufficient data to establish benefit over harm
U
IB
TR
 Osteoporosis and depression/anxiety are frequent, important comorbidities in COPD, are
IS
often under-diagnosed, and are associated with poor health status and prognosis.
D
T
O
 Gastroesophageal reflux (GERD) is associated with an increased risk of exacerbations and

N
O
poorer health status.

-D

L
When COPD is part of a multimorbidity care plan, attention should be directed to ensure
IA
ER
simplicity of treatment and to minimize polypharmacy.

AT
M
T
H
IG
R
INTRODUCTION
PY
O
C
COPD often coexists with other diseases (comorbidities) that may have a significant impact on prognosis.(305,462,463,1280-
1284) Some of these arise independently of COPD whereas others may be causally related, either with shared risk factors
or by one disease increasing the risk or compounding the severity of the other. It is possible that features of COPD, are
shared with other diseases and as such this mechanism represents a link between COPD and some of its
comorbidities.(1285,1286) The risk of comorbid disease can be increased by the sequelae of COPD e.g., reduced physical
activity or continued smoking. Whether or not COPD and comorbid diseases are related, management of the COPD
patient must include identification and treatment of its comorbidities. Importantly, comorbidities with symptoms also
associated with COPD may be overlooked e.g., heart failure and lung cancer (breathlessness) or depression (fatigue
and reduced physical activity).
Comorbidities are common at any severity of COPD(168) and the differential diagnosis can often be difficult. For
example, in a patient with both COPD and heart failure, an exacerbation of COPD may be accompanied by worsening
of heart failure or vice versa. Although COPD is negatively impacted by multiple comorbid diseases, COPD itself is one
of the most important comorbid conditions that adversely affects the outcomes of other disorders. For example,
patients with congestive heart failure or those undergoing cardiac procedures such as coronary artery bypass grafting
have greater morbidity and mortality when COPD is present compared to when it is absent.(1287,1288)
Below is a brief guide to the management of some common comorbidities occurring in people with COPD with stable
disease. The recommendations may be insufficient for the management of all COPD patients and are not a substitute
for the use of guidelines for the management of each individual comorbid condition.
Cardiovascular diseases (CVD)

► A large primary care population study in COPD patients with no history of cardiovascular disease found a 25%
increase in the adjusted risk of major adverse cardiac events including acute myocardial infarction, stroke, or
cardiovascular death.(1289)
Heart failure
► The prevalence of systolic or diastolic heart failure in COPD patients ranges from 20% to 70%,(1290) and its annual
incidence is between 3-4%. Incident heart failure is a significant and independent predictor of all-cause mortality.
► Unrecognized heart failure may mimic or accompany acute COPD; 40% of COPD patients that are mechanically
ventilated because of hypercapnic respiratory failure have evidence of left ventricular dysfunction.(1291,1292)
TE
► Treatment with β1-blockers improves survival in heart failure and is recommended in patients with heart failure
U
who also have COPD. Selective β1-blockers should be used, and only used, to treat people with COPD for approved
IB
TR
cardiovascular indications; not solely for the purpose of preventing exacerbations of COPD.(892)
IS
D
► Acute heart failure should be treated according to usual heart failure guidelines since there is no evidence to
T
O
N
support an alternative management strategy. Noninvasive ventilation added to conventional therapy improves
O
-D
outcomes for patients with either hypercapnic respiratory failure due to an exacerbation of COPD as well as heart
failure with acute pulmonary edema.(1293)
L
IA
ER
Ischaemic heart disease (IHD)

AT
M
► Ischaemic heart disease should be considered in all COPD patients depending on their risk factor profile.
T
H
IG
Cardiovascular risk may be assessed by the global risk calculator, which can be found on the US National Heart Blood
R
Lung Institute website(1294) and treatment initiated based on the current recommendations.
PY
O
C
► During, and for at least 90 days after, acute COPD exacerbations there is an increased risk of cardiovascular events
(death, myocardial infarction, stroke, unstable angina, and transient ischemic attack) in patients at high risk of
concomitant IHD.(1295) Hospitalization for an acute COPD exacerbation has been associated with 90-day mortality of
acute myocardial infarction, ischemic stroke, and intracranial hemorrhage.(1296) Patients who demonstrate abnormal
cardiac troponins in isolation are at increased risk of adverse outcomes including short-term (30-day) and long-term
mortality.(1297,1298)
► The treatment of ischaemic heart disease should be according to guidelines irrespective of the presence of COPD
and vice versa.
Arrhythmias
► Cardiac arrhythmias are common in COPD and vice versa.(1299) Atrial fibrillation is frequent and associated with a
lower FEV1.(1300)
► In COPD patients presenting with severe worsening dyspnea, associated atrial fibrillation is frequently documented,
and it may be either a trigger or a consequence of an acute exacerbation episode.(1301)
► The presence of atrial fibrillation does not alter the treatment of COPD. Bronchodilators have been previously
described as potentially pro-arrhythmic agents;(1302,1303) however, available evidence suggests an overall acceptable
safety profile for long-acting beta2-agonists,(1304) anticholinergic drugs (and ICS).(740,783,819,1305-1309) Nevertheless, caution
is advised when using short-acting beta2-agonists(1304,1310) and theophylline, which may precipitate atrial fibrillation
and make control of the ventricular response rate difficult.(1311-1313)
Peripheral vascular disease

► Peripheral artery disease (PAD) is commonly associated with atherosclerotic heart disease and may have significant
implications for functional activity as well as quality of life in people with COPD.(1314)
► In a large cohort of people with COPD of all degrees of severity, 8.8% were diagnosed with PAD that was higher
than the prevalence in non-COPD controls (1.8%).(1314)
► COPD patients with PAD reported a worse functional capacity and worse health status compared to those without
PAD. Clinicians should consider PAD in people with COPD to those at risk for vascular events and to fully understand
their functional impairments.
TE
Hypertension
U
IB
► Hypertension is likely to be the most frequently occurring comorbidity in COPD and may have implications for
TR
prognosis.(1285,1286) Diastolic dysfunction as a result of sub-optimally treated hypertension may be associated with
IS
D
exercise intolerance and mimic symptoms associated with an acute exacerbation thereby provoking hospitalization in
T
O
COPD.(1290) These data stress the importance of optimal blood pressure control in COPD patients with underlying
N
O
hypertension.(1315,1316)
-D
L
IA
► Hypertension should be treated according to usual guidelines. There is no evidence that hypertension should be
ER
treated differently in the presence of COPD. The role of treatment with selective beta-blockers is less prominent in
AT
recent hypertension guidelines and there is no evidence that in people with COPD and increased cardiovascular risk
M
T
cardio-selective beta-blockers either reduce the benefits of treatment with LABA or increase cardiovascular risk.(1317)
H
IG
R
► COPD should be treated as usual as there is no direct evidence that COPD should be treated differently in the
PY
O
presence of hypertension.
C
Lung cancer
Lung cancer is the leading cause of death from malignant disease worldwide, with more deaths from lung cancer than
from colon, breast and prostate cancer together and it causes an estimated 1.6 million deaths worldwide each
year.(1318) Unfortunately, the great majority of lung cancers are diagnosed at an advanced stage, resulting in poor
overall survival.(1319) Therefore, primary, and secondary prevention and early detection are important to improve
survival. There is evidence for an association between COPD and lung cancer that has been systematically confirmed
in several epidemiological and observational cohort studies.(1286,1320-1322) These two diseases appear to share more than
tobacco exposure as their common origin. Genetic susceptibility, epigenetic changes in DNA methylation, local
pulmonary chronic inflammation and abnormal lung repair mechanisms present in COPD are also thought to be the
most important potential contributors to lung cancer development.(1323-1325) Whether the spirometric severity of
airflow obstruction is directly or inversely associated with a greater risk for lung cancer development remains
controversial.(367,1322) The association between lung cancer and degree of emphysema is stronger than that existing
between lung cancer and degree of airflow obstruction and the greatest risk is observed in people with the
combination of emphysema diagnosed by CT and airflow obstruction determined by spirometry.(1326,1327) The best
preventive measure for lung cancer (as it is for COPD) is smoking prevention and in smokers, smoking cessation.(1328)
Several studies involving the use of low-dose chest computed tomography (LDCT) screening have shown improved
survival.(395,396,1329) The United States Preventive Services Task Force (USPSTF) updated its recommendation for lung
cancer screening in 2021.(1330) Their recommendation was based on a systematic review that examined the accuracy
of screening for lung cancer considering the benefits and harms associated with lung cancer screening. USPSTF also
commissioned collaborative modeling studies from the National Cancer Institute (NCI) Cancer Intervention and
surveillance modeling Network (CISNET) to provide the optimal age to begin and end lung cancer screening, the
optimal screening interval, and to assess the relative benefits and harms of different screening strategies. The UPSTF
now recommends annual screening for lung cancer with LDCT in adults aged 50-80 years who have a 20-pack year
smoking history and currently smoke or quit smoking within the past 15 years. They recommend stopping screening
once a person has not smoked for 15 years or develops a health problem that substantially limits life expectancy or
the ability or willingness to have curative lung surgery. Additionally, the CISNET modeling analysis supports screening
at a younger age with a lower smoking burden to address current racial and gender disparities that exist with lung
cancer screening.(1330-1334) In patients with smoking related COPD, annual screening for lung cancer with LDCT should
be conducted in those 50-80 years of age with a 20-pack year smoking history who currently smoke, or who have quit
smoking within the past 15 years. COPD has also been reported to be an independent risk factor for lung cancer
incidence in never smokers.(1335,1336) Risk factors include biomass fuel exposure, second-hand smoke, radon, air
pollution, a family history of lung cancer, and asbestos exposure. Routine annual screening with LDCT has not been
TE
conducted in people with COPD who are never smokers and annual LDCT screening is not currently recommended
U
because the possible harms of screening seem to outweigh the possible benefit of finding early lung cancer.(1337)
IB
TR
IS
Although this recommendation is supported by several major medical societies several important questions remain.
D
T
Several studies have suggested that the yield of CT screening would improve if additional variables such as age,
O
N
smoking history, BMI, presence of airflow obstruction and or emphysema and family history of lung cancer were added
O
-D
to the current screening criteria.(399,1338)

L
IA
ER
The implementation of a screening program, where available, could be useful, but has to be implemented in the
AT
appropriate environment to avoid over diagnosis, greater morbidity and mortality with needless diagnostic procedures
M
for benign abnormalities, anxiety and incomplete follow-up, as has been suggested by studies in primary care.(1339) On
T
H
the other hand, one Danish study showed that being part of a lung cancer screening programme significantly promotes
IG
smoking abstinence(1340) and a review of different studies concluded that smoking cessation during LDCT screening
R
PY
results in improved spirometry as well as a decrease in micronodules seen on the baseline CT, thus beneficially
O
C
affecting lung cancer and COPD.(1328) Smoking cessation interventions as part of CT scan screening programs could be
of use (Figure 5.1).
Inhaled corticosteroids (ICS) and lung cancer incidence
ICS are recommended in selected people with COPD and their potential impact on development of lung cancer has
been the subject of conflicting reports. Several retrospective analyses of large databases or observational cohorts(1341)
have suggested a reduction in lung cancer risk with the use of ICS but confounding factors have not been consistently
controlled for in all studies.(1342-1347) A more pronounced protective effect of ICS was reported in former compared to
current smokers,(1345) those with a concurrent diagnosis of asthma(1347) or, those prescribed a higher dose of ICS.(1346)
A systematic review that included two observational studies and 4 RCTs, reported a protective effect of ICS on lung
cancer risk in the observational studies that used a higher dose of ICS, but no benefit in the RCTs.(1348) An analysis
designed to avoid immortal time bias (839) and an observational study (> 65,000 patients) reported no effect of ICS use
on lung cancer incidence.(1349) In contrast, one database study reported an increased risk of lung cancer in patients
prescribed ICS compared to those not prescribed ICS.(1350) Reports from large prospective RCTs focused on lung
function decline, exacerbation reduction or mortality, conducted in patients with moderate to severe COPD where
cause of death was analyzed using clinical end-point committees reported no difference in cancer deaths in patients
randomized to ICS versus non-ICS use.(448,566,697,740,819,1308)
The conflicting results between observational and RCTs are probably due to differences in the patient populations,
characterization of lung cancer risk, follow-up time (shorter in interventional trials), impact of immortal time bias, and
the rigorousness used to detect lung cancer. Based on the available data ICS do not appear to increase or decrease the
TE
risk of lung cancer pending studies adequately planned to clarify these important questions.
U
IB
TR
Bronchiectasis D
IS
► With increasing use of computed tomography in the assessment of people with COPD, the presence of previously
T
O
unrecognized bronchiectasis is being identified.(1351) The prevalence of bronchiectasis in COPD patients has been
N
O
analyzed in several studies with conflicting results ranging from 20% to 69% (mean prevalence was 54.3%).(323)
-D
L
IA
► Whether this diagnosis based on radiological criteria has the same impact as a clinical diagnosis of bronchiectasis
ER
remains unknown at present. Two systematic reviews and meta-analyses have compared the characteristics of COPD
AT
patients with and without bronchiectasis. The results indicated that people with COPD and comorbid bronchiectasis
M
T
are more often male with a longer smoking history, greater daily sputum production, more frequent exacerbations,
H
IG
poorer lung function, higher level of inflammatory biomarkers, more chronic colonization by potentially pathogenic
R
PY
microorganisms, higher rate of Pseudomonas aeruginosa isolation and increased mortality.(322,323)

O
C
► Bronchiectasis should be treated according to usual guidelines.
► Regarding COPD treatment, some patients may need more aggressive and prolonged antibiotic therapy. ICS may
not be indicated in patients with bacterial colonization or recurrent lower respiratory tract infections.
Obstructive sleep apnea & insomnia

► COPD has an estimated prevalence in U.S. adults of 13.9%(1352,1353) and obstructive sleep apnea (OSA), a sleep
disorder hallmarked by repeated episodes of upper airway closure, affects 9% to 26% of the U.S. adult population.(1354)
► Patients with both COPD and OSA have a worse prognosis compared with either condition alone.(1355) During sleep,
patients with both COPD and OSA suffer more frequent episodes of oxygen desaturation and have more total sleep
time with hypoxemia and hypercapnia than OSA patients without COPD.(1356)
► The apneic events in patients with combined OSA and COPD have more profound hypoxemia and more cardiac
arrhythmias.(1357) Additionally, patients with combined COPD and OSA are more likely to develop daytime pulmonary
hypertension(1358,1359) than patients with just OSA or COPD alone.
► The use of positive pressure ventilation in patients with COPD and OSA has been reported to reduce all- cause
hospitalizations, emergency room visits, moderate and severe exacerbations and associated healthcare costs.(639,1360)
► Insomnia in COPD is associated with higher rates of outpatients’ visits and hospitalizations.(1361)
Periodontitis & dental hygiene

The association between COPD and periodontitis has been noted mainly in the dental literature although whether this
reflects common causative factors such as age, smoking and socioeconomic circumstances remains speculative.
Although both conditions have a common (neutrophilic) relationship whether this reflects cause or effect is difficult
to elucidate.(1362) In a more complete study the data supported shared pathophysiology between periodontitis and
COPD with similar aberrant neutrophil function, especially when associated with alpha-1-antitrypsin deficiency.(1363)
The risk of developing periodontitis increases with the number of emergency room visits for COPD.(1364) High antibody
levels to common periodontal pathogens is associated with less exacerbations of COPD.(1365) In a recent systematic
review low to moderate evidence suggests that periodontal treatment is associated with slower lung function decline,
reduced frequency of exacerbations and less use of healthcare resources in patients with COPD and chronic
periodontitis.(1366) In the absence of an effective curative treatment for COPD it is difficult to prove the reverse is also
TE
true.
U
IB
TR
Nevertheless, periodontitis is common in COPD and often requires treatment in its own right which may lead to a
D
IS
reduction in exacerbations.
T
O
N
Metabolic syndrome and diabetes

O
-D
► Studies have shown that metabolic syndrome and manifest diabetes are more frequent in COPD and the latter is
L
IA
likely to affect prognosis.(462)

ER
AT
M
► Insulin resistance has been associated with increased risk of COPD in women but not in men.(1367)
T
H
IG
► The prevalence of metabolic syndrome has been estimated to be more than 30%.(1368)
R
PY
O
► Diabetes should be treated according to usual guidelines for diabetes. COPD should be treated as usual.
C
Gastroesophageal reflux (GERD)

► GERD is an independent risk factor for exacerbations and is associated with worse health status.(439,1369,1370) The
mechanisms responsible for increased risk of exacerbations are not yet fully established.
► Proton pump inhibitors are often used for treatment of GERD. One small, single-blind study suggested these agents
decrease the risk of exacerbation,(1371) but their value in preventing these events remains controversial most effective
treatment for this condition in COPD has yet to be established.(1372,1373)
Osteoporosis
► Osteoporosis is an important and common comorbidity(463,1285) which is often under-diagnosed(1374) and associated
with poor health status and prognosis.
► Osteoporosis is often associated with emphysema,(1375) decreased body mass index(1376) and low fat-free mass.(1377)
Low bone mineral density and fractures are commonly in COPD patients even after adjustment for steroid use, age,
pack-years of smoking, current smoking, and exacerbations.(1378,1379)
► Osteoporosis should be treated according to usual guidelines.
► COPD should be treated as usual despite the presence of osteoporosis. An association between ICS and fractures
has been found in pharmaco- epidemiological studies; however, these studies have not fully taken severity of COPD
or exacerbations and their treatment into account.
► Systemic corticosteroids significantly increase the risk of osteoporosis and repeated courses for COPD
exacerbations should be avoided if possible
Anemia
Anemia is frequent in people with COPD, with a reported prevalence of 7.5% to 34%.(1380) People with COPD and
anemia are generally older, have more frequent cardiometabolic comorbidities, greater dyspnea, worse quality of life
and airflow obstruction, reduced exercise capacity, an increased risk of severe exacerbations and higher mortality.(1380-
1386)
Anemia due to chronic disease is the most common type seen in COPD, followed by iron deficiency anemia,(1387,1388)
TE
and is mainly related to chronic systemic inflammation and impaired iron utilization. However, other possible
U
IB
reversible factors should be investigated including use of long-term oxygen, theophylline, angiotensin-converting-
TR
enzyme inhibitors, angiotensin II receptor inhibitors, renal dysfunction, and androgens.(1389-1397)
D
IS
T
O
Although anemia has been established as an important comorbidity in COPD, optimal hemoglobin and hematocrit
N
levels in these patients have not yet been defined, and it is also unclear whether its correction alters outcomes.
O
-D
However, hemoglobin assessment is advisable, particularly in more severely affected patients. If anemia is diagnosed,
L
a systematic search for a treatable cause is recommended in accordance with appropriate clinical guidelines.
IA
ER
AT
Polycythemia
M
T
Secondary polycythemia has long been recognized as a common comorbidity in COPD with a reported prevalence of
H
IG
6% to 10.2% in COPD outpatients (when defined as hemoglobin ≥ 17g/dL in males and ≥ 15g/dL in females).(1382,1384,1398)
R
PY
Interestingly, in the COPDGene cohorts 9.2% of men and 3.5% of women had secondary polycythemia.(1399) Although
O
the prevalence of polycythemia in COPD has decreased following the introduction of long-term oxygen therapy
C
(LTOT),(1400) one study reported a prevalence of 8.4% in patients with severe COPD receiving LTOT.(1383)
Data from a large cohort (COPDGene cohort) of individuals with moderate to very severe COPD, indicate that male
sex, current smoking, living at high altitude (e.g., Denver, Colorado, USA), impaired DLco, and severe hypoxemia were
associated with increased risk for secondary polycythemia, whereas, LTOT use was associated with a decreased risk of
polycythemia.(1399) The coexistence of obstructive sleep apnea has also been associated with increased risk of
polycythemia in patients with COPD.(1401) Smoking causes an increase in carboxyhemoglobin, thereby increasing red
blood cell mass and risk of secondary polycythemia in people with COPD.(1402,1403)
Secondary polycythemia in COPD may be associated with pulmonary hypertension,(1404,1405) venous

thromboembolism,(1405) and mortality.(1406,1407) However, these findings should be interpreted with caution, since
secondary polycythemia may be related to the presence of severe uncorrected hypoxemia, which is a predictor of
mortality in COPD, as well as to the presence of concomitant interstitial lung disease or pulmonary vascular disease.
In COPD, if secondary polycythemia is present, a careful evaluation should be performed to determine uncorrected
hypoxemia or to rule out the presence of any comorbidities that require a specific intervention.
Anxiety and depression
► Anxiety and depression are important and underdiagnosed comorbidities in COPD(335,1408-1410) and both are
associated with a poor prognosis,(1409,1411) younger age, female sex, smoking, lower FEV1, cough, higher SGRQ score,
and a history of cardiovascular disease.(42,335,1410)
► There is no evidence that anxiety and depression should be treated differently in the presence of COPD.
► COPD should be treated as usual in patients with psychological disorders. The potential impact of pulmonary
rehabilitation should be stressed as studies have found that physical exercise has a beneficial effect on depression in
general.(1412,1413)
► COPD is very common in patients with other psychiatric illnesses, often under-diagnosed and treated.(1414,1415)
► A systematic review has shown that COPD patients are 1.9 times more likely to commit suicide than people without
COPD.(1416)
► Following a diagnosis of COPD patients are more likely to develop depression and the risk is greater in patients with
worse breathlessness.(1417)
TE
U
IB
Cognitive impairment
TR
IS
► Cognitive impairment (CI) is common in people with COPD.(1418) An average prevalence of 32% has been
D
T
suggested.(1419) The prevalence and severity varies by the type of assessment.(1420) Extensive neuropsychological testing
O
N
suggests that up to 56% of patients may suffer CI.(1421,1422) Longitudinal studies suggest greater risk of developing CI in
O
-D
COPD diagnosed in midlife,(1418,1423) and associate COPD with the development of dementia.(1424)
L
IA
ER
► CI has been reported in patients across the entire range of spirometric severity.(1422)
AT
M
► CI has been associated with impairment in basic activities of daily living,(1425,1426) and variably associated with
T
H
impaired health status.(1427,1428)

IG
R
PY
► The coexistence of CI and COPD has been associated with an increased risk of hospitalization(1429) and increased
O
C
length of stay during acute exacerbation hospitalization.(1430)
► The impact of CI on self-management skills in COPD patients remains unclear,(1425) although inhaler incompetency
has been linked to CI.(1425)
Frailty
► Frailty can be defined as the presence of five components: weakness, slowness, exhaustion, low physical activity,
and unintentional weight loss.(1431)
► In a cohort study, the prevalence of frailty among individuals with COPD was higher than in individuals without
COPD and may help identify people with COPD at risk of poor outcomes.(1432)
► In a meta-analysis it was reported that frailty and prefrailty were associated with all-cause mortality, acute
exacerbation, and hospitalization in patients with COPD.(1433)
► The European Respiratory Society has published a review of current evidence on treating frailty in adults with
chronic respiratory disease and includes clinical management options such as geriatric care, rehabilitation, nutrition,
pharmacological and psychological therapies.(1434)
COPD as part of multimorbidity

► An increasing number of people in any aging population will suffer from multi-morbidity, defined as the presence
of two or more chronic conditions, and COPD is present in most multi-morbid patients.
► Multi-morbid patients have symptoms from multiple diseases and thus symptoms and signs are complex and most
often attributable to several causes in the chronic state as well as during acute events.
► There is no evidence that COPD should be treated differently when part of multi-morbidity; however, it should be
kept in mind that most evidence comes from trials in people with COPD as the only significant disease.(464)
► Treatments should be kept simple in the light of the unbearable polypharmacy that these patients are often
exposed to.
Other considerations
TE
► Consider checking for vitamin D deficiency in COPD patients.
U
IB
TR
IS
D
T
O
N
O
-D
L
IA
ER
AT
M
T
H
IG
R
PY
O
C
CHAPTER 6: COVID-19 AND COPD
KEY POINTS:
 People with COPD presenting with new or worsening respiratory symptoms, fever, and/or
any other symptoms that could be COVID-19 related, even if these are mild, should be
tested for possible infection with SARS-CoV-2.
 Patients should keep taking their oral and inhaled respiratory medications for COPD as
directed.
 During periods of high prevalence of COVID-19 in the community, spirometry should be

restricted to patients requiring urgent or essential tests for the diagnosis of COPD, and/or
to assess lung function status for interventional procedures or surgery.
 Physical distancing and shielding, or sheltering-in-place, should not lead to social isolation
and inactivity. Patients should stay in contact with their friends and families by
telecommunication and continue to keep active. They should also ensure they have
enough medication.
TE
U
IB
 Patients should be encouraged to use reputable resources for medical information
TR
regarding COVID-19 and its management.
IS
D

T
Guidance for remote (phone/virtual/online) COPD patient follow-up and a printable

O
N
checklist are provided.

O
-D
L
IA
ER
AT
INTRODUCTION
M
T
H
IG
For COPD patients the worry of developing COVID-19 as well as the effects of the pandemic on the basic functions of
R
PY
society and/or social services pertaining to their health imposed additional stressors to their condition. The COVID-19
O
pandemic made routine management and diagnosis of COPD more difficult as a result of reductions in face-to-face
C
consultations, difficulties in performing spirometry and limitation in traditional pulmonary rehabilitation and home
care programmes. Patients also faced shortages of medication.(1435) Some health services are still working to catch up.
The dramatic spread of the SARS-CoV-2 virus was accompanied by an enormous number of publications on the virus
and its consequences. Over time knowledge has grown, but the emergence of SARS-CoV-2 variants and the
introduction of vaccines limits the interpretation of studies performed at earlier stages of the pandemic. The
statements made in this chapter utilize the published GOLD approach to data review and are based on the best
assessment of the current evidence.
RISK OF INFECTION WITH SARS-CoV-2

The spike protein of the virus binds to ACE2 (angiotensin-converting enzyme 2) during viral attachment to host cells
and that viral entry is also facilitated by transmembrane protease serine 2 (TMPRSS2).(1436) Differences in the
expression of ACE2 and TMPRSS2 may modulate the individual susceptibility to and clinical course of SARS-CoV-2
infection. ACE2 mRNA expression is increased in COPD,(1437-1439) and further increased in COPD patients with a higher
BMI and more frequent exacerbations.(1440,1441) It may be modulated by ICS use.(1437,1442-1444)
It is still not known definitively whether having COPD affects the risk of becoming infected with SARS-CoV-2. Very few
population studies using random sampling have assessed risk factors for testing positive for SARS-CoV-2, most have
looked at samples of patients referred for testing or presenting with symptoms and very few contain information on
comorbidities. A comprehensive review compared the prevalence of COPD among COVID-19 populations to the
country-specific populations in 16 countries worldwide with high quality data and found no significant differences in
ten countries, a higher prevalence of COPD in 4 and a lower prevalence in two countries.(1445) Most studies of people
in the community tested for SARS-CoV-2 have not shown chronic respiratory disease as an independent risk factor for
testing positive,(1446,1447) although at least one has.(1448)
Many studies reporting the comorbidities of patients admitted to hospital with COVID-19 have suggested a lower
prevalence of COPD than would be expected from population prevalence;(1449-1451) these findings are limited by small
sample sizes and incomplete data on comorbidities. A large study with comprehensive data on comorbidities showed
a high prevalence of COPD among those admitted (19%),(1452) although many patients had multiple comorbidities, and
a further study of a primary care cohort of 8.28 million patients also showed having COPD was an independent risk
factor for hospital admission (HR 1.55; 95%CI 1.46-1.64).(1448) A systematic review, including only high quality studies
from around the world, found that after accounting for confounding variables COPD patients were at slightly higher
TE
risk of hospitalization (adjusted odds ratio (aOR) 1.45; 95% CI 1.30,1.61).(1445)
U
IB
TR
COPD has also been reported to independently increase the risk of severe disease or death in some series(1275,1451-1458)
IS
but not all.(1448,1459-1461) Globally, looking at high quality studies and after accounting for confounding variables, COPD
D
T
patients were found to be at slightly higher risk of ICU admission (aOR 1.28; 95% CI 1.08,1.51), and mortality (aOR
O
N
1.41; 95% CI 1.37,1.65).(1445) In patients with COPD, decreased lung function, higher CAT score, underweight,
O
-D
depression and prior COPD treated in inpatient or secondary care have been shown to be factors predicting severe
L
COVID-19.(1462)
IA
ER
AT
Many factors have been proposed to account for the increased risk for poor outcomes including prior poor adherence
M
to therapy, difficulties performing self-management, limited access to care during the pandemic and a reduced
T
H
pulmonary reserve.(1463,1464) There is evidence of a fall in hospitalization rates for COPD during the pandemic.(1275-
IG
1277,1465) The reasons for this remain unclear, but patients experiencing symptoms of an exacerbation should be
R
PY
evaluated in the usual way during the pandemic and hospitalized if necessary.
O
C
In multivariate analyses pre-existing COPD does not appear to increase the risk of patients developing long term
symptoms post acute COVID.(1466,1467)
There are currently no peer-reviewed studies that have evaluated the effect of smoking on the risk of infection with
SARS-CoV-2, but studies suggest that smoking is associated with increased severity of disease and risk of death in
hospitalized COVID-19 patients.(1468,1469)
In summary, on current evidence, people with COPD do not seem to be at greatly increased risk of infection with SARS-
CoV-2, but this may reflect the effect of protective strategies. They are at an increased risk of hospitalization for
COVID-19 and may be at increased risk of developing severe disease and death.
INVESTIGATIONS
Testing for SARS-CoV-2 infection
People with COPD presenting with respiratory symptoms, fever or other symptoms suggesting SARS-CoV-2 infection,
even if mild, should be tested for possible infection (Figure 6.2). False-negative RT-PCR tests have been reported in
patients with CT findings of COVID-19 who eventually tested positive with serial sampling.(1470) If people with COPD
have been exposed to someone with known COVID-19 infection they should contact their health care provider to
define the need for specific testing. Antibody testing may be used to support clinical assessment of patients who
present late.
Detection of SARS-CoV-2 does not exclude the potential for co-infection with other respiratory pathogens.(1471) The
U.S. Centers for Disease Control and Prevention (CDC) encouraged testing for other causes of respiratory illness, in
addition to testing for SARS-CoV-2 depending on patient age, season, or clinical setting.
Some patients experience re-activation of long-lasting virus carriage or become re-infected, and this might be
influenced by comorbidities or drugs that hamper the immune response.(1472) Repeat testing should be performed in
TE
patients with suspected recurrence or relapse of COVID-19.
U
IB
TR
The lung microbiome is different in people with COPD compared to those without.(1473) The lung microbiome can
IS
modify the immune response to viral infections but, to date there is no direct evidence from human or animal studies
D
on the role of lung microbiome in modifying COVID-19 disease(1474) nor on its potential effects in people with COPD.
T
O
N
O
Spirometry & pulmonary function testing

-D
L
Performing spirometry and pulmonary function testing may lead to SARS-CoV-2 transmission as a result of coughing
IA
ER
and droplet formation during the tests.(1475,1476) During periods of high prevalence of COVID-19 in the community,
AT
spirometry should be restricted to patients requiring urgent or essential tests for the diagnosis of COPD, and/or to
M
assess lung function status for interventional procedures or surgery. The ATS and ERS have provided recommendations
T
H
regarding testing and precautions that should be taken.(1475,1476) Whenever possible, patients should have a RT-PCR
IG
R
test for SARS-CoV-2 performed and the results available prior to performing the test. Patients with a positive RT-PCR
PY
test should normally have the test delayed until negative. As the prevalence of COVID-19 changes over time operating
O
C
procedures should be reassessed and resumption of routine spirometry may be possible.(1477-1479)
When routine spirometry is not available, home measurement of peak expiratory flow (PEF) combined with validated
patient questionnaires could be used to support or refute a possible diagnosis of COPD.(375,1480-1482) However, PEF does
not correlate well with the results of spirometry(1483-1485) has low specificity(343) and cannot differentiate obstructive
and restrictive lung function abnormalities. When making a diagnosis of COPD, airflow obstruction could also be
confirmed by giving patients a personal electronic portable spirometers,(1486,1487) and instructing them in their use and
observing them in their homes using video conferencing technology.
Bronchoscopy
In some people with COPD, diagnostic and therapeutic bronchoscopy may be required. Elective bronchoscopy should
be delayed until patients have a negative PCR test.(1488,1489) In urgent cases where COVID-19 infection status is
unknown, all cases should be managed as if positive. A disposable bronchoscope should be used if available (1488) and
staff should wear PPE.
Radiology
Chest radiography is insensitive in mild or early COVID-19 infection(1490) and is not routinely indicated as a screening
test for COVID-19 in asymptomatic individuals. Chest radiography is indicated in people with COPD with moderate to
severe symptoms of COVID-19 and for those with evidence of worsening respiratory status (Figure 6.1).(1491) COVID-19
pneumonia changes are mostly bilateral.(1492) Chest radiography can be useful for excluding or confirming alternative
diagnoses (e.g., lobar pneumonia, pneumothorax, or pleural effusion). Point-of-care lung ultrasound can also be used
to detect the pulmonary manifestations of COVID-19.(1493)
TE
U
IB
TR
IS
D
T
O
N
O
-D
L
IA
ER
AT
M
T
H
IG
R
Computed tomography (CT) screening may show evidence of pneumonia in asymptomatic individuals infected with
PY
SARS-CoV-2(1494) and false-negative RT-PCR tests have been reported in patients with CT findings of COVID-19 who
O
C
eventually tested positive.(1470) Recommendations have been made on the use of CT as part of diagnostic testing and
severity assessment in COVID-19(1491) and there are no special considerations for people with COPD. The initial features
of COVID-19 on CT and their progression over time have been reviewed.(1495) COPD patients with COVID-19 have an
increased prevalence of ground-glass opacities, local patchy shadowing, and interstitial abnormalities on CT compared
with patients without COPD.(1496) A small case series of patients with emphysema and COVID-19 found that many had
bilateral ground glass opacities with areas of consolidation; however, the pattern was variable and patients had more
pronounced disease in the lung bases.(1497)
The availability of CT may be limited by infection control requirements(1498) and where access to CT is limited, chest
radiography may be preferred for patients with COVID-19 unless features of respiratory worsening warrant the use of
CT. An increased occurrence of deep venous thrombosis and pulmonary thromboembolism has been reported in
patients with COVID-19,(1499-1504) if pulmonary embolism is suspected chest CT angiography should be performed.
PROTECTIVE STRATEGIES FOR PATIENTS WITH COPD
During periods of high prevalence of COVID-19 in the community people with COPD should follow basic infection
control measures to help prevent SARS-CoV-2 infection including social distancing and washing hands which are
associated with reductions in the incidence COVID-19 (Figure 6.1).(1505) Wearing a mask or face covering can reduce
the risk of spreading infection (source control).(1506) The efficacy of masks and respirators in protecting patients against
infection are unknown but both surgical masks and N95 respirators were effective in preventing influenza-like illness
and laboratory-confirmed influenza among healthcare workers.(1507) The American College of Chest Physicians,
American Lung Association, ATS and COPD Foundation have issued a joint statement on the importance of patients
with chronic lung disease wearing facial coverings at times of high COVID-19 prevalence during the pandemic.(1508)
Wearing a tight-fitting N95 mask introduces an additional inspiratory resistance. Respiratory rate, peripheral oxygen
saturation and exhaled CO2 levels were adversely affected in COPD patients wearing a N95 mask for 10 minutes at rest
followed by 6 minutes of walking;(1509) however, wearing a surgical mask does not appear to affect ventilation even in
patients with severe airflow obstruction(1510) and overall the negative effects of using cloth or surgical face masks
during physical activity appear negligible.(1511) In some countries where wearing face masks was compulsory in certain
settings exemptions could be made for patients who are breathless and cannot tolerate wearing a mask; however,
TE
whenever required people with COPD should try to wear masks. In most cases, a looser face covering, or even a face
U
shield may be tolerable and effective.(1512)
IB
TR
IS
The normal rules for patients on LTOT should be followed if air travel is planned,(1513) although patients should avoid
D
travel unless essential. Supplementary oxygen should be delivered by nasal cannula(1514) with a surgical mask be worn
T
O
N
and distancing maintained if appropriate.

O
-D
Shielding, or sheltering-in-place, is a way to protect people who are extremely vulnerable from coming into contact
L
IA
with coronavirus. It is an alternative to full-scale physical distancing measures or lockdowns. It was introduced in
ER
some countries for patients with severe COPD. In the UK COPD patients were advised to shield if they had an FEV1 <
AT
M
50%, mMRC ≥ 3, a history of hospitalization for an exacerbation, or required LTOT or NIV. Modeling suggests shielding
T
was an effective strategy to protect individuals and control the impact of SARS-CoV-2.(1515) If people with COPD are
H
IG
asked to shield it is important that they are given advice about keeping active and exercising as much as possible whilst
R
PY
shielded. Plans should be made to ensure supplies of food, medications, oxygen, supportive health services and other
O
basic necessities can be maintained.

C
There are likely to be particular challenges in using shielding in low- and middle-income countries including the fact
that many families will not be able to designate a separate room for high-risk individuals and may rely on the income
or domestic support that these individuals provide.(1516)
Vaccination
COVID-19 vaccines are highly effective against SARS-CoV-2 infection requiring hospitalization, ICU admission, or an
emergency department or urgent care clinic visit, including those with chronic respiratory disease.(561) People with
COPD should have COVID-19 vaccination in line with national recommendations.
DIFFERENTIATING COVID-19 INFECTION FROM DAILY
SYMPTOMS OF COPD
Differentiating the symptoms of COVID-19 infection from the usual symptoms of COPD can be challenging. Cough and
breathlessness are found in over 60% of patients with COVID-19 but are usually also accompanied by fever (> 60% of
patients) as well as fatigue, confusion, diarrhea, nausea, vomiting, muscle aches and pains, anosmia, dysgeusia and
headaches.(1452)
In COVID-19 symptoms may be mild at first, but rapid deterioration in lung function may occur (Figure 6.2). The
prodrome of milder symptoms is especially problematic in patients with underlying COPD who may already have
diminished lung reserve. Lack of recognition of the prodromal symptoms may delay early diagnosis and preliminary
data suggest that people with COPD reporting exacerbations and suspected of having COVID-19 infection were
infrequently tested for its presence.(1517) A high index of suspicion for COVID-19 needs to be maintained in people with
COPD who present with symptoms of an exacerbations, especially if accompanied by fever, impaired taste or smell or
GI complaints.
TE
Persistent symptoms in people with COPD may cause diagnostic difficulty. A study found that only 65% of people had
U
returned to their previous level of health 14-21 days after testing positive for SARS-CoV-2.(1518) Some patients continue
IB
TR
to experience cough, fatigue and breathlessness for weeks and a smaller proportion for months.(1518-1520) Delayed
IS
recovery was more common in people with multiple chronic medical conditions but was not specifically linked to
D
having COPD.(1518)
T
O
N
O
-D
MAINTENANCE PHARMACOLOGICAL TREATMENT FOR

L
IA
ER
COPD DURING THE COVID-19 PANDEMIC

AT
M
T
H
The use of inhaled and systemic corticosteroids has been controversial in the prevention and treatment of COPD during
IG
the COVID-19 pandemic. ICS have an overall protective effect against exacerbations in COPD patients with a history
R
PY
of exacerbations (Chapter 3). However, there is an increased risk of pneumonia associated with ICS use, raising
O
concerns that immunosuppression with ICS could increase susceptibility to infections in some individuals.
C
Laboratory experiments show that corticosteroids reduce the production of anti-viral interferons (type I and III),
increasing the replication of rhinovirus and influenza virus.(1521-1523) In contrast, other laboratory data show that
corticosteroids and long acting bronchodilators can reduce the replication of coronaviruses including SARS-CoV-2.(1524)
These laboratory experiments suggesting a potential protective effect of ICS against COVID-19 have not been validated
by clinical studies.
A systematic literature review identified no clinical studies in COPD patients concerning the relationship between ICS
use and clinical outcomes with coronavirus infections including COVID-19, SARS and Middle East Respiratory Syndrome
(MERS).(1525) A more recent study has shown ICS use in COPD was not protective and raised the possibility that it
increased the risk of developing COVID-19(1526) but the results are likely to be confounded by the indication for ICS.(1527)
A systematic review of more recent studies found no evidence that ICS use was associated with worse outcomes;(1445)
however the conclusions were again limited by similar confounding, lack of reporting of and adjustment for
comorbidities, and studies with small sample sizes. In people who do not have COPD, ICS use appears to reduce the
risk of admission to hospital or death and reduce the duration of symptoms.(1528) There are no conclusive data to
support alteration of maintenance COPD pharmacological treatment either to reduce the risk of developing COVID-
19, or conversely because of concerns that pharmacological treatment may increase the risk of developing COVID-19.
Similarly, there is no data on the use of long-acting bronchodilators, LAMA or LABA, roflumilast, macrolides in people
with COPD and clinical outcomes/risk of SARS-CoV-2 infection; thus, unless evidence emerges, these patients should
continue these medications required for COPD.
TE
U
IB
TR
IS
D
T
O
N
O
-D
L
IA
ER
AT
M
T
H
IG
R
PY
O
C
Use of nebulizers
Aerosol therapy increases the droplet generation and risk of disease transmission. Although most of the aerosol
emitted comes from the device(1529,1530) there is a risk that patients may exhale contaminated aerosol and droplets
produced by coughing when using a nebulizer may be dispersed more widely by the driving gas. SARS-CoV-2 has been
shown to be viable in aerosols for up to 3 hours(1531) and transmission to health care workers exposed to a hospitalized
patient with COVID-19 receiving nebulized therapy has been reported.(1532) If possible, pressurized metered-dose
inhalers (pMDIs) and dry powder inhalers (DPIs) and soft mist inhalers (SMI) should be used for drug delivery instead
of nebulizers. The risks of nebulized therapy spreading infection to other people in patient’s homes may can be
minimized by avoiding use in the presence of other people, and ensuring that the nebulizer is used near open windows
or in areas of increased air circulation.(1533)
Nebulizers may be needed in critically ill patients with COVID-19 receiving ventilatory support. In this case, it is vital
to keep the circuit intact and prevent the transmission of the virus. Using a mesh nebulizer in ventilated patients
allows adding medication without requiring the circuit to be broken for aerosol drug delivery.(1534)
PULMONARY REHABILITATION
Many pulmonary rehabilitation programmes were suspended during the pandemic to reduce risks of spreading SARS-
CoV-2. When case rates are high, center-based rehabilitation is not appropriate. Patients should be encouraged to
keep active at home and can be supported by home-based rehabilitation programmes which, although likely to be less
effective than traditional pulmonary rehabilitation with supervision (Chapter 3), are likely to be better than not
offering rehabilitation. Technology-based solutions, such as web-based or smartphone applications(975,1535) may be
useful to support home rehabilitation. General principles of infection control should be applied and local guidance
followed.(1536)
REVIEW OF COPD PATIENTS

To minimize the spread of SARS-CoV-2 many health systems reduced face-to-face visits and introduced remote
TE
consultations using online, phone and video-links. Routine review of people with COPD can be undertaken
U
IB
remotely(1537) and we have produced a tool to support these interactions that includes instructions on how to prepare
TR
for the remote visit, set the visit agenda with the patient, and provides a standardized checklist for follow-up (see
D
IS
section on follow-up at the end of Chapter 6).
T
O
N
O
-D
TREATMENT OF COVID-19 IN PATIENTS WITH COPD

L
IA
ER
Randomized clinical trials of treatments targeting COVID-19 have focused on anti-viral agents and anti-inflammatory
AT
treatments. Some have produced positive results, including systemic steroids for hospitalized patients with severe
M
COVID-19.(1538) The WHO has produced a COVID-19 therapeutics living guideline(1539) which currently recommends
T
H
IG
antivirals, corticosteroids, IL-6 receptor blockers and baricitinib for the treatment of COVID-19. The European
R
Respiratory Society has also produced a living guideline on the management of hospitalized adults with COVID-19.(1540)
PY
O
Sub-group analysis of the effectiveness of these therapies in COPD patients have not been presented.
C
In the absence of subgroup data, we recommend that COPD patients suffering with COVID-19 should be treated with
the same standard of care treatments as other COVID-19 patients (Figure 6.3). Furthermore, we advocate that COPD
patients should be included in randomized controlled trials of COVID-19 treatments and that subgroup analysis of their
outcomes are presented.
TE
U
IB
TR
IS
D
T
O
N
O
-D
L
IA
ER
AT
M
T
H
IG
R
PY
O
C
EXACERBATIONS OF COPD
The prevention and treatment of exacerbations are important goals in COPD management (Chapter 3). COVID-19
infection has introduced unique obstacles to the prevention and management of exacerbations.(1464) These include
limited access to therapies due to their use for COVID-19 patients without COPD, disruptions in global supply chains
and the inability of patients to afford medications due to economic hardships associated with the pandemic.(1464)
Conversely, as countries went into lockdown and industrial activities shut down, pollutant emissions reduced
substantially and environmental air quality improved.(1541) This could have contributed to the reported reductions in
hospital admissions for COPD during the COVID-19 pandemic.(1276,1465,1542)
Coronaviruses are among the respiratory viruses that trigger COPD exacerbations.(1543) To date MERS-CoV, SARS-CoV,
and SARS-CoV-2 infection have not been reported in COPD exacerbations. Nonetheless, any COPD patients with SARS-
CoV-2 infection presenting with respiratory symptoms requiring changes in their maintenance medications would fulfil
the definition of an exacerbation (Chapter 4). Distinguishing the symptoms of a typical exacerbation from COVID-19
infection can be extremely difficult as many of the symptoms overlap. If COVID-19 infection is suspected, then RT-PCR
testing should be conducted. If COVID-19 infection is confirmed, then treatment for COVID-19 infection should be
conducted regardless of the presence of COPD.
SARS-CoV-2 infection causes a distinct pattern of pathophysiological changes including vascular injury, pneumonitis
associated with hypoxemia, coagulopathy, high levels of systemic inflammation (“cytokine storm”) and multi-organ
involvement.(1544,1545) These features are very different from typical COPD exacerbations.(1546) However, SARS-CoV-2
infection may resemble an exacerbation of COPD. Fever, anorexia, myalgias, and gastrointestinal symptoms are more
frequently reported in COVID-19 than in exacerbations of COPD, whereas sputum production is less uncommon.
Pronounced lymphopenia is a common finding of SARS-CoV-2 infection.(1501,1547) COPD patients who develop COVID-
19 reported more severe fatigue, dyspnea, and diarrhea than those without COPD.(1496)
In patients with COVID-19 lymphopenia, thrombocytopenia, elevated D-dimer, C-reactive peptide (CRP), procalcitonin,
creatinine kinase, transaminases, creatinine, and lactate dehydrogenase (LDH) are independently associated with
higher risk of poor outcomes.(1548) There is no reason to suspect that this is different in COPD patients with COVID-19
TE
(Figure 6.2).
U
IB
TR
Systemic corticosteroids
IS
D
Caution has been raised about the widespread use of systemic corticosteroids in patients with COVID-19.(1549,1550)
T
O
Observational studies in patients with SARS and MERS reported no association between systemic corticosteroids
N
O
(often at high dose) and improved survival, but suggested that corticosteroids induced side effects, including
-D
osteonecrosis, and reduced viral clearance.(1551-1554) The WHO initially recommended against the routine use of
L
IA
corticosteroids in COVID-19 infection at the beginning of the pandemic except in two clinical settings: adult respiratory
ER
distress syndrome (ARDS) and COPD exacerbations, where a specific indication for systemic corticosteroids was
AT
recognized.(1555)
M
T
H
IG
A large randomized trial in hospitalized patients with COVID-19 has shown that dexamethasone treatment at 6 mg/day
R
for up to 10 days reduced mortality in patients receiving either invasive mechanical ventilation or oxygen alone.(1538)
PY
O
A small observational study has also reported that methylprednisolone use was associated with improved survival in
C
COVID-19 patients with ARDS.(1556) Further studies have also reported the benefits of systemic glucocorticoids on
reduction of mortality at 28 days in patients with COVID-19 pneumonia, especially those that are not on invasive
mechanical ventilation or on pressor support.(1557)
Systemic steroids should be used in COPD exacerbations according to the usual indications (Chapter 4) whether or not
there is evidence of SARS-CoV-2 infection as there is no evidence that this approach modifies the susceptibility to
SARS-CoV-2 infection or worsens outcomes (Figure 6.2).
Antibiotics
Antibiotic treatment for a COPD exacerbation is indicated if patients have at least two of the three cardinal symptoms
including increased sputum purulence, or if the patient requires mechanical ventilation (Chapter 4).
Bacterial co-infections have been reported infrequently in COVID-19.(1558) However, the risk of co-infections increases
with the severity of COVID-19. Bacterial co-infections have been detected by multiplex PCR testing in up to 46% of
samples collected in a small cohort of COVID-19 patients admitted to an ICU.(1559) Diagnosing co-infection in COVID-19
patients may be difficult, particularly in critically ill patients, as the clinical presentation, biomarkers and imaging data
may be unhelpful. In practice, most hospitalized patients, particularly the severe ones, have been prescribed empirical
antibiotic therapy.(1547) Current WHO guidelines recommend broad-spectrum antibiotics in severe COVID-19 patients,
guided by local/national guidelines, and in milder COVID-19 infections when there is clinical suspicion of a bacterial
infection.(1555) In the absence of specific studies, these general considerations would also apply to people with COPD
infected with SARS-CoV-2.
Antibiotics should be used in COPD exacerbations according to the usual indications (Chapter 4) whether or not there
is evidence of SARS-COV-2 infection, particularly as people with COPD who develop COVID-19 are reported to more
frequently develop bacterial or fungal coinfections.(1496)
PULMONARY AND EXTRA-PULMONARY COMPLICATIONS

ARDS may be part of COVID-19 and could be considered the major pulmonary complication of COVID-19(1560) with viral
infection in areas of ongoing active injury contributing to persistent and temporally heterogeneous lung damage.(1561)
Some early reports suggested that ARDS in this setting may differ from the typical ARDS.(1562,1563) Subsequent studies,
however, suggested that classical ARDS also presented with a large variation in lung severity (1564) and there is
considerable overlap between classical ARDS and COVID-19 patients.(1565,1566) Whether the long-term consequences of
TE
this form of ARDS differ from fibrotic lesions described previously is unclear.(1567,1568)
U
IB
TR
Although the respiratory tract is the main target of COVID-19, extra-pulmonary involvement is frequent and
IS
contributes to morbidity, disability, and mortality.(1545,1569) Renal, cardiac, nervous, cutaneous, hepatic and
D
T
gastrointestinal manifestations occur.(1570) It remains unclear, however, if these manifestations are directly caused by
O
N
infection of SARS-CoV-2, or to secondary phenomena including inappropriate or overwhelming immune responses,

O
-D
angiopathy, treatment or ischemic damage due to the impairment of the respiratory functions. Concomitant
L
respiratory comorbidities, such COPD, may aggravate these processes. Compared to lung viral load, lower levels of
IA
ER
SARS-CoV-2 have been reported in the kidneys, liver, heart, and brain,(1571) suggesting secondary rather than primary
AT
involvement of these organs.

M
T
H
Anticoagulation
IG
R
PY
COVID-19 has been associated with a hypercoagulable state(1499) and venous thromboembolism (VTE) rates in both
O
ICU and ward patients are 2- to 4-fold higher than expected despite thromboprophylaxis with low molecular weight
C
heparin (LMWH) or unfractionated heparin.(1572) People with COPD are already at increased risk of VTE(1573,1574) and
those hospitalized with COVID-19 should receive pharmacologic thromboprophylaxis (Figure 6.2). In response to the
high rates despite prophylactics many institutional protocols have adopted intermediate-intensity (i.e., twice daily
LMWH rather than once daily) or even a therapeutic-intensity dose strategy for thromboprophylaxis.(1575) Generally,
LMWH is favored over unfractionated heparin to reduce staff exposure but clinicians should follow local guidelines on
dosing and drug.
VENTILATORY SUPPORT FOR COPD PATIENTS WITH

COVID-19 PNEUMONIA
The prevalence of hypoxic respiratory failure in patients with COVID-19 was around 19%.(1576) Ventilatory support has
been used in up to 20% of patients that develop severe hypoxemia due to COVID-19(1577) and approximately 5% of
patients require ICU care and advanced respiratory support.(1578) Since the introduction of vaccination the rates of ICU
admission have fallen.(1579) However, some patients still require ventilatory support and these individuals still have a
high risk of mortality.(1454,1580,1581) COPD has been reported to increase the risk respiratory failure and ICU admissions
in some, but not all studies.(1448,1453)
There was wide variation (2.3% to 33%) in the early reported rates of use of invasive mechanical ventilation (IMV) in
hospitalized patients with moderate to severe hypoxemic respiratory failure due to COVID-19.(1582) This may, in part,
have reflected differences in use of non-invasive ventilation (NIV) and high flow nasal therapy (HFNT),(1582) possibly as
a result of advocation of early intubation during the pandemic’s initial phases because of concerns about viral
dissemination.(1583,1584) Data supporting those concerns are lacking.(1585)
Although early reports showed mixed outcomes,(1586) several studies have now shown showed HFNT significantly
reduces rates of intubation and IMV, although with variable effects on mortality.(1587,1588) HFTN should be considered
in preference to NIV for acute hypoxemic respiratory failure despite conventional oxygen therapy as it may have a
lower failure rate.(1589-1591) Prone positioning has also been suggested for awake non intubated hypoxemic
patients.(1592)
NIV is the normal standard of care for COPD patients with acute respiratory failure (Chapter 4). NIV may be beneficial
for the treatment of hypercapnic respiratory in COPD patients with COVID-19 pneumonia, but it also has the potential
to worsen lung injury as a result of high transpulmonary pressures and tidal volumes.(1593) Patients on HFNT or NIV
TE
should be monitored closely for worsening and early intubation and IMV with adoption of a protective lung strategy,
U
similar to that used in other forms of ARDS, considered.(1594,1595) A PaO2/FiO2 < 150 mmHg may be a useful indicator
IB
TR
for NIV failure and increased risk of mortality.(1596)
IS
D
T
At the start of the COVID-19 pandemic, there was a reasonable rationale for using extracorporeal membrane
O
N
oxygenation ECMO in patients with very severe COVID-19-related ARDS, and results from large cohorts suggest
O
-D
outcomes during the first wave of the pandemic were similar to those in non-COVID-19 cohorts.(1582,1597-1603) As the
L
pandemic continued, mortality of patients supported with ECMO has increased, possibly because of differences in
IA
ER
patients referred for ECMO as a result of more widespread use of NIV and corticosteroids prior to intubation, changes
AT
in mechanical ventilation strategies and possible pathophysiological changes due to emerging viral variants.(1604)
M
Indications in COVID-19 remain similar to indications for other causes of ARDS(1605,1606) and ECMO should be considered
T
H
only after other strategies fail to achieve goals of oxygenation or ventilation.(1600,1601,1603)

IG
R
PY
Aerosol generation can occur when any form of additional pressures or flows are applied to the upper or lower
O
C
respiratory tract.(1607) Data regarding aerosol dispersion with the use of NIV is limited and contradictory;(1530,1607-1609)
however, staff should use appropriate personal protective equipment (PPE)(1591,1610) and viral filters fitted to exhalation
ports of invasive or noninvasive ventilation devices. Isolation hoods have also been suggested by some to be used to
further decrease staff exposure.(1611)
REHABILITATION
COPD patients with COVID-19 are particularly at risk for poor nutritional status and skeletal muscle loss.(334) Hospital
treatment should therefore include dietary support and early mobilization. Mechanical ventilation, sedation, and
prolonged bed rest, may lead to post-traumatic stress disorder(1612) and respiratory, cognitive, and mental health
impairments as well as physical deconditioning.(1613,1614) Older people and people with COPD, are more susceptible to
these consequences.(1615,1616)
Rehabilitation should be provided to all COPD patients with COVID-19, particularly to those that have been more
severely affected or required ICU admission. A multinational task force has recommended early rehabilitation during
the hospital admission and the screening for traits treatable with rehabilitation in all patients at discharge, and at 6-8
weeks after discharge for patients with severe COVID-19.(1617)
FOLLOW-UP OF COPD PATIENTS WHO DEVELOPED

COVID-19
Several organizations have developed guidelines to address the evaluation and management of patients recovering
from COVID-19(1519,1617-1620) but none of these have specific recommendations for patients with underlying COPD.
Assessment protocols generally include a comprehensive physical, cognitive, and psychological assessment and there
is no reason why these should not also apply to patients with COPD; however. high quality data on the outcomes of
these evaluation and management strategies are still lacking.
The intensity of the monitoring of people with COPD who developed COVID-19 should be determined by the severity
of the initial episode.
Patients who developed mild COVID-19 should be followed with the usual protocols used for COPD patients (Chapter
TE
3). Patients who developed moderate COVID-19, including hospitalization and pneumonia but no respiratory failure,
U
IB
should be monitored more frequently and accurately than the usual COPD patients with particular attention to the
TR
need for oxygen therapy.
IS
D
T
One year after COVID-19 one third of patients have residual CT abnormalities,(1621) with ground-glass opacities and
O
N
fibrotic-like changes seen in 20% of patients, but no specific data are available on patients with COPD. The frequency
O
-D
of CT abnormalities was higher in severe/critical cases than in mild/moderate cases (38% vs. 21%). Gradual
L
improvement is seen on CT over time but fibrotic changes showed little improvement between 4-7 months and one
IA
ER
year after COVID-19. If chest X-ray abnormalities have not resolved at hospital discharge, a chest X-ray, possibly a CT
AT
scan should be considered at 6 months to one year. Complications occurring during/after the COVID-19 episode
M
should also be monitored.

T
H
IG
R
COPD patients are at higher risk of developing severe COVID-19(1594,1622) and multimorbid survivors frequently have
PY
required prolonged ICU stays.(1594) Until we have evidence from prospective studies, COPD survivors of severe COVID-
O
C
19 should be considered at high risk of developing a “critical illness”(1623) or “chronic critical illness”,(1624) a severe
heterogeneous condition linked not only to the acute infectious episode but also to the underlying conditions before
they became severely ill.(1614)
There are informative candidate models for the comprehensive management of complex care delivery that are already
published and undergoing study in the primary care setting, and these may be adapted for application after
COVID-19.(1625)
REMOTE COPD PATIENT FOLLOW-UP
Introduction
During the COVID-19 pandemic, the Global Initiative for Chronic Obstructive Lung Disease (GOLD) recognized that
there was a need for developing new approaches to interact with COPD patients. Remote consultations are superb
tools to minimize the risk of transmitting coronavirus and will be necessary for some time. The systems put in place to
facilitate remote consultations should also help increase the efficiency and capacity of the health care system into the
future.(1626)
In this short document, GOLD provides guidance to support the remote interaction with COPD patients who are usually
seen in primary or secondary care. The tool includes instructions on how i) to prepare for the remote visit; ii) to set up
the visit agenda with the patient; and iii) provides a standardized checklist for follow-up of COPD patients whether in-
person, by phone or in a virtual/online setting.
The principles of good record keeping and clinical practice should always apply: i) treat patients with dignity; ii) respect
people’s right to privacy and confidentiality; iii) listen to the patient’s needs and act in their best interest; and iv) base
TE
your recommendations on the best available evidence.
U
IB
TR
Triage and prioritizing process
IS
D
The process of triage should help decide: a.) whether to offer an in-person as opposed to a remote (telephone or
T
O
virtual/online) consultation, and b.) who to prioritize.

N
O
-D
Remote follow-up could be considered in the following situations:

L
► Patient or caregiver can understand the process and provide information clearly;
IA
ER
► Regular COPD follow-up or patient followed for a known condition;

AT
► Medical records and laboratory test results are accessible to the healthcare professionals;
M
► Prescription and access to medication is possible and follow-up to the prescription can be arranged if
T
H
necessary.
IG
R
PY
In-person follow-up should be prioritized in these situations:

O
C
► Patient and caregiver have difficulty providing information;

► Patient needs immediate attention due to the presence of severe medical symptoms;
► Changes in patient’s symptoms require a differential diagnosis work-up with the need for a physical exam
and/or laboratory testing;
► Patient treatment can only be given in person and cannot be given at home.
Prioritization of in-person visits should take into consideration the COPD patient disease severity (symptom burden
and risk of exacerbations), recent emergency department visit and/or hospital admission, associated significant
comorbidities, age, and/or living alone at home.
Consideration and instruction for remote COPD follow-up

Ensure documentation of the whole visit (in writing) as you would normally do for an in-person follow-up. The
documentation should reflect that this is a remote follow-up (telephone or virtual/online) and should be specific about
how the information was obtained.
1. Start the call by

a. Introducing yourself and, if necessary, any other health care professional(s) who may be with you (e.g.,
case manager, student, resident, etc.);
b. Verifying who you are speaking with (patient name and date of birth), and patient consent to receive
remote follow-up;
c. If applicable, informing patient that the speakerphone is on;
2. Welcome the patient to the call

a. Verify technical issues;
b. Ask the patient if (s)he can hear you well;
c. Describe what to do if the connection fails;
3. Explain that this is a remote visit and give the reason why;
4. Check if there are others listening to the conversation, and if patient consents to all those present;
5. Set the agenda (agree on elements to be discussed, time allotted, etc.);
6. Conduct the follow-up visit using the instructions below in the COPD Follow-up Checklist and remember to
TE
keep the focus on the main issues raised by the patient;
U
IB
TR
7. End and summarize the visit
IS
a. Ask the patient to summarize what the discussion and main issues have been, reinforce any action
D
T
plan or intervention you have agreed upon (if any homework);

O
N
b. Set up a date for follow-up;

O
-D
c. Agree upon ending the meeting.

L
IA
ER
AT
M
T
H
IG
R
PY
O
C
COPD FOLLOW-UP CHECKLIST
In-person Follow-up □ Phone Follow-up □ Virtual/online Follow-up □
Date: YYYY / MM / DD Diagnosis:
1. BASELINE SYMPTOMS – Breathlessness on a regular day: mMRC /4

Daily sputum production: □ no □ yes, color: Regular cough □ no □ yes
Recent change in symptoms □ no □ yes Maintenance Medication and adherence:
If yes, since when:
□ SABA □ LABA+LAMA
□ Sputum color: □ Sputum volume ↑ = ↓ □ LABA □ LABA+ICS
□ LAMA □ LABA+LAMA+ICS
□ Dyspnea ↑ = ↓ □ Fatigue ↑ = ↓
□Other:
□ Cough ↑ = ↓ □ Other Non pharmacological Rx:
□ Signs of hypercapnia CAT: /40 O2: CPAP: BIPAP :
2. COVID-19 – If patient is feeling unwell, check other symptoms: □ Fever____ □ Sore throat □ Anosmia □ Others________
Contact with someone COVID-19 positive? □ no □ yes Tested for COVID-19? □ no □ yes If yes □ positive □ negative
3. WRITTEN ACTION PLAN – no □ yes □
TE
Instruction and any additional treatment: __________________________________
U
IB
Last time it has been used (date):
TR
IS
D
4. RECENT ADMISSIONS AND EMERGENCY VISITS Comments:
T
O
N
Hospital/ER Where Date Length Reason (Dx)

O
-D
L
IA
5. COPD Self-management (healthy behaviors) – Integrated (patient has used it in his daily life)?
ER
Smoke-free environment yes no cannot tell

AT
Medication adherence yes no cannot tell

M
Prevention/management of exacerbations yes no cannot tell

T
H
Breathing control yes no cannot tell

IG
Stress management yes no cannot tell

R
Physical activity and exercise yes no cannot tell

PY
Other _____________ yes no

O
C
Comments and what patient should prioritize based on his/her need:
6. MAIN ISSUES
1. 2. 3.
7. SUMMARY, INTERVENTIONS & PLAN
(healthcare professional name & signature)
Instructions for using the COPD follow-up checklist
1. Introduction
a. Identify dates, Dx and whether this follow-up is being done in-person, by phone or remotely.
2. Section 1 – Baseline symptoms
a. Go over the patient symptoms and whether there have been changes in dyspnea, cough, sputum
volume and color (from least to most purulent: mucus; mucopurulent; purulent).
b. Identify maintenance pharmacological and non-pharmacological treatment and whether the patient
is observing treatment as prescribed.
3. Section 2 – COVID-19
a. Assess whether the patient has any symptoms of COVID-19 and would need to be tested. Have at
hand local numbers where the patient can be referred to for testing and treatment.
b. If the patient has already been tested identify when the results will be obtained, or whether the
result was positive or negative. If positive, is there a follow-up test planned, and dates.
c. Verify patient is practicing COVID-19 precautions (face masks, hand washing, social distancing, or
shielding if necessary).
4. Section 3 – Action Plan
a. Describe if the patient already has a written action plan. See example of an action plan from the
Living well with COPD program [1]. Describe if the education for this action plan has already been
TE
U
done. Describe if the written action plan includes a prescription to be self-administered at home or
IB
TR
whether the patient need to call his contact person / physician to obtain the prescription. Describe
when it was used the last time and if used appropriately. IS
D
5. Section 4 – Recent Admissions and ER visits
T
O
a. Write down recent admissions and ER visits, dates and where they took place.
N
O
6. Section 5 – COPD Self-Management behaviors

-D
a. Go over each of the self-management behaviors described in the list. You should cover what is
L
IA
pertinent to the patient treatable traits (dyspnea and/or exacerbation) [2]. Describe whether the
ER
patient has integrated these strategies in their daily life (yes), not at all (e.g., it has not been
AT
discussed or not applicable), and whether the patient is unsure “cannot tell”.
M
T
7. Section 6 – Main issues

H
IG
a. Identify with the patient the main issues of the call. Up to a maximum of 3 items that can be covered
R
PY
for the duration of the call. Avoid covering too many issues in one visit.
O
8. Section 7 – Summary, Intervention and Plan

C
a. Finalize by describing the interventions done during the remote visit, the ones to be put in place, and
agreed by the patient, the plan, including whether the patient needs to be referred to other services,
healthcare professionals, etc. and when the next follow-up will take place (describe whether will it
be in-person or remote).
REFERENCES
1. Halpin DMG, Celli BR, Criner GJ, et al. The GOLD Summit on chronic obstructive pulmonary disease in low- and middle-
income countries. Int J Tuberc Lung Dis 2019; 23(11): 1131-41 https://pubmed.ncbi.nlm.nih.gov/31718748.
2. Meghji J, Mortimer K, Agusti A, et al. Improving lung health in low-income and middle-income countries: from
challenges to solutions. Lancet 2021; 397(10277): 928-40 https://pubmed.ncbi.nlm.nih.gov/33631128.
3. Mathers CD, Loncar D. Projections of global mortality and burden of disease from 2002 to 2030. PLoS Med 2006; 3(11):
e442 https://pubmed.ncbi.nlm.nih.gov/17132052.
4. Halpin DMG, Celli BR, Criner GJ, et al. It is time for the world to take COPD seriously: a statement from the GOLD board
of directors. Eur Respir J 2019; 54(1): 1900914 https://pubmed.ncbi.nlm.nih.gov/31273036.
5. United Nations. Sustainable Development Goals, online information available here:
https://www.un.org/sustainabledevelopment/sustainable-development-goals/ [accessed Oct 2023].
6. Celli B, Fabbri L, Criner G, et al. Definition and Nomenclature of Chronic Obstructive Pulmonary Disease: Time for Its
Revision. Am J Respir Crit Care Med 2022; 206(11): 1317-25 https://pubmed.ncbi.nlm.nih.gov/35914087.
7. Agusti A, Melen E, DeMeo DL, Breyer-Kohansal R, Faner R. Pathogenesis of chronic obstructive pulmonary disease:
understanding the contributions of gene-environment interactions across the lifespan. Lancet Respir Med 2022; 10(5):
512-24 https://pubmed.ncbi.nlm.nih.gov/35427533.
8. Sin DD, Doiron D, Agusti A, et al. Air pollution and COPD: GOLD 2023 committee report. Eur Respir J 2023; 61(5):
https://pubmed.ncbi.nlm.nih.gov/36958741.
9. Yang IA, Jenkins CR, Salvi SS. Chronic obstructive pulmonary disease in never-smokers: risk factors, pathogenesis, and
implications for prevention and treatment. Lancet Respir Med 2022; 10(5): 497-511
TE
U
10. Cho MH, Hobbs BD, Silverman EK. Genetics of chronic obstructive pulmonary disease: understanding the pathobiology
IB
and heterogeneity of a complex disorder. Lancet Respir Med 2022; 10(5): 485-96
TR
11. IS
Martinez FJ, Agusti A, Celli BR, et al. Treatment Trials in Young Patients with Chronic Obstructive Pulmonary Disease and
D
Pre-Chronic Obstructive Pulmonary Disease Patients: Time to Move Forward. Am J Respir Crit Care Med 2022; 205(3):
T
O
N
12. Wan ES, Castaldi PJ, Cho MH, et al. Epidemiology, genetics, and subtyping of preserved ratio impaired spirometry
O
-D
(PRISm) in COPDGene. Respir Res 2014; 15(1): 89 https://pubmed.ncbi.nlm.nih.gov/25096860.

13. Agusti A, Faner R. COPD beyond smoking: new paradigm, novel opportunities. Lancet Respir Med 2018; 6(5): 324-6
L
IA
ER
14. Lozano R, Naghavi M, Foreman K, et al. Global and regional mortality from 235 causes of death for 20 age groups in
AT
1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380(9859): 2095-128
M
T
15. Vos T, Flaxman AD, Naghavi M, et al. Years lived with disability (YLDs) for 1160 sequelae of 289 diseases and injuries
H
IG
1990-2010: a systematic analysis for the Global Burden of Disease Study 2010. Lancet 2012; 380(9859): 2163-96
R
PY
16. Stern DA, Morgan WJ, Wright AL, Guerra S, Martinez FD. Poor airway function in early infancy and lung function by age
O
C
22 years: a non-selective longitudinal cohort study. Lancet 2007; 370(9589): 758-64

17. Tashkin DP, Altose MD, Bleecker ER, et al. The lung health study: airway responsiveness to inhaled methacholine in
smokers with mild to moderate airflow limitation. The Lung Health Study Research Group. Am Rev Respir Dis 1992;
145(2 Pt 1): 301-10 https://pubmed.ncbi.nlm.nih.gov/1736734.
18. Eisner MD, Anthonisen N, Coultas D, et al. An official American Thoracic Society public policy statement: Novel risk
factors and the global burden of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2010; 182(5): 693-
718 https://pubmed.ncbi.nlm.nih.gov/20802169.
19. Salvi SS, Barnes PJ. Chronic obstructive pulmonary disease in non-smokers. Lancet 2009; 374(9691): 733-43
20. World Health Organization. World Health Organization (WHO) Website [accessed Oct 2023]. http://www.who.int.
21. Safiri S, Carson-Chahhoud K, Noori M, et al. Burden of chronic obstructive pulmonary disease and its attributable risk
factors in 204 countries and territories, 1990-2019: results from the Global Burden of Disease Study 2019. Bmj 2022;
378: e069679 https://pubmed.ncbi.nlm.nih.gov/35896191.
22. World Health Organization. The Global Health Observatory, Global Health Estimates: Life expectancy and leading causes
of death and disability [accessed Oct 2023]. https://www.who.int/data/gho/data/themes/mortality-and-global-health-
estimates.
23. Halbert RJ, Natoli JL, Gano A, Badamgarav E, Buist AS, Mannino DM. Global burden of COPD: systematic review and
meta-analysis. Eur Respir J 2006; 28(3): 523-32 https://pubmed.ncbi.nlm.nih.gov/16611654.
24. Quach A, Giovannelli J, Cherot-Kornobis N, et al. Prevalence and underdiagnosis of airway obstruction among middle-
aged adults in northern France: The ELISABET study 2011-2013. Respir Med 2015; 109(12): 1553-61
25. Adeloye D, Chua S, Lee C, et al. Global and regional estimates of COPD prevalence: Systematic review and meta-
analysis. J Glob Health 2015; 5(2): 020415 https://pubmed.ncbi.nlm.nih.gov/26755942.
26. Ntritsos G, Franek J, Belbasis L, et al. Gender-specific estimates of COPD prevalence: a systematic review and meta-
analysis. Int J Chron Obstruct Pulmon Dis 2018; 13: 1507-14 https://pubmed.ncbi.nlm.nih.gov/29785100.
27. Varmaghani M, Dehghani M, Heidari E, Sharifi F, Moghaddam SS, Farzadfar F. Global prevalence of chronic obstructive
pulmonary disease: systematic review and meta-analysis. East Mediterr Health J 2019; 25(1): 47-57
28. Menezes AM, Perez-Padilla R, Jardim JR, et al. Chronic obstructive pulmonary disease in five Latin American cities (the
PLATINO study): a prevalence study. Lancet 2005; 366(9500): 1875-81 https://pubmed.ncbi.nlm.nih.gov/16310554.
29. Schirnhofer L, Lamprecht B, Vollmer WM, et al. COPD prevalence in Salzburg, Austria: results from the Burden of
Obstructive Lung Disease (BOLD) Study. Chest 2007; 131(1): 29-36 https://pubmed.ncbi.nlm.nih.gov/17218553.
30. Marshall DC, Al Omari O, Goodall R, et al. Trends in prevalence, mortality, and disability-adjusted life-years relating to
chronic obstructive pulmonary disease in Europe: an observational study of the global burden of disease database,
2001-2019. BMC Pulm Med 2022; 22(1): 289 https://pubmed.ncbi.nlm.nih.gov/35902833.
31. BOLD. Burden of Obstructive Lung Disease Initiative Webpage, published by Imperial College London, available here:
https://www.imperial.ac.uk/nhli/bold/ [accessed Oct 2023].
32. Burney P, Patel J, Minelli C, et al. Prevalence and Population-Attributable Risk for Chronic Airflow Obstruction in a Large
Multinational Study. Am J Respir Crit Care Med 2021; 203(11): 1353-65 https://pubmed.ncbi.nlm.nih.gov/33171069.
33. Lamprecht B, McBurnie MA, Vollmer WM, et al. COPD in never smokers: results from the population-based burden of
obstructive lung disease study. Chest 2011; 139(4): 752-63 https://pubmed.ncbi.nlm.nih.gov/20884729.
TE
34. Al Ghobain M, Alhamad EH, Alorainy HS, Al Kassimi F, Lababidi H, Al-Hajjaj MS. The prevalence of chronic obstructive
U
pulmonary disease in Riyadh, Saudi Arabia: a BOLD study. Int J Tuberc Lung Dis 2015; 19(10): 1252-7
IB
TR
35. IS
Denguezli M, Daldoul H, Harrabi I, et al. COPD in Nonsmokers: Reports from the Tunisian Population-Based Burden of
D
Obstructive Lung Disease Study. PLoS One 2016; 11(3): e0151981 https://pubmed.ncbi.nlm.nih.gov/27010214.
T
36. El Rhazi K, Nejjari C, BenJelloun MC, El Biaze M, Attassi M, Garcia-Larsen V. Prevalence of chronic obstructive
O
N
pulmonary disease in Fez, Morocco: results from the BOLD study. Int J Tuberc Lung Dis 2016; 20(1): 136-41
O
-D
37. Obaseki DO, Erhabor GE, Gnatiuc L, Adewole OO, Buist SA, Burney PG. Chronic Airflow Obstruction in a Black African
L
Population: Results of BOLD Study, Ile-Ife, Nigeria. COPD 2016; 13(1): 42-9 https://pubmed.ncbi.nlm.nih.gov/26451840.
IA
ER
38. Adeloye D, Song P, Zhu Y, et al. Global, regional, and national prevalence of, and risk factors for, chronic obstructive
AT
pulmonary disease (COPD) in 2019: a systematic review and modelling analysis. Lancet Respir Med 2022; 10(5): 447-58
M
T
39. Fallahzadeh A, Sharifnejad Tehrani Y, Sheikhy A, et al. The burden of chronic respiratory disease and attributable risk
H
factors in North Africa and Middle East: findings from global burden of disease study (GBD) 2019. Respir Res 2022;
IG
R
23(1): 268 https://pubmed.ncbi.nlm.nih.gov/36175873.

PY
40. Divo MJ, Celli BR, Poblador-Plou B, et al. Chronic Obstructive Pulmonary Disease (COPD) as a disease of early aging:
O
Evidence from the EpiChron Cohort. PLoS One 2018; 13(2): e0193143 https://pubmed.ncbi.nlm.nih.gov/29470502.
C
41. Agusti A, Noell G, Brugada J, Faner R. Lung function in early adulthood and health in later life: a transgenerational
cohort analysis. Lancet Respir Med 2017; 5(12): 935-45 https://pubmed.ncbi.nlm.nih.gov/29150410.
42. Chen W, Thomas J, Sadatsafavi M, FitzGerald JM. Risk of cardiovascular comorbidity in patients with chronic obstructive
pulmonary disease: a systematic review and meta-analysis. Lancet Respir Med 2015; 3(8): 631-9
43. Mannino DM, Higuchi K, Yu TC, et al. Economic Burden of COPD in the Presence of Comorbidities. Chest 2015; 148(1):
44. World Health Organization. Evidence-Informed Policy Network: EVIPnet in Action [accessed Oct 2023].
https://www.who.int/initiatives/evidence-informed-policy-network.
45. Buist AS, McBurnie MA, Vollmer WM, et al. International variation in the prevalence of COPD (the BOLD Study): a
population-based prevalence study. Lancet 2007; 370(9589): 741-50 https://pubmed.ncbi.nlm.nih.gov/17765523.
46. Duong M, Islam S, Rangarajan S, et al. Global differences in lung function by region (PURE): an international,
community-based prospective study. Lancet Respir Med 2013; 1(8): 599-609
47. Schneider A, Gantner L, Maag I, Borst MM, Wensing M, Szecsenyi J. Are ICD-10 codes appropriate for performance
assessment in asthma and COPD in general practice? Results of a cross sectional observational study. BMC Health Serv
Res 2005; 5(1): 11 https://pubmed.ncbi.nlm.nih.gov/15683548.
48. Cooke CR, Joo MJ, Anderson SM, et al. The validity of using ICD-9 codes and pharmacy records to identify patients with
chronic obstructive pulmonary disease. BMC Health Serv Res 2011; 11: 37 https://pubmed.ncbi.nlm.nih.gov/21324188.
49. Stein BD, Bautista A, Schumock GT, et al. The validity of International Classification of Diseases, Ninth Revision, Clinical
Modification diagnosis codes for identifying patients hospitalized for COPD exacerbations. Chest 2012; 141(1): 87-93
50. Jensen HH, Godtfredsen NS, Lange P, Vestbo J. Potential misclassification of causes of death from COPD. Eur Respir J
2006; 28(4): 781-5 https://pubmed.ncbi.nlm.nih.gov/16807258.
51. Hoyert DL, Xu JQ. Deaths: preliminary data for 2011. Natl Vital Stat Rep 2011; 61(6): 1-65
52. GBD Chronic Respiratory Disease Collaborators. Prevalence and attributable health burden of chronic respiratory
diseases, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017. Lancet Respir Med 2020; 8(6):
53. Mortality GBD, Causes of Death C. Global, regional, and national age-sex specific all-cause and cause-specific mortality
for 240 causes of death, 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013. Lancet 2015;
385(9963): 117-71 https://pubmed.ncbi.nlm.nih.gov/25530442.
54. Lopez AD, Shibuya K, Rao C, et al. Chronic obstructive pulmonary disease: current burden and future projections. Eur
Respir J 2006; 27(2): 397-412 https://pubmed.ncbi.nlm.nih.gov/16452599.
55. World Health Organization. Projections of mortality and causes of death, 2016 and 2060, online information available
here: https://colinmathers.com/2022/05/10/projections-of-global-deaths-from-2016-to-2060/ [accessed Oct 2023].
56. Forum of International Respiratory Societies (FIRS). The global impact of respiratory disease. Third Edition. ERS, 2021
available at: https://www.firsnet.org/images/publications/FIRS_Master_09202021.pdf [accessed Oct 2023].
57. Guarascio AJ, Ray SM, Finch CK, Self TH. The clinical and economic burden of chronic obstructive pulmonary disease in
the USA. Clinicoecon Outcomes Res 2013; 5: 235-45 https://pubmed.ncbi.nlm.nih.gov/23818799.
58. Zafari Z, Li S, Eakin MN, Bellanger M, Reed RM. Projecting Long-term Health and Economic Burden of COPD in the
United States. Chest 2021; 159(4): 1400-10 https://pubmed.ncbi.nlm.nih.gov/33011203.
59. Gutierrez Villegas C, Paz-Zulueta M, Herrero-Montes M, Paras-Bravo P, Madrazo Perez M. Cost analysis of chronic
TE
obstructive pulmonary disease (COPD): a systematic review. Health Econ Rev 2021; 11(1): 31
U
IB
TR
60. Stolbrink M, Thomson H, Hadfield RM, et al. The availability, cost, and affordability of essential medicines for asthma
IS
and COPD in low-income and middle-income countries: a systematic review. Lancet Glob Health 2022; 10(10): e1423-
D
T
61. Sin DD, Stafinski T, Ng YC, Bell NR, Jacobs P. The impact of chronic obstructive pulmonary disease on work loss in the
O
N
United States. Am J Respir Crit Care Med 2002; 165(5): 704-7 https://pubmed.ncbi.nlm.nih.gov/11874818.
O
62. Murray CJ, Lopez AD. Alternative projections of mortality and disability by cause 1990-2020: Global Burden of Disease
-D
Study. Lancet 1997; 349(9064): 1498-504 https://pubmed.ncbi.nlm.nih.gov/9167458.

L
63. Chen X, Zhou CW, Fu YY, et al. Global, regional, and national burden of chronic respiratory diseases and associated risk
IA
ER
factors, 1990-2019: Results from the Global Burden of Disease Study 2019. Front Med (Lausanne) 2023; 10: 1066804
AT
64. Li H, Liang H, Wei L, et al. Health Inequality in the Global Burden of Chronic Obstructive Pulmonary Disease: Findings
M
T
from the Global Burden of Disease Study 2019. Int J Chron Obstruct Pulmon Dis 2022; 17: 1695-702
H
IG
R
65. GBD Chronic Respiratory Disease Collaborators. Global, regional, and national deaths, prevalence, disability-adjusted
PY
life years, and years lived with disability for chronic obstructive pulmonary disease and asthma, 1990-2015: a
O
systematic analysis for the Global Burden of Disease Study 2015. Lancet Respir Med 2017; 5(9): 691-706
C
66. Murray CJ, Atkinson C, Bhalla K, et al. The state of US health, 1990-2010: burden of diseases, injuries, and risk factors.
JAMA 2013; 310(6): 591-608 https://pubmed.ncbi.nlm.nih.gov/23842577.
67. Kohansal R, Martinez-Camblor P, Agusti A, Buist AS, Mannino DM, Soriano JB. The natural history of chronic airflow
obstruction revisited: an analysis of the Framingham offspring cohort. Am J Respir Crit Care Med 2009; 180(1): 3-10
68. Rennard SI, Vestbo J. COPD: the dangerous underestimate of 15%. Lancet 2006; 367(9518): 1216-9
69. Bardsen T, Roksund OD, Benestad MR, et al. Tracking of lung function from 10 to 35 years after being born extremely
preterm or with extremely low birth weight. Thorax 2022; 77(8): 790-8 https://pubmed.ncbi.nlm.nih.gov/35410959.
70. Raad D, Gaddam S, Schunemann HJ, et al. Effects of water-pipe smoking on lung function: a systematic review and
meta-analysis. Chest 2011; 139(4): 764-74 https://pubmed.ncbi.nlm.nih.gov/20671057.
71. She J, Yang P, Wang Y, et al. Chinese water-pipe smoking and the risk of COPD. Chest 2014; 146(4): 924-31
72. Gunen H, Tarraf H, Nemati A, Al Ghobain M, Al Mutairi S, Aoun Bacha Z. Waterpipe tobacco smoking. Tuberk Toraks
73. Tan WC, Lo C, Jong A, et al. Marijuana and chronic obstructive lung disease: a population-based study. CMAJ 2009;
74. Yin P, Jiang CQ, Cheng KK, et al. Passive smoking exposure and risk of COPD among adults in China: the Guangzhou
Biobank Cohort Study. Lancet 2007; 370(9589): 751-7 https://pubmed.ncbi.nlm.nih.gov/17765524.
75. Chen P, Li Y, Wu D, Liu F, Cao C. Secondhand Smoke Exposure and the Risk of Chronic Obstructive Pulmonary Disease: A
Systematic Review and Meta-Analysis. Int J Chron Obstruct Pulmon Dis 2023; 18: 1067-76
76. Tager IB, Ngo L, Hanrahan JP. Maternal smoking during pregnancy. Effects on lung function during the first 18 months
of life. Am J Respir Crit Care Med 1995; 152(3): 977-83 https://pubmed.ncbi.nlm.nih.gov/7663813.
77. Orozco-Levi M, Garcia-Aymerich J, Villar J, Ramirez-Sarmiento A, Anto JM, Gea J. Wood smoke exposure and risk of
chronic obstructive pulmonary disease. Eur Respir J 2006; 27(3): 542-6 https://pubmed.ncbi.nlm.nih.gov/16507854.
78. Mortimer K, Montes de Oca M, Salvi S, et al. Household air pollution and COPD: cause and effect or confounding by
other aspects of poverty? Int J Tuberc Lung Dis 2022; 26(3): 206-16 https://pubmed.ncbi.nlm.nih.gov/35197160.
79. Gan WQ, FitzGerald JM, Carlsten C, Sadatsafavi M, Brauer M. Associations of ambient air pollution with chronic
obstructive pulmonary disease hospitalization and mortality. Am J Respir Crit Care Med 2013; 187(7): 721-7
80. Ezzati M. Indoor air pollution and health in developing countries. Lancet 2005; 366(9480): 104-6
81. Zhou Y, Zou Y, Li X, et al. Lung function and incidence of chronic obstructive pulmonary disease after improved cooking
fuels and kitchen ventilation: a 9-year prospective cohort study. PLoS Med 2014; 11(3): e1001621
82. Sana A, Somda SMA, Meda N, Bouland C. Chronic obstructive pulmonary disease associated with biomass fuel use in
women: a systematic review and meta-analysis. BMJ Open Respir Res 2018; 5(1): e000246
83. Assad NA, Balmes J, Mehta S, Cheema U, Sood A. Chronic obstructive pulmonary disease secondary to household air
pollution. Semin Respir Crit Care Med 2015; 36(3): 408-21 https://pubmed.ncbi.nlm.nih.gov/26024348.
84. Sherrill DL, Lebowitz MD, Burrows B. Epidemiology of chronic obstructive pulmonary disease. Clin Chest Med 1990;
TE
U
85. Ramirez-Venegas A, Velazquez-Uncal M, Aranda-Chavez A, et al. Bronchodilators for hyperinflation in COPD associated
IB
TR
with biomass smoke: clinical trial. Int J Chron Obstruct Pulmon Dis 2019; 14: 1753-62
https://pubmed.ncbi.nlm.nih.gov/31496674. IS
D
86. Guldaval F, Polat G, Doruk S, et al. What are the Differences Between Smoker and Non-smoker COPD Cases? Is it a
T
Different Phenotype? Turk Thorac J 2021; 22(4): 284-8 https://pubmed.ncbi.nlm.nih.gov/35110244.

O
N
87. Ramirez-Venegas A, Montiel-Lopez F, Falfan-Valencia R, Perez-Rubio G, Sansores RH. The "Slow Horse Racing Effect" on
O
Lung Function in Adult Life in Chronic Obstructive Pulmonary Disease Associated to Biomass Exposure. Front Med
-D
(Lausanne) 2021; 8: 700836 https://pubmed.ncbi.nlm.nih.gov/34307427.

L
88. Salvi SS, Brashier BB, Londhe J, et al. Phenotypic comparison between smoking and non-smoking chronic obstructive
IA
ER
pulmonary disease. Respir Res 2020; 21(1): 50 https://pubmed.ncbi.nlm.nih.gov/32050955.

AT
89. Paulin LM, Diette GB, Blanc PD, et al. Occupational exposures are associated with worse morbidity in patients with
chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2015; 191(5): 557-65
M
T
H
90. Lytras T, Kogevinas M, Kromhout H, et al. Occupational exposures and 20-year incidence of COPD: the European
IG
R
Community Respiratory Health Survey. Thorax 2018; 73(11): 1008-15 https://pubmed.ncbi.nlm.nih.gov/29574416.

PY
91. Faruque MO, Boezen HM, Kromhout H, Vermeulen R, Bultmann U, Vonk JM. Airborne occupational exposures and the
O
risk of developing respiratory symptoms and airway obstruction in the Lifelines Cohort Study. Thorax 2021; 76(8): 790-7
C
92. De Matteis S, Jarvis D, Darnton A, et al. The occupations at increased risk of COPD: analysis of lifetime job-histories in
the population-based UK Biobank Cohort. Eur Respir J 2019; 54(1): 1900186
93. Marchetti N, Garshick E, Kinney GL, et al. Association between occupational exposure and lung function, respiratory
symptoms, and high-resolution computed tomography imaging in COPDGene. Am J Respir Crit Care Med 2014; 190(7):
94. Hnizdo E, Sullivan PA, Bang KM, Wagner G. Association between chronic obstructive pulmonary disease and
employment by industry and occupation in the US population: a study of data from the Third National Health and
Nutrition Examination Survey. Am J Epidemiol 2002; 156(8): 738-46 https://pubmed.ncbi.nlm.nih.gov/12370162.
95. Balmes J, Becklake M, Blanc P, et al. American Thoracic Society Statement: Occupational contribution to the burden of
airway disease. Am J Respir Crit Care Med 2003; 167(5): 787-97 https://pubmed.ncbi.nlm.nih.gov/12598220.
96. Institute for Health Metrics and Evaluation. GBD Compare—Viz Hub. https://vizhub.healthdata.org/gbd-compare/
[Accessed Oct 2023]. 2022:
97. GBD Risk Factors Collaborators. Global burden of 87 risk factors in 204 countries and territories, 1990-2019: a
systematic analysis for the Global Burden of Disease Study 2019. Lancet 2020; 396(10258): 1223-49
98. Guo C, Zhang Z, Lau AKH, et al. Effect of long-term exposure to fine particulate matter on lung function decline and risk
of chronic obstructive pulmonary disease in Taiwan: a longitudinal, cohort study. Lancet Planet Health 2018; 2(3): e114-
99. Bourbeau J, Doiron D, Biswas S, et al. Ambient Air Pollution and Dysanapsis: Associations with Lung Function and
Chronic Obstructive Pulmonary Disease in the Canadian Cohort Obstructive Lung Disease Study. Am J Respir Crit Care
Med 2022; 206(1): 44-55 https://pubmed.ncbi.nlm.nih.gov/35380941.
100. Li J, Sun S, Tang R, et al. Major air pollutants and risk of COPD exacerbations: a systematic review and meta-analysis. Int
J Chron Obstruct Pulmon Dis 2016; 11: 3079-91 https://pubmed.ncbi.nlm.nih.gov/28003742.
101. Ross BA, Doiron D, Benedetti A, et al. Short-term air pollution exposure and exacerbation events in mild to moderate
COPD: a case-crossover study within the CanCOLD cohort. Thorax 2023; 78(10): 974-82
102. McCloskey SC, Patel BD, Hinchliffe SJ, Reid ED, Wareham NJ, Lomas DA. Siblings of patients with severe chronic
obstructive pulmonary disease have a significant risk of airflow obstruction. Am J Respir Crit Care Med 2001; 164(8 Pt
1): 1419-24 https://pubmed.ncbi.nlm.nih.gov/11704589.
103. Stoller JK, Aboussouan LS. Alpha1-antitrypsin deficiency. Lancet 2005; 365(9478): 2225-36
104. Blanco I, Diego I, Bueno P, Perez-Holanda S, Casas-Maldonado F, Miravitlles M. Prevalence of alpha(1)-antitrypsin PiZZ
genotypes in patients with COPD in Europe: a systematic review. Eur Respir Rev 2020; 29(157): 200014
105. Martinez-Gonzalez C, Blanco I, Diego I, Bueno P, Miravitlles M. Estimated Prevalence and Number of PiMZ Genotypes of
Alpha-1 Antitrypsin in Seventy-Four Countries Worldwide. Int J Chron Obstruct Pulmon Dis 2021; 16: 2617-30
106. Franciosi AN, Hobbs BD, McElvaney OJ, et al. Clarifying the Risk of Lung Disease in SZ Alpha-1 Antitrypsin Deficiency. Am
J Respir Crit Care Med 2020; 202(1): 73-82 https://pubmed.ncbi.nlm.nih.gov/32197047.
107. Molloy K, Hersh CP, Morris VB, et al. Clarification of the risk of chronic obstructive pulmonary disease in alpha1-
antitrypsin deficiency PiMZ heterozygotes. Am J Respir Crit Care Med 2014; 189(4): 419-27
TE
U
108. Stockley RA. Alpha-1 Antitrypsin Deficiency: The Learning Goes On. Am J Respir Crit Care Med 2020; 202(1): 6-7
IB
TR
109. IS
Hunninghake GM, Cho MH, Tesfaigzi Y, et al. MMP12, lung function, and COPD in high-risk populations. N Engl J Med
D
T
110. Ding Z, Wang K, Li J, Tan Q, Tan W, Guo G. Association between glutathione S-transferase gene M1 and T1
O
N
polymorphisms and chronic obstructive pulmonary disease risk: A meta-analysis. Clin Genet 2019; 95(1): 53-62
O
-D
111. Cho MH, Boutaoui N, Klanderman BJ, et al. Variants in FAM13A are associated with chronic obstructive pulmonary
L
disease. Nat Genet 2010; 42(3): 200-2 https://pubmed.ncbi.nlm.nih.gov/20173748.

IA
ER
112. Pillai SG, Ge D, Zhu G, et al. A genome-wide association study in chronic obstructive pulmonary disease (COPD):
AT
identification of two major susceptibility loci. PLoS Genet 2009; 5(3): e1000421
M
T
113. Soler Artigas M, Wain LV, Repapi E, et al. Effect of five genetic variants associated with lung function on the risk of
H
chronic obstructive lung disease, and their joint effects on lung function. Am J Respir Crit Care Med 2011; 184(7): 786-
IG
R
PY
114. Repapi E, Sayers I, Wain LV, et al. Genome-wide association study identifies five loci associated with lung function. Nat
O
Genet 2010; 42(1): 36-44 https://pubmed.ncbi.nlm.nih.gov/20010834.

C
115. Cho MH, McDonald ML, Zhou X, et al. Risk loci for chronic obstructive pulmonary disease: a genome-wide association
study and meta-analysis. Lancet Respir Med 2014; 2(3): 214-25 https://pubmed.ncbi.nlm.nih.gov/24621683.
116. Lange P, Celli B, Agusti A, et al. Lung-Function Trajectories Leading to Chronic Obstructive Pulmonary Disease. N Engl J
117. Agusti A, Faner R. Lung function trajectories in health and disease. Lancet Respir Med 2019; 7(4): 358-64
118. Regan EA, Lynch DA, Curran-Everett D, et al. Clinical and Radiologic Disease in Smokers With Normal Spirometry. JAMA
Intern Med 2015; 175(9): 1539-49 https://pubmed.ncbi.nlm.nih.gov/26098755.
119. Lawlor DA, Ebrahim S, Davey Smith G. Association of birth weight with adult lung function: findings from the British
Women's Heart and Health Study and a meta-analysis. Thorax 2005; 60(10): 851-8
120. Green M, Mead J, Turner JM. Variability of maximum expiratory flow-volume curves. J Appl Physiol 1974; 37(1): 67-74
121. Ito K, Barnes PJ. COPD as a disease of accelerated lung aging. Chest 2009; 135(1): 173-80
122. Martin TR, Feldman HA, Fredberg JJ, Castile RG, Mead J, Wohl ME. Relationship between maximal expiratory flows and
lung volumes in growing humans. J Appl Physiol (1985) 1988; 65(2): 822-8 https://pubmed.ncbi.nlm.nih.gov/3170432.
123. Rawlins EL, Okubo T, Xue Y, et al. The role of Scgb1a1+ Clara cells in the long-term maintenance and repair of lung
airway, but not alveolar, epithelium. Cell Stem Cell 2009; 4(6): 525-34 https://pubmed.ncbi.nlm.nih.gov/19497281.
124. Smith BM, Kirby M, Hoffman EA, et al. Association of Dysanapsis With Chronic Obstructive Pulmonary Disease Among
Older Adults. JAMA 2020; 323(22): 2268-80 https://pubmed.ncbi.nlm.nih.gov/32515814.
125. Dharmage SC, Bui DS, Walters EH, et al. Lifetime spirometry patterns of obstruction and restriction, and their risk
factors and outcomes: a prospective cohort study. Lancet Respir Med 2023; 11(3): 273-82
126. Bose S, Pascoe C, McEvoy C. Lifetime lung function trajectories and COPD: when the train derails. Lancet Respir Med
127. Fletcher C, Peto R. The natural history of chronic airflow obstruction. Br Med J 1977; 1(6077): 1645-8
128. Mercado N, Ito K, Barnes PJ. Accelerated ageing of the lung in COPD: new concepts. Thorax 2015; 70(5): 482-9
129. Cordoba-Lanus E, Cazorla-Rivero S, Garcia-Bello MA, et al. Telomere length dynamics over 10-years and related
outcomes in patients with COPD. Respir Res 2021; 22(1): 56 https://pubmed.ncbi.nlm.nih.gov/33608013.
130. Hernandez Cordero AI, Yang CX, Li X, et al. Epigenetic marker of telomeric age is associated with exacerbations and
hospitalizations in chronic obstructive pulmonary disease. Respir Res 2021; 22(1): 316
131. Hernandez Cordero AI, Yang CX, Milne S, et al. Epigenetic blood biomarkers of ageing and mortality in COPD. Eur Respir
J 2021; 58(6): https://pubmed.ncbi.nlm.nih.gov/34561282.
132. Barker DJ, Godfrey KM, Fall C, Osmond C, Winter PD, Shaheen SO. Relation of birth weight and childhood respiratory
infection to adult lung function and death from chronic obstructive airways disease. BMJ 1991; 303(6804): 671-5
133. Todisco T, de Benedictis FM, Iannacci L, et al. Mild prematurity and respiratory functions. Eur J Pediatr 1993; 152(1): 55-
TE
134. Smith BM, Traboulsi H, Austin JHM, et al. Human airway branch variation and chronic obstructive pulmonary disease.
U
Proc Natl Acad Sci U S A 2018; 115(5): E974-E81 https://pubmed.ncbi.nlm.nih.gov/29339516.
IB
TR
135. Vameghestahbanati M, Kirby M, Tanabe N, et al. Central Airway Tree Dysanapsis Extends to the Peripheral Airways. Am
IS
D
136. Leary D, Bhatawadekar SA, Parraga G, Maksym GN. Modeling stochastic and spatial heterogeneity in a human airway
T
tree to determine variation in respiratory system resistance. J Appl Physiol (1985) 2012; 112(1): 167-75
O
N
O
137. Tawhai MH, Hunter P, Tschirren J, Reinhardt J, McLennan G, Hoffman EA. CT-based geometry analysis and finite
-D
element models of the human and ovine bronchial tree. J Appl Physiol (1985) 2004; 97(6): 2310-21
L
IA
ER
138. Young HM, Guo F, Eddy RL, Maksym G, Parraga G. Oscillometry and pulmonary MRI measurements of ventilation
AT
heterogeneity in obstructive lung disease: relationship to quality of life and disease control. J Appl Physiol (1985) 2018;
M
T
139. Agusti A, Hogg JC. Update on the Pathogenesis of Chronic Obstructive Pulmonary Disease. N Engl J Med 2019; 381(13):
H
IG
R
140. Celli BR, Agusti A. COPD: time to improve its taxonomy? ERJ Open Res 2018; 4(1): 00132-2017
PY
O
141. Zhou Y, Zhong NS, Li X, et al. Tiotropium in Early-Stage Chronic Obstructive Pulmonary Disease. N Engl J Med 2017;
C

142. Martinez FJ, Han MK, Allinson JP, et al. At the Root: Defining and Halting Progression of Early Chronic Obstructive
Pulmonary Disease. Am J Respir Crit Care Med 2018; 197(12): 1540-51 https://pubmed.ncbi.nlm.nih.gov/29406779.
143. Colak Y, Afzal S, Nordestgaard BG, Lange P, Vestbo J. Importance of Early COPD in Young Adults for Development of
Clinical COPD: Findings from the Copenhagen General Population Study. Am J Respir Crit Care Med 2021; 203(10): 1245-
144. Cosio BG, Pascual-Guardia S, Borras-Santos A, et al. Phenotypic characterisation of early COPD: a prospective case-
control study. ERJ Open Res 2020; 6(4): 00047-2020 https://pubmed.ncbi.nlm.nih.gov/33043045.
145. Han MK, Agusti A, Celli BR, et al. From GOLD 0 to Pre-COPD. Am J Respir Crit Care Med 2021; 203(4): 414-23
146. Martinez F. A, A., Celli, B.R., Han, M.K., Allinson, J., Bhatt, S.P. Treatment Trials in Pre-COPD and Young COPD: Time to
Move Forward. Am J Respir Crit Care Med 2021; in press:
147. Wan ES. The Clinical Spectrum of PRISm. Am J Respir Crit Care Med 2022; 206(5): 524-5
148. Higbee DH, Granell R, Davey Smith G, Dodd JW. Prevalence, risk factors, and clinical implications of preserved ratio
impaired spirometry: a UK Biobank cohort analysis. Lancet Respir Med 2022; 10(2): 149-57
149. Perez-Padilla R, Montes de Oca M, Thirion-Romero I, et al. Trajectories of Spirometric Patterns, Obstructive and PRISm,
in a Population-Based Cohort in Latin America. Int J Chron Obstruct Pulmon Dis 2023; 18: 1277-85
150. Wan ES, Balte P, Schwartz JE, et al. Association Between Preserved Ratio Impaired Spirometry and Clinical Outcomes in
US Adults. JAMA 2021; 326(22): 2287-98 https://pubmed.ncbi.nlm.nih.gov/34905031.
151. Wijnant SRA, De Roos E, Kavousi M, et al. Trajectory and mortality of preserved ratio impaired spirometry: the
Rotterdam Study. Eur Respir J 2020; 55(1): https://pubmed.ncbi.nlm.nih.gov/31601717.
152. Wan ES, Hokanson JE, Regan EA, et al. Significant Spirometric Transitions and Preserved Ratio Impaired Spirometry
Among Ever Smokers. Chest 2022; 161(3): 651-61 https://pubmed.ncbi.nlm.nih.gov/34592319.
153. Washio Y, Sakata S, Fukuyama S, et al. Risks of Mortality and Airflow Limitation in Japanese Individuals with Preserved
Ratio Impaired Spirometry. Am J Respir Crit Care Med 2022; 206(5): 563-72
154. Marott JL, Ingebrigtsen TS, Colak Y, Vestbo J, Lange P. Trajectory of Preserved Ratio Impaired Spirometry: Natural
History and Long-Term Prognosis. Am J Respir Crit Care Med 2021; 204(8): 910-20
155. Zheng J, Zhou R, Zhang Y, et al. Preserved Ratio Impaired Spirometry in Relationship to Cardiovascular Outcomes: A
Large Prospective Cohort Study. Chest 2023; 163(3): 610-23 https://pubmed.ncbi.nlm.nih.gov/36372304.
156. Han MK, Ye W, Wang D, et al. Bronchodilators in Tobacco-Exposed Persons with Symptoms and Preserved Lung
Function. N Engl J Med 2022; 387(13): 1173-84 https://pubmed.ncbi.nlm.nih.gov/36066078.
157. Silva GE, Sherrill DL, Guerra S, Barbee RA. Asthma as a risk factor for COPD in a longitudinal study. Chest 2004; 126(1):
158. Vonk JM, Jongepier H, Panhuysen CI, Schouten JP, Bleecker ER, Postma DS. Risk factors associated with the presence of
irreversible airflow limitation and reduced transfer coefficient in patients with asthma after 26 years of follow up.
Thorax 2003; 58(4): 322-7 https://pubmed.ncbi.nlm.nih.gov/12668795.
159. Lange P, Parner J, Vestbo J, Schnohr P, Jensen G. A 15-year follow-up study of ventilatory function in adults with
asthma. N Engl J Med 1998; 339(17): 1194-200 https://pubmed.ncbi.nlm.nih.gov/9780339.
TE
160. McGeachie MJ, Yates KP, Zhou X, et al. Patterns of Growth and Decline in Lung Function in Persistent Childhood
U
Asthma. N Engl J Med 2016; 374(19): 1842-52 https://pubmed.ncbi.nlm.nih.gov/27168434.
IB
TR
161. de Marco R, Accordini S, Marcon A, et al. Risk factors for chronic obstructive pulmonary disease in a European cohort of
IS
young adults. Am J Respir Crit Care Med 2011; 183(7): 891-7 https://pubmed.ncbi.nlm.nih.gov/20935112.
D
162. Fabbri LM, Romagnoli M, Corbetta L, et al. Differences in airway inflammation in patients with fixed airflow obstruction
T
due to asthma or chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2003; 167(3): 418-24
O
N
O
163. To T, Zhu J, Larsen K, et al. Progression from Asthma to Chronic Obstructive Pulmonary Disease. Is Air Pollution a Risk
-D
Factor? Am J Respir Crit Care Med 2016; 194(4): 429-38 https://pubmed.ncbi.nlm.nih.gov/26950751.

L
164. Rijcken B, Schouten JP, Weiss ST, Speizer FE, van der Lende R. The relationship of nonspecific bronchial responsiveness
IA
ER
to respiratory symptoms in a random population sample. Am Rev Respir Dis 1987; 136(1): 62-8
AT
165. Hospers JJ, Postma DS, Rijcken B, Weiss ST, Schouten JP. Histamine airway hyper-responsiveness and mortality from
M
T
chronic obstructive pulmonary disease: a cohort study. Lancet 2000; 356(9238): 1313-7
H
IG
R
166. Tashkin DP, Altose MD, Connett JE, Kanner RE, Lee WW, Wise RA. Methacholine reactivity predicts changes in lung
PY
function over time in smokers with early chronic obstructive pulmonary disease. The Lung Health Study Research
O
Group. Am J Respir Crit Care Med 1996; 153(6 Pt 1): 1802-11 https://pubmed.ncbi.nlm.nih.gov/8665038.
C
167. de Oca MM, Halbert RJ, Lopez MV, et al. The chronic bronchitis phenotype in subjects with and without COPD: the
PLATINO study. Eur Respir J 2012; 40(1): 28-36 https://pubmed.ncbi.nlm.nih.gov/22282547.
168. Agusti A, Calverley PM, Celli B, et al. Characterisation of COPD heterogeneity in the ECLIPSE cohort. Respir Res 2010;
169. Kim V, Han MK, Vance GB, et al. The chronic bronchitic phenotype of COPD: an analysis of the COPDGene Study. Chest
170. Lu M, Yao W, Zhong N, et al. Chronic obstructive pulmonary disease in the absence of chronic bronchitis in China.
Respirology 2010; 15(7): 1072-8 https://pubmed.ncbi.nlm.nih.gov/20723142.
171. Speizer FE, Fay ME, Dockery DW, Ferris BG, Jr. Chronic obstructive pulmonary disease mortality in six U.S. cities. Am Rev
Respir Dis 1989; 140(3 Pt 2): S49-55 https://pubmed.ncbi.nlm.nih.gov/2782760.
172. Trupin L, Earnest G, San Pedro M, et al. The occupational burden of chronic obstructive pulmonary disease. Eur Respir J
173. Matheson MC, Benke G, Raven J, et al. Biological dust exposure in the workplace is a risk factor for chronic obstructive
pulmonary disease. Thorax 2005; 60(8): 645-51 https://pubmed.ncbi.nlm.nih.gov/16061705.
174. Pelkonen M, Notkola IL, Nissinen A, Tukiainen H, Koskela H. Thirty-year cumulative incidence of chronic bronchitis and
COPD in relation to 30-year pulmonary function and 40-year mortality: a follow-up in middle-aged rural men. Chest
175. Miravitlles M, de la Roza C, Morera J, et al. Chronic respiratory symptoms, spirometry and knowledge of COPD among
general population. Respir Med 2006; 100(11): 1973-80 https://pubmed.ncbi.nlm.nih.gov/16626950.
176. Ehrlich RI, White N, Norman R, et al. Predictors of chronic bronchitis in South African adults. Int J Tuberc Lung Dis 2004;
177. Barish CF, Wu WC, Castell DO. Respiratory complications of gastroesophageal reflux. Arch Intern Med 1985; 145(10):
178. Smyrnios NA, Irwin RS, Curley FJ. Chronic cough with a history of excessive sputum production. The spectrum and
frequency of causes, key components of the diagnostic evaluation, and outcome of specific therapy. Chest 1995; 108(4):
179. Fahy JV, Dickey BF. Airway mucus function and dysfunction. N Engl J Med 2010; 363(23): 2233-47
180. Rose MC, Voynow JA. Respiratory tract mucin genes and mucin glycoproteins in health and disease. Physiol Rev 2006;
181. Thornton DJ, Rousseau K, McGuckin MA. Structure and function of the polymeric mucins in airways mucus. Annu Rev
Physiol 2008; 70: 459-86 https://pubmed.ncbi.nlm.nih.gov/17850213.
182. Tesfaigzi Y. Regulation of mucous cell metaplasia in bronchial asthma. Curr Mol Med 2008; 8(5): 408-15
183. Chen Y, Zhao YH, Di YP, Wu R. Characterization of human mucin 5B gene expression in airway epithelium and the
genomic clone of the amino-terminal and 5'-flanking region. Am J Respir Cell Mol Biol 2001; 25(5): 542-53
184. Nguyen LP, Omoluabi O, Parra S, et al. Chronic exposure to beta-blockers attenuates inflammation and mucin content
in a murine asthma model. Am J Respir Cell Mol Biol 2008; 38(3): 256-62 https://pubmed.ncbi.nlm.nih.gov/18096872.
185. Hogg JC. Pathophysiology of airflow limitation in chronic obstructive pulmonary disease. Lancet 2004; 364(9435): 709-
186. Hayashi T, Ishii A, Nakai S, Hasegawa K. Ultrastructure of goblet-cell metaplasia from Clara cell in the allergic asthmatic
TE
airway inflammation in a mouse model of asthma in vivo. Virchows Arch 2004; 444(1): 66-73
U
IB
TR
187. Bosse Y, Riesenfeld EP, Pare PD, Irvin CG. It's not all smooth muscle: non-smooth-muscle elements in control of
IS
resistance to airflow. Annu Rev Physiol 2010; 72: 437-62 https://pubmed.ncbi.nlm.nih.gov/20148684.
D
188. Holtzman MJ, Byers DE, Benoit LA, et al. Immune pathways for translating viral infection into chronic airway disease.
T
Adv Immunol 2009; 102: 245-76 https://pubmed.ncbi.nlm.nih.gov/19477323.

O
N
189. Lappalainen U, Whitsett JA, Wert SE, Tichelaar JW, Bry K. Interleukin-1beta causes pulmonary inflammation,
O
emphysema, and airway remodeling in the adult murine lung. Am J Respir Cell Mol Biol 2005; 32(4): 311-8
-D
L
190. Deshmukh HS, Shaver C, Case LM, et al. Acrolein-activated matrix metalloproteinase 9 contributes to persistent mucin
IA
ER
production. Am J Respir Cell Mol Biol 2008; 38(4): 446-54 https://pubmed.ncbi.nlm.nih.gov/18006877.

AT
191. Curran DR, Cohn L. Advances in mucous cell metaplasia: a plug for mucus as a therapeutic focus in chronic airway
disease. Am J Respir Cell Mol Biol 2010; 42(3): 268-75 https://pubmed.ncbi.nlm.nih.gov/19520914.
M
T
192. Peng J, Yang XO, Chang SH, Yang J, Dong C. IL-23 signaling enhances Th2 polarization and regulates allergic airway
H
inflammation. Cell Res 2010; 20(1): 62-71 https://pubmed.ncbi.nlm.nih.gov/19935773.

IG
R
193. Hung LY, Velichko S, Huang F, Thai P, Wu R. Regulation of airway innate and adaptive immune responses: the IL-17
PY
paradigm. Crit Rev Immunol 2008; 28(4): 269-79 https://pubmed.ncbi.nlm.nih.gov/19166380.

O
194. Mullen JB, Wright JL, Wiggs BR, Pare PD, Hogg JC. Reassessment of inflammation of airways in chronic bronchitis. Br
C
Med J (Clin Res Ed) 1985; 291(6504): 1235-9 https://pubmed.ncbi.nlm.nih.gov/3933614.

195. Saetta M, Turato G, Facchini FM, et al. Inflammatory cells in the bronchial glands of smokers with chronic bronchitis.
Am J Respir Crit Care Med 1997; 156(5): 1633-9 https://pubmed.ncbi.nlm.nih.gov/9372687.
196. Hogg JC, Chu FS, Tan WC, et al. Survival after lung volume reduction in chronic obstructive pulmonary disease: insights
from small airway pathology. Am J Respir Crit Care Med 2007; 176(5): 454-9
197. Caramori G, Di Gregorio C, Carlstedt I, et al. Mucin expression in peripheral airways of patients with chronic obstructive
pulmonary disease. Histopathology 2004; 45(5): 477-84 https://pubmed.ncbi.nlm.nih.gov/15500651.
198. Okajima Y, Come CE, Nardelli P, et al. Luminal Plugging on Chest CT Scan: Association With Lung Function, Quality of
Life, and COPD Clinical Phenotypes. Chest 2020; 158(1): 121-30 https://pubmed.ncbi.nlm.nih.gov/32017932.
199. Dunican EM, Elicker BM, Henry T, et al. Mucus Plugs and Emphysema in the Pathophysiology of Airflow Obstruction and
Hypoxemia in Smokers. Am J Respir Crit Care Med 2021; 203(8): 957-68 https://pubmed.ncbi.nlm.nih.gov/33180550.
200. Diaz AA, Orejas JL, Grumley S, et al. Airway-Occluding Mucus Plugs and Mortality in Patients With Chronic Obstructive
Pulmonary Disease. Jama 2023; 329(21): 1832-9 https://pubmed.ncbi.nlm.nih.gov/37210745.
201. Burgel PR, Martin C. Mucus hypersecretion in COPD: should we only rely on symptoms? Eur Respir Rev 2010; 19(116):
202. de Marco R, Accordini S, Cerveri I, et al. Incidence of chronic obstructive pulmonary disease in a cohort of young adults
according to the presence of chronic cough and phlegm. Am J Respir Crit Care Med 2007; 175(1): 32-9
203. Guerra S, Sherrill DL, Venker C, Ceccato CM, Halonen M, Martinez FD. Chronic bronchitis before age 50 years predicts
incident airflow limitation and mortality risk. Thorax 2009; 64(10): 894-900
204. Allinson JP, Hardy R, Donaldson GC, Shaheen SO, Kuh D, Wedzicha JA. The Presence of Chronic Mucus Hypersecretion
across Adult Life in Relation to Chronic Obstructive Pulmonary Disease Development. Am J Respir Crit Care Med 2016;
205. Radicioni G, Ceppe A, Ford AA, et al. Airway mucin MUC5AC and MUC5B concentrations and the initiation and
progression of chronic obstructive pulmonary disease: an analysis of the SPIROMICS cohort. Lancet Respir Med 2021;
206. Kesimer M, Ford AA, Ceppe A, et al. Airway Mucin Concentration as a Marker of Chronic Bronchitis. N Engl J Med 2017;
207. Sherman CB, Xu X, Speizer FE, Ferris BG, Jr., Weiss ST, Dockery DW. Longitudinal lung function decline in subjects with
respiratory symptoms. Am Rev Respir Dis 1992; 146(4): 855-9 https://pubmed.ncbi.nlm.nih.gov/1416410.
208. Vestbo J, Lange P. Can GOLD Stage 0 provide information of prognostic value in chronic obstructive pulmonary disease?
209. Dowson LJ, Guest PJ, Stockley RA. The relationship of chronic sputum expectoration to physiologic, radiologic, and
health status characteristics in alpha(1)-antitrypsin deficiency (PiZ). Chest 2002; 122(4): 1247-55
210. Vestbo J, Prescott E, Lange P. Association of chronic mucus hypersecretion with FEV1 decline and chronic obstructive
pulmonary disease morbidity. Copenhagen City Heart Study Group. Am J Respir Crit Care Med 1996; 153(5): 1530-5
211. Stanescu D, Sanna A, Veriter C, et al. Airways obstruction, chronic expectoration, and rapid decline of FEV1 in smokers
are associated with increased levels of sputum neutrophils. Thorax 1996; 51(3): 267-71
TE
U
212. Peto R, Speizer FE, Cochrane AL, et al. The relevance in adults of air-flow obstruction, but not of mucus hypersecretion,
IB
TR
to mortality from chronic lung disease. Results from 20 years of prospective observation. Am Rev Respir Dis 1983;
128(3): 491-500 https://pubmed.ncbi.nlm.nih.gov/6614643. IS
D
213. Ebi-Kryston KL. Respiratory symptoms and pulmonary function as predictors of 10-year mortality from respiratory
T
disease, cardiovascular disease, and all causes in the Whitehall Study. J Clin Epidemiol 1988; 41(3): 251-60
O
N
O
214. Ebi-Kryston KL. Predicting 15 year chronic bronchitis mortality in the Whitehall Study. J Epidemiol Community Health
-D

L
215. Wiles FJ, Hnizdo E. Relevance of airflow obstruction and mucus hypersecretion to mortality. Respir Med 1991; 85(1): 27-
IA
ER
AT
216. Lange P, Nyboe J, Appleyard M, Jensen G, Schnohr P. Relation of ventilatory impairment and of chronic mucus
hypersecretion to mortality from obstructive lung disease and from all causes. Thorax 1990; 45(8): 579-85
M
T
H
217. Annesi I, Kauffmann F. Is respiratory mucus hypersecretion really an innocent disorder? A 22-year mortality survey of
IG
R
1,061 working men. Am Rev Respir Dis 1986; 134(4): 688-93 https://pubmed.ncbi.nlm.nih.gov/3767125.
PY
218. Prescott E, Lange P, Vestbo J. Chronic mucus hypersecretion in COPD and death from pulmonary infection. Eur Respir J
O

C
219. Kim V, Sternberg AL, Washko G, et al. Severe chronic bronchitis in advanced emphysema increases mortality and
hospitalizations. COPD 2013; 10(6): 667-78 https://pubmed.ncbi.nlm.nih.gov/23978192.
220. Wu F, Fan H, Liu J, et al. Association Between Non-obstructive Chronic Bronchitis and Incident Chronic Obstructive
Pulmonary Disease and All-Cause Mortality: A Systematic Review and Meta-Analysis. Front Med (Lausanne) 2021; 8:
221. Fortis S, Shannon ZK, Garcia CJ, et al. Association of Nonobstructive Chronic Bronchitis With All-Cause Mortality: A
Systematic Literature Review and Meta-analysis. Chest 2022; 162(1): 92-100
222. Allinson JP, Hardy R, Donaldson GC, Shaheen SO, Kuh D, Wedzicha JA. Combined Impact of Smoking and Early-Life
Exposures on Adult Lung Function Trajectories. Am J Respir Crit Care Med 2017; 196(8): 1021-30
223. Martinez-Garcia MA, Faner R, Oscullo G, et al. Chronic Bronchial Infection Is Associated with More Rapid Lung Function
Decline in Chronic Obstructive Pulmonary Disease. Ann Am Thorac Soc 2022; 19(11): 1842-7
224. Fan H, Wu F, Liu J, et al. Pulmonary tuberculosis as a risk factor for chronic obstructive pulmonary disease: a systematic
review and meta-analysis. Ann Transl Med 2021; 9(5): 390 https://pubmed.ncbi.nlm.nih.gov/33842611.
225. Byrne AL, Marais BJ, Mitnick CD, Lecca L, Marks GB. Tuberculosis and chronic respiratory disease: a systematic review.
Int J Infect Dis 2015; 32: 138-46 https://pubmed.ncbi.nlm.nih.gov/25809770.
226. Menezes AM, Hallal PC, Perez-Padilla R, et al. Tuberculosis and airflow obstruction: evidence from the PLATINO study in
Latin America. Eur Respir J 2007; 30(6): 1180-5 https://pubmed.ncbi.nlm.nih.gov/17804445.
227. Jordan TS, Spencer EM, Davies P. Tuberculosis, bronchiectasis and chronic airflow obstruction. Respirology 2010; 15(4):
228. Bigna JJ, Kenne AM, Asangbeh SL, Sibetcheu AT. Prevalence of chronic obstructive pulmonary disease in the global
population with HIV: a systematic review and meta-analysis. Lancet Glob Health 2018; 6(2): e193-e202
229. Thudium RF, Ronit A, Afzal S, et al. Faster lung function decline in people living with HIV despite adequate treatment: a
longitudinal matched cohort study. Thorax 2023; 78(6): 535-42 https://pubmed.ncbi.nlm.nih.gov/36639241.
230. Hernandez Cordero AI, Yang CX, Obeidat M, et al. DNA methylation is associated with airflow obstruction in patients
living with HIV. Thorax 2021; 76(5): 448-55 https://pubmed.ncbi.nlm.nih.gov/33443234.
231. Lee H, Kovacs C, Mattman A, et al. The impact of IgG subclass deficiency on the risk of mortality in hospitalized patients
with COPD. Respir Res 2022; 23(1): 141 https://pubmed.ncbi.nlm.nih.gov/35641962.
232. Landis SH, Muellerova H, Mannino DM, et al. Continuing to Confront COPD International Patient Survey: methods,
COPD prevalence, and disease burden in 2012-2013. Int J Chron Obstruct Pulmon Dis 2014; 9: 597-611
233. Foreman MG, Zhang L, Murphy J, et al. Early-onset chronic obstructive pulmonary disease is associated with female sex,
maternal factors, and African American race in the COPDGene Study. Am J Respir Crit Care Med 2011; 184(4): 414-20
234. Lopez Varela MV, Montes de Oca M, Halbert RJ, et al. Sex-related differences in COPD in five Latin American cities: the
PLATINO study. Eur Respir J 2010; 36(5): 1034-41 https://pubmed.ncbi.nlm.nih.gov/20378599.
235. Silverman EK, Weiss ST, Drazen JM, et al. Gender-related differences in severe, early-onset chronic obstructive
pulmonary disease. Am J Respir Crit Care Med 2000; 162(6): 2152-8 https://pubmed.ncbi.nlm.nih.gov/11112130.
236. Amaral AFS, Strachan DP, Burney PGJ, Jarvis DL. Female Smokers Are at Greater Risk of Airflow Obstruction Than Male
Smokers. UK Biobank. Am J Respir Crit Care Med 2017; 195(9): 1226-35 https://pubmed.ncbi.nlm.nih.gov/28075609.
TE
237. Martinez FJ, Curtis JL, Sciurba F, et al. Sex differences in severe pulmonary emphysema. Am J Respir Crit Care Med 2007;
U
IB
TR
238. Tam A, Churg A, Wright JL, et al. Sex Differences in Airway Remodeling in a Mouse Model of Chronic Obstructive
IS
D
239. Bhakta NR, Bime C, Kaminsky DA, et al. Race and Ethnicity in Pulmonary Function Test Interpretation: An Official
T
American Thoracic Society Statement. Am J Respir Crit Care Med 2023; 207(8): 978-95
O
N
O
240. Townend J, Minelli C, Mortimer K, et al. The association between chronic airflow obstruction and poverty in 12 sites of
-D
the multinational BOLD study. Eur Respir J 2017; 49(6): https://pubmed.ncbi.nlm.nih.gov/28572124.

L
241. Beran D, Zar HJ, Perrin C, Menezes AM, Burney P, Forum of International Respiratory Societies working group c. Burden
IA
ER
of asthma and chronic obstructive pulmonary disease and access to essential medicines in low-income and middle-
AT
income countries. Lancet Respir Med 2015; 3(2): 159-70 https://pubmed.ncbi.nlm.nih.gov/25680912.

242. Gershon AS, Warner L, Cascagnette P, Victor JC, To T. Lifetime risk of developing chronic obstructive pulmonary disease:
M
T
a longitudinal population study. Lancet 2011; 378(9795): 991-6 https://pubmed.ncbi.nlm.nih.gov/21907862.

H
243. Hogg JC, Timens W. The pathology of chronic obstructive pulmonary disease. Annu Rev Pathol 2009; 4: 435-59
IG
R
PY
244. Barnes PJ. Inflammatory mechanisms in patients with chronic obstructive pulmonary disease. J Allergy Clin Immunol
O

C
245. Barnes PJ. Cellular and molecular mechanisms of chronic obstructive pulmonary disease. Clin Chest Med 2014; 35(1):
246. Sze MA, Dimitriu PA, Suzuki M, et al. Host Response to the Lung Microbiome in Chronic Obstructive Pulmonary Disease.
247. Lee SH, Goswami S, Grudo A, et al. Antielastin autoimmunity in tobacco smoking-induced emphysema. Nat Med 2007;
248. Barnes PJ. Immunology of asthma and chronic obstructive pulmonary disease. Nat Rev Immunol 2008; 8(3): 183-92
249. Global Initiative for Asthma (GINA). 2017 Asthma, COPD and Asthma-COPD Overlap Syndrome (ACOS) available here:
https://ginasthma.org/wp-content/uploads/2019/11/GINA-GOLD-2017-overlap-pocket-guide-wms-2017-ACO.pdf
[accessed Oct 2023].
250. Domej W, Oettl K, Renner W. Oxidative stress and free radicals in COPD--implications and relevance for treatment. Int J
Chron Obstruct Pulmon Dis 2014; 9: 1207-24 https://pubmed.ncbi.nlm.nih.gov/25378921.
251. Malhotra D, Thimmulappa R, Vij N, et al. Heightened endoplasmic reticulum stress in the lungs of patients with chronic
obstructive pulmonary disease: the role of Nrf2-regulated proteasomal activity. Am J Respir Crit Care Med 2009;
252. Stockley RA. Neutrophils and protease/antiprotease imbalance. Am J Respir Crit Care Med 1999; 160(5 Pt 2): S49-52
253. Johnson SR. Untangling the protease web in COPD: metalloproteinases in the silent zone. Thorax 2016; 71(2): 105-6
254. Katzenstein AL, Mukhopadhyay S, Myers JL. Diagnosis of usual interstitial pneumonia and distinction from other
fibrosing interstitial lung diseases. Hum Pathol 2008; 39(9): 1275-94 https://pubmed.ncbi.nlm.nih.gov/18706349.
255. Washko GR, Hunninghake GM, Fernandez IE, et al. Lung volumes and emphysema in smokers with interstitial lung
abnormalities. N Engl J Med 2011; 364(10): 897-906 https://pubmed.ncbi.nlm.nih.gov/21388308.
256. Putman RK, Hatabu H, Araki T, et al. Association Between Interstitial Lung Abnormalities and All-Cause Mortality. JAMA
257. Churg A, Tai H, Coulthard T, Wang R, Wright JL. Cigarette smoke drives small airway remodeling by induction of growth
factors in the airway wall. Am J Respir Crit Care Med 2006; 174(12): 1327-34
258. Rennard SI, Wachenfeldt K. Rationale and emerging approaches for targeting lung repair and regeneration in the
treatment of chronic obstructive pulmonary disease. Proc Am Thorac Soc 2011; 8(4): 368-75
259. Hogg JC, McDonough JE, Gosselink JV, Hayashi S. What drives the peripheral lung-remodeling process in chronic
obstructive pulmonary disease? Proc Am Thorac Soc 2009; 6(8): 668-72 https://pubmed.ncbi.nlm.nih.gov/20008873.
260. Peinado VI, Barbera JA, Ramirez J, et al. Endothelial dysfunction in pulmonary arteries of patients with mild COPD. Am J
Physiol 1998; 274(6): L908-13 https://pubmed.ncbi.nlm.nih.gov/9609729.
261. McDonough JE, Yuan R, Suzuki M, et al. Small-airway obstruction and emphysema in chronic obstructive pulmonary
disease. N Engl J Med 2011; 365(17): 1567-75 https://pubmed.ncbi.nlm.nih.gov/22029978.
262. Hogg JC, Chu F, Utokaparch S, et al. The nature of small-airway obstruction in chronic obstructive pulmonary disease. N
Engl J Med 2004; 350(26): 2645-53 https://pubmed.ncbi.nlm.nih.gov/15215480.
263. O'Donnell DE, Laveneziana P. The clinical importance of dynamic lung hyperinflation in COPD. COPD 2006; 3(4): 219-32
264. Gagnon P, Guenette JA, Langer D, et al. Pathogenesis of hyperinflation in chronic obstructive pulmonary disease. Int J
TE
U
265. O'Donnell DE, Lam M, Webb KA. Spirometric correlates of improvement in exercise performance after anticholinergic
IB
TR
therapy in chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1999; 160(2): 542-9
D
266. O'Donnell DE, Webb KA. Exertional breathlessness in patients with chronic airflow limitation. The role of lung
T
hyperinflation. Am Rev Respir Dis 1993; 148(5): 1351-7 https://pubmed.ncbi.nlm.nih.gov/8239175.

O
N
267. O'Donnell DE, Laveneziana P. Dyspnea and activity limitation in COPD: mechanical factors. COPD 2007; 4(3): 225-36
O
-D
268. O'Donnell DE, Webb KA. The major limitation to exercise performance in COPD is dynamic hyperinflation. J Appl Physiol
L
(1985) 2008; 105(2): 753-5; discussion 5-7 https://pubmed.ncbi.nlm.nih.gov/18678624.

IA
ER
269. O'Donnell DE, Revill SM, Webb KA. Dynamic hyperinflation and exercise intolerance in chronic obstructive pulmonary
AT
disease. Am J Respir Crit Care Med 2001; 164(5): 770-7 https://pubmed.ncbi.nlm.nih.gov/11549531.

270. Ozgur ES, Nayci SA, Ozge C, Tasdelen B. An integrated index combined by dynamic hyperinflation and exercise capacity
M
T
in the prediction of morbidity and mortality in COPD. Respir Care 2012; 57(9): 1452-9
H
IG
R
271. Albuquerque AL, Nery LE, Villaca DS, et al. Inspiratory fraction and exercise impairment in COPD patients GOLD stages
PY
II-III. Eur Respir J 2006; 28(5): 939-44 https://pubmed.ncbi.nlm.nih.gov/16870665.

O
272. Casanova C, Cote C, de Torres JP, et al. Inspiratory-to-total lung capacity ratio predicts mortality in patients with chronic
C
obstructive pulmonary disease. Am J Respir Crit Care Med 2005; 171(6): 591-7
273. Jubran A, Tobin MJ. Pathophysiologic basis of acute respiratory distress in patients who fail a trial of weaning from
mechanical ventilation. Am J Respir Crit Care Med 1997; 155(3): 906-15 https://pubmed.ncbi.nlm.nih.gov/9117025.
274. Tantucci C, Donati P, Nicosia F, et al. Inspiratory capacity predicts mortality in patients with chronic obstructive
pulmonary disease. Respir Med 2008; 102(4): 613-9 https://pubmed.ncbi.nlm.nih.gov/18083020.
275. Hyatt RE. Expiratory flow limitation. J Appl Physiol Respir Environ Exerc Physiol 1983; 55(1 Pt 1): 1-7
276. Gagnon P, Saey D, Provencher S, et al. Walking exercise response to bronchodilation in mild COPD: a randomized trial.
Respir Med 2012; 106(12): 1695-705 https://pubmed.ncbi.nlm.nih.gov/22999808.
277. Deesomchok A, Webb KA, Forkert L, et al. Lung hyperinflation and its reversibility in patients with airway obstruction of
varying severity. COPD 2010; 7(6): 428-37 https://pubmed.ncbi.nlm.nih.gov/21166631.
278. O'Donnell CR, Bankier AA, Stiebellehner L, Reilly JJ, Brown R, Loring SH. Comparison of plethysmographic and helium
dilution lung volumes: which is best for COPD? Chest 2010; 137(5): 1108-15
279. Wanger J, Clausen JL, Coates A, et al. Standardisation of the measurement of lung volumes. Eur Respir J 2005; 26(3):
280. Tantucci C, Duguet A, Similowski T, Zelter M, Derenne JP, Milic-Emili J. Effect of salbutamol on dynamic hyperinflation in
chronic obstructive pulmonary disease patients. Eur Respir J 1998; 12(4): 799-804
281. O'Donnell DE, Voduc N, Fitzpatrick M, Webb KA. Effect of salmeterol on the ventilatory response to exercise in chronic
obstructive pulmonary disease. Eur Respir J 2004; 24(1): 86-94 https://pubmed.ncbi.nlm.nih.gov/15293609.
282. O'Donnell DE, Fluge T, Gerken F, et al. Effects of tiotropium on lung hyperinflation, dyspnoea and exercise tolerance in
COPD. Eur Respir J 2004; 23(6): 832-40 https://pubmed.ncbi.nlm.nih.gov/15218994.
283. O'Donnell DE, D'Arsigny C, Webb KA. Effects of hyperoxia on ventilatory limitation during exercise in advanced chronic
284. Somfay A, Porszasz J, Lee SM, Casaburi R. Dose-response effect of oxygen on hyperinflation and exercise endurance in
nonhypoxaemic COPD patients. Eur Respir J 2001; 18(1): 77-84 https://pubmed.ncbi.nlm.nih.gov/11510809.
285. Palange P, Valli G, Onorati P, et al. Effect of heliox on lung dynamic hyperinflation, dyspnea, and exercise endurance
capacity in COPD patients. J Appl Physiol (1985) 2004; 97(5): 1637-42 https://pubmed.ncbi.nlm.nih.gov/15234959.
286. Porszasz J, Emtner M, Goto S, Somfay A, Whipp BJ, Casaburi R. Exercise training decreases ventilatory requirements and
exercise-induced hyperinflation at submaximal intensities in patients with COPD. Chest 2005; 128(4): 2025-34
287. Spahija J, Marchie M, Ghezzo H, Grassino A. Factors discriminating spontaneous pursed-lips breathing use in patients
with COPD. COPD 2010; 7(4): 254-61 https://pubmed.ncbi.nlm.nih.gov/20673034.
288. Petrovic M, Reiter M, Zipko H, Pohl W, Wanke T. Effects of inspiratory muscle training on dynamic hyperinflation in
patients with COPD. Int J Chron Obstruct Pulmon Dis 2012; 7: 797-805 https://pubmed.ncbi.nlm.nih.gov/23233798.
289. Fishman A, Martinez F, Naunheim K, et al. A randomized trial comparing lung-volume-reduction surgery with medical
therapy for severe emphysema. N Engl J Med 2003; 348(21): 2059-73 https://pubmed.ncbi.nlm.nih.gov/12759479.
290. Criner GJ, Delage A, Voelker K, et al. Improving Lung Function in Severe Heterogenous Emphysema with the Spiration
Valve System (EMPROVE). A Multicenter, Open-Label Randomized Controlled Clinical Trial. Am J Respir Crit Care Med
TE
291. Criner GJ, Sue R, Wright S, et al. A Multicenter Randomized Controlled Trial of Zephyr Endobronchial Valve Treatment in
U
Heterogeneous Emphysema (LIBERATE). Am J Respir Crit Care Med 2018; 198(9): 1151-64
IB
TR
292. IS
Rodriguez-Roisin R, Drakulovic M, Rodriguez DA, Roca J, Barbera JA, Wagner PD. Ventilation-perfusion imbalance and
D
chronic obstructive pulmonary disease staging severity. J Appl Physiol (1985) 2009; 106(6): 1902-8
T
O
N
293. Elbehairy AF, Ciavaglia CE, Webb KA, et al. Pulmonary Gas Exchange Abnormalities in Mild Chronic Obstructive
O
Pulmonary Disease. Implications for Dyspnea and Exercise Intolerance. Am J Respir Crit Care Med 2015; 191(12): 1384-
-D
L
294. Sakao S, Voelkel NF, Tatsumi K. The vascular bed in COPD: pulmonary hypertension and pulmonary vascular alterations.
IA
ER
Eur Respir Rev 2014; 23(133): 350-5 https://pubmed.ncbi.nlm.nih.gov/25176971.

AT
295. Iyer KS, Newell JD, Jr., Jin D, et al. Quantitative Dual-Energy Computed Tomography Supports a Vascular Etiology of
Smoking-induced Inflammatory Lung Disease. Am J Respir Crit Care Med 2016; 193(6): 652-61
M
T
H
296. Alford SK, van Beek EJ, McLennan G, Hoffman EA. Heterogeneity of pulmonary perfusion as a mechanistic image-based
IG
R
phenotype in emphysema susceptible smokers. Proc Natl Acad Sci U S A 2010; 107(16): 7485-90
PY
O
297. Peinado VI, Pizarro S, Barbera JA. Pulmonary vascular involvement in COPD. Chest 2008; 134(4): 808-14
C
298. Kovacs G, Agusti A, Barbera JA, et al. Pulmonary Vascular Involvement in Chronic Obstructive Pulmonary Disease. Is
There a Pulmonary Vascular Phenotype? Am J Respir Crit Care Med 2018; 198(8): 1000-11
299. Zhang L, Liu Y, Zhao S, et al. The Incidence and Prevalence of Pulmonary Hypertension in the COPD Population: A
Systematic Review and Meta-Analysis. Int J Chron Obstruct Pulmon Dis 2022; 17: 1365-79
300. Kovacs G, Avian A, Bachmaier G, et al. Severe Pulmonary Hypertension in COPD: Impact on Survival and Diagnostic
Approach. Chest 2022; 162(1): 202-12 https://pubmed.ncbi.nlm.nih.gov/35092746.
301. Wells JM, Washko GR, Han MK, et al. Pulmonary arterial enlargement and acute exacerbations of COPD. N Engl J Med
302. Parker CM, Voduc N, Aaron SD, Webb KA, O'Donnell DE. Physiological changes during symptom recovery from
moderate exacerbations of COPD. Eur Respir J 2005; 26(3): 420-8 https://pubmed.ncbi.nlm.nih.gov/16135722.
303. Barbera JA, Roca J, Ferrer A, et al. Mechanisms of worsening gas exchange during acute exacerbations of chronic
304. Celli BR, Fabbri LM, Aaron SD, et al. An Updated Definition and Severity Classification of Chronic Obstructive Pulmonary
Disease Exacerbations: The Rome Proposal. Am J Respir Crit Care Med 2021; 204(11): 1251-8
305. Miller J, Edwards LD, Agusti A, et al. Comorbidity, systemic inflammation and outcomes in the ECLIPSE cohort. Respir
306. Dharmage S, Agusti A. Personal communication. 2022:
307. Stolz D, Mkorombindo T, Schumann DM, et al. Towards the elimination of chronic obstructive pulmonary disease: a
Lancet Commission. Lancet 2022; 400(10356): 921-72 https://pubmed.ncbi.nlm.nih.gov/36075255.
308. Kessler R, Partridge MR, Miravitlles M, et al. Symptom variability in patients with severe COPD: a pan-European cross-
sectional study. Eur Respir J 2011; 37(2): 264-72 https://pubmed.ncbi.nlm.nih.gov/21115606.
309. Montes de Oca M, Perez-Padilla R, Talamo C, et al. Acute bronchodilator responsiveness in subjects with and without
airflow obstruction in five Latin American cities: the PLATINO study. Pulm Pharmacol Ther 2010; 23(1): 29-35
310. Miravitlles M, Worth H, Soler Cataluna JJ, et al. Observational study to characterise 24-hour COPD symptoms and their
relationship with patient-reported outcomes: results from the ASSESS study. Respir Res 2014; 15(1): 122
311. Laviolette L, Laveneziana P, Faculty ERSRS. Dyspnoea: a multidimensional and multidisciplinary approach. Eur Respir J
312. Elliott MW, Adams L, Cockcroft A, MacRae KD, Murphy K, Guz A. The language of breathlessness. Use of verbal
descriptors by patients with cardiopulmonary disease. Am Rev Respir Dis 1991; 144(4): 826-32
313. Phillips DB, Elbehairy AF, James MD, et al. Impaired Ventilatory Efficiency, Dyspnea, and Exercise Intolerance in Chronic
Obstructive Pulmonary Disease: Results from the CanCOLD Study. Am J Respir Crit Care Med 2022; 205(12): 1391-402
314. Mullerova H, Lu C, Li H, Tabberer M. Prevalence and burden of breathlessness in patients with chronic obstructive
pulmonary disease managed in primary care. PLoS One 2014; 9(1): e85540 https://pubmed.ncbi.nlm.nih.gov/24427316.
315. Lapperre T, Bodtger U, Kjærsgaard Klein D, et al. Dysfunctional breathing impacts symptom burden in Chronic
Obstructive Pulmonary Disease (COPD). European Respiratory Journal 2020; 56(suppl 64): 124
TE
316. Vidotto LS, Carvalho CRF, Harvey A, Jones M. Dysfunctional breathing: what do we know? J Bras Pneumol 2019; 45(1):
U
IB
TR
317. Verberkt CA, van den Beuken-van Everdingen MHJ, Schols J, Hameleers N, Wouters EFM, Janssen DJA. Effect of
IS
Sustained-Release Morphine for Refractory Breathlessness in Chronic Obstructive Pulmonary Disease on Health Status:
D
A Randomized Clinical Trial. JAMA Intern Med 2020; 180(10): 1306-14 https://pubmed.ncbi.nlm.nih.gov/32804188.
T
318. Lewthwaite H, Jensen D, Ekstrom M. How to Assess Breathlessness in Chronic Obstructive Pulmonary Disease. Int J
O
N

O
319. O'Donnell DE, Milne KM, James MD, de Torres JP, Neder JA. Dyspnea in COPD: New Mechanistic Insights and
-D
Management Implications. Adv Ther 2020; 37(1): 41-60 https://pubmed.ncbi.nlm.nih.gov/31673990.

L
320. Cho SH, Lin HC, Ghoshal AG, et al. Respiratory disease in the Asia-Pacific region: Cough as a key symptom. Allergy
IA
ER
Asthma Proc 2016; 37(2): 131-40 https://pubmed.ncbi.nlm.nih.gov/26802834.

AT
321. Medical Research Council Committee on the Aetiology of Chronic Bronchitis. Definition and classification of chronic
bronchitis for clinical and epidemiological purposes. A report to the Medical Research Council by their Committee on
M
T
the Aetiology of Chronic Bronchitis. Lancet 1965; 1(7389): 775-9 https://pubmed.ncbi.nlm.nih.gov/4165081.

H
322. Du Q, Jin J, Liu X, Sun Y. Bronchiectasis as a Comorbidity of Chronic Obstructive Pulmonary Disease: A Systematic
IG
R
Review and Meta-Analysis. PLoS One 2016; 11(3): e0150532 https://pubmed.ncbi.nlm.nih.gov/26978269.

PY
323. Ni Y, Shi G, Yu Y, Hao J, Chen T, Song H. Clinical characteristics of patients with chronic obstructive pulmonary disease
O
with comorbid bronchiectasis: a systemic review and meta-analysis. Int J Chron Obstruct Pulmon Dis 2015; 10: 1465-75
C
324. Soler N, Esperatti M, Ewig S, Huerta A, Agusti C, Torres A. Sputum purulence-guided antibiotic use in hospitalised
patients with exacerbations of COPD. Eur Respir J 2012; 40(6): 1344-53 https://pubmed.ncbi.nlm.nih.gov/22523352.
325. Brusse-Keizer MG, Grotenhuis AJ, Kerstjens HA, et al. Relation of sputum colour to bacterial load in acute exacerbations
of COPD. Respir Med 2009; 103(4): 601-6 https://pubmed.ncbi.nlm.nih.gov/19027281.
326. Stockley RA, O'Brien C, Pye A, Hill SL. Relationship of sputum color to nature and outpatient management of acute
exacerbations of COPD. Chest 2000; 117(6): 1638-45 https://pubmed.ncbi.nlm.nih.gov/10858396.
327. Goertz YMJ, Looijmans M, Prins JB, et al. Fatigue in patients with chronic obstructive pulmonary disease: protocol of the
Dutch multicentre, longitudinal, observational FAntasTIGUE study. BMJ Open 2018; 8(4): e021745
328. Ream E, Richardson A. Fatigue in patients with cancer and chronic obstructive airways disease: a phenomenological
enquiry. Int J Nurs Stud 1997; 34(1): 44-53 https://pubmed.ncbi.nlm.nih.gov/9055120.
329. Small SP, Lamb M. Measurement of fatigue in chronic obstructive pulmonary disease and in asthma. Int J Nurs Stud
330. von Haehling S, Anker SD. Cachexia as a major underestimated and unmet medical need: facts and numbers. J Cachexia
Sarcopenia Muscle 2010; 1(1): 1-5 https://pubmed.ncbi.nlm.nih.gov/21475699.
331. Schols AM, Soeters PB, Dingemans AM, Mostert R, Frantzen PJ, Wouters EF. Prevalence and characteristics of
nutritional depletion in patients with stable COPD eligible for pulmonary rehabilitation. Am Rev Respir Dis 1993; 147(5):
332. Attaway AH, Welch N, Hatipoglu U, Zein JG, Dasarathy S. Muscle loss contributes to higher morbidity and mortality in
COPD: An analysis of national trends. Respirology 2021; 26(1): 62-71 https://pubmed.ncbi.nlm.nih.gov/32542761.
333. Rutten EP, Calverley PM, Casaburi R, et al. Changes in body composition in patients with chronic obstructive pulmonary
disease: do they influence patient-related outcomes? Ann Nutr Metab 2013; 63(3): 239-47
334. Schols AM, Broekhuizen R, Weling-Scheepers CA, Wouters EF. Body composition and mortality in chronic obstructive
pulmonary disease. Am J Clin Nutr 2005; 82(1): 53-9 https://pubmed.ncbi.nlm.nih.gov/16002800.
335. Hanania NA, Mullerova H, Locantore NW, et al. Determinants of depression in the ECLIPSE chronic obstructive
pulmonary disease cohort. Am J Respir Crit Care Med 2011; 183(5): 604-11 https://pubmed.ncbi.nlm.nih.gov/20889909.
336. Blakemore A, Dickens C, Chew-Graham CA, et al. Depression predicts emergency care use in people with chronic
obstructive pulmonary disease: a large cohort study in primary care. Int J Chron Obstruct Pulmon Dis 2019; 14: 1343-53
337. Agusti A, Rapsomaniki E, Beasley R, et al. Treatable traits in the NOVELTY study. Respirology 2022; 27(11): 929-40
338. Holleman DR, Jr., Simel DL. Does the clinical examination predict airflow limitation? JAMA 1995; 273(4): 313-9
339. Kesten S, Chapman KR. Physician perceptions and management of COPD. Chest 1993; 104(1): 254-8
340. Miller MR, Hankinson J, Brusasco V, et al. Standardisation of spirometry. Eur Respir J 2005; 26(2): 319-38
341. Pellegrino R, Viegi G, Brusasco V, et al. Interpretative strategies for lung function tests. Eur Respir J 2005; 26(5): 948-68
342. Colak Y, Nordestgaard BG, Vestbo J, Lange P, Afzal S. Prognostic significance of chronic respiratory symptoms in
TE
individuals with normal spirometry. Eur Respir J 2019; 54(3): https://pubmed.ncbi.nlm.nih.gov/31248954.
U
343. Jackson H, Hubbard R. Detecting chronic obstructive pulmonary disease using peak flow rate: cross sectional survey.
IB
TR
BMJ 2003; 327(7416): 653-4 https://pubmed.ncbi.nlm.nih.gov/14500437.
344. IS
Quanjer PH, Stanojevic S, Cole TJ, et al. Multi-ethnic reference values for spirometry for the 3-95-yr age range: the
D
global lung function 2012 equations. Eur Respir J 2012; 40(6): 1324-43 https://pubmed.ncbi.nlm.nih.gov/22743675.
T
345. Walker PP, Calverley PM. The volumetric response to bronchodilators in stable chronic obstructive pulmonary disease.
O
N
COPD 2008; 5(3): 147-52 https://pubmed.ncbi.nlm.nih.gov/18568838.

O
346. Calverley PM, Albert P, Walker PP. Bronchodilator reversibility in chronic obstructive pulmonary disease: use and
-D
limitations. Lancet Respir Med 2013; 1(7): 564-73 https://pubmed.ncbi.nlm.nih.gov/24461617.

L
347. Enright PL, Beck KC, Sherrill DL. Repeatability of spirometry in 18,000 adult patients. Am J Respir Crit Care Med 2004;
IA
ER

AT
348. Fortis S, Eberlein M, Georgopoulos D, Comellas AP. Predictive value of prebronchodilator and postbronchodilator
spirometry for COPD features and outcomes. BMJ Open Respir Res 2017; 4(1): e000213
M
T
H
349. Buhr RG, Barjaktarevic IZ, Quibrera PM, et al. Reversible Airflow Obstruction Predicts Future Chronic Obstructive
IG
R
Pulmonary Disease Development in the SPIROMICS Cohort: An Observational Cohort Study. Am J Respir Crit Care Med
PY

O
350. van Dijk W, Tan W, Li P, et al. Clinical relevance of fixed ratio vs lower limit of normal of FEV1/FVC in COPD: patient-
C
reported outcomes from the CanCOLD cohort. Ann Fam Med 2015; 13(1): 41-8
351. Guder G, Brenner S, Angermann CE, et al. "GOLD or lower limit of normal definition? A comparison with expert-based
diagnosis of chronic obstructive pulmonary disease in a prospective cohort-study". Respir Res 2012; 13(1): 13
352. Bhatt SP, Sieren JC, Dransfield MT, et al. Comparison of spirometric thresholds in diagnosing smoking-related airflow
obstruction. Thorax 2014; 69(5): 409-14 https://pubmed.ncbi.nlm.nih.gov/23525095.
353. Çolak Y, Afzal S, Nordestgaard BG, Vestbo J, Lange P. Young and middle-aged adults with airflow limitation according to
lower limit of normal but not fixed ratio have high morbidity and poor survival: a population-based prospective
cohort study. Eur Respir J 2018; 51(3): https://pubmed.ncbi.nlm.nih.gov/29449425.
354. Bhatt SP, Balte PP, Schwartz JE, et al. Discriminative Accuracy of FEV1:FVC Thresholds for COPD-Related Hospitalization
and Mortality. JAMA 2019; 321(24): 2438-47 https://pubmed.ncbi.nlm.nih.gov/31237643.
355. Vaz Fragoso CA, McAvay G, Van Ness PH, et al. Phenotype of normal spirometry in an aging population. Am J Respir Crit
Care Med 2015; 192(7): 817-25 https://pubmed.ncbi.nlm.nih.gov/26114439.
356. Vaz Fragoso CA, McAvay G, Van Ness PH, et al. Phenotype of Spirometric Impairment in an Aging Population. Am J
Respir Crit Care Med 2016; 193(7): 727-35 https://pubmed.ncbi.nlm.nih.gov/26540012.
357. Aaron SD, Tan WC, Bourbeau J, et al. Diagnostic Instability and Reversals of Chronic Obstructive Pulmonary Disease
Diagnosis in Individuals with Mild to Moderate Airflow Obstruction. Am J Respir Crit Care Med 2017; 196(3): 306-14
358. Schermer TR, Robberts B, Crockett AJ, et al. Should the diagnosis of COPD be based on a single spirometry test? NPJ
Prim Care Respir Med 2016; 26: 16059 https://pubmed.ncbi.nlm.nih.gov/27684728.
359. Albert P, Agusti A, Edwards L, et al. Bronchodilator responsiveness as a phenotypic characteristic of established chronic
obstructive pulmonary disease. Thorax 2012; 67(8): 701-8 https://pubmed.ncbi.nlm.nih.gov/22696176.
360. Hansen JE, Porszasz J. Counterpoint: Is an increase in FEV(1) and/or FVC >/= 12% of control and >/= 200 mL the best
way to assess positive bronchodilator response? No. Chest 2014; 146(3): 538-41
361. Allinson JP, Afzal S, Colak Y, et al. Changes in lung function in European adults born between 1884 and 1996 and
implications for the diagnosis of lung disease: a cross-sectional analysis of ten population-based studies. Lancet Respir
362. Qaseem A, Snow V, Shekelle P, et al. Diagnosis and management of stable chronic obstructive pulmonary disease: a
clinical practice guideline from the American College of Physicians. Ann Intern Med 2007; 147(9): 633-8
363. U. S. Preventive Services Task Force, Mangione CM, Barry MJ, et al. Screening for Chronic Obstructive Pulmonary
Disease: US Preventive Services Task Force Reaffirmation Recommendation Statement. JAMA 2022; 327(18): 1806-11
364. Hill K, Goldstein RS, Guyatt GH, et al. Prevalence and underdiagnosis of chronic obstructive pulmonary disease among
patients at risk in primary care. CMAJ 2010; 182(7): 673-8 https://pubmed.ncbi.nlm.nih.gov/20371646.
365. Lopez Varela MV, Montes de Oca M, Rey A, et al. Development of a simple screening tool for opportunistic COPD case
finding in primary care in Latin America: The PUMA study. Respirology 2016; 21(7): 1227-34
366. Kim T, Choi H, Seo JI, et al. Prevalence, Trend, and Risk Factors for Early Chronic Obstructive Pulmonary Disease: An
Analysis of the Nationwide Population-Based Survey from 2010 to 2019 in South Korea. Copd 2023; 20(1): 153-61
TE
U
367. Tammemagi MC, Lam SC, McWilliams AM, Sin DD. Incremental value of pulmonary function and sputum DNA image
IB
TR
cytometry in lung cancer risk prediction. Cancer Prev Res (Phila) 2011; 4(4): 552-61
D
368. de-Torres JP, Wilson DO, Sanchez-Salcedo P, et al. Lung cancer in patients with chronic obstructive pulmonary disease.
T
Development and validation of the COPD Lung Cancer Screening Score. Am J Respir Crit Care Med 2015; 191(3): 285-91
O
N
O
369. Agusti A, Fabbri LM, Baraldi E, et al. Spirometry: A practical lifespan predictor of global health and chronic respiratory
-D
and non-respiratory diseases. Eur J Intern Med 2021; 89: 3-9 https://pubmed.ncbi.nlm.nih.gov/34016514.
L
370. Haroon S, Adab P, Riley RD, Fitzmaurice D, Jordan RE. Predicting risk of undiagnosed COPD: development and validation
IA
ER
of the TargetCOPD score. Eur Respir J 2017; 49(6): 1602191 https://pubmed.ncbi.nlm.nih.gov/28642308.

AT
371. Lambe T, Adab P, Jordan RE, et al. Model-based evaluation of the long-term cost-effectiveness of systematic case-
finding for COPD in primary care. Thorax 2019; 74(8): 730-9 https://pubmed.ncbi.nlm.nih.gov/31285359.
M
T
372. Tan WC, Sin DD, Bourbeau J, et al. Characteristics of COPD in never-smokers and ever-smokers in the general
H
population: results from the CanCOLD study. Thorax 2015; 70(9): 822-9 https://pubmed.ncbi.nlm.nih.gov/26048404.
IG
R
373. Han MK, Steenrod AW, Bacci ED, et al. Identifying Patients with Undiagnosed COPD in Primary Care Settings: Insight
PY
from Screening Tools and Epidemiologic Studies. Chronic Obstr Pulm Dis 2015; 2(2): 103-21
O
C
374. Siddharthan T, Wosu AC, Pollard SL, et al. A Novel Case-Finding Instrument for Chronic Obstructive Pulmonary Disease
in Low- and Middle-Income Country Settings. Int J Chron Obstruct Pulmon Dis 2020; 15: 2769-77
375. Martinez FJ, Mannino D, Leidy NK, et al. A New Approach for Identifying Patients with Undiagnosed Chronic Obstructive
376. Dirven JA, Tange HJ, Muris JW, van Haaren KM, Vink G, van Schayck OC. Early detection of COPD in general practice:
implementation, workload and socioeconomic status. A mixed methods observational study. Prim Care Respir J 2013;
377. Le Rouzic O, Roche N, Cortot AB, et al. Defining the "Frequent Exacerbator" Phenotype in COPD: A Hypothesis-Free
Approach. Chest 2018; 153(5): 1106-15 https://pubmed.ncbi.nlm.nih.gov/29054347.
378. Jordan RE, Adab P, Sitch A, et al. Targeted case finding for chronic obstructive pulmonary disease versus routine
practice in primary care (TargetCOPD): a cluster-randomised controlled trial. Lancet Respir Med 2016; 4(9): 720-30
379. Haroon S, Jordan R, Takwoingi Y, Adab P. Diagnostic accuracy of screening tests for COPD: a systematic review and
meta-analysis. BMJ Open 2015; 5(10): e008133 https://pubmed.ncbi.nlm.nih.gov/26450427.
380. Huynh C, Whitmore GA, Vandemheen KL, et al. Derivation and validation of the UCAP-Q case-finding questionnaire to
detect undiagnosed asthma and COPD. Eur Respir J 2022; 60(3): https://pubmed.ncbi.nlm.nih.gov/35332067.
381. Pan Z, Dickens AP, Chi C, et al. Accuracy and cost-effectiveness of different screening strategies for identifying
undiagnosed COPD among primary care patients (>/=40 years) in China: a cross-sectional screening test accuracy study:
findings from the Breathe Well group. BMJ Open 2021; 11(9): e051811 https://pubmed.ncbi.nlm.nih.gov/34556515.
382. Zhou J, Li X, Wang X, Yu N, Wang W. Accuracy of portable spirometers in the diagnosis of chronic obstructive pulmonary
disease A meta-analysis. NPJ Prim Care Respir Med 2022; 32(1): 15 https://pubmed.ncbi.nlm.nih.gov/35440665.
383. Siddharthan T, Pollard SL, Quaderi SA, et al. Discriminative Accuracy of Chronic Obstructive Pulmonary Disease
Screening Instruments in 3 Low- and Middle-Income Country Settings. JAMA 2022; 327(2): 151-60
384. Tamaki K, Sakihara E, Miyata H, et al. Utility of Self-Administered Questionnaires for Identifying Individuals at Risk of
COPD in Japan: The OCEAN (Okinawa COPD casE finding AssessmeNt) Study. Int J Chron Obstruct Pulmon Dis 2021; 16:
385. Sogbetun F, Eschenbacher WL, Welge JA, Panos RJ. A comparison of five surveys that identify individuals at risk for
airflow obstruction and chronic obstructive pulmonary disease. Respir Med 2016; 120: 1-9
386. Martinez FJ, Han MK, Lopez C, et al. Discriminative Accuracy of the CAPTURE Tool for Identifying Chronic Obstructive
Pulmonary Disease in US Primary Care Settings. Jama 2023; 329(6): 490-501
387. Yawn BP, Duvall K, Peabody J, et al. The impact of screening tools on diagnosis of chronic obstructive pulmonary disease
in primary care. Am J Prev Med 2014; 47(5): 563-75 https://pubmed.ncbi.nlm.nih.gov/25241196.
388. Bertens LC, Reitsma JB, van Mourik Y, et al. COPD detected with screening: impact on patient management and
prognosis. Eur Respir J 2014; 44(6): 1571-8 https://pubmed.ncbi.nlm.nih.gov/24925924.
389. Yawn BP, Martinez FJ. POINT: Can Screening for COPD Improve Outcomes? Yes. Chest 2020; 157(1): 7-9
390. Campos M, Hagenlocker B, Lascano J, Riley L. Impact of a Computerized Clinical Decision Support System to Improve
Chronic Obstructive Pulmonary Disease Diagnosis and Testing for Alpha-1 Antitrypsin Deficiency. Ann Am Thorac Soc
TE
391. Yawn BP, Han M, Make BM, et al. Protocol Summary of the COPD Assessment in Primary Care To Identify Undiagnosed
U
Respiratory Disease and Exacerbation Risk (CAPTURE) Validation in Primary Care Study. Chronic Obstr Pulm Dis 2021;
IB
TR
392. IS
Siddharthan T, Pollard SL, Quaderi SA, et al. Effectiveness-implementation of COPD case finding and self-management
D
action plans in low- and middle-income countries: global excellence in COPD outcomes (GECo) study protocol. Trials
T
2018; 19(1): 571 https://pubmed.ncbi.nlm.nih.gov/30340648.

O
N
393. Li Y, Wen F, Ma Q, et al. Use of CAPTURE to Identify Individuals Who May or May Not Require Treatment for Chronic
O
Obstructive Pulmonary Disease. Am J Respir Crit Care Med 2023; 208(4): 435-41
-D
L
394. Webber EM, Lin JS, Thomas RG. Screening for Chronic Obstructive Pulmonary Disease: Updated Evidence Report and
IA
ER
Systematic Review for the US Preventive Services Task Force. JAMA 2022; 327(18): 1812-6
AT
395. de Koning HJ, van der Aalst CM, de Jong PA, et al. Reduced Lung-Cancer Mortality with Volume CT Screening in a
M
T
Randomized Trial. N Engl J Med 2020; 382(6): 503-13 https://pubmed.ncbi.nlm.nih.gov/31995683.

H
396. National Lung Screening Trial Research Team, Aberle DR, Adams AM, et al. Reduced lung-cancer mortality with low-
IG
R
dose computed tomographic screening. N Engl J Med 2011; 365(5): 395-409

PY
O
397. Perrotta F, D'Agnano V, Scialò F, et al. Evolving concepts in COPD and lung cancer: a narrative review. Minerva Med
C

398. Ruparel M, Quaife SL, Dickson JL, et al. Prevalence, Symptom Burden, and Underdiagnosis of Chronic Obstructive
Pulmonary Disease in a Lung Cancer Screening Cohort. Ann Am Thorac Soc 2020; 17(7): 869-78
399. Young RP, Hopkins RJ. Diagnosing COPD and targeted lung cancer screening. Eur Respir J 2012; 40(4): 1063-4
400. Hopkins RJ, Duan F, Chiles C, et al. Reduced Expiratory Flow Rate among Heavy Smokers Increases Lung Cancer Risk.
Results from the National Lung Screening Trial-American College of Radiology Imaging Network Cohort. Ann Am Thorac
Soc 2017; 14(3): 392-402 https://pubmed.ncbi.nlm.nih.gov/28076701.
401. Balata H, Harvey J, Barber PV, et al. Spirometry performed as part of the Manchester community-based lung cancer
screening programme detects a high prevalence of airflow obstruction in individuals without a prior diagnosis of COPD.
402. Undrunas A, Kasprzyk P, Rajca A, Kuziemski K, Rzyman W, Zdrojewski T. Prevalence, symptom burden and under-
diagnosis of chronic obstructive pulmonary disease in Polish lung cancer screening population: a cohort observational
study. BMJ Open 2022; 12(4): e055007 https://pubmed.ncbi.nlm.nih.gov/35410926.
403. Carr LL, Jacobson S, Lynch DA, et al. Features of COPD as Predictors of Lung Cancer. Chest 2018; 153(6): 1326-35
404. Maldonado F, Bartholmai BJ, Swensen SJ, Midthun DE, Decker PA, Jett JR. Are airflow obstruction and radiographic
evidence of emphysema risk factors for lung cancer? A nested case-control study using quantitative emphysema
analysis. Chest 2010; 138(6): 1295-302 https://pubmed.ncbi.nlm.nih.gov/20348193.
405. Kishi K, Gurney JW, Schroeder DR, Scanlon PD, Swensen SJ, Jett JR. The correlation of emphysema or airway obstruction
with the risk of lung cancer: a matched case-controlled study. Eur Respir J 2002; 19(6): 1093-8
406. Wilson DO, Weissfeld JL, Balkan A, et al. Association of radiographic emphysema and airflow obstruction with lung
cancer. Am J Respir Crit Care Med 2008; 178(7): 738-44 https://pubmed.ncbi.nlm.nih.gov/18565949.
407. Sanchez-Salcedo P, Wilson DO, de-Torres JP, et al. Improving selection criteria for lung cancer screening. The potential
role of emphysema. Am J Respir Crit Care Med 2015; 191(8): 924-31 https://pubmed.ncbi.nlm.nih.gov/25668622.
408. Balkan A, Bulut Y, Fuhrman CR, et al. COPD phenotypes in a lung cancer screening population. Clin Respir J 2016; 10(1):
409. Labaki WW, Xia M, Murray S, et al. Quantitative Emphysema on Low-Dose CT Imaging of the Chest and Risk of Lung
Cancer and Airflow Obstruction: An Analysis of the National Lung Screening Trial. Chest 2021; 159(5): 1812-20
410. Tang LYW, Coxson HO, Lam S, Leipsic J, Tam RC, Sin DD. Towards large-scale case-finding: training and validation of
residual networks for detection of chronic obstructive pulmonary disease using low-dose CT. Lancet Digit Health 2020;
2(5): e259-e67 https://pubmed.ncbi.nlm.nih.gov/33328058.
411. Bradley C, Boland A, Clarke L, et al. Diagnosis and treatment outcomes from prebronchodilator spirometry performed
alongside lung cancer screening in a Lung Health Check programme. Thorax 2023; 78(6): 543-50
412. Crosbie PA, Balata H, Evison M, et al. Implementing lung cancer screening: baseline results from a community-based
'Lung Health Check' pilot in deprived areas of Manchester. Thorax 2019; 74(4): 405-9
413. Tisi S, Creamer AW, Dickson J, et al. Prevalence and clinical characteristics of non-malignant CT detected incidental
findings in the SUMMIT lung cancer screening cohort. BMJ Open Respir Res 2023; 10(1):
TE
U
414. Koo HK, Jin KN, Kim DK, Chung HS, Lee CH. Association of incidental emphysema with annual lung function decline and
IB
TR
future development of airflow limitation. Int J Chron Obstruct Pulmon Dis 2016; 11: 161-6
D
415. Mohamed Hoesein FA, de Hoop B, Zanen P, et al. CT-quantified emphysema in male heavy smokers: association with
T
lung function decline. Thorax 2011; 66(9): 782-7 https://pubmed.ncbi.nlm.nih.gov/21474499.

O
N
416. Roberts HR, Wells AU, Milne DG, et al. Airflow obstruction in bronchiectasis: correlation between computed
O
tomography features and pulmonary function tests. Thorax 2000; 55(3): 198-204
-D
L
417. Vestbo J, Edwards LD, Scanlon PD, et al. Changes in forced expiratory volume in 1 second over time in COPD. N Engl J
IA
ER

AT
418. Halpin DM. Do the 'missing millions' of COPD patients want to be found? Thorax 2023; 78(6): 531-2
M
T
419. Jones PW. Health status and the spiral of decline. COPD 2009; 6(1): 59-63 https://pubmed.ncbi.nlm.nih.gov/19229709.
H
420. Han MK, Muellerova H, Curran-Everett D, et al. GOLD 2011 disease severity classification in COPDGene: a prospective
IG
R
cohort study. Lancet Respir Med 2013; 1(1): 43-50 https://pubmed.ncbi.nlm.nih.gov/24321803.

PY
421. American Thoracic Society (ATS). Surveillance for respiratory hazards in the occupational setting Am Rev Respir Dis
O
1982; 126: 952-6

C
422. Bestall JC, Paul EA, Garrod R, Garnham R, Jones PW, Wedzicha JA. Usefulness of the Medical Research Council (MRC)
dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax 1999; 54(7):
423. Sundh J, Janson C, Lisspers K, Stallberg B, Montgomery S. The Dyspnoea, Obstruction, Smoking, Exacerbation (DOSE)
index is predictive of mortality in COPD. Prim Care Respir J 2012; 21(3): 295-301
424. Nishimura K, Izumi T, Tsukino M, Oga T. Dyspnea is a better predictor of 5-year survival than airway obstruction in
patients with COPD. Chest 2002; 121(5): 1434-40 https://pubmed.ncbi.nlm.nih.gov/12006425.
425. Jones PW. Health status measurement in chronic obstructive pulmonary disease. Thorax 2001; 56(11): 880-7
426. Guyatt GH, Berman LB, Townsend M, Pugsley SO, Chambers LW. A measure of quality of life for clinical trials in chronic
lung disease. Thorax 1987; 42(10): 773-8 https://pubmed.ncbi.nlm.nih.gov/3321537.
427. Jones PW, Quirk FH, Baveystock CM, Littlejohns P. A self-complete measure of health status for chronic airflow
limitation. The St. George's Respiratory Questionnaire. Am Rev Respir Dis 1992; 145(6): 1321-7
428. Jones PW, Harding G, Berry P, Wiklund I, Chen WH, Kline Leidy N. Development and first validation of the COPD
Assessment Test. Eur Respir J 2009; 34(3): 648-54 https://pubmed.ncbi.nlm.nih.gov/19720809.
429. Karloh M, Fleig Mayer A, Maurici R, Pizzichini MMM, Jones PW, Pizzichini E. The COPD Assessment Test: What Do We
Know So Far?: A Systematic Review and Meta-Analysis About Clinical Outcomes Prediction and Classification of Patients
Into GOLD Stages. Chest 2016; 149(2): 413-25 https://pubmed.ncbi.nlm.nih.gov/26513112.
430. Nishimura K, Mitsuma S, Kobayashi A, et al. COPD and disease-specific health status in a working population. Respir Res
431. Miravitlles M, Soriano JB, Garcia-Rio F, et al. Prevalence of COPD in Spain: impact of undiagnosed COPD on quality of
life and daily life activities. Thorax 2009; 64(10): 863-8 https://pubmed.ncbi.nlm.nih.gov/19553233.
432. Jones PW, Tabberer M, Chen WH. Creating scenarios of the impact of COPD and their relationship to COPD Assessment
Test (CAT) scores. BMC Pulm Med 2011; 11: 42 https://pubmed.ncbi.nlm.nih.gov/21835018.
433. Jones PW, Adamek L, Nadeau G, Banik N. Comparisons of health status scores with MRC grades in COPD: implications
for the GOLD 2011 classification. Eur Respir J 2013; 42(3): 647-54 https://pubmed.ncbi.nlm.nih.gov/23258783.
434. Hurst JR, Wedzicha JA. What is (and what is not) a COPD exacerbation: thoughts from the new GOLD guidelines. Thorax
435. Wedzicha JA, Seemungal TA. COPD exacerbations: defining their cause and prevention. Lancet 2007; 370(9589): 786-96
436. Seemungal TA, Donaldson GC, Paul EA, Bestall JC, Jeffries DJ, Wedzicha JA. Effect of exacerbation on quality of life in
patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 1998; 157(5 Pt 1): 1418-22
437. Burge S, Wedzicha JA. COPD exacerbations: definitions and classifications. Eur Respir J Suppl 2003; 41: 46s-53s
438. Soler-Cataluna JJ, Martinez-Garcia MA, Roman Sanchez P, Salcedo E, Navarro M, Ochando R. Severe acute
exacerbations and mortality in patients with chronic obstructive pulmonary disease. Thorax 2005; 60(11): 925-31
439. Hurst JR, Vestbo J, Anzueto A, et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N Engl J
440. Han MK, Quibrera PM, Carretta EE, et al. Frequency of exacerbations in patients with chronic obstructive pulmonary
TE
disease: an analysis of the SPIROMICS cohort. Lancet Respir Med 2017; 5(8): 619-26
U
IB
TR
441. Mullerova H, Maselli DJ, Locantore N, et al. Hospitalized exacerbations of COPD: risk factors and outcomes in the
IS
ECLIPSE cohort. Chest 2015; 147(4): 999-1007 https://pubmed.ncbi.nlm.nih.gov/25356881.
D
442. Soriano JB, Lamprecht B, Ramirez AS, et al. Mortality prediction in chronic obstructive pulmonary disease comparing
T
the GOLD 2007 and 2011 staging systems: a pooled analysis of individual patient data. Lancet Respir Med 2015; 3(6):
O
N
O
443. Bafadhel M, Peterson S, De Blas MA, et al. Predictors of exacerbation risk and response to budesonide in patients with
-D
chronic obstructive pulmonary disease: a post-hoc analysis of three randomised trials. Lancet Respir Med 2018; 6(2):
L
IA
ER
444. Siddiqui SH, Guasconi A, Vestbo J, et al. Blood Eosinophils: A Biomarker of Response to Extrafine
AT
Beclomethasone/Formoterol in Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med 2015; 192(4): 523-5
M
T
445. Papi A, Vestbo J, Fabbri L, et al. Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic
H
obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial. Lancet 2018;
IG
R

PY
446. Pascoe S, Locantore N, Dransfield MT, Barnes NC, Pavord ID. Blood eosinophil counts, exacerbations, and response to
O
the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a
C
secondary analysis of data from two parallel randomised controlled trials. Lancet Respir Med 2015; 3(6): 435-42
447. Vestbo J, Papi A, Corradi M, et al. Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist
therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled
trial. Lancet 2017; 389(10082): 1919-29 https://pubmed.ncbi.nlm.nih.gov/28385353.
448. Lipson DA, Barnhart F, Brealey N, et al. Once-Daily Single-Inhaler Triple versus Dual Therapy in Patients with COPD. N
449. Hartl S, Breyer MK, Burghuber OC, et al. Blood eosinophil count in the general population: typical values and potential
confounders. Eur Respir J 2020; 55(5): 1901874 https://pubmed.ncbi.nlm.nih.gov/32060069.
450. Kolsum U, Southworth T, Jackson N, Singh D. Blood eosinophil counts in COPD patients compared to controls. Eur Respir
J 2019; 54(4): 1900633 https://pubmed.ncbi.nlm.nih.gov/31221811.
451. George L, Taylor AR, Esteve-Codina A, et al. Blood eosinophil count and airway epithelial transcriptome relationships in
COPD versus asthma. Allergy 2020; 75(2): 370-80 https://pubmed.ncbi.nlm.nih.gov/31506971.
452. Higham A, Beech A, Wolosianka S, et al. Type 2 inflammation in eosinophilic chronic obstructive pulmonary disease.
Allergy 2021; 76(6): 1861-4 https://pubmed.ncbi.nlm.nih.gov/33206402.
453. Singh D, Agusti A, Martinez FJ, et al. Blood Eosinophils and Chronic Obstructive Pulmonary Disease: A Global Initiative
for Chronic Obstructive Lung Disease Science Committee 2022 Review. Am J Respir Crit Care Med 2022; 206(1): 17-24
454. Landis SH, Suruki R, Hilton E, Compton C, Galwey NW. Stability of Blood Eosinophil Count in Patients with COPD in the
UK Clinical Practice Research Datalink. COPD 2017; 14(4): 382-8 https://pubmed.ncbi.nlm.nih.gov/28569614.
455. Oshagbemi OA, Burden AM, Braeken DCW, et al. Stability of Blood Eosinophils in Patients with Chronic Obstructive
Pulmonary Disease and in Control Subjects, and the Impact of Sex, Age, Smoking, and Baseline Counts. Am J Respir Crit
456. Southworth T, Beech G, Foden P, Kolsum U, Singh D. The reproducibility of COPD blood eosinophil counts. Eur Respir J
2018; 52(1): https://pubmed.ncbi.nlm.nih.gov/29724922.
457. Casanova C, Celli BR, de-Torres JP, et al. Prevalence of persistent blood eosinophilia: relation to outcomes in patients
with COPD. Eur Respir J 2017; 50(5): https://pubmed.ncbi.nlm.nih.gov/29167301.
458. Vedel-Krogh S, Nielsen SF, Lange P, Vestbo J, Nordestgaard BG. Blood Eosinophils and Exacerbations in Chronic
Obstructive Pulmonary Disease. The Copenhagen General Population Study. Am J Respir Crit Care Med 2016; 193(9):
459. Yun JH, Lamb A, Chase R, et al. Blood eosinophil count thresholds and exacerbations in patients with chronic
obstructive pulmonary disease. J Allergy Clin Immunol 2018; 141(6): 2037-47 e10
460. Tan WC, Bourbeau J, Nadeau G, et al. High eosinophil counts predict decline in FEV(1): results from the CanCOLD study.
Eur Respir J 2021; 57(5): https://pubmed.ncbi.nlm.nih.gov/33303555.
461. Park HY, Chang Y, Kang D, et al. Blood eosinophil counts and the development of obstructive lung disease: the Kangbuk
Samsung Health Study. Eur Respir J 2021; 58(4): https://pubmed.ncbi.nlm.nih.gov/33737406.
462. Mannino DM, Thorn D, Swensen A, Holguin F. Prevalence and outcomes of diabetes, hypertension and cardiovascular
disease in COPD. Eur Respir J 2008; 32(4): 962-9 https://pubmed.ncbi.nlm.nih.gov/18579551.
463. Soriano JB, Visick GT, Muellerova H, Payvandi N, Hansell AL. Patterns of comorbidities in newly diagnosed COPD and
asthma in primary care. Chest 2005; 128(4): 2099-107 https://pubmed.ncbi.nlm.nih.gov/16236861.
464. National Institute for Health and Care Excellence. Multimorbidity: clinical assessment and management; NICE guideline
[NG56]Published date: 21 September 2016 [accessed Oct 2023]. 2016. https://www.nice.org.uk/guidance/ng56.
TE
465. Vanfleteren LE, Spruit MA, Groenen M, et al. Clusters of comorbidities based on validated objective measurements and
U
systemic inflammation in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2013; 187(7):
IB
TR
466. IS
Brenner DR, Boffetta P, Duell EJ, et al. Previous lung diseases and lung cancer risk: a pooled analysis from the
D
International Lung Cancer Consortium. Am J Epidemiol 2012; 176(7): 573-85
T
O
N
467. Fry JS, Hamling JS, Lee PN. Systematic review with meta-analysis of the epidemiological evidence relating FEV1 decline
O
to lung cancer risk. BMC Cancer 2012; 12: 498 https://pubmed.ncbi.nlm.nih.gov/23101666.

-D
468. Wagner PD. Possible mechanisms underlying the development of cachexia in COPD. Eur Respir J 2008; 31(3): 492-501
L
IA
ER
469. Maltais F, Decramer M, Casaburi R, et al. An official American Thoracic Society/European Respiratory Society
AT
statement: update on limb muscle dysfunction in chronic obstructive pulmonary disease. Am J Respir Crit Care Med
2014; 189(9): e15-62 https://pubmed.ncbi.nlm.nih.gov/24787074.
M
T
470. Goossens LM, Leimer I, Metzdorf N, Becker K, Rutten-van Molken MP. Does the 2013 GOLD classification improve the
H
ability to predict lung function decline, exacerbations and mortality: a post-hoc analysis of the 4-year UPLIFT trial. BMC
IG
R
Pulm Med 2014; 14: 163 https://pubmed.ncbi.nlm.nih.gov/25326750.

PY
471. Kim J, Yoon HI, Oh YM, et al. Lung function decline rates according to GOLD group in patients with chronic obstructive
O
pulmonary disease. Int J Chron Obstruct Pulmon Dis 2015; 10: 1819-27 https://pubmed.ncbi.nlm.nih.gov/26379432.
C
472. Blakemore WS, Forster RE, Morton JW, Ogilvie CM. A standardized breath holding technique for the clinical
measurement of the diffusing capacity of the lung for carbon monoxide. J Clin Invest 1957; 36(1 Part 1): 1-17
473. American Thoracic Society (ATS). Lung function testing: selection of reference values and interpretative strategies.
American Thoracic Society. Am Rev Respir Dis 1991; 144(5): 1202-18 https://pubmed.ncbi.nlm.nih.gov/1952453.
474. Macintyre N, Crapo RO, Viegi G, et al. Standardisation of the single-breath determination of carbon monoxide uptake in
the lung. Eur Respir J 2005; 26(4): 720-35 https://pubmed.ncbi.nlm.nih.gov/16204605.
475. Stanojevic S, Graham BL, Cooper BG, et al. Official ERS technical standards: Global Lung Function Initiative reference
values for the carbon monoxide transfer factor for Caucasians. Eur Respir J 2017; 50(3):
476. Gochicoa-Rangel L, Perez-Padilla R, Vazquez-Garcia JC, et al. Long-Term Stability of a Portable Carbon Monoxide Single-
Breath Diffusing Capacity Instrument. Respir Care 2017; 62(2): 231-5 https://pubmed.ncbi.nlm.nih.gov/27677305.
477. Balasubramanian A, MacIntyre NR, Henderson RJ, et al. Diffusing Capacity of Carbon Monoxide in Assessment of COPD.
Chest 2019; 156(6): 1111-9 https://pubmed.ncbi.nlm.nih.gov/31352035.
478. Elbehairy AF, O'Donnell CD, Abd Elhameed A, et al. Low resting diffusion capacity, dyspnea, and exercise intolerance in
chronic obstructive pulmonary disease. J Appl Physiol (1985) 2019; 127(4): 1107-16
479. Farkhooy A, Janson C, Arnardottir RH, Malinovschi A, Emtner M, Hedenstrom H. Impaired carbon monoxide diffusing
capacity is the strongest predictor of exercise intolerance in COPD. COPD 2013; 10(2): 180-5
480. Balasubramanian A, Putcha N, MacIntyre NR, et al. Diffusing Capacity and Mortality in Chronic Obstructive Pulmonary
Disease. Ann Am Thorac Soc 2023; 20(1): 38-46 https://pubmed.ncbi.nlm.nih.gov/35969416.
481. Boutou AK, Shrikrishna D, Tanner RJ, et al. Lung function indices for predicting mortality in COPD. Eur Respir J 2013;
482. de-Torres JP, O'Donnell DE, Marin JM, et al. Clinical and Prognostic Impact of Low Diffusing Capacity for Carbon
Monoxide Values in Patients With Global Initiative for Obstructive Lung Disease I COPD. Chest 2021; 160(3): 872-8
483. Haruna A, Muro S, Nakano Y, et al. CT scan findings of emphysema predict mortality in COPD. Chest 2010; 138(3): 635-
484. Ferguson MK, Gaissert HA, Grab JD, Sheng S. Pulmonary complications after lung resection in the absence of chronic
obstructive pulmonary disease: the predictive role of diffusing capacity. J Thorac Cardiovasc Surg 2009; 138(6): 1297-
485. Harvey BG, Strulovici-Barel Y, Kaner RJ, et al. Risk of COPD with obstruction in active smokers with normal spirometry
and reduced diffusion capacity. Eur Respir J 2015; 46(6): 1589-97 https://pubmed.ncbi.nlm.nih.gov/26541521.
486. Casanova C, Gonzalez-Davila E, Martinez-Gonzalez C, et al. Natural Course of the Diffusing Capacity of the Lungs for
Carbon Monoxide in COPD: Importance of Sex. Chest 2021; 160(2): 481-90 https://pubmed.ncbi.nlm.nih.gov/33878339.
487. Kang J, Oh YM, Lee JH, et al. Distinctive patterns of pulmonary function change according to baseline lung volume and
diffusing capacity. Int J Tuberc Lung Dis 2020; 24(6): 597-605 https://pubmed.ncbi.nlm.nih.gov/32553011.
488. Lacasse Y, Theriault S, St-Pierre B, et al. Oximetry neither to prescribe long-term oxygen therapy nor to screen for
severe hypoxaemia. ERJ Open Res 2021; 7(4): https://pubmed.ncbi.nlm.nih.gov/34671670.
489. Scioscia G, Blanco I, Arismendi E, et al. Different dyspnoea perception in COPD patients with frequent and infrequent
exacerbations. Thorax 2017; 72(2): 117-21 https://pubmed.ncbi.nlm.nih.gov/27586869.
490. Durheim MT, Smith PJ, Babyak MA, et al. Six-minute-walk distance and accelerometry predict outcomes in chronic
TE
obstructive pulmonary disease independent of Global Initiative for Chronic Obstructive Lung Disease 2011 Group. Ann
U
Am Thorac Soc 2015; 12(3): 349-56 https://pubmed.ncbi.nlm.nih.gov/25568929.
IB
TR
491. Pinto-Plata VM, Cote C, Cabral H, Taylor J, Celli BR. The 6-min walk distance: change over time and value as a predictor
IS
of survival in severe COPD. Eur Respir J 2004; 23(1): 28-33 https://pubmed.ncbi.nlm.nih.gov/14738227.
D
492. Oga T, Nishimura K, Tsukino M, Sato S, Hajiro T. Analysis of the factors related to mortality in chronic obstructive
T
pulmonary disease: role of exercise capacity and health status. Am J Respir Crit Care Med 2003; 167(4): 544-9
O
N
O
493. Polkey MI, Spruit MA, Edwards LD, et al. Six-minute-walk test in chronic obstructive pulmonary disease: minimal
-D
clinically important difference for death or hospitalization. Am J Respir Crit Care Med 2013; 187(4): 382-6
L
IA
ER
494. Celli B, Tetzlaff K, Criner G, et al. The 6-Minute-Walk Distance Test as a Chronic Obstructive Pulmonary Disease
AT
Stratification Tool. Insights from the COPD Biomarker Qualification Consortium. Am J Respir Crit Care Med 2016;
M
T
495. Revill SM, Morgan MD, Singh SJ, Williams J, Hardman AE. The endurance shuttle walk: a new field test for the
H
assessment of endurance capacity in chronic obstructive pulmonary disease. Thorax 1999; 54(3): 213-22
IG
R
PY
496. Casanova C, Cote CG, Marin JM, et al. The 6-min walking distance: long-term follow up in patients with COPD. Eur Respir
O
J 2007; 29(3): 535-40 https://pubmed.ncbi.nlm.nih.gov/17107991.

C
497. Puente-Maestu L, Palange P, Casaburi R, et al. Use of exercise testing in the evaluation of interventional efficacy: an
official ERS statement. Eur Respir J 2016; 47(2): 429-60 https://pubmed.ncbi.nlm.nih.gov/26797036.
498. Beekman E, Mesters I, Hendriks EJ, et al. Course length of 30 metres versus 10 metres has a significant influence on six-
minute walk distance in patients with COPD: an experimental crossover study. J Physiother 2013; 59(3): 169-76
499. Waschki B, Kirsten A, Holz O, et al. Physical activity is the strongest predictor of all-cause mortality in patients with
COPD: a prospective cohort study. Chest 2011; 140(2): 331-42 https://pubmed.ncbi.nlm.nih.gov/21273294.
500. Martinez-Garcia MA, de la Rosa-Carrillo D, Soler-Cataluna JJ, et al. Bronchial Infection and Temporal Evolution of
Bronchiectasis in Patients With Chronic Obstructive Pulmonary Disease. Clin Infect Dis 2021; 72(3): 403-10
501. Klooster K, ten Hacken NH, Hartman JE, Kerstjens HA, van Rikxoort EM, Slebos DJ. Endobronchial Valves for Emphysema
without Interlobar Collateral Ventilation. N Engl J Med 2015; 373(24): 2325-35
502. Galban CJ, Han MK, Boes JL, et al. Computed tomography-based biomarker provides unique signature for diagnosis of
COPD phenotypes and disease progression. Nat Med 2012; 18(11): 1711-5 https://pubmed.ncbi.nlm.nih.gov/23042237.
503. Vasilescu DM, Martinez FJ, Marchetti N, et al. Noninvasive Imaging Biomarker Identifies Small Airway Damage in Severe
Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med 2019; 200(5): 575-81
504. Bhatt SP, Soler X, Wang X, et al. Association between Functional Small Airway Disease and FEV1 Decline in Chronic
505. Ezponda A, Casanova C, Divo M, et al. Chest CT-assessed comorbidities and all-cause mortality risk in COPD patients in
the BODE cohort. Respirology 2022; 27(4): 286-93 https://pubmed.ncbi.nlm.nih.gov/35132732.
506. Hatabu H, Hunninghake GM, Richeldi L, et al. Interstitial lung abnormalities detected incidentally on CT: a Position
Paper from the Fleischner Society. Lancet Respir Med 2020; 8(7): 726-37 https://pubmed.ncbi.nlm.nih.gov/32649920.
507. Rose JA, Menon AA, Hino T, et al. Suspected Interstitial Lung Disease in COPDGene Study. Am J Respir Crit Care Med
508. Ash SY, Choi B, Oh A, Lynch DA, Humphries SM. Deep Learning Assessment of Progression of Emphysema and Fibrotic
Interstitial Lung Abnormality. Am J Respir Crit Care Med 2023; 208(6): 666-75
509. Putman RK, Gudmundsson G, Axelsson GT, et al. Imaging Patterns Are Associated with Interstitial Lung Abnormality
Progression and Mortality. Am J Respir Crit Care Med 2019; 200(2): 175-83 https://pubmed.ncbi.nlm.nih.gov/30673508.
510. WHO meeting participants. Alpha 1-antitrypsin deficiency: memorandum from a WHO meeting. Bull World Health
Organ 1997; 75(5): 397-415 https://pubmed.ncbi.nlm.nih.gov/9447774.
511. Miravitlles M, Dirksen A, Ferrarotti I, et al. European Respiratory Society statement: diagnosis and treatment of
pulmonary disease in alpha(1)-antitrypsin deficiency. Eur Respir J 2017; 50(5):
512. Parr DG, Stoel BC, Stolk J, Stockley RA. Pattern of emphysema distribution in alpha1-antitrypsin deficiency influences
lung function impairment. Am J Respir Crit Care Med 2004; 170(11): 1172-8
513. Guerra B, Haile SR, Lamprecht B, et al. Large-scale external validation and comparison of prognostic models: an
TE
application to chronic obstructive pulmonary disease. BMC Med 2018; 16(1): 33
U
IB
TR
514. Celli BR, Cote CG, Marin JM, et al. The body-mass index, airflow obstruction, dyspnea, and exercise capacity index in
IS
chronic obstructive pulmonary disease. N Engl J Med 2004; 350(10): 1005-12
D
T
515. Jones RC, Donaldson GC, Chavannes NH, et al. Derivation and validation of a composite index of severity in chronic
O
N
obstructive pulmonary disease: the DOSE Index. Am J Respir Crit Care Med 2009; 180(12): 1189-95
O
-D
516. Puhan MA, Garcia-Aymerich J, Frey M, et al. Expansion of the prognostic assessment of patients with chronic
L
obstructive pulmonary disease: the updated BODE index and the ADO index. Lancet 2009; 374(9691): 704-11
IA
ER
AT
517. Stockley RA, Halpin DMG, Celli BR, Singh D. Chronic Obstructive Pulmonary Disease Biomarkers and Their
Interpretation. Am J Respir Crit Care Med 2019; 199(10): 1195-204 https://pubmed.ncbi.nlm.nih.gov/30592902.
M
T
518. Agusti A, Bel E, Thomas M, et al. Treatable traits: toward precision medicine of chronic airway diseases. Eur Respir J
H

IG
R
519. Agusti A, Fabbri LM, Singh D, et al. Inhaled corticosteroids in COPD: friend or foe? Eur Respir J 2018; 52(6): 1801219
PY
O
520. Montes de Oca M. Smoking Cessation/Vaccinations. Clin Chest Med 2020; 41(3): 495-512
C
521. Willemse BW, Postma DS, Timens W, ten Hacken NH. The impact of smoking cessation on respiratory symptoms, lung
function, airway hyperresponsiveness and inflammation. Eur Respir J 2004; 23(3): 464-76
522. Bauer CMT, Morissette MC, Stampfli MR. The influence of cigarette smoking on viral infections: translating bench
science to impact COPD pathogenesis and acute exacerbations of COPD clinically. Chest 2013; 143(1): 196-206
523. Crowley TJ, Macdonald MJ, Walter MI. Behavioral anti-smoking trial in chronic obstructive pulmonary disease patients.
Psychopharmacology (Berl) 1995; 119(2): 193-204 https://pubmed.ncbi.nlm.nih.gov/7659767.
524. Jimenez-Ruiz CA, Masa F, Miravitlles M, et al. Smoking characteristics: differences in attitudes and dependence
between healthy smokers and smokers with COPD. Chest 2001; 119(5): 1365-70
525. Shahab L, Jarvis MJ, Britton J, West R. Prevalence, diagnosis and relation to tobacco dependence of chronic obstructive
pulmonary disease in a nationally representative population sample. Thorax 2006; 61(12): 1043-7
526. Wagena EJ, Arrindell WA, Wouters EF, van Schayck CP. Are patients with COPD psychologically distressed? Eur Respir J
527. van Eerd EA, van der Meer RM, van Schayck OC, Kotz D. Smoking cessation for people with chronic obstructive
pulmonary disease. Cochrane Database Syst Rev 2016; 2016(8): CD010744 https://pubmed.ncbi.nlm.nih.gov/27545342.
528. Hoogendoorn M, Feenstra TL, Hoogenveen RT, Rutten-van Molken MP. Long-term effectiveness and cost-effectiveness
of smoking cessation interventions in patients with COPD. Thorax 2010; 65(8): 711-8
529. Wei X, Guo K, Shang X, et al. Effects of different interventions on smoking cessation in chronic obstructive pulmonary
disease patients: A systematic review and network meta-analysis. Int J Nurs Stud 2022; 136: 104362
530. Heatherton TF, Kozlowski LT, Frecker RC, Fagerstrom KO. The Fagerstrom Test for Nicotine Dependence: a revision of
the Fagerstrom Tolerance Questionnaire. Br J Addict 1991; 86(9): 1119-27 https://pubmed.ncbi.nlm.nih.gov/1932883.
531. John U, Meyer C, Schumann A, et al. A short form of the Fagerstrom Test for Nicotine Dependence and the Heaviness of
Smoking Index in two adult population samples. Addict Behav 2004; 29(6): 1207-12
532. Frazer K, Callinan JE, McHugh J, et al. Legislative smoking bans for reducing harms from secondhand smoke exposure,
smoking prevalence and tobacco consumption. Cochrane Database Syst Rev 2016; 2(2): CD005992
533. The Tobacco Use and Dependence Clinical Practice Guideline Panel. A clinical practice guideline for treating tobacco use
and dependence: A US Public Health Service report. The Tobacco Use and Dependence Clinical Practice Guideline Panel,
Staff, and Consortium Representatives. JAMA 2000; 283(24): 3244-54 https://pubmed.ncbi.nlm.nih.gov/10866874.
534. The tobacco use and dependence clinical practice guideline panel s, and consortium representatives,. A clinical practice
guideline for treating tobacco use and dependence. JAMA 2000; 28: 3244-54
535. Clinical Practice Guideline Treating Tobacco U, Dependence Update Panel L, Staff. A clinical practice guideline for
treating tobacco use and dependence: 2008 update. A U.S. Public Health Service report. Am J Prev Med 2008; 35(2):
536. Glynn TJ, Manley M, Smoking T, Cancer P. How to help your patients stop smoking: a National Cancer Institute manual
TE
for physicians. [Bethesda, Md.]: Smoking, Tobacco, and Cancer Program, Division of Cancer Prevention and Control,
U
National Cancer Institute, U.S. Dept. of Health and Human Services, Public Health Service, National Institutes of Health;
IB
TR
1990.
537. IS
Stead LF, Buitrago D, Preciado N, Sanchez G, Hartmann-Boyce J, Lancaster T. Physician advice for smoking cessation.
D
Cochrane Database Syst Rev 2013; 2013(5): CD000165 https://pubmed.ncbi.nlm.nih.gov/23728631.
T
538. Strassmann R, Bausch B, Spaar A, Kleijnen J, Braendli O, Puhan MA. Smoking cessation interventions in COPD: a network
O
N
meta-analysis of randomised trials. Eur Respir J 2009; 34(3): 634-40 https://pubmed.ncbi.nlm.nih.gov/19357145.

O
539. Wongsurakiat P, Maranetra KN, Wasi C, Kositanont U, Dejsomritrutai W, Charoenratanakul S. Acute respiratory illness
-D
in patients with COPD and the effectiveness of influenza vaccination: a randomized controlled study. Chest 2004;
L

IA
ER
540. Poole PJ, Chacko E, Wood-Baker RW, Cates CJ. Influenza vaccine for patients with chronic obstructive pulmonary
AT
disease. Cochrane Database Syst Rev 2006; (1): CD002733 https://pubmed.ncbi.nlm.nih.gov/16437444.

541. Wongsurakiat P, Lertakyamanee J, Maranetra KN, Jongriratanakul S, Sangkaew S. Economic evaluation of influenza
M
T
vaccination in Thai chronic obstructive pulmonary disease patients. J Med Assoc Thai 2003; 86(6): 497-508
H
IG
R
542. Nichol KL, Margolis KL, Wuorenma J, Von Sternberg T. The efficacy and cost effectiveness of vaccination against
PY
influenza among elderly persons living in the community. N Engl J Med 1994; 331(12): 778-84
O
C
543. Fiore AE, Shay DK, Broder K, et al. Prevention and control of seasonal influenza with vaccines: recommendations of the
Advisory Committee on Immunization Practices (ACIP), 2009. MMWR Recomm Rep 2009; 58(RR-8): 1-52
544. Edwards KM, Dupont WD, Westrich MK, Plummer WD, Jr., Palmer PS, Wright PF. A randomized controlled trial of cold-
adapted and inactivated vaccines for the prevention of influenza A disease. J Infect Dis 1994; 169(1): 68-76
545. Hak E, van Essen GA, Buskens E, Stalman W, de Melker RA. Is immunising all patients with chronic lung disease in the
community against influenza cost effective? Evidence from a general practice based clinical prospective cohort study in
Utrecht, The Netherlands. J Epidemiol Community Health 1998; 52(2): 120-5
546. Huang CL, Nguyen PA, Kuo PL, Iqbal U, Hsu YH, Jian WS. Influenza vaccination and reduction in risk of ischemic heart
disease among chronic obstructive pulmonary elderly. Comput Methods Programs Biomed 2013; 111(2): 507-11
547. Kobayashi M, Pilishvili T, Farrar JL, et al. Pneumococcal Vaccine for Adults Aged >/=19 Years: Recommendations of the
Advisory Committee on Immunization Practices, United States, 2023. MMWR Recomm Rep 2023; 72(3): 1-39
548. Walters JA, Smith S, Poole P, Granger RH, Wood-Baker R. Injectable vaccines for preventing pneumococcal infection in
patients with chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2010; (11): CD001390
549. Walters JA, Tang JN, Poole P, Wood-Baker R. Pneumococcal vaccines for preventing pneumonia in chronic obstructive
550. Alfageme I, Vazquez R, Reyes N, et al. Clinical efficacy of anti-pneumococcal vaccination in patients with COPD. Thorax
551. Dransfield MT, Harnden S, Burton RL, et al. Long-term comparative immunogenicity of protein conjugate and free
polysaccharide pneumococcal vaccines in chronic obstructive pulmonary disease. Clin Infect Dis 2012; 55(5): e35-44
552. Bonten MJ, Huijts SM, Bolkenbaas M, et al. Polysaccharide conjugate vaccine against pneumococcal pneumonia in
adults. N Engl J Med 2015; 372(12): 1114-25 https://pubmed.ncbi.nlm.nih.gov/25785969.
553. Ignatova GL, Avdeev SN, Antonov VN. Comparative effectiveness of pneumococcal vaccination with PPV23 and PCV13
in COPD patients over a 5-year follow-up cohort study. Sci Rep 2021; 11(1): 15948
554. Ofori-Anyinam O, Leroux-Roels G, Drame M, et al. Immunogenicity and safety of an inactivated quadrivalent influenza
vaccine co-administered with a 23-valent pneumococcal polysaccharide vaccine versus separate administration, in
adults >/=50years of age: Results from a phase III, randomized, non-inferiority trial. Vaccine 2017; 35(46): 6321-8
555. Walsh EE, Perez Marc G, Zareba AM, et al. Efficacy and Safety of a Bivalent RSV Prefusion F Vaccine in Older Adults. N
556. Papi A, Ison MG, Langley JM, et al. Respiratory Syncytial Virus Prefusion F Protein Vaccine in Older Adults. N Engl J Med
557. Cong B, Dighero I, Zhang T, Chung A, Nair H, Li Y. Understanding the age spectrum of respiratory syncytial virus
associated hospitalisation and mortality burden based on statistical modelling methods: a systematic analysis. BMC
Med 2023; 21(1): 224 https://pubmed.ncbi.nlm.nih.gov/37365569.
TE
558. Melgar M, Britton A, Roper LE, et al. Use of Respiratory Syncytial Virus Vaccines in Older Adults: Recommendations of
U
the Advisory Committee on Immunization Practices - United States, 2023. MMWR Morb Mortal Wkly Rep 2023; 72(29):
IB
TR
559. IS
Centers for Disease Control and Prevention Mortality and Morbidity Weekly Report. Use of Tetanus Toxoid, Reduced
D
Diphtheria Toxoid, and Acellular Pertussis Vaccines: Updated Recommendations of the Advisory Committee on
T
Immunization Practices — United States, 2019, online article available here:

O
N
https://www.cdc.gov/mmwr/volumes/69/wr/mm6903a5.htm [accessed Oct 2023].

O
560. Centers for Disease Control and Prevention. Lung Disease including Asthma and Adult Vaccination, 2016, online
-D
information available here: https://www.cdc.gov/vaccines/adults/rec-vac/health-conditions/lung-disease.html

L

IA
ER
561. Thompson MG, Stenehjem E, Grannis S, et al. Effectiveness of Covid-19 Vaccines in Ambulatory and Inpatient Care
AT
Settings. N Engl J Med 2021; 385(15): 1355-71 https://pubmed.ncbi.nlm.nih.gov/34496194.

562. Maltais F, Bjermer L, Kerwin EM, et al. Efficacy of umeclidinium/vilanterol versus umeclidinium and salmeterol
M
T
monotherapies in symptomatic patients with COPD not receiving inhaled corticosteroids: the EMAX randomised trial.
H
Respir Res 2019; 20(1): 238 https://pubmed.ncbi.nlm.nih.gov/31666084.

IG
R
563. Lange P, Marott JL, Vestbo J, et al. Prediction of the clinical course of chronic obstructive pulmonary disease, using the
PY
new GOLD classification: a study of the general population. Am J Respir Crit Care Med 2012; 186(10): 975-81
O
C
564. Agusti A, Edwards LD, Celli B, et al. Characteristics, stability and outcomes of the 2011 GOLD COPD groups in the
ECLIPSE cohort. Eur Respir J 2013; 42(3): 636-46 https://pubmed.ncbi.nlm.nih.gov/23766334.
565. Oba Y, Keeney E, Ghatehorde N, Dias S. Dual combination therapy versus long-acting bronchodilators alone for chronic
obstructive pulmonary disease (COPD): a systematic review and network meta-analysis. Cochrane Database Syst Rev
2018; 12(12): CD012620 https://pubmed.ncbi.nlm.nih.gov/30521694.
566. Rabe KF, Martinez FJ, Ferguson GT, et al. Triple Inhaled Therapy at Two Glucocorticoid Doses in Moderate-to-Very-
Severe COPD. N Engl J Med 2020; 383(1): 35-48 https://pubmed.ncbi.nlm.nih.gov/32579807.
567. Karner C, Cates CJ. Long-acting beta(2)-agonist in addition to tiotropium versus either tiotropium or long-acting beta(2)-
agonist alone for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2012; 4(4): CD008989
568. Martinez FJ, Calverley PM, Goehring UM, Brose M, Fabbri LM, Rabe KF. Effect of roflumilast on exacerbations in
patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a
multicentre randomised controlled trial. Lancet 2015; 385(9971): 857-66 https://pubmed.ncbi.nlm.nih.gov/25684586.
569. Martinez FJ, Rabe KF, Sethi S, et al. Effect of Roflumilast and Inhaled Corticosteroid/Long-Acting Beta-2-Agonist on
Chronic Obstructive Pulmonary Disease Exacerbations (RE2SPOND) A Randomized Clinical Trial. Am J Respir Crit Care
Med 2016; 194(5): 559-67
570. Rabe KF, Calverley PMA, Martinez FJ, Fabbri LM. Effect of roflumilast in patients with severe COPD and a history of
hospitalisation. Eur Respir J 2017; 50(1): https://pubmed.ncbi.nlm.nih.gov/28679611.
571. Albert RK, Connett J, Bailey WC, et al. Azithromycin for prevention of exacerbations of COPD. N Engl J Med 2011;
572. Han MK, Tayob N, Murray S, et al. Predictors of chronic obstructive pulmonary disease exacerbation reduction in
response to daily azithromycin therapy. Am J Respir Crit Care Med 2014; 189(12): 1503-8
573. Chapman KR, Hurst JR, Frent SM, et al. Long-Term Triple Therapy De-escalation to Indacaterol/Glycopyrronium in
Patients with Chronic Obstructive Pulmonary Disease (SUNSET): A Randomized, Double-Blind, Triple-Dummy Clinical
Trial. Am J Respir Crit Care Med 2018; 198(3): 329-39 https://pubmed.ncbi.nlm.nih.gov/29779416.
574. Calverley PMA, Tetzlaff K, Vogelmeier C, et al. Eosinophilia, Frequent Exacerbations, and Steroid Response in Chronic
575. Capstick T, Atack K, The Leeds Teaching Hospitals NHS Trust. The Leeds Inhaler Device Guide: Inhaler Technique
Instructions for Healthcare Professionals and Patients. 1st Edition. Available at https://www.cpwy.org/wp-
content/uploads/sites/128/2022/03/4.-Leeds-Inhaler-Device-Instruction-Guide-vs-11-Final.pdf [accessed Oct 2023].
2018:
576. Laube BL, Janssens HM, de Jongh FH, et al. What the pulmonary specialist should know about the new inhalation
therapies. Eur Respir J 2011; 37(6): 1308-31 https://pubmed.ncbi.nlm.nih.gov/21310878.
577. Asthma + Lung UK. Using your inhalers. Available at https://www.asthma.org.uk/advice/inhalers-medicines-
treatments/using-inhalers/ [accessed Oct 2023].
578. Janknegt R, Kooistra J, Metting E, Dekhuijzen R. Rational selection of inhalation devices in the treatment of chronic
obstructive pulmonary disease by means of the System of Objectified Judgement Analysis (SOJA). Eur J Hosp Pharm
2021; 28(2): e4 https://pubmed.ncbi.nlm.nih.gov/32920532.
579. Ciciliani AM, Langguth P, Wachtel H. Handling forces for the use of different inhaler devices. Int J Pharm 2019; 560: 315-
580. Klijn SL, Hiligsmann M, Evers S, Roman-Rodriguez M, van der Molen T, van Boven JFM. Effectiveness and success factors
TE
of educational inhaler technique interventions in asthma & COPD patients: a systematic review. NPJ Prim Care Respir
U
Med 2017; 27(1): 24 https://pubmed.ncbi.nlm.nih.gov/28408742.
IB
TR
581. Pernigotti D, Stonham C, Panigone S, et al. Reducing carbon footprint of inhalers: analysis of climate and clinical
IS
implications of different scenarios in five European countries. BMJ Open Respir Res 2021; 8(1):
D
T
582. Carpenter DM, Roberts CA, Sage AJ, George J, Horne R. A Review of Electronic Devices to Assess Inhaler Technique. Curr
O
N
Allergy Asthma Rep 2017; 17(3): 17 https://pubmed.ncbi.nlm.nih.gov/28290015.

O
583. Chan AH, Harrison J, Black PN, Mitchell EA, Foster JM. Using electronic monitoring devices to measure inhaler
-D
adherence: a practical guide for clinicians. J Allergy Clin Immunol Pract 2015; 3(3): 335-49 e1-5
L
IA
ER
584. Bowler R, Allinder M, Jacobson S, et al. Real-world use of rescue inhaler sensors, electronic symptom questionnaires
AT
and physical activity monitors in COPD. BMJ Open Respir Res 2019; 6(1): e000350
M
T
585. J WHK, Wouters H, Bosnic-Anticevich S, et al. Factors associated with health status and exacerbations in COPD
H
maintenance therapy with dry powder inhalers. NPJ Prim Care Respir Med 2022; 32(1): 18
IG
R
PY
586. Clark AR, Weers JG, Dhand R. The Confusing World of Dry Powder Inhalers: It Is All About Inspiratory Pressures, Not
O
Inspiratory Flow Rates. J Aerosol Med Pulm Drug Deliv 2020; 33(1): 1-11 https://pubmed.ncbi.nlm.nih.gov/31613682.
C
587. Mahler DA, Halpin DMG. Peak Inspiratory Flow as a Predictive Therapeutic Biomarker in COPD. Chest 2021; 160(2): 491-
588. Leving MT, van Boven JFM, Bosnic-Anticevich SZ, et al. Suboptimal Peak Inspiratory Flow and Critical Inhalation Errors
are Associated with Higher COPD-Related Healthcare Costs. Int J Chron Obstruct Pulmon Dis 2022; 17: 2401-15
589. Halpin DMG, Worsley S, Ismaila AS, et al. INTREPID: single- versus multiple-inhaler triple therapy for COPD in usual
clinical practice. ERJ Open Res 2021; 7(2): 00950-2020 https://pubmed.ncbi.nlm.nih.gov/34109236.
590. Souza ML, Meneghini AC, Ferraz E, Vianna EO, Borges MC. Knowledge of and technique for using inhalation devices
among asthma patients and COPD patients. J Bras Pneumol 2009; 35(9): 824-31
591. Melani AS, Bonavia M, Cilenti V, et al. Inhaler mishandling remains common in real life and is associated with reduced
disease control. Respir Med 2011; 105(6): 930-8 https://pubmed.ncbi.nlm.nih.gov/21367593.
592. Sanchis J, Gich I, Pedersen S, Aerosol Drug Management Improvement T. Systematic Review of Errors in Inhaler Use:
Has Patient Technique Improved Over Time? Chest 2016; 150(2): 394-406 https://pubmed.ncbi.nlm.nih.gov/27060726.
593. Cho-Reyes S, Celli BR, Dembek C, Yeh K, Navaie M. Inhalation Technique Errors with Metered-Dose Inhalers Among
Patients with Obstructive Lung Diseases: A Systematic Review and Meta-Analysis of U.S. Studies. Chronic Obstr Pulm Dis
594. van der Palen J, Klein JJ, Schildkamp AM. Comparison of a new multidose powder inhaler (Diskus/Accuhaler) and the
Turbuhaler regarding preference and ease of use. J Asthma 1998; 35(2): 147-52
595. van der Palen J, van der Valk P, Goosens M, Groothuis-Oudshoorn K, Brusse-Keizer M. A randomised cross-over trial
investigating the ease of use and preference of two dry powder inhalers in patients with asthma or chronic obstructive
pulmonary disease. Expert Opin Drug Deliv 2013; 10(9): 1171-8 https://pubmed.ncbi.nlm.nih.gov/23815552.
596. Van Der Palen J, Eijsvogel MM, Kuipers BF, Schipper M, Vermue NA. Comparison of the Diskus inhaler and the
Handihaler regarding preference and ease of use. J Aerosol Med 2007; 20(1): 38-44
597. van der Palen J, Klein JJ, Kerkhoff AH, van Herwaarden CL. Evaluation of the effectiveness of four different inhalers in
patients with chronic obstructive pulmonary disease. Thorax 1995; 50(11): 1183-7
598. van der Palen J, Ginko T, Kroker A, et al. Preference, satisfaction and errors with two dry powder inhalers in patients
with COPD. Expert Opin Drug Deliv 2013; 10(8): 1023-31 https://pubmed.ncbi.nlm.nih.gov/23745954.
599. Pascual S, Feimer J, De Soyza A, et al. Preference, satisfaction and critical errors with Genuair and Breezhaler inhalers in
patients with COPD: a randomised, cross-over, multicentre study. NPJ Prim Care Respir Med 2015; 25: 15018
600. Yawn BP, Colice GL, Hodder R. Practical aspects of inhaler use in the management of chronic obstructive pulmonary
disease in the primary care setting. Int J Chron Obstruct Pulmon Dis 2012; 7: 495-502
601. Sulaiman I, Cushen B, Greene G, et al. Objective Assessment of Adherence to Inhalers by Patients with Chronic
602. Clark B, Wells BJ, Saha AK, et al. Low Peak Inspiratory Flow Rates are Common Among COPD Inpatients and are
Associated with Increased Healthcare Resource Utilization: A Retrospective Cohort Study. Int J Chron Obstruct Pulmon
Dis 2022; 17: 1483-94 https://pubmed.ncbi.nlm.nih.gov/35791340.
TE
603. Barbara S, Kritikos V, Bosnic-Anticevich S. Inhaler technique: does age matter? A systematic review. Eur Respir Rev
U
IB
TR
604. Gray SL, Williams DM, Pulliam CC, Sirgo MA, Bishop AL, Donohue JF. Characteristics predicting incorrect metered-dose
IS
inhaler technique in older subjects. Arch Intern Med 1996; 156(9): 984-8 https://pubmed.ncbi.nlm.nih.gov/8624178.
D
605. Maricoto T, Santos D, Carvalho C, Teles I, Correia-de-Sousa J, Taborda-Barata L. Assessment of Poor Inhaler Technique
T
in Older Patients with Asthma or COPD: A Predictive Tool for Clinical Risk and Inhaler Performance. Drugs Aging 2020;
O
N

O
606. Barrons R, Pegram A, Borries A. Inhaler device selection: special considerations in elderly patients with chronic
-D
obstructive pulmonary disease. Am J Health Syst Pharm 2011; 68(13): 1221-32

L
IA
ER
607. Ho SF, MS OM, Steward JA, Breay P, Burr ML. Inhaler technique in older people in the community. Age Ageing 2004;
AT

608. Newman SP. Spacer devices for metered dose inhalers. Clin Pharmacokinet 2004; 43(6): 349-60
M
T
H
609. Mitchell JP, Nagel MW. Valved holding chambers (VHCs) for use with pressurised metered-dose inhalers (pMDIs): a
IG
R
review of causes of inconsistent medication delivery. Prim Care Respir J 2007; 16(4): 207-14
PY
O
610. Dantic DE. A critical review of the effectiveness of "teach-back" technique in teaching COPD patients self-management
C
using respiratory inhalers. Health Educ J 2014; 73: 41-50

611. Jia X, Zhou S, Luo D, Zhao X, Zhou Y, Cui YM. Effect of pharmacist-led interventions on medication adherence and
inhalation technique in adult patients with asthma or COPD: A systematic review and meta-analysis. J Clin Pharm Ther
612. Willard-Grace R, Chirinos C, Wolf J, et al. Lay Health Coaching to Increase Appropriate Inhaler Use in COPD: A
Randomized Controlled Trial. Ann Fam Med 2020; 18(1): 5-14 https://pubmed.ncbi.nlm.nih.gov/31937527.
613. Sulaiman I, Greene G, MacHale E, et al. A randomised clinical trial of feedback on inhaler adherence and technique in
patients with severe uncontrolled asthma. Eur Respir J 2018; 51(1): https://pubmed.ncbi.nlm.nih.gov/29301919.
614. Spruit MA, Singh SJ, Garvey C, et al. An official American Thoracic Society/European Respiratory Society statement: key
concepts and advances in pulmonary rehabilitation. Am J Respir Crit Care Med 2013; 188(8): e13-64
615. Vogiatzis I, Rochester CL, Spruit MA, Troosters T, Clini EM, American Thoracic Society/European Respiratory Society
Task Force on Policy in Pulmonary R. Increasing implementation and delivery of pulmonary rehabilitation: key messages
from the new ATS/ERS policy statement. Eur Respir J 2016; 47(5): 1336-41 https://pubmed.ncbi.nlm.nih.gov/27132269.
616. Garvey C, Bayles MP, Hamm LF, et al. Pulmonary Rehabilitation Exercise Prescription in Chronic Obstructive Pulmonary
Disease: Review of Selected Guidelines: AN OFFICIAL STATEMENT FROM THE AMERICAN ASSOCIATION OF
CARDIOVASCULAR AND PULMONARY REHABILITATION. J Cardiopulm Rehabil Prev 2016; 36(2): 75-83
617. Stone PW, Hickman K, Steiner MC, Roberts CM, Quint JK, Singh SJ. Predictors of Referral to Pulmonary Rehabilitation
from UK Primary Care. Int J Chron Obstruct Pulmon Dis 2020; 15: 2941-52 https://pubmed.ncbi.nlm.nih.gov/33235443.
618. Alison JA, McKeough ZJ, Johnston K, et al. Australian and New Zealand Pulmonary Rehabilitation Guidelines. Respirology
619. Wootton SL, Hill K, Alison JA, et al. Effects of Ongoing Feedback During a 12-Month Maintenance Walking Program on
Daily Physical Activity in People with COPD. Lung 2019; 197(3): 315-9 https://pubmed.ncbi.nlm.nih.gov/30982940.
620. Singh SJ, Morgan MD, Scott S, Walters D, Hardman AE. Development of a shuttle walking test of disability in patients
with chronic airways obstruction. Thorax 1992; 47(12): 1019-24 https://pubmed.ncbi.nlm.nih.gov/1494764.
621. Dowson C, Laing R, Barraclough R, et al. The use of the Hospital Anxiety and Depression Scale (HADS) in patients with
chronic obstructive pulmonary disease: a pilot study. N Z Med J 2001; 114(1141): 447-9
622. Kunik ME, Veazey C, Cully JA, et al. COPD education and cognitive behavioral therapy group treatment for clinically
significant symptoms of depression and anxiety in COPD patients: a randomized controlled trial. Psychol Med 2008;
623. Blackstock FC, Webster KE, McDonald CF, Hill CJ. Comparable improvements achieved in chronic obstructive pulmonary
disease through pulmonary rehabilitation with and without a structured educational intervention: a randomized
controlled trial. Respirology 2014; 19(2): 193-202 https://pubmed.ncbi.nlm.nih.gov/24261584.
624. Effing TW, Vercoulen JH, Bourbeau J, et al. Definition of a COPD self-management intervention: International Expert
Group consensus. Eur Respir J 2016; 48(1): 46-54 https://pubmed.ncbi.nlm.nih.gov/27076595.
625. Ashikaga T, Vacek PM, Lewis SO. Evaluation of a community-based education program for individuals with chronic
obstructive pulmonary disease. J Rehabil 1980; 46(2): 23-7 https://pubmed.ncbi.nlm.nih.gov/7392019.
626. Janelli LM, Scherer YK, Schmieder LE. Can a pulmonary health teaching program alter patients' ability to cope with
COPD? Rehabil Nurs 1991; 16(4): 199-202 https://pubmed.ncbi.nlm.nih.gov/1852971.
627. Cranston JM, Crockett AJ, Moss JR, Alpers JH. Domiciliary oxygen for chronic obstructive pulmonary disease. Cochrane
Database Syst Rev 2005; 2005(4): CD001744 https://pubmed.ncbi.nlm.nih.gov/16235285.
TE
628. Long-term Oxygen Treatment Trial Research Group. A randomized trial of long-term oxygen for COPD with moderate
U
desaturation. N Engl J Med 2016; 375(17): 1617
IB
TR
629. Ekstrom M, Ahmadi Z, Bornefalk-Hermansson A, Abernethy A, Currow D. Oxygen for breathlessness in patients with
IS
chronic obstructive pulmonary disease who do not qualify for home oxygen therapy. Cochrane Database Syst Rev 2016;
D
11(11): CD006429 https://pubmed.ncbi.nlm.nih.gov/27886372.
T
630. Jacobs SS, Krishnan JA, Lederer DJ, et al. Home Oxygen Therapy for Adults with Chronic Lung Disease. An Official
O
N
American Thoracic Society Clinical Practice Guideline. Am J Respir Crit Care Med 2020; 202(10): e121-e41
O
-D
631. Alison JA, McKeough ZJ, Leung RWM, et al. Oxygen compared to air during exercise training in COPD with exercise-
L
induced desaturation. Eur Respir J 2019; 53(5): 1802429 https://pubmed.ncbi.nlm.nih.gov/30880289.

IA
ER
632. Ahmedzai S, Balfour-Lynn IM, Bewick T, et al. Managing passengers with stable respiratory disease planning air travel:
AT
British Thoracic Society recommendations. Thorax 2011; 66 Suppl 1: i1-30 https://pubmed.ncbi.nlm.nih.gov/21856702.

633. Berg BW, Dillard TA, Rajagopal KR, Mehm WJ. Oxygen supplementation during air travel in patients with chronic
M
T
obstructive lung disease. Chest 1992; 101(3): 638-41 https://pubmed.ncbi.nlm.nih.gov/1541125.

H
634. Edvardsen A, Akero A, Christensen CC, Ryg M, Skjonsberg OH. Air travel and chronic obstructive pulmonary disease: a
IG
R
new algorithm for pre-flight evaluation. Thorax 2012; 67(11): 964-9 https://pubmed.ncbi.nlm.nih.gov/22767877.
PY
635. Christensen CC, Ryg M, Refvem OK, Skjonsberg OH. Development of severe hypoxaemia in chronic obstructive
O
pulmonary disease patients at 2,438 m (8,000 ft) altitude. Eur Respir J 2000; 15(4): 635-9
C
636. Raveling T, Vonk J, Struik FM, et al. Chronic non-invasive ventilation for chronic obstructive pulmonary disease.
637. Struik FM, Lacasse Y, Goldstein R, Kerstjens HM, Wijkstra PJ. Nocturnal non-invasive positive pressure ventilation for
stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2013; 2013(6): CD002878
638. Srivali N, Thongprayoon C, Tangpanithandee S, Cheungpasitporn W, Won C. The use of continuous positive airway
pressure in COPD-OSA overlap syndrome: A systematic review. Sleep Med 2023; 108: 55-60
639. Marin JM, Soriano JB, Carrizo SJ, Boldova A, Celli BR. Outcomes in patients with chronic obstructive pulmonary disease
and obstructive sleep apnea: the overlap syndrome. Am J Respir Crit Care Med 2010; 182(3): 325-31
640. Elliott MW, Nava S. Noninvasive ventilation for acute exacerbations of chronic obstructive pulmonary disease: "Don't
think twice, it's alright!". Am J Respir Crit Care Med 2012; 185(2): 121-3 https://pubmed.ncbi.nlm.nih.gov/22246701.
641. Chandra D, Stamm JA, Taylor B, et al. Outcomes of noninvasive ventilation for acute exacerbations of chronic
obstructive pulmonary disease in the United States, 1998-2008. Am J Respir Crit Care Med 2012; 185(2): 152-9
642. Lindenauer PK, Stefan MS, Shieh MS, Pekow PS, Rothberg MB, Hill NS. Outcomes associated with invasive and
noninvasive ventilation among patients hospitalized with exacerbations of chronic obstructive pulmonary disease.
JAMA Intern Med 2014; 174(12): 1982-93 https://pubmed.ncbi.nlm.nih.gov/25347545.
643. Wilson ME, Dobler CC, Morrow AS, et al. Association of Home Noninvasive Positive Pressure Ventilation With Clinical
Outcomes in Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-analysis. JAMA 2020; 323(5): 455-
644. Murphy PB, Rehal S, Arbane G, et al. Effect of Home Noninvasive Ventilation With Oxygen Therapy vs Oxygen Therapy
Alone on Hospital Readmission or Death After an Acute COPD Exacerbation: A Randomized Clinical Trial. JAMA 2017;
645. Galli JA, Krahnke JS, James Mamary A, Shenoy K, Zhao H, Criner GJ. Home non-invasive ventilation use following acute
hypercapnic respiratory failure in COPD. Respir Med 2014; 108(5): 722-8 https://pubmed.ncbi.nlm.nih.gov/24702885.
646. Coughlin S, Liang WE, Parthasarathy S. Retrospective Assessment of Home Ventilation to Reduce Rehospitalization in
Chronic Obstructive Pulmonary Disease. J Clin Sleep Med 2015; 11(6): 663-70
647. Clini E, Sturani C, Rossi A, et al. The Italian multicentre study on noninvasive ventilation in chronic obstructive
pulmonary disease patients. Eur Respir J 2002; 20(3): 529-38 https://pubmed.ncbi.nlm.nih.gov/12358325.
648. Kohnlein T, Windisch W, Kohler D, et al. Non-invasive positive pressure ventilation for the treatment of severe stable
chronic obstructive pulmonary disease: a prospective, multicentre, randomised, controlled clinical trial. Lancet Respir
649. Struik FM, Sprooten RT, Kerstjens HA, et al. Nocturnal non-invasive ventilation in COPD patients with prolonged
hypercapnia after ventilatory support for acute respiratory failure: a randomised, controlled, parallel-group study.
650. Casanova C, Celli BR, Tost L, et al. Long-term controlled trial of nocturnal nasal positive pressure ventilation in patients
with severe COPD. Chest 2000; 118(6): 1582-90 https://pubmed.ncbi.nlm.nih.gov/11115443.
651. White DP, Criner GJ, Dreher M, et al. The role of noninvasive ventilation in the management and mitigation of
exacerbations and hospital admissions/readmissions for the patient with moderate to severe COPD (multimedia
TE
activity). Chest 2015; 147(6): 1704-5 https://pubmed.ncbi.nlm.nih.gov/26033131.
U
652. Lightowler JV, Wedzicha JA, Elliott MW, Ram FS. Non-invasive positive pressure ventilation to treat respiratory failure
IB
TR
resulting from exacerbations of chronic obstructive pulmonary disease: Cochrane systematic review and meta-analysis.
BMJ 2003; 326(7382): 185 https://pubmed.ncbi.nlm.nih.gov/12543832. IS
D
653. Kolodziej MA, Jensen L, Rowe B, Sin D. Systematic review of noninvasive positive pressure ventilation in severe stable
T

O
N
654. Kessler R, Stahl E, Vogelmeier C, et al. Patient understanding, detection, and experience of COPD exacerbations: an
O
observational, interview-based study. Chest 2006; 130(1): 133-42 https://pubmed.ncbi.nlm.nih.gov/16840393.

-D
655. Johnson-Warrington V, Mitchell KE, Singh SJ. Is a practice incremental shuttle walk test needed for patients with chronic
L
obstructive pulmonary disease admitted to hospital for an acute exacerbation? Respiration 2015; 90(3): 206-10
IA
ER
AT
656. Rochester CL, Vogiatzis I, Holland AE, et al. An Official American Thoracic Society/European Respiratory Society Policy
Statement: Enhancing Implementation, Use, and Delivery of Pulmonary Rehabilitation. Am J Respir Crit Care Med 2015;
M
T

H
657. Janjua S, Pike KC, Carr R, Coles A, Fortescue R, Batavia M. Interventions to improve adherence to pharmacological
IG
R
therapy for chronic obstructive pulmonary disease (COPD). Cochrane Database Syst Rev 2021; 9(9): CD013381
PY
O
658. American Academy of H, Palliative M, Center to Advance Palliative C, et al. National Consensus Project for Quality
C
Palliative Care: Clinical Practice Guidelines for quality palliative care, executive summary. J Palliat Med 2004; 7(5): 611-
659. Au DH, Udris EM, Fihn SD, McDonell MB, Curtis JR. Differences in health care utilization at the end of life among
patients with chronic obstructive pulmonary disease and patients with lung cancer. Arch Intern Med 2006; 166(3): 326-
660. Levy MH, Adolph MD, Back A, et al. Palliative care. J Natl Compr Canc Netw 2012; 10(10): 1284-309
661. Morrison RS, Maroney-Galin C, Kralovec PD, Meier DE. The growth of palliative care programs in United States
hospitals. J Palliat Med 2005; 8(6): 1127-34 https://pubmed.ncbi.nlm.nih.gov/16351525.
662. Han MK, Martinez CH, Au DH, et al. Meeting the challenge of COPD care delivery in the USA: a multiprovider
perspective. Lancet Respir Med 2016; 4(6): 473-526 https://pubmed.ncbi.nlm.nih.gov/27185520.
663. Ambrosino N, Fracchia C. Strategies to relieve dyspnoea in patients with advanced chronic respiratory diseases. A
narrative review. Pulmonology 2019; 25(5): 289-98 https://pubmed.ncbi.nlm.nih.gov/31129045.
664. Ekstrom M, Nilsson F, Abernethy AA, Currow DC. Effects of opioids on breathlessness and exercise capacity in chronic
obstructive pulmonary disease. A systematic review. Ann Am Thorac Soc 2015; 12(7): 1079-92
665. Rocker GM, Simpson AC, Joanne Young B, et al. Opioid therapy for refractory dyspnea in patients with advanced chronic
obstructive pulmonary disease: patients' experiences and outcomes. CMAJ Open 2013; 1(1): E27-36
666. Marciniuk DD, Goodridge D, Hernandez P, et al. Managing dyspnea in patients with advanced chronic obstructive
pulmonary disease: a Canadian Thoracic Society clinical practice guideline. Can Respir J 2011; 18(2): 69-78
667. Vieira PJ, Chiappa AM, Cipriano G, Jr., Umpierre D, Arena R, Chiappa GR. Neuromuscular electrical stimulation improves
clinical and physiological function in COPD patients. Respir Med 2014; 108(4): 609-20
668. Galbraith S, Fagan P, Perkins P, Lynch A, Booth S. Does the use of a handheld fan improve chronic dyspnea? A
randomized, controlled, crossover trial. J Pain Symptom Manage 2010; 39(5): 831-8
669. Marchetti N, Lammi MR, Travaline JM, Ciccolella D, Civic B, Criner GJ. Air Current Applied to the Face Improves Exercise
Performance in Patients with COPD. Lung 2015; 193(5): 725-31 https://pubmed.ncbi.nlm.nih.gov/26255060.
670. Ekström M, Ferreira D, Chang S, et al. Effect of Regular, Low-Dose, Extended-release Morphine on Chronic
Breathlessness in Chronic Obstructive Pulmonary Disease: The BEAMS Randomized Clinical Trial. Jama 2022; 328(20):
671. Abdallah SJ, Wilkinson-Maitland C, Saad N, et al. Effect of morphine on breathlessness and exercise endurance in
advanced COPD: a randomised crossover trial. Eur Respir J 2017; 50(4): 1701235
672. Nici L, Mammen MJ, Charbek E, et al. Pharmacologic Management of Chronic Obstructive Pulmonary Disease. An
Official American Thoracic Society Clinical Practice Guideline. Am J Respir Crit Care Med 2020; 201(9): e56-e69
673. Uronis HE, Ekstrom MP, Currow DC, McCrory DC, Samsa GP, Abernethy AP. Oxygen for relief of dyspnoea in people with
chronic obstructive pulmonary disease who would not qualify for home oxygen: a systematic review and meta-analysis.
TE
674. von Trott P, Oei SL, Ramsenthaler C. Acupuncture for Breathlessness in Advanced Diseases: A Systematic Review and
U
Meta-analysis. J Pain Symptom Manage 2020; 59(2): 327-38 e3 https://pubmed.ncbi.nlm.nih.gov/31539602.
IB
TR
675. Higginson IJ, Bausewein C, Reilly CC, et al. An integrated palliative and respiratory care service for patients with
IS
advanced disease and refractory breathlessness: a randomised controlled trial. Lancet Respir Med 2014; 2(12): 979-87
D
T
676. Simon ST, Higginson IJ, Booth S, Harding R, Bausewein C. Benzodiazepines for the relief of breathlessness in advanced
O
N
malignant and non-malignant diseases in adults. Cochrane Database Syst Rev 2010; (1): CD007354
O
-D
677. Bausewein C, Booth S, Gysels M, Higginson I. Non-pharmacological interventions for breathlessness in advanced stages
L
of malignant and non-malignant diseases. Cochrane Database Syst Rev 2008; (2): CD005623
IA
ER
AT
678. Putcha N, Anzueto AR, Calverley PMA, et al. Mortality and Exacerbation Risk by Body Mass Index in Patients with COPD
in TIOSPIR and UPLIFT. Ann Am Thorac Soc 2022; 19(2): 204-13 https://pubmed.ncbi.nlm.nih.gov/34406915.
M
T
679. Ferreira IM, Brooks D, White J, Goldstein R. Nutritional supplementation for stable chronic obstructive pulmonary
H
disease. Cochrane Database Syst Rev 2012; 12: CD000998 https://pubmed.ncbi.nlm.nih.gov/23235577.

IG
R
680. Gouzi F, Maury J, Heraud N, et al. Additional Effects of Nutritional Antioxidant Supplementation on Peripheral Muscle
PY
during Pulmonary Rehabilitation in COPD Patients: A Randomized Controlled Trial. Oxid Med Cell Longev 2019; 2019:
O
C
681. van Beers M, Rutten-van Molken M, van de Bool C, et al. Clinical outcome and cost-effectiveness of a 1-year nutritional
intervention programme in COPD patients with low muscle mass: The randomized controlled NUTRAIN trial. Clin Nutr
682. Yohannes AM, Alexopoulos GS. Depression and anxiety in patients with COPD. Eur Respir Rev 2014; 23(133): 345-9
683. Farver-Vestergaard I, Jacobsen D, Zachariae R. Efficacy of psychosocial interventions on psychological and physical
health outcomes in chronic obstructive pulmonary disease: a systematic review and meta-analysis. Psychother
Psychosom 2015; 84(1): 37-50 https://pubmed.ncbi.nlm.nih.gov/25547641.
684. Payne C, Wiffen PJ, Martin S. Interventions for fatigue and weight loss in adults with advanced progressive illness.
Cochrane Database Syst Rev 2012; 1: CD008427 https://pubmed.ncbi.nlm.nih.gov/22258985.
685. Murray SA, Kendall M, Boyd K, Sheikh A. Illness trajectories and palliative care. BMJ 2005; 330(7498): 1007-11
686. Eriksen N, Vestbo J. Management and survival of patients admitted with an exacerbation of COPD: comparison of two
Danish patient cohorts. Clin Respir J 2010; 4(4): 208-14 https://pubmed.ncbi.nlm.nih.gov/20887343.
687. Groenewegen KH, Schols AM, Wouters EF. Mortality and mortality-related factors after hospitalization for acute
exacerbation of COPD. Chest 2003; 124(2): 459-67 https://pubmed.ncbi.nlm.nih.gov/12907529.
688. Gudmundsson G, Ulrik CS, Gislason T, et al. Long-term survival in patients hospitalized for chronic obstructive
pulmonary disease: a prospective observational study in the Nordic countries. Int J Chron Obstruct Pulmon Dis 2012; 7:
689. Disler RT, Green A, Luckett T, et al. Experience of advanced chronic obstructive pulmonary disease: metasynthesis of
qualitative research. J Pain Symptom Manage 2014; 48(6): 1182-99 https://pubmed.ncbi.nlm.nih.gov/24780181.
690. Halpin DMG, Seamark DA, Seamark CJ. Palliative and end-of-life care for patients with respiratory diseases. Eur Respir
Monograph 2009; 43: 327-53
691. Patel K, Janssen DJ, Curtis JR. Advance care planning in COPD. Respirology 2012; 17(1): 72-8
692. Pinnock H, Kendall M, Murray SA, et al. Living and dying with severe chronic obstructive pulmonary disease: multi-
perspective longitudinal qualitative study. BMJ 2011; 342: d142 https://pubmed.ncbi.nlm.nih.gov/21262897.
693. Weber C, Stirnemann J, Herrmann FR, Pautex S, Janssens JP. Can early introduction of specialized palliative care limit
intensive care, emergency and hospital admissions in patients with severe and very severe COPD? a randomized study.
BMC Palliat Care 2014; 13: 47 https://pubmed.ncbi.nlm.nih.gov/25927907.
694. Ek K, Andershed B, Sahlberg-Blom E, Ternestedt BM. "The unpredictable death"-The last year of life for patients with
advanced COPD: Relatives' stories. Palliat Support Care 2015; 13(5): 1213-22
695. National Hospice and Palliative Care Organization. Web Page. 2019. http://www.nhpco.org (accessed Oct 2022).
696. Whittaker H, Rothnie KJ, Quint JK. Cause-specific mortality in COPD subpopulations: a cohort study of 339 647 people in
England. Thorax 2023: https://pubmed.ncbi.nlm.nih.gov/37328279.
697. Calverley PM, Anderson JA, Celli B, et al. Salmeterol and fluticasone propionate and survival in chronic obstructive
pulmonary disease. N Engl J Med 2007; 356(8): 775-89 https://pubmed.ncbi.nlm.nih.gov/17314337.
698. Vestbo J, Anderson J, Brook RD, et al. The Study to Understand Mortality and Morbidity in COPD (SUMMIT) study
protocol. Eur Respir J 2013; 41(5): 1017-22 https://pubmed.ncbi.nlm.nih.gov/23018908.
699. Anthonisen NR, Skeans MA, Wise RA, et al. The effects of a smoking cessation intervention on 14.5-year mortality: a
randomized clinical trial. Ann Intern Med 2005; 142(4): 233-9 https://pubmed.ncbi.nlm.nih.gov/15710956.
TE
700. Lu HY, Chen CF, Lee DL, Tsai YJ, Lin PC. Effects of Early Pulmonary Rehabilitation on Hospitalized Patients with Acute
U
Exacerbation of Chronic Obstructive Pulmonary Disease: A Systematic Review and Meta-Analysis. Int J Chron Obstruct
IB
TR
Pulmon Dis 2023; 18: 881-93 https://pubmed.ncbi.nlm.nih.gov/37215744.
701. IS
Ryrso CK, Godtfredsen NS, Kofod LM, et al. Lower mortality after early supervised pulmonary rehabilitation following
D
COPD-exacerbations: a systematic review and meta-analysis. BMC Pulm Med 2018; 18(1): 154
T
O
N
702. Puhan MA, Gimeno-Santos E, Scharplatz M, Troosters T, Walters EH, Steurer J. Pulmonary rehabilitation following
O
exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2011; (10): CD005305
-D
L
703. Puhan MA, Gimeno-Santos E, Cates CJ, Troosters T. Pulmonary rehabilitation following exacerbations of chronic
IA
ER
obstructive pulmonary disease. Cochrane Database Syst Rev 2016; 12(12): Cd005305
AT
704. Lindenauer PK, Stefan MS, Pekow PS, et al. Association Between Initiation of Pulmonary Rehabilitation After
M
T
Hospitalization for COPD and 1-Year Survival Among Medicare Beneficiaries. JAMA 2020; 323(18): 1813-23
H
IG
R
705. NOTT Nocturnal Oxygen Therapy Trial Group. Continuous or nocturnal oxygen therapy in hypoxemic chronic obstructive
PY
lung disease: a clinical trial. Nocturnal Oxygen Therapy Trial Group. Ann Intern Med 1980; 93(3): 391-8
O
C
706. MRC Working Party. Long term domiciliary oxygen therapy in chronic hypoxic cor pulmonale complicating chronic
bronchitis and emphysema. Report of the Medical Research Council Working Party. Lancet 1981; 1(8222): 681-6
707. Lacasse Y, Casaburi R, Sliwinski P, et al. Home oxygen for moderate hypoxaemia in chronic obstructive pulmonary
disease: a systematic review and meta-analysis. Lancet Respir Med 2022; 10(11): 1029-37
708. Park SY, Yoo KH, Park YB, et al. The Long-term Efficacy of Domiciliary Noninvasive Positive-Pressure Ventilation in
Chronic Obstructive Pulmonary Disease: A Meta-Analysis of Randomized Controlled Trials. Tuberc Respir Dis (Seoul)
709. McEvoy RD, Pierce RJ, Hillman D, et al. Nocturnal non-invasive nasal ventilation in stable hypercapnic COPD: a
randomised controlled trial. Thorax 2009; 64(7): 561-6 https://pubmed.ncbi.nlm.nih.gov/19213769.
710. Vock DM, Durheim MT, Tsuang WM, et al. Survival Benefit of Lung Transplantation in the Modern Era of Lung
Allocation. Ann Am Thorac Soc 2017; 14(2): 172-81 https://pubmed.ncbi.nlm.nih.gov/27779905.
711. van der Meer RM, Wagena EJ, Ostelo RW, Jacobs JE, van Schayck CP. Smoking cessation for chronic obstructive
712. Stead LF, Koilpillai P, Fanshawe TR, Lancaster T. Combined pharmacotherapy and behavioural interventions for smoking
cessation. Cochrane Database Syst Rev 2016; 3(3): CD008286 https://pubmed.ncbi.nlm.nih.gov/27009521.
713. Okuyemi KS, Nollen NL, Ahluwalia JS. Interventions to facilitate smoking cessation. Am Fam Physician 2006; 74(2): 262-
714. Fiore MC, Bailey WC, Cohen SJ. Smoking Cessation: information for specialists. Rockville, MD; 1996.
715. Lee PN, Fariss MW. A systematic review of possible serious adverse health effects of nicotine replacement therapy.
Arch Toxicol 2017; 91(4): 1565-94 https://pubmed.ncbi.nlm.nih.gov/27699443.
716. Bullen C, Howe C, Laugesen M, et al. Electronic cigarettes for smoking cessation: a randomised controlled trial. Lancet
717. Hajek P, Phillips-Waller A, Przulj D, et al. E-cigarettes compared with nicotine replacement therapy within the UK Stop
Smoking Services: the TEC RCT. Health Technol Assess 2019; 23(43): 1-82 https://pubmed.ncbi.nlm.nih.gov/31434605.
718. Hanewinkel R, Niederberger K, Pedersen A, Unger JB, Galimov A. E-cigarettes and nicotine abstinence: a meta-analysis
of randomised controlled trials. Eur Respir Rev 2022; 31(163): https://pubmed.ncbi.nlm.nih.gov/35321930.
719. Morphett K, Fraser D, Borland R, et al. A Pragmatic Randomized Comparative Trial of e-Cigarettes and Other Nicotine
Products for Quitting or Long-Term Substitution in Smokers. Nicotine Tob Res 2022; 24(7): 1079-88
720. Walker N, Parag V, Verbiest M, Laking G, Laugesen M, Bullen C. Nicotine patches used in combination with e-cigarettes
(with and without nicotine) for smoking cessation: a pragmatic, randomised trial. Lancet Respir Med 2020; 8(1): 54-64
721. He T, Oks M, Esposito M, Steinberg H, Makaryus M. "Tree-in-Bloom": Severe Acute Lung Injury Induced by Vaping
Cannabis Oil. Ann Am Thorac Soc 2017; 14(3): 468-70 https://pubmed.ncbi.nlm.nih.gov/28248584.
722. Henry TS, Kanne JP, Kligerman SJ. Imaging of Vaping-Associated Lung Disease. N Engl J Med 2019; 381(15): 1486-7
723. Layden JE, Ghinai I, Pray I, et al. Pulmonary Illness Related to E-Cigarette Use in Illinois and Wisconsin - Final Report. N
724. Centers for Disease Control and Prevention; U.S. Department of Health & Human Services. Outbreak of Lung Injury
Associated with E-Cigarette Use, or Vaping https://www.cdc.gov/tobacco/basic_information/e-cigarettes/severe-lung-
disease.html [accessed Oct 2023].
TE
725. Blount BC, Karwowski MP, Shields PG, et al. Vitamin E Acetate in Bronchoalveolar-Lavage Fluid Associated with EVALI. N
U
IB
TR
726. Garcia-Arcos I, Geraghty P, Baumlin N, et al. Chronic electronic cigarette exposure in mice induces features of COPD in a
IS
nicotine-dependent manner. Thorax 2016; 71(12): 1119-29 https://pubmed.ncbi.nlm.nih.gov/27558745.
D
727. Higham A, Bostock D, Booth G, Dungwa JV, Singh D. The effect of electronic cigarette and tobacco smoke exposure on
T
COPD bronchial epithelial cell inflammatory responses. Int J Chron Obstruct Pulmon Dis 2018; 13: 989-1000
O
N
O
728. Higham A, Rattray NJ, Dewhurst JA, et al. Electronic cigarette exposure triggers neutrophil inflammatory responses.
-D
Respir Res 2016; 17(1): 56 https://pubmed.ncbi.nlm.nih.gov/27184092.

L
729. Lerner CA, Sundar IK, Yao H, et al. Vapors produced by electronic cigarettes and e-juices with flavorings induce toxicity,
IA
ER
oxidative stress, and inflammatory response in lung epithelial cells and in mouse lung. PLoS One 2015; 10(2): e0116732
AT
730. Reidel B, Radicioni G, Clapp PW, et al. E-Cigarette Use Causes a Unique Innate Immune Response in the Lung, Involving
M
T
Increased Neutrophilic Activation and Altered Mucin Secretion. Am J Respir Crit Care Med 2018; 197(4): 492-501
H
IG
R
731. Gotts JE, Jordt SE, McConnell R, Tarran R. What are the respiratory effects of e-cigarettes? BMJ 2019; 366: l5275
PY
O
732. Xie W, Kathuria H, Galiatsatos P, et al. Association of Electronic Cigarette Use With Incident Respiratory Conditions
C
Among US Adults From 2013 to 2018. JAMA Netw Open 2020; 3(11): e2020816
733. Bowler RP, Hansel NN, Jacobson S, et al. Electronic Cigarette Use in US Adults at Risk for or with COPD: Analysis from
Two Observational Cohorts. J Gen Intern Med 2017; 32(12): 1315-22 https://pubmed.ncbi.nlm.nih.gov/28884423.
734. Li J, Hui X, Fu J, Ahmed MM, Yao L, Yang K. Electronic cigarettes versus nicotine-replacement therapy for smoking
cessation: A systematic review and meta-analysis of randomized controlled trials. Tob Induc Dis 2022; 20: 90
735. Jimenez Ruiz CA, Ramos Pinedo A, Cicero Guerrero A, Mayayo Ulibarri M, Cristobal Fernandez M, Lopez Gonzalez G.
Characteristics of COPD smokers and effectiveness and safety of smoking cessation medications. Nicotine Tob Res 2012;
736. Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA, Maslen TK. Randomised, double blind, placebo controlled
study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE
trial. BMJ 2000; 320(7245): 1297-303 https://pubmed.ncbi.nlm.nih.gov/10807619.
737. Anthonisen NR, Connett JE, Kiley JP, et al. Effects of smoking intervention and the use of an inhaled anticholinergic
bronchodilator on the rate of decline of FEV1. The Lung Health Study. JAMA 1994; 272(19): 1497-505
738. Pauwels RA, Lofdahl CG, Laitinen LA, et al. Long-term treatment with inhaled budesonide in persons with mild chronic
obstructive pulmonary disease who continue smoking. European Respiratory Society Study on Chronic Obstructive
Pulmonary Disease. N Engl J Med 1999; 340(25): 1948-53 https://pubmed.ncbi.nlm.nih.gov/10379018.
739. Vestbo J, Sorensen T, Lange P, Brix A, Torre P, Viskum K. Long-term effect of inhaled budesonide in mild and moderate
chronic obstructive pulmonary disease: a randomised controlled trial. Lancet 1999; 353(9167): 1819-23
740. Tashkin DP, Celli B, Senn S, et al. A 4-year trial of tiotropium in chronic obstructive pulmonary disease. N Engl J Med
741. Celli BR, Anderson JA, Cowans NJ, et al. Pharmacotherapy and Lung Function Decline in Patients with Chronic
Obstructive Pulmonary Disease. A Systematic Review. Am J Respir Crit Care Med 2021; 203(6): 689-98
742. World Health Organization. WHO package of essential noncommunicable (PEN) disease interventions for primary health
care. Geneva. Licence: CC BY-NC-SA 3.0 IGO, online document available here:
https://www.who.int/publications/i/item/who-package-of-essential-noncommunicable-(pen)-disease-interventions-
for-primary-health-care [accessed Oct 2023].
743. O'Donnell DE, Sciurba F, Celli B, et al. Effect of fluticasone propionate/salmeterol on lung hyperinflation and exercise
endurance in COPD. Chest 2006; 130(3): 647-56 https://pubmed.ncbi.nlm.nih.gov/16963658.
744. Berger R, Smith D. Effect of inhaled metaproterenol on exercise performance in patients with stable "fixed" airway
obstruction. Am Rev Respir Dis 1988; 138(3): 624-9 https://pubmed.ncbi.nlm.nih.gov/3202416.
745. Hay JG, Stone P, Carter J, et al. Bronchodilator reversibility, exercise performance and breathlessness in stable chronic
746. Chrystyn H, Mulley BA, Peake MD. Dose response relation to oral theophylline in severe chronic obstructive airways
disease. BMJ 1988; 297(6662): 1506-10 https://pubmed.ncbi.nlm.nih.gov/3147048.
747. Gross NJ, Petty TL, Friedman M, Skorodin MS, Silvers GW, Donohue JF. Dose response to ipratropium as a nebulized
solution in patients with chronic obstructive pulmonary disease. A three-center study. Am Rev Respir Dis 1989; 139(5):
TE
748. Higgins BG, Powell RM, Cooper S, Tattersfield AE. Effect of salbutamol and ipratropium bromide on airway calibre and
U
bronchial reactivity in asthma and chronic bronchitis. Eur Respir J 1991; 4(4): 415-20
IB
TR
749. IS
Vathenen AS, Britton JR, Ebden P, Cookson JB, Wharrad HJ, Tattersfield AE. High-dose inhaled albuterol in severe
D
chronic airflow limitation. Am Rev Respir Dis 1988; 138(4): 850-5 https://pubmed.ncbi.nlm.nih.gov/2462383.
T
750. Donohue JF, Anzueto A, Brooks J, Mehta R, Kalberg C, Crater G. A randomized, double-blind dose-ranging study of the
O
N
novel LAMA GSK573719 in patients with COPD. Respir Med 2012; 106(7): 970-9
O
-D
751. Donohue JF, Kalberg C, Shah P, et al. Dose response of umeclidinium administered once or twice daily in patients with
L
COPD: a pooled analysis of two randomized, double-blind, placebo-controlled studies. J Clin Pharmacol 2014; 54(11):
IA
ER
AT
752. Chowdhury BA, Seymour SM, Michele TM, Durmowicz AG, Liu D, Rosebraugh CJ. The risks and benefits of indacaterol--
the FDA's review. N Engl J Med 2011; 365(24): 2247-9 https://pubmed.ncbi.nlm.nih.gov/22168640.
M
T
753. O'Driscoll BR, Kay EA, Taylor RJ, Weatherby H, Chetty MC, Bernstein A. A long-term prospective assessment of home
H
nebulizer treatment. Respir Med 1992; 86(4): 317-25 https://pubmed.ncbi.nlm.nih.gov/1448587.

IG
R
754. Jenkins SC, Heaton RW, Fulton TJ, Moxham J. Comparison of domiciliary nebulized salbutamol and salbutamol from a
PY
metered-dose inhaler in stable chronic airflow limitation. Chest 1987; 91(6): 804-7
O
C
755. Sestini P, Renzoni E, Robinson S, Poole P, Ram FS. Short-acting beta 2 agonists for stable chronic obstructive pulmonary
756. Cazzola M, Rogliani P, Ruggeri P, et al. Chronic treatment with indacaterol and airway response to salbutamol in stable
COPD. Respir Med 2013; 107(6): 848-53 https://pubmed.ncbi.nlm.nih.gov/23490225.
757. Kew KM, Mavergames C, Walters JA. Long-acting beta2-agonists for chronic obstructive pulmonary disease. Cochrane
758. Han J, Dai L, Zhong N. Indacaterol on dyspnea in chronic obstructive pulmonary disease: a systematic review and meta-
analysis of randomized placebo-controlled trials. BMC Pulm Med 2013; 13: 26
759. Geake JB, Dabscheck EJ, Wood-Baker R, Cates CJ. Indacaterol, a once-daily beta2-agonist, versus twice-daily beta(2)-
agonists or placebo for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2015; 1(1): CD010139
760. Koch A, Pizzichini E, Hamilton A, et al. Lung function efficacy and symptomatic benefit of olodaterol once daily delivered
via Respimat(R) versus placebo and formoterol twice daily in patients with GOLD 2-4 COPD: results from two replicate
48-week studies. Int J Chron Obstruct Pulmon Dis 2014; 9: 697-714 https://pubmed.ncbi.nlm.nih.gov/25045258.
761. Kempsford R, Norris V, Siederer S. Vilanterol trifenatate, a novel inhaled long-acting beta2 adrenoceptor agonist, is well
tolerated in healthy subjects and demonstrates prolonged bronchodilation in subjects with asthma and COPD. Pulm
Pharmacol Ther 2013; 26(2): 256-64 https://pubmed.ncbi.nlm.nih.gov/23232038.
762. Lipworth BJ, McDevitt DG, Struthers AD. Hypokalemic and ECG sequelae of combined beta-agonist/diuretic therapy.
Protection by conventional doses of spironolactone but not triamterene. Chest 1990; 98(4): 811-5
763. Uren NG, Davies SW, Jordan SL, Lipkin DP. Inhaled bronchodilators increase maximum oxygen consumption in chronic
left ventricular failure. Eur Heart J 1993; 14(6): 744-50 https://pubmed.ncbi.nlm.nih.gov/8325299.
764. Khoukaz G, Gross NJ. Effects of salmeterol on arterial blood gases in patients with stable chronic obstructive pulmonary
disease. Comparison with albuterol and ipratropium. Am J Respir Crit Care Med 1999; 160(3): 1028-30
765. McGarvey L, Niewoehner D, Magder S, et al. One-Year Safety of Olodaterol Once Daily via Respimat(R) in Patients with
GOLD 2-4 Chronic Obstructive Pulmonary Disease: Results of a Pre-Specified Pooled Analysis. COPD 2015; 12(5): 484-93
766. Dahl R, Chung KF, Buhl R, et al. Efficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-
daily formoterol in COPD. Thorax 2010; 65(6): 473-9 https://pubmed.ncbi.nlm.nih.gov/20522841.
767. Melani AS. Long-acting muscarinic antagonists. Expert Rev Clin Pharmacol 2015; 8(4): 479-501
768. Barnes P. Bronchodilators: basic pharmacology. In: Calverley PMA, Pride NB, eds. Chronic Obstructive Pulmonary
Disease. London: Chapman and Hall; 1995: 391-417.
769. Appleton S, Jones T, Poole P, et al. Ipratropium bromide versus long-acting beta-2 agonists for stable chronic
obstructive pulmonary disease. Cochrane Database Syst Rev 2006; 2006(3): CD006101
770. Jones PW, Singh D, Bateman ED, et al. Efficacy and safety of twice-daily aclidinium bromide in COPD patients: the
ATTAIN study. Eur Respir J 2012; 40(4): 830-6 https://pubmed.ncbi.nlm.nih.gov/22441743.
771. Karner C, Chong J, Poole P. Tiotropium versus placebo for chronic obstructive pulmonary disease. Cochrane Database
TE
Syst Rev 2014; 2014(7): CD009285 https://pubmed.ncbi.nlm.nih.gov/25046211.
U
772. Calzetta L, Ritondo BL, Zappa MC, et al. The impact of long-acting muscarinic antagonists on mucus hypersecretion and
IB
TR
cough in chronic obstructive pulmonary disease: a systematic review. Eur Respir Rev 2022; 31(164):
D
773. Kesten S, Casaburi R, Kukafka D, Cooper CB. Improvement in self-reported exercise participation with the combination
T
of tiotropium and rehabilitative exercise training in COPD patients. Int J Chron Obstruct Pulmon Dis 2008; 3(1): 127-36
O
N
O
774. Casaburi R, Kukafka D, Cooper CB, Witek TJ, Jr., Kesten S. Improvement in exercise tolerance with the combination of
-D
tiotropium and pulmonary rehabilitation in patients with COPD. Chest 2005; 127(3): 809-17
L
IA
ER
775. Vogelmeier C, Hederer B, Glaab T, et al. Tiotropium versus salmeterol for the prevention of exacerbations of COPD. N
AT

776. Decramer ML, Chapman KR, Dahl R, et al. Once-daily indacaterol versus tiotropium for patients with severe chronic
M
T
obstructive pulmonary disease (INVIGORATE): a randomised, blinded, parallel-group study. Lancet Respir Med 2013;
H

IG
R
777. Tashkin DP. Long-acting anticholinergic use in chronic obstructive pulmonary disease: efficacy and safety. Curr Opin
PY
Pulm Med 2010; 16(2): 97-105 https://pubmed.ncbi.nlm.nih.gov/20019615.

O
778. Disse B, Speck GA, Rominger KL, Witek TJ, Jr., Hammer R. Tiotropium (Spiriva): mechanistical considerations and clinical
C
profile in obstructive lung disease. Life Sci 1999; 64(6-7): 457-64 https://pubmed.ncbi.nlm.nih.gov/10069510.
779. Kesten S, Jara M, Wentworth C, Lanes S. Pooled clinical trial analysis of tiotropium safety. Chest 2006; 130(6): 1695-703
780. Anthonisen NR, Connett JE, Enright PL, Manfreda J, Lung Health Study Research G. Hospitalizations and mortality in the
Lung Health Study. Am J Respir Crit Care Med 2002; 166(3): 333-9 https://pubmed.ncbi.nlm.nih.gov/12153966.
781. Michele TM, Pinheiro S, Iyasu S. The safety of tiotropium--the FDA's conclusions. N Engl J Med 2010; 363(12): 1097-9
782. Verhamme KM, Afonso A, Romio S, Stricker BC, Brusselle GG, Sturkenboom MC. Use of tiotropium Respimat Soft Mist
Inhaler versus HandiHaler and mortality in patients with COPD. Eur Respir J 2013; 42(3): 606-15
783. Wise RA, Anzueto A, Cotton D, et al. Tiotropium Respimat inhaler and the risk of death in COPD. N Engl J Med 2013;
784. Packe GE, Cayton RM, Mashhoudi N. Nebulised ipratropium bromide and salbutamol causing closed-angle glaucoma.
Lancet 1984; 2(8404): 691 https://pubmed.ncbi.nlm.nih.gov/6147708.
785. Mulpeter KM, Walsh JB, O'Connor M, O'Connell F, Burke C. Ocular hazards of nebulized bronchodilators. Postgrad Med
J 1992; 68(796): 132-3 https://pubmed.ncbi.nlm.nih.gov/1533281.
786. Hall SK. Acute angle-closure glaucoma as a complication of combined beta-agonist and ipratropium bromide therapy in
the emergency department. Ann Emerg Med 1994; 23(4): 884-7 https://pubmed.ncbi.nlm.nih.gov/8161065.
787. Aubier M. Pharmacotherapy of respiratory muscles. Clin Chest Med 1988; 9(2): 311-24
788. McKay SE, Howie CA, Thomson AH, Whiting B, Addis GJ. Value of theophylline treatment in patients handicapped by
chronic obstructive lung disease. Thorax 1993; 48(3): 227-32 https://pubmed.ncbi.nlm.nih.gov/8497820.
789. Moxham J. Aminophylline and the respiratory muscles: an alternative view. Clin Chest Med 1988; 9(2): 325-36
790. Ram FS, Jones PW, Castro AA, et al. Oral theophylline for chronic obstructive pulmonary disease. Cochrane Database
791. ZuWallack RL, Mahler DA, Reilly D, et al. Salmeterol plus theophylline combination therapy in the treatment of COPD.
792. Zacarias EC, Castro AA, Cendon S. Effect of theophylline associated with short-acting or long-acting inhaled beta2-
agonists in patients with stable chronic obstructive pulmonary disease: a systematic review. J Bras Pneumol 2007;
793. Cosio BG, Shafiek H, Iglesias A, et al. Oral Low-dose Theophylline on Top of Inhaled Fluticasone-Salmeterol Does Not
Reduce Exacerbations in Patients With Severe COPD: A Pilot Clinical Trial. Chest 2016; 150(1): 123-30
794. Zhou Y, Wang X, Zeng X, et al. Positive benefits of theophylline in a randomized, double-blind, parallel-group, placebo-
controlled study of low-dose, slow-release theophylline in the treatment of COPD for 1 year. Respirology 2006; 11(5):
795. Devereux G, Cotton S, Fielding S, et al. Effect of Theophylline as Adjunct to Inhaled Corticosteroids on Exacerbations in
Patients With COPD: A Randomized Clinical Trial. JAMA 2018; 320(15): 1548-59
796. Jenkins CR, Wen FQ, Martin A, et al. The effect of low-dose corticosteroids and theophylline on the risk of acute
exacerbations of COPD: the TASCS randomised controlled trial. Eur Respir J 2021; 57(6):
TE
797. Cazzola M, Molimard M. The scientific rationale for combining long-acting beta2-agonists and muscarinic antagonists in
U
COPD. Pulm Pharmacol Ther 2010; 23(4): 257-67 https://pubmed.ncbi.nlm.nih.gov/20381630.
IB
TR
798. Ray R, Tombs L, Naya I, Compton C, Lipson DA, Boucot I. Efficacy and safety of the dual bronchodilator combination
IS
umeclidinium/vilanterol in COPD by age and airflow limitation severity: A pooled post hoc analysis of seven clinical
D
trials. Pulm Pharmacol Ther 2019; 57: 101802 https://pubmed.ncbi.nlm.nih.gov/31096036.
T
799. Gross N, Tashkin D, Miller R, Oren J, Coleman W, Linberg S. Inhalation by nebulization of albuterol-ipratropium
O
N
combination (Dey combination) is superior to either agent alone in the treatment of chronic obstructive pulmonary
O
disease. Dey Combination Solution Study Group. Respiration 1998; 65(5): 354-62
-D
L
800. Tashkin DP, Pearle J, Iezzoni D, Varghese ST. Formoterol and tiotropium compared with tiotropium alone for treatment
IA
ER
of COPD. COPD 2009; 6(1): 17-25 https://pubmed.ncbi.nlm.nih.gov/19229704.

AT
801. Farne HA, Cates CJ. Long-acting beta2-agonist in addition to tiotropium versus either tiotropium or long-acting beta2-
agonist alone for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2015; 10(10): CD008989
M
T
H
802. Halpin DMG, Rothnie KJ, Banks V, et al. Comparative Adherence and Persistence of Single- and Multiple-Inhaler Triple
IG
R
Therapies Among Patients with Chronic Obstructive Pulmonary Disease in an English Real-World Primary Care Setting.
PY
Int J Chron Obstruct Pulmon Dis 2022; 17: 2417-29 https://pubmed.ncbi.nlm.nih.gov/36185170.

O
803. van der Molen T, Cazzola M. Beyond lung function in COPD management: effectiveness of LABA/LAMA combination
C
therapy on patient-centred outcomes. Prim Care Respir J 2012; 21(1): 101-8

804. Mahler DA, Decramer M, D'Urzo A, et al. Dual bronchodilation with QVA149 reduces patient-reported dyspnoea in
COPD: the BLAZE study. Eur Respir J 2014; 43(6): 1599-609 https://pubmed.ncbi.nlm.nih.gov/24176997.
805. Singh D, Ferguson GT, Bolitschek J, et al. Tiotropium + olodaterol shows clinically meaningful improvements in quality of
life. Respir Med 2015; 109(10): 1312-9 https://pubmed.ncbi.nlm.nih.gov/26320402.
806. Bateman ED, Chapman KR, Singh D, et al. Aclidinium bromide and formoterol fumarate as a fixed-dose combination in
COPD: pooled analysis of symptoms and exacerbations from two six-month, multicentre, randomised studies
(ACLIFORM and AUGMENT). Respir Res 2015; 16(1): 92 https://pubmed.ncbi.nlm.nih.gov/26233481.
807. Martinez FJ, Fabbri LM, Ferguson GT, et al. Baseline Symptom Score Impact on Benefits of Glycopyrrolate/Formoterol
Metered Dose Inhaler in COPD. Chest 2017; 152(6): 1169-78 https://pubmed.ncbi.nlm.nih.gov/28720336.
808. Vogelmeier CF, Kerwin EM, Bjermer LH, et al. Impact of baseline COPD symptom severity on the benefit from dual
versus mono-bronchodilators: an analysis of the EMAX randomised controlled trial. Ther Adv Respir Dis 2020; 14:
809. Mahler DA, Kerwin E, Ayers T, et al. FLIGHT1 and FLIGHT2: Efficacy and Safety of QVA149 (Indacaterol/Glycopyrrolate)
versus Its Monocomponents and Placebo in Patients with Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care
810. Bai C, Ichinose M, Lee SH, et al. Lung function and long-term safety of tiotropium/olodaterol in East Asian patients with
chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2017; 12: 3329-39
811. Wedzicha JA, Decramer M, Ficker JH, et al. Analysis of chronic obstructive pulmonary disease exacerbations with the
dual bronchodilator QVA149 compared with glycopyrronium and tiotropium (SPARK): a randomised, double-blind,
parallel-group study. Lancet Respir Med 2013; 1(3): 199-209 https://pubmed.ncbi.nlm.nih.gov/24429126.
812. Calverley PMA, Anzueto AR, Carter K, et al. Tiotropium and olodaterol in the prevention of chronic obstructive
pulmonary disease exacerbations (DYNAGITO): a double-blind, randomised, parallel-group, active-controlled trial.
Lancet Respir Med 2018; 6(5): 337-44 https://pubmed.ncbi.nlm.nih.gov/29605624.
813. Wedzicha JA, Banerji D, Chapman KR, et al. Indacaterol-Glycopyrronium versus Salmeterol-Fluticasone for COPD. N Engl
J Med 2016; 374(23): 2222-34 https://pubmed.ncbi.nlm.nih.gov/27181606.
814. Suissa S, Dell'Aniello S, Ernst P. Comparative Effectiveness and Safety of LABA-LAMA vs LABA-ICS Treatment of COPD in
Real-World Clinical Practice. Chest 2019; 155(6): 1158-65 https://pubmed.ncbi.nlm.nih.gov/30922950.
815. Barnes PJ. New anti-inflammatory targets for chronic obstructive pulmonary disease. Nat Rev Drug Discov 2013; 12(7):
816. Boardman C, Chachi L, Gavrila A, et al. Mechanisms of glucocorticoid action and insensitivity in airways disease. Pulm
Pharmacol Ther 2014; 29(2): 129-43 https://pubmed.ncbi.nlm.nih.gov/25218650.
817. Sonnex K, Alleemudder H, Knaggs R. Impact of smoking status on the efficacy of inhaled corticosteroids in chronic
obstructive pulmonary disease: a systematic review. BMJ Open 2020; 10(4): e037509
818. Yang IA, Clarke MS, Sim EH, Fong KM. Inhaled corticosteroids for stable chronic obstructive pulmonary disease.
819. Vestbo J, Anderson JA, Brook RD, et al. Fluticasone furoate and vilanterol and survival in chronic obstructive pulmonary
disease with heightened cardiovascular risk (SUMMIT): a double-blind randomised controlled trial. Lancet 2016;
820. Calverley PMA, Anderson JA, Brook RD, et al. Fluticasone Furoate, Vilanterol, and Lung Function Decline in Patients with
TE
Moderate Chronic Obstructive Pulmonary Disease and Heightened Cardiovascular Risk. Am J Respir Crit Care Med 2018;
U
IB
TR
821. Suissa S, Dell'Aniello S, Gonzalez AV, Ernst P. Inhaled corticosteroid use and the incidence of lung cancer in COPD. Eur
IS
Respir J 2020; 55(2): 1901720 https://pubmed.ncbi.nlm.nih.gov/31744837.
D
822. Nannini LJ, Lasserson TJ, Poole P. Combined corticosteroid and long-acting beta(2)-agonist in one inhaler versus long-
T
acting beta(2)-agonists for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2012; 2012(9):
O
N
CD006829 https://pubmed.ncbi.nlm.nih.gov/22972099.
O
823. Nannini LJ, Poole P, Milan SJ, Kesterton A. Combined corticosteroid and long-acting beta(2)-agonist in one inhaler
-D
versus inhaled corticosteroids alone for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2013;
L
2013(8): CD006826 https://pubmed.ncbi.nlm.nih.gov/23990350.

IA
ER
824. Vestbo J, Leather D, Diar Bakerly N, et al. Effectiveness of Fluticasone Furoate-Vilanterol for COPD in Clinical Practice. N
AT

825. Beech AS, Lea S, Kolsum U, et al. Bacteria and sputum inflammatory cell counts; a COPD cohort analysis. Respir Res
M
T

H
826. Dicker AJ, Huang JTJ, Lonergan M, et al. The sputum microbiome, airway inflammation, and mortality in chronic
IG
R
obstructive pulmonary disease. J Allergy Clin Immunol 2021; 147(1): 158-67

PY
O
827. Wang Z, Locantore N, Haldar K, et al. Inflammatory Endotype-associated Airway Microbiome in Chronic Obstructive
C
Pulmonary Disease Clinical Stability and Exacerbations: A Multicohort Longitudinal Analysis. Am J Respir Crit Care Med
828. Martinez-Garcia MA, Faner R, Oscullo G, et al. Inhaled Steroids, Circulating Eosinophils, Chronic Airway Infection, and
Pneumonia Risk in Chronic Obstructive Pulmonary Disease. A Network Analysis. Am J Respir Crit Care Med 2020; 201(9):
829. Roche N, Chapman KR, Vogelmeier CF, et al. Blood Eosinophils and Response to Maintenance Chronic Obstructive
Pulmonary Disease Treatment. Data from the FLAME Trial. Am J Respir Crit Care Med 2017; 195(9): 1189-97
830. Watz H, Tetzlaff K, Wouters EF, et al. Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary
disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trial. Lancet Respir Med 2016;
831. Leitao Filho FS, Takiguchi H, Akata K, et al. Effects of Inhaled Corticosteroid/Long-Acting beta(2)-Agonist Combination
on the Airway Microbiome of Patients with Chronic Obstructive Pulmonary Disease: A Randomized Controlled Clinical
Trial (DISARM). Am J Respir Crit Care Med 2021; 204(10): 1143-52 https://pubmed.ncbi.nlm.nih.gov/34464242.
832. Dransfield MT, Bourbeau J, Jones PW, et al. Once-daily inhaled fluticasone furoate and vilanterol versus vilanterol only
for prevention of exacerbations of COPD: two replicate double-blind, parallel-group, randomised controlled trials.
833. Crim C, Dransfield MT, Bourbeau J, et al. Pneumonia risk with inhaled fluticasone furoate and vilanterol compared with
vilanterol alone in patients with COPD. Ann Am Thorac Soc 2015; 12(1): 27-34
834. Crim C, Calverley PMA, Anderson JA, et al. Pneumonia risk with inhaled fluticasone furoate and vilanterol in COPD
patients with moderate airflow limitation: The SUMMIT trial. Respir Med 2017; 131: 27-34
835. Pavord ID, Lettis S, Anzueto A, Barnes N. Blood eosinophil count and pneumonia risk in patients with chronic
obstructive pulmonary disease: a patient-level meta-analysis. Lancet Respir Med 2016; 4(9): 731-41
836. Johnell O, Pauwels R, Lofdahl CG, et al. Bone mineral density in patients with chronic obstructive pulmonary disease
treated with budesonide Turbuhaler. Eur Respir J 2002; 19(6): 1058-63 https://pubmed.ncbi.nlm.nih.gov/12108857.
837. Ferguson GT, Calverley PMA, Anderson JA, et al. Prevalence and progression of osteoporosis in patients with COPD:
results from the TOwards a Revolution in COPD Health study. Chest 2009; 136(6): 1456-65
838. Loke YK, Cavallazzi R, Singh S. Risk of fractures with inhaled corticosteroids in COPD: systematic review and meta-
analysis of randomised controlled trials and observational studies. Thorax 2011; 66(8): 699-708
839. Suissa S, Kezouh A, Ernst P. Inhaled corticosteroids and the risks of diabetes onset and progression. Am J Med 2010;
840. Wang JJ, Rochtchina E, Tan AG, Cumming RG, Leeder SR, Mitchell P. Use of inhaled and oral corticosteroids and the
long-term risk of cataract. Ophthalmology 2009; 116(4): 652-7 https://pubmed.ncbi.nlm.nih.gov/19243828.
841. Andrejak C, Nielsen R, Thomsen VO, Duhaut P, Sorensen HT, Thomsen RW. Chronic respiratory disease, inhaled
corticosteroids and risk of non-tuberculous mycobacteriosis. Thorax 2013; 68(3): 256-62
842. Dong YH, Chang CH, Wu FL, et al. Use of inhaled corticosteroids in patients with COPD and the risk of TB and influenza:
A systematic review and meta-analysis of randomized controlled trials. a systematic review and meta-analysis of
TE
randomized controlled trials. Chest 2014; 145(6): 1286-97 https://pubmed.ncbi.nlm.nih.gov/24504044.
U
843. Lee CH, Kim K, Hyun MK, Jang EJ, Lee NR, Yim JJ. Use of inhaled corticosteroids and the risk of tuberculosis. Thorax
IB
TR
844. IS
Castellana G, Castellana M, Castellana C, et al. Inhaled Corticosteroids And Risk Of Tuberculosis In Patients With
D
Obstructive Lung Diseases: A Systematic Review And Meta-Analysis Of Non-randomized Studies. Int J Chron Obstruct
T

O
N
845. Price D, Yawn B, Brusselle G, Rossi A. Risk-to-benefit ratio of inhaled corticosteroids in patients with COPD. Prim Care
O

-D
846. Nadeem NJ, Taylor SJ, Eldridge SM. Withdrawal of inhaled corticosteroids in individuals with COPD--a systematic review
L
and comment on trial methodology. Respir Res 2011; 12(1): 107 https://pubmed.ncbi.nlm.nih.gov/21838890.
IA
ER
847. van der Valk P, Monninkhof E, van der Palen J, Zielhuis G, van Herwaarden C. Effect of discontinuation of inhaled
AT
corticosteroids in patients with chronic obstructive pulmonary disease: the COPE study. Am J Respir Crit Care Med 2002;
M
T
848. Wouters EF, Postma DS, Fokkens B, et al. Withdrawal of fluticasone propionate from combined salmeterol/fluticasone
H
treatment in patients with COPD causes immediate and sustained disease deterioration: a randomised controlled trial.
IG
R

PY
849. Kunz LIZ, Postma DS, Klooster K, et al. Relapse in FEV1 Decline After Steroid Withdrawal in COPD. Chest 2015; 148(2):
O
C
850. Magnussen H, Disse B, Rodriguez-Roisin R, et al. Withdrawal of inhaled glucocorticoids and exacerbations of COPD. N
851. Brusselle G, Price D, Gruffydd-Jones K, et al. The inevitable drift to triple therapy in COPD: an analysis of prescribing
pathways in the UK. Int J Chron Obstruct Pulmon Dis 2015; 10: 2207-17 https://pubmed.ncbi.nlm.nih.gov/26527869.
852. Welte T, Miravitlles M, Hernandez P, et al. Efficacy and tolerability of budesonide/formoterol added to tiotropium in
patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009; 180(8): 741-50
853. Singh D, Brooks J, Hagan G, Cahn A, O'Connor BJ. Superiority of "triple" therapy with salmeterol/fluticasone propionate
and tiotropium bromide versus individual components in moderate to severe COPD. Thorax 2008; 63(7): 592-8
854. Jung KS, Park HY, Park SY, et al. Comparison of tiotropium plus fluticasone propionate/salmeterol with tiotropium in
COPD: a randomized controlled study. Respir Med 2012; 106(3): 382-9 https://pubmed.ncbi.nlm.nih.gov/21975275.
855. Hanania NA, Crater GD, Morris AN, Emmett AH, O'Dell DM, Niewoehner DE. Benefits of adding fluticasone
propionate/salmeterol to tiotropium in moderate to severe COPD. Respir Med 2012; 106(1): 91-101
856. Frith PA, Thompson PJ, Ratnavadivel R, et al. Glycopyrronium once-daily significantly improves lung function and health
status when combined with salmeterol/fluticasone in patients with COPD: the GLISTEN study, a randomised controlled
trial. Thorax 2015; 70(6): 519-27 https://pubmed.ncbi.nlm.nih.gov/25841237.
857. Lipson DA, Barnacle H, Birk R, et al. FULFIL Trial: Once-Daily Triple Therapy for Patients with Chronic Obstructive
858. Siler TM, Kerwin E, Singletary K, Brooks J, Church A. Efficacy and Safety of Umeclidinium Added to Fluticasone
Propionate/Salmeterol in Patients with COPD: Results of Two Randomized, Double-Blind Studies. COPD 2016; 13(1): 1-
859. Singh D, Papi A, Corradi M, et al. Single inhaler triple therapy versus inhaled corticosteroid plus long-acting beta2-
agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised
controlled trial. Lancet 2016; 388(10048): 963-73 https://pubmed.ncbi.nlm.nih.gov/27598678.
860. Bardsley S, Criner GJ, Halpin DMG, et al. Single-inhaler triple therapy fluticasone furoate/umeclidinium/vilanterol versus
dual therapy in current and former smokers with COPD: IMPACT trial post hoc analysis. Respir Med 2022; 205: 107040
861. Vestbo J, Fabbri L, Papi A, et al. Inhaled corticosteroid containing combinations and mortality in COPD. Eur Respir J
862. Lipson DA, Crim C, Criner GJ, et al. Reduction in All-Cause Mortality with Fluticasone Furoate/Umeclidinium/Vilanterol
in Patients with Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med 2020; 201(12): 1508-16
863. Manson SC, Brown RE, Cerulli A, Vidaurre CF. The cumulative burden of oral corticosteroid side effects and the
economic implications of steroid use. Respir Med 2009; 103(7): 975-94 https://pubmed.ncbi.nlm.nih.gov/19372037.
864. Walters JA, Tan DJ, White CJ, Gibson PG, Wood-Baker R, Walters EH. Systemic corticosteroids for acute exacerbations of
chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2014; (9): CD001288
865. Renkema TE, Schouten JP, Koeter GH, Postma DS. Effects of long-term treatment with corticosteroids in COPD. Chest
866. Rice KL, Rubins JB, Lebahn F, et al. Withdrawal of chronic systemic corticosteroids in patients with COPD: a randomized
trial. Am J Respir Crit Care Med 2000; 162(1): 174-8 https://pubmed.ncbi.nlm.nih.gov/10903238.
TE
867. Rabe KF. Update on roflumilast, a phosphodiesterase 4 inhibitor for the treatment of chronic obstructive pulmonary
U
disease. Br J Pharmacol 2011; 163(1): 53-67 https://pubmed.ncbi.nlm.nih.gov/21232047.
IB
TR
868. Calverley PM, Rabe KF, Goehring UM, et al. Roflumilast in symptomatic chronic obstructive pulmonary disease: two
IS
randomised clinical trials. Lancet 2009; 374(9691): 685-94 https://pubmed.ncbi.nlm.nih.gov/19716960.
D
869. Fabbri LM, Calverley PM, Izquierdo-Alonso JL, et al. Roflumilast in moderate-to-severe chronic obstructive pulmonary
T
disease treated with longacting bronchodilators: two randomised clinical trials. Lancet 2009; 374(9691): 695-703
O
N
O
870. Chong J, Leung B, Poole P. Phosphodiesterase 4 inhibitors for chronic obstructive pulmonary disease. Cochrane
-D

L
871. Francis RS, May JR, Spicer CC. Chemotherapy of bronchitis. Influence of penicillin and tetracycline administered daily, or
IA
ER
intermittently for exacerbations. A report to the Research Committee of the British Tuberculosis Association by its
AT
Bronchitis Subcommittee. Br Med J 1961; 2(5258): 979-85 https://pubmed.ncbi.nlm.nih.gov/13894512.

872. Francis RS, Spicer CC. Chemotherapy in chronic bronchitis. Influence of daily penicillin and tetracycline on exacerbations
M
T
and their cost. Br Med J 1960; 1(5169): 297-303 https://pubmed.ncbi.nlm.nih.gov/13824401.

H
873. Johnston RN, McNeill RS, Smith DH, et al. Five-year winter chemoprophylaxis for chronic bronchitis. Br Med J 1969;
IG
R

PY
874. Herath SC, Poole P. Prophylactic antibiotic therapy for chronic obstructive pulmonary disease (COPD). Cochrane
O
Database of Systematic Reviews 2013; (11): CD009764 https://pubmed.ncbi.nlm.nih.gov/24288145.

C
875. Ni W, Shao X, Cai X, et al. Prophylactic use of macrolide antibiotics for the prevention of chronic obstructive pulmonary
disease exacerbation: a meta-analysis. PLoS One 2015; 10(3): e0121257 https://pubmed.ncbi.nlm.nih.gov/25812085.
876. Seemungal TA, Wilkinson TM, Hurst JR, Perera WR, Sapsford RJ, Wedzicha JA. Long-term erythromycin therapy is
associated with decreased chronic obstructive pulmonary disease exacerbations. Am J Respir Crit Care Med 2008;
877. Uzun S, Djamin RS, Kluytmans JA, et al. Azithromycin maintenance treatment in patients with frequent exacerbations of
chronic obstructive pulmonary disease (COLUMBUS): a randomised, double-blind, placebo-controlled trial. Lancet
878. Sethi S, Jones PW, Theron MS, et al. Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive
pulmonary disease: a randomized controlled trial. Respir Res 2010; 11(1): 10
879. Allinson JP, Vlies BH, Brill SE, et al. A Double-Blind, Randomized, Placebo-controlled Trial of Long-Term Doxycycline
Therapy on Exacerbation Rate in Patients with Stable Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med
880. Cazzola M, Calzetta L, Page C, et al. Influence of N-acetylcysteine on chronic bronchitis or COPD exacerbations: a meta-
analysis. Eur Respir Rev 2015; 24(137): 451-61 https://pubmed.ncbi.nlm.nih.gov/26324807.
881. Poole P, Chong J, Cates CJ. Mucolytic agents versus placebo for chronic bronchitis or chronic obstructive pulmonary
882. Dal Negro RW, Wedzicha JA, Iversen M, et al. Effect of erdosteine on the rate and duration of COPD exacerbations: the
RESTORE study. Eur Respir J 2017; 50(4): PA675 https://pubmed.ncbi.nlm.nih.gov/29025888.
883. Rogliani P, Matera MG, Page C, Puxeddu E, Cazzola M, Calzetta L. Efficacy and safety profile of mucolytic/antioxidant
agents in chronic obstructive pulmonary disease: a comparative analysis across erdosteine, carbocysteine, and N-
acetylcysteine. Respir Res 2019; 20(1): 104 https://pubmed.ncbi.nlm.nih.gov/31133026.
884. Poole P, Sathananthan K, Fortescue R. Mucolytic agents versus placebo for chronic bronchitis or chronic obstructive
885. Pavord ID, Chanez P, Criner GJ, et al. Mepolizumab for Eosinophilic Chronic Obstructive Pulmonary Disease. N Engl J
886. Criner GJ, Celli BR, Brightling CE, et al. Benralizumab for the Prevention of COPD Exacerbations. N Engl J Med 2019;
887. Bhatt SP, Rabe KF, Hanania NA, et al. Dupilumab for COPD with Type 2 Inflammation Indicated by Eosinophil Counts. N
888. Lee JH, Kim HJ, Kim YH. The Effectiveness of Anti-leukotriene Agents in Patients with COPD: A Systemic Review and
Meta-analysis. Lung 2015; 193(4): 477-86 https://pubmed.ncbi.nlm.nih.gov/25972156.
889. Liu L, Wang JL, Xu XY, Feng M, Hou Y, Chen L. Leukotriene receptor antagonists do not improve lung function decline in
COPD: a meta-analysis. Eur Rev Med Pharmacol Sci 2018; 22(3): 829-34 https://pubmed.ncbi.nlm.nih.gov/29461616.
890. Rennard SI, Fogarty C, Kelsen S, et al. The safety and efficacy of infliximab in moderate to severe chronic obstructive
891. Fraser A, Poole P. Immunostimulants versus placebo for preventing exacerbations in adults with chronic bronchitis or
chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2022; 11(11): Cd013343
892. Dransfield MT, Voelker H, Bhatt SP, et al. Metoprolol for the Prevention of Acute Exacerbations of COPD. N Engl J Med
893. Criner GJ, Connett JE, Aaron SD, et al. Simvastatin for the prevention of exacerbations in moderate-to-severe COPD. N
TE
U
894. Ingebrigtsen TS, Marott JL, Nordestgaard BG, Lange P, Hallas J, Vestbo J. Statin use and exacerbations in individuals with
IB
TR
chronic obstructive pulmonary disease. Thorax 2015; 70(1): 33-40 https://pubmed.ncbi.nlm.nih.gov/25349333.
895. IS
Lehouck A, Mathieu C, Carremans C, et al. High doses of vitamin D to reduce exacerbations in chronic obstructive
D
pulmonary disease: a randomized trial. Ann Intern Med 2012; 156(2): 105-14
T
O
N
896. Jolliffe DA, Greenberg L, Hooper RL, et al. Vitamin D to prevent exacerbations of COPD: systematic review and meta-
O
analysis of individual participant data from randomised controlled trials. Thorax 2019; 74(4): 337-45
-D
L
897. Rafiq R, Aleva FE, Schrumpf JA, et al. Vitamin D supplementation in chronic obstructive pulmonary disease patients with
IA
ER
low serum vitamin D: a randomized controlled trial. Am J Clin Nutr 2022; 116(2): 491-9
AT
898. World Health Organization. Adherence to long-term therapies : evidence for action (2003) [edited by Eduardo Sabaté].
M
T
Online document available at https://apps.who.int/iris/handle/10665/42682 [accessed Oct 2023].

H
899. Chen R, Gao Y, Wang H, Shang H, Xuan J. Association Between Adherence to Maintenance Medication in Patients with
IG
R
COPD and Acute Exacerbation Occurrence and Cost in China: A Retrospective Cohort Database Study. Int J Chron
PY
Obstruct Pulmon Dis 2020; 15: 963-71 https://pubmed.ncbi.nlm.nih.gov/32440108.

O
900. Chrystyn H, Small M, Milligan G, Higgins V, Gil EG, Estruch J. Impact of patients' satisfaction with their inhalers on
C
treatment compliance and health status in COPD. Respir Med 2014; 108(2): 358-65
901. Ierodiakonou D, Sifaki-Pistolla D, Kampouraki M, et al. Adherence to inhalers and comorbidities in COPD patients. A
cross-sectional primary care study from Greece. BMC Pulm Med 2020; 20(1): 253
902. Ingebrigtsen TS, Marott JL, Nordestgaard BG, et al. Low use and adherence to maintenance medication in chronic
obstructive pulmonary disease in the general population. J Gen Intern Med 2015; 30(1): 51-9
903. Moreira ATA, Pinto CR, Lemos ACM, Assuncao-Costa L, Souza GS, Martins Netto E. Evidence of the association between
adherence to treatment and mortality among patients with COPD monitored at a public disease management program
in Brazil. J Bras Pneumol 2021; 48(1): e20210120 https://pubmed.ncbi.nlm.nih.gov/34909924.
904. van Boven JF, Chavannes NH, van der Molen T, Rutten-van Molken MP, Postma MJ, Vegter S. Clinical and economic
impact of non-adherence in COPD: a systematic review. Respir Med 2014; 108(1): 103-13
905. van Boven JF, Tommelein E, Boussery K, et al. Improving inhaler adherence in patients with chronic obstructive
pulmonary disease: a cost-effectiveness analysis. Respir Res 2014; 15(1): 66
906. Vestbo J, Anderson JA, Calverley PM, et al. Adherence to inhaled therapy, mortality and hospital admission in COPD.
907. Wisniewski D, Porzezinska M, Gruchala-Niedoszytko M, Niedoszytko M, Slominski JM, Jassem E. Factors influencing
adherence to treatment in COPD patients and its relationship with disease exacerbations. Pneumonol Alergol Pol 2014;
908. Kim JA, Lim MK, Kim K, Park J, Rhee CK. Adherence to Inhaled Medications and its Effect on Healthcare Utilization and
Costs Among High-Grade Chronic Obstructive Pulmonary Disease Patients. Clin Drug Investig 2018; 38(4): 333-40
909. Moradkhani B, Mollazadeh S, Niloofar P, Bashiri A, Oghazian MB. Association between medication adherence and
health-related quality of life in patients with chronic obstructive pulmonary disease. J Pharm Health Care Sci 2021; 7(1):
910. Bhattarai B, Walpola R, Mey A, Anoopkumar-Dukie S, Khan S. Barriers and Strategies for Improving Medication
Adherence Among People Living With COPD: A Systematic Review. Respir Care 2020; 65(11): 1738-50
911. Unni EJ, Gupta S, Sternbach N. Using the Medication Adherence Reasons Scale (MAR-Scale) in asthma and chronic
obstructive pulmonary disease to determine the extent and identify the reasons for non-adherence. Respir Med 2021;
179: 106337 https://pubmed.ncbi.nlm.nih.gov/33639405.
912. Jarab AS, Mukattash TL. Exploring variables associated with medication non-adherence in patients with COPD. Int J Clin
Pharm 2019; 41(5): 1202-9 https://pubmed.ncbi.nlm.nih.gov/31468254.
913. Montes de Oca M, Menezes A, Wehrmeister FC, et al. Adherence to inhaled therapies of COPD patients from seven
Latin American countries: The LASSYC study. PLoS One 2017; 12(11): e0186777
914. Ngo CQ, Phan DM, Vu GV, et al. Inhaler Technique and Adherence to Inhaled Medications among Patients with Acute
Exacerbation of Chronic Obstructive Pulmonary Disease in Vietnam. Int J Environ Res Public Health 2019; 16(2):
TE
915. Shrestha R, Pant A, Shakya Shrestha S, Shrestha B, Gurung RB, Karmacharya BM. A Cross-Sectional Study of Medication
U
Adherence Pattern and Factors Affecting the Adherence in Chronic Obstructive Pulmonary Disease. Kathmandu Univ
IB
TR
Med J (KUMJ) 2015; 13(49): 64-70 https://pubmed.ncbi.nlm.nih.gov/26620752.
916. IS
Rand CS. I took the medicine like you told me, doctor: Self-report of adherence with medical regimens. In: Stone A, ed.
D
The science of self-report: implications for research and practice. Mahway, NJ: Lawrence Erlbaum Associates; 2000:
T
257-76.
O
N
917. DiMatteo MR. Variations in patients' adherence to medical recommendations: a quantitative review of 50 years of
O
research. Med Care 2004; 42(3): 200-9 https://pubmed.ncbi.nlm.nih.gov/15076819.

-D
918. Bourbeau J, Bartlett SJ. Patient adherence in COPD. Thorax 2008; 63(9): 831-8
L
IA
ER
919. Swiatoniowska N, Chabowski M, Polanski J, Mazur G, Jankowska-Polanska B. Adherence to Therapy in Chronic

AT
Obstructive Pulmonary Disease: A Systematic Review. Adv Exp Med Biol 2020; 1271: 37-47
M
T
920. Le TT, Bjarnadottir M, Qato DM, Magder L, Zafari Z, Simoni-Wastila L. Prediction of treatment nonadherence among
H
older adults with chronic obstructive pulmonary disease using Medicare real-world data. J Manag Care Spec Pharm
IG
R

PY
921. Tottenborg SS, Lange P, Johnsen SP, Nielsen H, Ingebrigtsen TS, Thomsen RW. Socioeconomic inequalities in adherence
O
to inhaled maintenance medications and clinical prognosis of COPD. Respir Med 2016; 119: 160-7
C
922. Tabyshova A, Sooronbaev T, Akylbekov A, et al. Medication availability and economic barriers to adherence in asthma
and COPD patients in low-resource settings. NPJ Prim Care Respir Med 2022; 32(1): 20
923. Bosnic-Anticevich S, Chrystyn H, Costello RW, et al. The use of multiple respiratory inhalers requiring different
inhalation techniques has an adverse effect on COPD outcomes. Int J Chron Obstruct Pulmon Dis 2017; 12: 59-71
924. Gallefoss F, Bakke PS. Impact of patient education and self-management on morbidity in asthmatics and patients with
chronic obstructive pulmonary disease. Respir Med 2000; 94(3): 279-87 https://pubmed.ncbi.nlm.nih.gov/10783940.
925. Chapman KR, Stockley RA, Dawkins C, Wilkes MM, Navickis RJ. Augmentation therapy for alpha1 antitrypsin deficiency:
a meta-analysis. COPD 2009; 6(3): 177-84 https://pubmed.ncbi.nlm.nih.gov/19811373.
926. The Alpha-1-Antitrypsin Deficiency Registry Study Group. Survival and FEV1 decline in individuals with severe deficiency
of alpha1-antitrypsin. The Alpha-1-Antitrypsin Deficiency Registry Study Group. Am J Respir Crit Care Med 1998; 158(1):
927. Dirksen A, Dijkman JH, Madsen F, et al. A randomized clinical trial of alpha(1)-antitrypsin augmentation therapy. Am J
Respir Crit Care Med 1999; 160(5 Pt 1): 1468-72 https://pubmed.ncbi.nlm.nih.gov/10556107.
928. Dirksen A, Piitulainen E, Parr DG, et al. Exploring the role of CT densitometry: a randomised study of augmentation
therapy in alpha1-antitrypsin deficiency. Eur Respir J 2009; 33(6): 1345-53 https://pubmed.ncbi.nlm.nih.gov/19196813.
929. McElvaney NG, Burdon J, Holmes M, et al. Long-term efficacy and safety of alpha1 proteinase inhibitor treatment for
emphysema caused by severe alpha1 antitrypsin deficiency: an open-label extension trial (RAPID-OLE). Lancet Respir
930. Stockley RA, Edgar RG, Pillai A, Turner AM. Individualized lung function trends in alpha-1-antitrypsin deficiency: a need
for patience in order to provide patient centered management? Int J Chron Obstruct Pulmon Dis 2016; 11: 1745-56
931. Stoller JK, Aboussouan LS. A review of alpha1-antitrypsin deficiency. Am J Respir Crit Care Med 2012; 185(3): 246-59
932. Sandhaus RA, Turino G, Brantly ML, et al. The Diagnosis and Management of Alpha-1 Antitrypsin Deficiency in the Adult.
Chronic Obstr Pulm Dis 2016; 3(3): 668-82 https://pubmed.ncbi.nlm.nih.gov/28848891.
933. Schildmann EK, Remi C, Bausewein C. Levodropropizine in the management of cough associated with cancer or
nonmalignant chronic disease--a systematic review. J Pain Palliat Care Pharmacother 2011; 25(3): 209-18
934. Barbera JA, Roger N, Roca J, Rovira I, Higenbottam TW, Rodriguez-Roisin R. Worsening of pulmonary gas exchange with
nitric oxide inhalation in chronic obstructive pulmonary disease. Lancet 1996; 347(8999): 436-40
935. Blanco I, Santos S, Gea J, et al. Sildenafil to improve respiratory rehabilitation outcomes in COPD: a controlled trial. Eur
936. Goudie AR, Lipworth BJ, Hopkinson PJ, Wei L, Struthers AD. Tadalafil in patients with chronic obstructive pulmonary
disease: a randomised, double-blind, parallel-group, placebo-controlled trial. Lancet Respir Med 2014; 2(4): 293-300
937. Mullen JB, Wright JL, Wiggs BR, Pare PD, Hogg JC. Structure of central airways in current smokers and ex-smokers with
and without mucus hypersecretion: relationship to lung function. Thorax 1987; 42(11): 843-8
TE
U
938. Burgel PR, Nadel JA. Roles of epidermal growth factor receptor activation in epithelial cell repair and mucin production
IB
TR
in airway epithelium. Thorax 2004; 59(11): 992-6 https://pubmed.ncbi.nlm.nih.gov/15516478.
939. IS
Alghamdi SM, Alsulayyim AS, Alasmari AM, et al. Oscillatory positive expiratory pressure therapy in COPD (O-COPD): a
D
randomised controlled trial. Thorax 2023; 78(2): 136-43 https://pubmed.ncbi.nlm.nih.gov/35948418.
T
940. Coppolo DP, Schloss J, Suggett JA, Mitchell JP. Non-Pharmaceutical Techniques for Obstructive Airway Clearance
O
N
Focusing on the Role of Oscillating Positive Expiratory Pressure (OPEP): A Narrative Review. Pulm Ther 2022; 8(1): 1-41
O
-D
941. Kellett F, Redfern J, Niven RM. Evaluation of nebulised hypertonic saline (7%) as an adjunct to physiotherapy in patients
L
with stable bronchiectasis. Respir Med 2005; 99(1): 27-31 https://pubmed.ncbi.nlm.nih.gov/15672845.

IA
ER
942. Kellett F, Robert NM. Nebulised 7% hypertonic saline improves lung function and quality of life in bronchiectasis. Respir
AT

943. Clarke SW, Lopez-Vidriero MT, Pavia D, Thomson ML. The effect of sodium 2-mercapto-ethane sulphonate and
M
T
hypertonic saline aerosols on bronchial clearance in chronic bronchitis. Br J Clin Pharmacol 1979; 7(1): 39-44
H
IG
R
944. Valderramas SR, Atallah AN. Effectiveness and safety of hypertonic saline inhalation combined with exercise training in
PY
patients with chronic obstructive pulmonary disease: a randomized trial. Respir Care 2009; 54(3): 327-33
O
C
945. Zhang Y, Song A, Liu J, Dai J, Lin J. Therapeutic effect of nebulized hypertonic saline for muco-obstructive lung diseases:
a systematic review and meta-analysis with trial sequential analysis. J Investig Med 2021; 69(3): 742-8
946. Calzetta L, Rogliani P, Matera MG, Cazzola M. A Systematic Review With Meta-Analysis of Dual Bronchodilation With
LAMA/LABA for the Treatment of Stable COPD. Chest 2016; 149(5): 1181-96
947. McGarvey L, Morice AH, Smith JA, et al. Effect of aclidinium bromide on cough and sputum symptoms in moderate-to-
severe COPD in three phase III trials. BMJ Open Respir Res 2016; 3(1): e000148
948. Hasani A, Toms N, Agnew JE, Sarno M, Harrison AJ, Dilworth P. The effect of inhaled tiotropium bromide on lung
mucociliary clearance in patients with COPD. Chest 2004; 125(5): 1726-34 https://pubmed.ncbi.nlm.nih.gov/15136383.
949. Powrie DJ, Wilkinson TM, Donaldson GC, et al. Effect of tiotropium on sputum and serum inflammatory markers and
exacerbations in COPD. Eur Respir J 2007; 30(3): 472-8 https://pubmed.ncbi.nlm.nih.gov/17504798.
950. O'Donnell AE, Barker AF, Ilowite JS, Fick RB. Treatment of idiopathic bronchiectasis with aerosolized recombinant
human DNase I. rhDNase Study Group. Chest 1998; 113(5): 1329-34 https://pubmed.ncbi.nlm.nih.gov/9596315.
951. Wilkinson M, Sugumar K, Milan SJ, Hart A, Crockett A, Crossingham I. Mucolytics for bronchiectasis. Cochrane Database
952. Ehre C, Rushton ZL, Wang B, et al. An Improved Inhaled Mucolytic to Treat Airway Muco-obstructive Diseases. Am J
Respir Crit Care Med 2019; 199(2): 171-80 https://pubmed.ncbi.nlm.nih.gov/30212240.
953. Rowe SM, Jones I, Dransfield MT, et al. Efficacy and Safety of the CFTR Potentiator Icenticaftor (QBW251) in COPD:
Results from a Phase 2 Randomized Trial. Int J Chron Obstruct Pulmon Dis 2020; 15: 2399-409
954. Garner JL, Shaipanich T, Hartman JE, et al. A prospective safety and feasibility study of metered cryospray for patients
with chronic bronchitis in COPD. Eur Respir J 2020; 56(6): https://pubmed.ncbi.nlm.nih.gov/32586881.
955. Slebos DJ, Breen D, Coad J, et al. Safety and Histological Effect of Liquid Nitrogen Metered Spray Cryotherapy in the
Lung. Am J Respir Crit Care Med 2017; 196(10): 1351-2 https://pubmed.ncbi.nlm.nih.gov/28358989.
956. Slebos DJ, Klooster K, Koegelenberg CF, et al. Targeted lung denervation for moderate to severe COPD: a pilot study.
957. Valipour A, Shah PL, Herth FJ, et al. Two-Year Outcomes for the Double-Blind, Randomized, Sham-Controlled Study of
Targeted Lung Denervation in Patients with Moderate to Severe COPD: AIRFLOW-2. Int J Chron Obstruct Pulmon Dis
2020; 15: 2807-16 https://pubmed.ncbi.nlm.nih.gov/33177818.
958. Schrijver J, Lenferink A, Brusse-Keizer M, et al. Self-management interventions for people with chronic obstructive
959. Fan VS, Gaziano JM, Lew R, et al. A comprehensive care management program to prevent chronic obstructive
pulmonary disease hospitalizations: a randomized, controlled trial. Ann Intern Med 2012; 156(10): 673-83
960. Peytremann-Bridevaux I, Taffe P, Burnand B, Bridevaux PO, Puhan MA. Mortality of patients with COPD participating in
chronic disease management programmes: a happy end? Thorax 2014; 69(9): 865-6
961. Kessler R, Casan-Clara P, Koehler D, et al. COMET: a multicomponent home-based disease-management programme
versus routine care in severe COPD. Eur Respir J 2018; 51(1): 1701612 https://pubmed.ncbi.nlm.nih.gov/29326333.
962. Rose L, Istanboulian L, Carriere L, et al. Program of Integrated Care for Patients with Chronic Obstructive Pulmonary
TE
Disease and Multiple Comorbidities (PIC COPD(+)): a randomised controlled trial. Eur Respir J 2018; 51(1):
U
IB
TR
963. Aboumatar H, Naqibuddin M, Chung S, et al. Effect of a Hospital-Initiated Program Combining Transitional Care and
IS
Long-term Self-management Support on Outcomes of Patients Hospitalized With Chronic Obstructive Pulmonary
D
Disease: A Randomized Clinical Trial. JAMA 2019; 322(14): 1371-80 https://pubmed.ncbi.nlm.nih.gov/31593271.
T
964. Benzo R, Vickers K, Novotny PJ, et al. Health Coaching and Chronic Obstructive Pulmonary Disease Rehospitalization. A
O
N
Randomized Study. Am J Respir Crit Care Med 2016; 194(6): 672-80 https://pubmed.ncbi.nlm.nih.gov/26953637.
O
965. Benzo R, McEvoy C. Effect of Health Coaching Delivered by a Respiratory Therapist or Nurse on Self-Management
-D
Abilities in Severe COPD: Analysis of a Large Randomized Study. Respir Care 2019; 64(9): 1065-72
L
IA
ER
966. Poot CC, Meijer E, Kruis AL, Smidt N, Chavannes NH, Honkoop PJ. Integrated disease management interventions for
AT
patients with chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2021; 9(9): CD009437
M
T
967. Kruis AL, Boland MR, Assendelft WJ, et al. Effectiveness of integrated disease management for primary care chronic
H
obstructive pulmonary disease patients: results of cluster randomised trial. BMJ 2014; 349: g5392
IG
R
PY
968. Gregersen TL, Green A, Frausing E, Ringbaek T, Brondum E, Suppli Ulrik C. Do telemedical interventions improve quality
O
of life in patients with COPD? A systematic review. Int J Chron Obstruct Pulmon Dis 2016; 11: 809-22
C
969. Cartwright M, Hirani SP, Rixon L, et al. Effect of telehealth on quality of life and psychological outcomes over 12 months
(Whole Systems Demonstrator telehealth questionnaire study): nested study of patient reported outcomes in a
pragmatic, cluster randomised controlled trial. BMJ 2013; 346: f653 https://pubmed.ncbi.nlm.nih.gov/23444424.
970. Pitta F, Troosters T, Spruit MA, Probst VS, Decramer M, Gosselink R. Characteristics of physical activities in daily life in
971. Watz H, Pitta F, Rochester CL, et al. An official European Respiratory Society statement on physical activity in COPD. Eur
972. Garcia-Aymerich J, Lange P, Benet M, Schnohr P, Anto JM. Regular physical activity reduces hospital admission and
mortality in chronic obstructive pulmonary disease: a population based cohort study. Thorax 2006; 61(9): 772-8
973. Yohannes AM, Baldwin RC, Connolly M. Mortality predictors in disabling chronic obstructive pulmonary disease in old
age. Age Ageing 2002; 31(2): 137-40 https://pubmed.ncbi.nlm.nih.gov/11937477.
974. Mantoani LC, Rubio N, McKinstry B, MacNee W, Rabinovich RA. Interventions to modify physical activity in patients with
COPD: a systematic review. Eur Respir J 2016; 48(1): 69-81 https://pubmed.ncbi.nlm.nih.gov/27103381.
975. Spielmanns M, Gloeckl R, Jarosch I, et al. Using a smartphone application maintains physical activity following
pulmonary rehabilitation in patients with COPD: a randomised controlled trial. Thorax 2023; 78(5): 442-50
976. Robinson SA, Shimada SL, Quigley KS, Moy ML. A web-based physical activity intervention benefits persons with low
self-efficacy in COPD: results from a randomized controlled trial. J Behav Med 2019; 42(6): 1082-90
977. Nguyen HQ, Moy ML, Liu IA, et al. Effect of Physical Activity Coaching on Acute Care and Survival Among Patients With
Chronic Obstructive Pulmonary Disease: A Pragmatic Randomized Clinical Trial. JAMA Netw Open 2019; 2(8): e199657
978. Wan ES, Kantorowski A, Polak M, et al. Long-term effects of web-based pedometer-mediated intervention on COPD
exacerbations. Respir Med 2020; 162: 105878 https://pubmed.ncbi.nlm.nih.gov/32056676.
979. Yang Y, Wei L, Wang S, et al. The effects of pursed lip breathing combined with diaphragmatic breathing on pulmonary
function and exercise capacity in patients with COPD: a systematic review and meta-analysis. Physiother Theory Pract
980. Lahham A, McDonald CF, Holland AE. Exercise training alone or with the addition of activity counseling improves
physical activity levels in COPD: a systematic review and meta-analysis of randomized controlled trials. Int J Chron
981. Ortega F, Toral J, Cejudo P, et al. Comparison of effects of strength and endurance training in patients with chronic
982. Garber CE, Blissmer B, Deschenes MR, et al. American College of Sports Medicine position stand. Quantity and quality
of exercise for developing and maintaining cardiorespiratory, musculoskeletal, and neuromotor fitness in apparently
healthy adults: guidance for prescribing exercise. Med Sci Sports Exerc 2011; 43(7): 1334-59
983. Horowitz MB, Littenberg B, Mahler DA. Dyspnea ratings for prescribing exercise intensity in patients with COPD. Chest
TE
984. Puhan MA, Busching G, Schunemann HJ, VanOort E, Zaugg C, Frey M. Interval versus continuous high-intensity exercise
U
in chronic obstructive pulmonary disease: a randomized trial. Ann Intern Med 2006; 145(11): 816-25
IB
TR
985. IS
Vogiatzis I, Nanas S, Roussos C. Interval training as an alternative modality to continuous exercise in patients with
D
T
986. Liu X, Fu C, Hu W, et al. The effect of Tai Chi on the pulmonary rehabilitation of chronic obstructive pulmonary disease:
O
N
a systematic review and meta-analysis. Ann Palliat Med 2021; 10(4): 3763-82
O
-D
987. Ramirez-Venegas A, Ward J, Lentine T, Mahler DA. Salmeterol reduces dyspnea and improves lung function in patients
L
with COPD. Chest 1997; 112(2): 336-40 https://pubmed.ncbi.nlm.nih.gov/9266866.

IA
ER
988. Bernard S, Whittom F, Leblanc P, et al. Aerobic and strength training in patients with chronic obstructive pulmonary
AT

989. Velloso M, do Nascimento NH, Gazzotti MR, Jardim JR. Evaluation of effects of shoulder girdle training on strength and
M
T
performance of activities of daily living in patients with chronic obstructive pulmonary disease. Int J Chron Obstruct
H

IG
R
990. Cardim AB, Marinho PE, Nascimento JF, Jr., Fuzari HK, Dornelas de Andrade A. Does Whole-Body Vibration Improve the
PY
Functional Exercise Capacity of Subjects With COPD? A Meta-Analysis. Respir Care 2016; 61(11): 1552-9
O
C
991. Beaumont M, Forget P, Couturaud F, Reychler G. Effects of inspiratory muscle training in COPD patients: A systematic
review and meta-analysis. Clin Respir J 2018; 12(7): 2178-88 https://pubmed.ncbi.nlm.nih.gov/29665262.
992. Charususin N, Gosselink R, Decramer M, et al. Randomised controlled trial of adjunctive inspiratory muscle training for
patients with COPD. Thorax 2018; 73(10): 942-50 https://pubmed.ncbi.nlm.nih.gov/29914940.
993. Chuang HY, Chang HY, Fang YY, Guo SE. The effects of threshold inspiratory muscle training in patients with chronic
obstructive pulmonary disease: A randomised experimental study. J Clin Nurs 2017; 26(23-24): 4830-8
994. Beaumont M, Mialon P, Le Ber C, et al. Effects of inspiratory muscle training on dyspnoea in severe COPD patients
during pulmonary rehabilitation: controlled randomised trial. Eur Respir J 2018; 51(1): 1701107
995. McCarthy B, Casey D, Devane D, Murphy K, Murphy E, Lacasse Y. Pulmonary rehabilitation for chronic obstructive
996. Moecke DP, Zhu K, Gill J, et al. Safety and Efficacy of Inpatient Pulmonary Rehabilitation for Patients Hospitalized with
an Acute Exacerbation of Chronic Obstructive Pulmonary Disease: Systematic Review and Meta-analyses. Ann Am
Thorac Soc 2023; 20(2): 307-19 https://pubmed.ncbi.nlm.nih.gov/36191273.
997. Sahin H, Naz I, Varol Y, Aksel N, Tuksavul F, Ozsoz A. Is a pulmonary rehabilitation program effective in COPD patients
with chronic hypercapnic failure? Expert Rev Respir Med 2016; 10(5): 593-8
998. Stolz D, Boersma W, Blasi F, et al. Exertional hypoxemia in stable COPD is common and predicted by circulating
proadrenomedullin. Chest 2014; 146(2): 328-38 https://pubmed.ncbi.nlm.nih.gov/24722847.
999. Long-Term Oxygen Treatment Trial Research G, Albert RK, Au DH, et al. A Randomized Trial of Long-Term Oxygen for
COPD with Moderate Desaturation. N Engl J Med 2016; 375(17): 1617-27 https://pubmed.ncbi.nlm.nih.gov/27783918.
1000. Nonoyama ML, Brooks D, Lacasse Y, Guyatt GH, Goldstein RS. Oxygen therapy during exercise training in chronic
obstructive pulmonary disease. Cochrane Database Syst Rev 2007; 2007(2): CD005372
1001. Pisani L, Fasano L, Corcione N, et al. Change in pulmonary mechanics and the effect on breathing pattern of high flow
oxygen therapy in stable hypercapnic COPD. Thorax 2017; 72(4): 373-5 https://pubmed.ncbi.nlm.nih.gov/28104830.
1002. Vitacca M, Paneroni M, Zampogna E, et al. High-Flow Oxygen Therapy During Exercise Training in Patients With Chronic
Obstructive Pulmonary Disease and Chronic Hypoxemia: A Multicenter Randomized Controlled Trial. Phys Ther 2020;
1003. Carlucci A, Rossi V, Cirio S, et al. Portable High-Flow Nasal Oxygen during Walking in Patients with Severe Chronic
Obstructive Pulmonary Disease: A Randomized Controlled Trial. Respiration 2021; 100(12): 1158-64
1004. Stefan MS, Pekow PS, Priya A, et al. Association between Initiation of Pulmonary Rehabilitation and Rehospitalizations
in Patients Hospitalized with Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med 2021; 204(9): 1015-23
1005. Greening NJ, Williams JE, Hussain SF, et al. An early rehabilitation intervention to enhance recovery during hospital
admission for an exacerbation of chronic respiratory disease: randomised controlled trial. BMJ 2014; 349: g4315
1006. Rutkowski S, Rutkowska A, Kiper P, et al. Virtual Reality Rehabilitation in Patients with Chronic Obstructive Pulmonary
Disease: A Randomized Controlled Trial. Int J Chron Obstruct Pulmon Dis 2020; 15: 117-24
1007. Coultas DB, Jackson BE, Russo R, et al. Home-based Physical Activity Coaching, Physical Activity, and Health Care
TE
Utilization in Chronic Obstructive Pulmonary Disease. Chronic Obstructive Pulmonary Disease Self-Management
U
Activation Research Trial Secondary Outcomes. Ann Am Thorac Soc 2018; 15(4): 470-8
IB
TR
1008. IS
Stone PW, Hickman K, Steiner MC, Roberts CM, Quint JK, Singh SJ. Predictors of pulmonary rehabilitation completion in
D
the UK. ERJ Open Res 2021; 7(1): https://pubmed.ncbi.nlm.nih.gov/33585658.
T
1009. Holland AE, Mahal A, Hill CJ, et al. Home-based rehabilitation for COPD using minimal resources: a randomised,
O
N
controlled equivalence trial. Thorax 2017; 72(1): 57-65 https://pubmed.ncbi.nlm.nih.gov/27672116.

O
1010. Maltais F, Bourbeau J, Shapiro S, et al. Effects of home-based pulmonary rehabilitation in patients with chronic
-D
obstructive pulmonary disease: a randomized trial. Ann Intern Med 2008; 149(12): 869-78
L
IA
ER
1011. Bourne S, DeVos R, North M, et al. Online versus face-to-face pulmonary rehabilitation for patients with chronic
AT
obstructive pulmonary disease: randomised controlled trial. BMJ Open 2017; 7(7): e014580
M
T
1012. Horton EJ, Mitchell KE, Johnson-Warrington V, et al. Comparison of a structured home-based rehabilitation programme
H
with conventional supervised pulmonary rehabilitation: a randomised non-inferiority trial. Thorax 2018; 73(1): 29-36
IG
R
PY
1013. Nolan CM, Kaliaraju D, Jones SE, et al. Home versus outpatient pulmonary rehabilitation in COPD: a propensity-matched
O
cohort study. Thorax 2019; 74(10): 996-8 https://pubmed.ncbi.nlm.nih.gov/31278173.

C
1014. Guell MR, Cejudo P, Ortega F, et al. Benefits of Long-Term Pulmonary Rehabilitation Maintenance Program in Patients
with Severe Chronic Obstructive Pulmonary Disease. Three-Year Follow-up. Am J Respir Crit Care Med 2017; 195(5):
1015. Gordon CS, Waller JW, Cook RM, Cavalera SL, Lim WT, Osadnik CR. Effect of Pulmonary Rehabilitation on Symptoms of
Anxiety and Depression in COPD: A Systematic Review and Meta-Analysis. Chest 2019; 156(1): 80-91
1016. Lacasse Y, Cates CJ, McCarthy B, Welsh EJ. This Cochrane Review is closed: deciding what constitutes enough research
and where next for pulmonary rehabilitation in COPD. Cochrane Database Syst Rev 2015; (11): ED000107
1017. Baltzan MA, Kamel H, Alter A, Rotaple M, Wolkove N. Pulmonary rehabilitation improves functional capacity in patients
80 years of age or older. Can Respir J 2004; 11(6): 407-13 https://pubmed.ncbi.nlm.nih.gov/15510248.
1018. Berry MJ, Rejeski WJ, Adair NE, Zaccaro D. Exercise rehabilitation and chronic obstructive pulmonary disease stage. Am
1019. Verrill D, Barton C, Beasley W, Lippard WM. The effects of short-term and long-term pulmonary rehabilitation on
functional capacity, perceived dyspnea, and quality of life. Chest 2005; 128(2): 673-83
1020. Cox NS, Dal Corso S, Hansen H, et al. Telerehabilitation for chronic respiratory disease. Cochrane Database Syst Rev
2021; 1(1): CD013040 https://pubmed.ncbi.nlm.nih.gov/33511633.
1021. Houchen-Wolloff L, Steiner MC. Pulmonary rehabilitation at a time of social distancing: prime time for tele-
rehabilitation? Thorax 2020; 75(6): 446-7 https://pubmed.ncbi.nlm.nih.gov/32398319.
1022. Holland AE, Malaguti C, Hoffman M, et al. Home-based or remote exercise testing in chronic respiratory disease, during
the COVID-19 pandemic and beyond: A rapid review. Chron Respir Dis 2020; 17: 1479973120952418
1023. Silva J, Hipólito N, Machado P, Flora S, Cruz J. Technological features of smartphone apps for physical activity promotion
in patients with COPD: A systematic review. Pulmonology 2023: https://pubmed.ncbi.nlm.nih.gov/37394341.
1024. Collins PF, Elia M, Kurukulaaratchy RJ, Stratton RJ. The influence of deprivation on malnutrition risk in outpatients with
chronic obstructive pulmonary disease (COPD). Clin Nutr 2018; 37(1): 144-8
1025. Collins PF, Stratton RJ, Kurukulaaratchy RJ, Elia M. Influence of deprivation on health care use, health care costs, and
mortality in COPD. Int J Chron Obstruct Pulmon Dis 2018; 13: 1289-96 https://pubmed.ncbi.nlm.nih.gov/29719384.
1026. Gunay E, Kaymaz D, Selcuk NT, Ergun P, Sengul F, Demir N. Effect of nutritional status in individuals with chronic
obstructive pulmonary disease undergoing pulmonary rehabilitation. Respirology 2013; 18(8): 1217-22
1027. Hoong JM, Ferguson M, Hukins C, Collins PF. Economic and operational burden associated with malnutrition in chronic
obstructive pulmonary disease. Clin Nutr 2017; 36(4): 1105-9 https://pubmed.ncbi.nlm.nih.gov/27496063.
1028. Nguyen HT, Collins PF, Pavey TG, Nguyen NV, Pham TD, Gallegos DL. Nutritional status, dietary intake, and health-
related quality of life in outpatients with COPD. Int J Chron Obstruct Pulmon Dis 2019; 14: 215-26
1029. Collins PF, Elia M, Stratton RJ. Nutritional support and functional capacity in chronic obstructive pulmonary disease: a
systematic review and meta-analysis. Respirology 2013; 18(4): 616-29 https://pubmed.ncbi.nlm.nih.gov/23432923.
1030. King DA, Cordova F, Scharf SM. Nutritional aspects of chronic obstructive pulmonary disease. Proc Am Thorac Soc 2008;
1031. Creutzberg EC, Wouters EF, Vanderhoven-Augustin IM, Dentener MA, Schols AM. Disturbances in leptin metabolism are
TE
related to energy imbalance during acute exacerbations of chronic obstructive pulmonary disease. Am J Respir Crit Care
U
Med 2000; 162(4 Pt 1): 1239-45 https://pubmed.ncbi.nlm.nih.gov/11029324.
IB
TR
1032. Schols A. Nutrition as a metabolic modulator in COPD. Chest 2013; 144(4): 1340-5
D
1033. Wilson DO, Rogers RM, Wright EC, Anthonisen NR. Body weight in chronic obstructive pulmonary disease. The National
T
Institutes of Health Intermittent Positive-Pressure Breathing Trial. Am Rev Respir Dis 1989; 139(6): 1435-8
O
N
O
1034. Kim V, Kretschman DM, Sternberg AL, DeCamp MM, Jr., Criner GJ, National Emphysema Treatment Trial Research G.
-D
Weight gain after lung reduction surgery is related to improved lung function and ventilatory efficiency. Am J Respir Crit
L

IA
ER
1035. Casaburi R. Skeletal muscle dysfunction in chronic obstructive pulmonary disease. Med Sci Sports Exerc 2001; 33(7
AT
Suppl): S662-70 https://pubmed.ncbi.nlm.nih.gov/11462075.

1036. Engelen MP, Schols AM, Baken WC, Wesseling GJ, Wouters EF. Nutritional depletion in relation to respiratory and
M
T
peripheral skeletal muscle function in out-patients with COPD. Eur Respir J 1994; 7(10): 1793-7
H
IG
R
1037. Franssen FM, Wouters EF, Schols AM. The contribution of starvation, deconditioning and ageing to the observed
PY
alterations in peripheral skeletal muscle in chronic organ diseases. Clin Nutr 2002; 21(1): 1-14
O
C
1038. Schols AM, Soeters PB, Mostert R, Pluymers RJ, Wouters EF. Physiologic effects of nutritional support and anabolic
steroids in patients with chronic obstructive pulmonary disease. A placebo-controlled randomized trial. Am J Respir Crit
Care Med 1995; 152(4 Pt 1): 1268-74 https://pubmed.ncbi.nlm.nih.gov/7551381.
1039. Steiner MC, Barton RL, Singh SJ, Morgan MD. Nutritional enhancement of exercise performance in chronic obstructive
pulmonary disease: a randomised controlled trial. Thorax 2003; 58(9): 745-51
1040. Vermeeren MA, Wouters EF, Geraerts-Keeris AJ, Schols AM. Nutritional support in patients with chronic obstructive
pulmonary disease during hospitalization for an acute exacerbation; a randomized controlled feasibility trial. Clin Nutr
1041. van Wetering CR, Hoogendoorn M, Broekhuizen R, et al. Efficacy and costs of nutritional rehabilitation in muscle-
wasted patients with chronic obstructive pulmonary disease in a community-based setting: a prespecified subgroup
analysis of the INTERCOM trial. J Am Med Dir Assoc 2010; 11(3): 179-87 https://pubmed.ncbi.nlm.nih.gov/20188315.
1042. Deutz NE, Ziegler TR, Matheson EM, et al. Reduced mortality risk in malnourished hospitalized older adult patients with
COPD treated with a specialized oral nutritional supplement: Sub-group analysis of the NOURISH study. Clin Nutr 2021;
1043. Marchetti N, Criner GJ. Surgical Approaches to Treating Emphysema: Lung Volume Reduction Surgery, Bullectomy, and
Lung Transplantation. Semin Respir Crit Care Med 2015; 36(4): 592-608 https://pubmed.ncbi.nlm.nih.gov/26238644.
1044. Travaline JM, Addonizio VP, Criner GJ. Effect of bullectomy on diaphragm strength. Am J Respir Crit Care Med 1995;
152(5 Pt 1): 1697-701 https://pubmed.ncbi.nlm.nih.gov/7582315.
1045. Marchetti N, Criner KT, Keresztury MF, Furukawa S, Criner GJ. The acute and chronic effects of bullectomy on
cardiovascular function at rest and during exercise. J Thorac Cardiovasc Surg 2008; 135(1): 205-6, 6 e1
1046. Kanoh S, Kobayashi H, Motoyoshi K. Intrabullous blood injection for lung volume reduction. Thorax 2008; 63(6): 564-5
1047. Kemp SV, Zoumot Z, Shah PL. Three-Year Follow-Up of a Patient with a Giant Bulla Treated by Bronchoscopic
Intrabullous Autologous Blood Instillation. Respiration 2016; 92(4): 283-4 https://pubmed.ncbi.nlm.nih.gov/27606975.
1048. Zoumot Z, Kemp SV, Caneja C, Singh S, Shah PL. Bronchoscopic intrabullous autologous blood instillation: a novel
approach for the treatment of giant bullae. Ann Thorac Surg 2013; 96(4): 1488-91
1049. Cooper JD, Trulock EP, Triantafillou AN, et al. Bilateral pneumectomy (volume reduction) for chronic obstructive
pulmonary disease. J Thorac Cardiovasc Surg 1995; 109(1): 106-16; discussion 16-9
1050. Stolk J, Versteegh MI, Montenij LJ, et al. Densitometry for assessment of effect of lung volume reduction surgery for
emphysema. Eur Respir J 2007; 29(6): 1138-43 https://pubmed.ncbi.nlm.nih.gov/17331971.
1051. Criner G, Cordova FC, Leyenson V, et al. Effect of lung volume reduction surgery on diaphragm strength. Am J Respir Crit
Care Med 1998; 157(5 Pt 1): 1578-85 https://pubmed.ncbi.nlm.nih.gov/9603141.
1052. Martinez FJ, de Oca MM, Whyte RI, Stetz J, Gay SE, Celli BR. Lung-volume reduction improves dyspnea, dynamic
hyperinflation, and respiratory muscle function. Am J Respir Crit Care Med 1997; 155(6): 1984-90
1053. Fessler HE, Permutt S. Lung volume reduction surgery and airflow limitation. Am J Respir Crit Care Med 1998; 157(3 Pt
1): 715-22 https://pubmed.ncbi.nlm.nih.gov/9517581.
1054. Washko GR, Fan VS, Ramsey SD, et al. The effect of lung volume reduction surgery on chronic obstructive pulmonary
TE
disease exacerbations. Am J Respir Crit Care Med 2008; 177(2): 164-9 https://pubmed.ncbi.nlm.nih.gov/17962632.
U
1055. Geddes D, Davies M, Koyama H, et al. Effect of lung-volume-reduction surgery in patients with severe emphysema. N
IB
TR
1056. IS
van Geffen WH, Slebos DJ, Herth FJ, Kemp SV, Weder W, Shah PL. Surgical and endoscopic interventions that reduce
D
lung volume for emphysema: a systemic review and meta-analysis. Lancet Respir Med 2019; 7(4): 313-24
T
O
N
1057. Lim E, Sousa I, Shah PL, Diggle P, Goldstraw P. Lung Volume Reduction Surgery: Reinterpreted With Longitudinal Data
O
Analyses Methodology. Ann Thorac Surg 2020; 109(5): 1496-501 https://pubmed.ncbi.nlm.nih.gov/31891694.

-D
1058. National Emphysema Treatment Trial Research Group, Fishman A, Fessler H, et al. Patients at high risk of death after
L
lung-volume-reduction surgery. N Engl J Med 2001; 345(15): 1075-83 https://pubmed.ncbi.nlm.nih.gov/11596586.

IA
ER
1059. Greening NJ, Vaughan P, Oey I, et al. Individualised risk in patients undergoing lung volume reduction surgery: the
AT
Glenfield BFG score. Eur Respir J 2017; 49(6): https://pubmed.ncbi.nlm.nih.gov/28572121.

1060. Imfeld S, Bloch KE, Weder W, Russi EW. The BODE index after lung volume reduction surgery correlates with survival.
M
T

H
1061. Caviezel C, Schaffter N, Schneiter D, et al. Outcome After Lung Volume Reduction Surgery in Patients With Severely
IG
R
Impaired Diffusion Capacity. Ann Thorac Surg 2018; 105(2): 379-85 https://pubmed.ncbi.nlm.nih.gov/29223424.
PY
1062. Caviezel C, Froehlich T, Schneiter D, et al. Identification of target zones for lung volume reduction surgery using three-
O
dimensional computed tomography rendering. ERJ Open Res 2020; 6(3): https://pubmed.ncbi.nlm.nih.gov/32963992.
C
1063. Ramsey SD, Berry K, Etzioni R, et al. Cost effectiveness of lung-volume-reduction surgery for patients with severe
emphysema. N Engl J Med 2003; 348(21): 2092-102 https://pubmed.ncbi.nlm.nih.gov/12759480.
1064. Ginsburg ME, Thomashow BM, Bulman WA, et al. The safety, efficacy, and durability of lung-volume reduction surgery:
A 10-year experience. J Thorac Cardiovasc Surg 2016; 151(3): 717-24 e1 https://pubmed.ncbi.nlm.nih.gov/26670190.
1065. Abdelsattar ZM, Allen M, Blackmon S, et al. Contemporary Practice Patterns of Lung Volume Reduction Surgery in the
United States. Ann Thorac Surg 2021; 112(3): 952-60 https://pubmed.ncbi.nlm.nih.gov/33161015.
1066. Stanifer BP, Ginsburg ME. Lung volume reduction surgery in the post-National Emphysema Treatment Trial era. J Thorac
Dis 2018; 10(Suppl 23): S2744-S7 https://pubmed.ncbi.nlm.nih.gov/30210827.
1067. Buttery S, Lewis A, Oey I, et al. Patient experience of lung volume reduction procedures for emphysema: a qualitative
service improvement project. ERJ Open Res 2017; 3(3): https://pubmed.ncbi.nlm.nih.gov/28835891.
1068. McNulty W, Jordan S, Hopkinson NS. Attitudes and access to lung volume reduction surgery for COPD: a survey by the
British Thoracic Society. BMJ Open Respir Res 2014; 1(1): e000023 https://pubmed.ncbi.nlm.nih.gov/25478175.
1069. Rathinam S, Oey I, Steiner M, Spyt T, Morgan MD, Waller DA. The role of the emphysema multidisciplinary team in a
successful lung volume reduction surgery programmedagger. Eur J Cardiothorac Surg 2014; 46(6): 1021-6; discussion 6
1070. Chambers DC, Cherikh WS, Goldfarb SB, et al. The International Thoracic Organ Transplant Registry of the International
Society for Heart and Lung Transplantation: Thirty-fifth adult lung and heart-lung transplant report-2018; Focus theme:
Multiorgan Transplantation. J Heart Lung Transplant 2018; 37(10): 1169-83
1071. Weill D, Benden C, Corris PA, et al. A consensus document for the selection of lung transplant candidates: 2014--an
update from the Pulmonary Transplantation Council of the International Society for Heart and Lung Transplantation. J
Heart Lung Transplant 2015; 34(1): 1-15 https://pubmed.ncbi.nlm.nih.gov/25085497.
1072. Arjuna A, Olson MT, Walia R. Current trends in candidate selection, contraindications, and indications for lung
transplantation. J Thorac Dis 2021; 13(11): 6514-27 https://pubmed.ncbi.nlm.nih.gov/34992831.
1073. Christie JD, Edwards LB, Kucheryavaya AY, et al. The Registry of the International Society for Heart and Lung
Transplantation: 29th adult lung and heart-lung transplant report-2012. J Heart Lung Transplant 2012; 31(10): 1073-86
1074. Stavem K, Bjortuft O, Borgan O, Geiran O, Boe J. Lung transplantation in patients with chronic obstructive pulmonary
disease in a national cohort is without obvious survival benefit. J Heart Lung Transplant 2006; 25(1): 75-84
1075. Tanash HA, Riise GC, Hansson L, Nilsson PM, Piitulainen E. Survival benefit of lung transplantation in individuals with
severe alpha1-anti-trypsin deficiency (PiZZ) and emphysema. J Heart Lung Transplant 2011; 30(12): 1342-7
1076. Tanash HA, Riise GC, Ekstrom MP, Hansson L, Piitulainen E. Survival benefit of lung transplantation for chronic
obstructive pulmonary disease in Sweden. Ann Thorac Surg 2014; 98(6): 1930-5
1077. Eskander A, Waddell TK, Faughnan ME, Chowdhury N, Singer LG. BODE index and quality of life in advanced chronic
obstructive pulmonary disease before and after lung transplantation. J Heart Lung Transplant 2011; 30(12): 1334-41
1078. Lahzami S, Bridevaux PO, Soccal PM, et al. Survival impact of lung transplantation for COPD. Eur Respir J 2010; 36(1): 74-
1079. Thabut G, Ravaud P, Christie JD, et al. Determinants of the survival benefit of lung transplantation in patients with
TE
U
IB
TR
1080. ISHLT: The International Society for Heart & Lung Transplantation [Internet]. Slide Sets - Overall Lung Transplantation
IS
Statistics. Available from: https://ishltregistries.org/registries/slides.asp (accessed Oct 2022).
D
1081. Thabut G, Christie JD, Ravaud P, et al. Survival after bilateral versus single lung transplantation for patients with chronic
T
obstructive pulmonary disease: a retrospective analysis of registry data. Lancet 2008; 371(9614): 744-51
O
N
O
1082. Pochettino A, Kotloff RM, Rosengard BR, et al. Bilateral versus single lung transplantation for chronic obstructive
-D
pulmonary disease: intermediate-term results. Ann Thorac Surg 2000; 70(6): 1813-8; discussion 8-9
L
IA
ER
1083. Dickson RP, Davis RD, Rea JB, Palmer SM. High frequency of bronchogenic carcinoma after single-lung transplantation. J
AT
Heart Lung Transplant 2006; 25(11): 1297-301 https://pubmed.ncbi.nlm.nih.gov/17097492.

1084. Gonzalez FJ, Alvarez E, Moreno P, et al. The influence of the native lung on early outcomes and survival after single lung
M
T
transplantation. PLoS One 2021; 16(4): e0249758 https://pubmed.ncbi.nlm.nih.gov/33826650.

H
1085. Minai OA, Shah S, Mazzone P, et al. Bronchogenic carcinoma after lung transplantation: characteristics and outcomes. J
IG
R
Thorac Oncol 2008; 3(12): 1404-9 https://pubmed.ncbi.nlm.nih.gov/19057264.

PY
1086. Weill D, Torres F, Hodges TN, Olmos JJ, Zamora MR. Acute native lung hyperinflation is not associated with poor
O
outcomes after single lung transplant for emphysema. J Heart Lung Transplant 1999; 18(11): 1080-7
C
1087. Yonan NA, el-Gamel A, Egan J, Kakadellis J, Rahman A, Deiraniya AK. Single lung transplantation for emphysema:
predictors for native lung hyperinflation. J Heart Lung Transplant 1998; 17(2): 192-201
1088. Benvenuto LJ, Costa J, Piloni D, et al. Right single lung transplantation or double lung transplantation compared with left
single lung transplantation in chronic obstructive pulmonary disease. J Heart Lung Transplant 2020; 39(9): 870-7
1089. Mal H, Brugiere O, Sleiman C, et al. Morbidity and mortality related to the native lung in single lung transplantation for
emphysema. J Heart Lung Transplant 2000; 19(2): 220-3 https://pubmed.ncbi.nlm.nih.gov/10703700.
1090. Ramos KJ, Harhay MO, Mulligan MS. Which Shall I Choose? Lung Transplantation Listing Preference for Individuals with
Interstitial Lung Disease and Chronic Obstructive Pulmonary Disease. Ann Am Thorac Soc 2019; 16(2): 193-5
1091. Theodore J, Lewiston N. Lung transplantation comes of age. N Engl J Med 1990; 322(11): 772-4
1092. Tiong LU, Davies R, Gibson PG, et al. Lung volume reduction surgery for diffuse emphysema. Cochrane Database Syst
Rev 2006; (4): CD001001 https://pubmed.ncbi.nlm.nih.gov/17054132.
1093. Criner GJ, Cordova F, Sternberg AL, Martinez FJ. The National Emphysema Treatment Trial (NETT) Part II: Lessons
learned about lung volume reduction surgery. Am J Respir Crit Care Med 2011; 184(8): 881-93
1094. Herth FJ, Valipour A, Shah PL, et al. Segmental volume reduction using thermal vapour ablation in patients with severe
emphysema: 6-month results of the multicentre, parallel-group, open-label, randomised controlled STEP-UP trial.
1095. Kemp SV, Slebos DJ, Kirk A, et al. A Multicenter Randomized Controlled Trial of Zephyr Endobronchial Valve Treatment
in Heterogeneous Emphysema (TRANSFORM). Am J Respir Crit Care Med 2017; 196(12): 1535-43
1096. Valipour A, Slebos DJ, Herth F, et al. Endobronchial Valve Therapy in Patients with Homogeneous Emphysema. Results
from the IMPACT Study. Am J Respir Crit Care Med 2016; 194(9): 1073-82 https://pubmed.ncbi.nlm.nih.gov/27580428.
1097. van Geffen WH, Klooster K, Hartman JE, et al. Pleural Adhesion Assessment as a Predictor for Pneumothorax after
Endobronchial Valve Treatment. Respiration 2017; 94(2): 224-31 https://pubmed.ncbi.nlm.nih.gov/28637047.
1098. Hopkinson NS, Kemp SV, Toma TP, et al. Atelectasis and survival after bronchoscopic lung volume reduction for COPD.
Eur Respir J 2011; 37(6): 1346-51 https://pubmed.ncbi.nlm.nih.gov/20947683.
1099. Garner J, Kemp SV, Toma TP, et al. Survival after Endobronchial Valve Placement for Emphysema: A 10-Year Follow-up
Study. Am J Respir Crit Care Med 2016; 194(4): 519-21 https://pubmed.ncbi.nlm.nih.gov/27525462.
1100. Gompelmann D, Benjamin N, Bischoff E, et al. Survival after Endoscopic Valve Therapy in Patients with Severe
Emphysema. Respiration 2019; 97(2): 145-52 https://pubmed.ncbi.nlm.nih.gov/30227420.
1101. Hartman JE, Welling JBA, Klooster K, Carpaij OA, Augustijn SWS, Slebos DJ. Survival in COPD patients treated with
bronchoscopic lung volume reduction. Respir Med 2022; 196: 106825 https://pubmed.ncbi.nlm.nih.gov/35325741.
1102. Mansfield C, Sutphin J, Shriner K, Criner GJ, Celli BR. Patient Preferences for Endobronchial Valve Treatment of Severe
Emphysema. Chronic Obstr Pulm Dis 2018; 6(1): 51-63 https://pubmed.ncbi.nlm.nih.gov/30775424.
1103. Naunheim KS, Wood DE, Mohsenifar Z, et al. Long-term follow-up of patients receiving lung-volume-reduction surgery
versus medical therapy for severe emphysema by the National Emphysema Treatment Trial Research Group. Ann
Thorac Surg 2006; 82(2): 431-43 https://pubmed.ncbi.nlm.nih.gov/16888872.
TE
1104. DeCamp MM, Blackstone EH, Naunheim KS, et al. Patient and surgical factors influencing air leak after lung volume
U
reduction surgery: lessons learned from the National Emphysema Treatment Trial. Ann Thorac Surg 2006; 82(1): 197-
IB
TR
206; discussion -7 https://pubmed.ncbi.nlm.nih.gov/16798215.
1105. IS
Shah PL, Slebos DJ, Cardoso PF, et al. Bronchoscopic lung-volume reduction with Exhale airway stents for emphysema
D
(EASE trial): randomised, sham-controlled, multicentre trial. Lancet 2011; 378(9795): 997-1005
T
O
N
1106. Come CE, Kramer MR, Dransfield MT, et al. A randomised trial of lung sealant versus medical therapy for advanced
O
emphysema. Eur Respir J 2015; 46(3): 651-62 https://pubmed.ncbi.nlm.nih.gov/25837041.

-D
1107. Shah PL, Gompelmann D, Valipour A, et al. Thermal vapour ablation to reduce segmental volume in patients with
L
severe emphysema: STEP-UP 12 month results. Lancet Respir Med 2016; 4(9): e44-e5
IA
ER
AT
1108. Deslee G, Mal H, Dutau H, et al. Lung Volume Reduction Coil Treatment vs Usual Care in Patients With Severe
Emphysema: The REVOLENS Randomized Clinical Trial. JAMA 2016; 315(2): 175-84
M
T
H
1109. Sciurba FC, Criner GJ, Strange C, et al. Effect of Endobronchial Coils vs Usual Care on Exercise Tolerance in Patients With
IG
R
Severe Emphysema: The RENEW Randomized Clinical Trial. JAMA 2016; 315(20): 2178-89
PY
O
1110. Shah PL, Zoumot Z, Singh S, et al. Endobronchial coils for the treatment of severe emphysema with hyperinflation
C
(RESET): a randomised controlled trial. Lancet Respir Med 2013; 1(3): 233-40
1111. Slebos DJ, Cicenia J, Sciurba FC, et al. Predictors of Response to Endobronchial Coil Therapy in Patients With Advanced
Emphysema. Chest 2019; 155(5): 928-37 https://pubmed.ncbi.nlm.nih.gov/30797746.
1112. Bavaria JE, Pochettino A, Kotloff RM, et al. Effect of volume reduction on lung transplant timing and selection for
chronic obstructive pulmonary disease. J Thorac Cardiovasc Surg 1998; 115(1): 9-17; discussion -8
1113. Senbaklavaci O, Wisser W, Ozpeker C, et al. Successful lung volume reduction surgery brings patients into better
condition for later lung transplantation. Eur J Cardiothorac Surg 2002; 22(3): 363-7
1114. Slama A, Taube C, Kamler M, Aigner C. Lung volume reduction followed by lung transplantation-considerations on
selection criteria and outcome. J Thorac Dis 2018; 10(Suppl 27): S3366-S75
1115. Reece TB, Mitchell JD, Zamora MR, et al. Native lung volume reduction surgery relieves functional graft compression
after single-lung transplantation for chronic obstructive pulmonary disease. J Thorac Cardiovasc Surg 2008; 135(4): 931-
1116. Anderson MB, Kriett JM, Kapelanski DP, Perricone A, Smith CM, Jamieson SW. Volume reduction surgery in the native
lung after single lung transplantation for emphysema. J Heart Lung Transplant 1997; 16(7): 752-7
1117. Crespo MM, Johnson BA, McCurry KR, Landreneau RJ, Sciurba FC. Use of endobronchial valves for native lung
hyperinflation associated with respiratory failure in a single-lung transplant recipient for emphysema. Chest 2007;
1118. Venuta F, De Giacomo T, Rendina EA, et al. Thoracoscopic volume reduction of the native lung after single lung
transplantation for emphysema. Am J Respir Crit Care Med 1998; 157(1): 292-3
1119. Kemp SV, Carby M, Cetti EJ, Herth FJ, Shah PL. A potential role for endobronchial valves in patients with lung transplant.
J Heart Lung Transplant 2010; 29(11): 1310-2 https://pubmed.ncbi.nlm.nih.gov/20708411.
1120. Perch M, Riise GC, Hogarth K, et al. Endoscopic treatment of native lung hyperinflation using endobronchial valves in
single-lung transplant patients: a multinational experience. Clin Respir J 2015; 9(1): 104-10
1121. Shigemura N, Gilbert S, Bhama JK, et al. Lung transplantation after lung volume reduction surgery. Transplantation
1122. Slama A, Ceulemans LJ, Hedderich C, et al. Lung Volume Reduction Followed by Lung Transplantation in Emphysema-A
Multicenter Matched Analysis. Transpl Int 2022; 35: 10048 https://pubmed.ncbi.nlm.nih.gov/35497884.
1123. Fuehner T, Clajus C, Fuge J, et al. Lung transplantation after endoscopic lung volume reduction. Respiration 2015; 90(3):
1124. Bhatt SP, Terry NL, Nath H, et al. Association Between Expiratory Central Airway Collapse and Respiratory Outcomes
Among Smokers. JAMA 2016; 315(5): 498-505 https://pubmed.ncbi.nlm.nih.gov/26836732.
1125. Ernst A, Majid A, Feller-Kopman D, et al. Airway stabilization with silicone stents for treating adult
tracheobronchomalacia: a prospective observational study. Chest 2007; 132(2): 609-16
1126. Wright CD, Mathisen DJ. Tracheobronchoplasty for tracheomalacia. Ann Cardiothorac Surg 2018; 7(2): 261-5
TE
U
1127. Hartman JE, Garner JL, Shah PL, Slebos DJ. New bronchoscopic treatment modalities for patients with chronic
IB
TR
bronchitis. Eur Respir Rev 2021; 30(159): https://pubmed.ncbi.nlm.nih.gov/33472961.
1128. IS
Valipour A, Fernandez-Bussy S, Ing AJ, et al. Bronchial Rheoplasty for Treatment of Chronic Bronchitis. Twelve-Month
D
Results from a Multicenter Clinical Trial. Am J Respir Crit Care Med 2020; 202(5): 681-9
T
O
N
1129. U.S. National Library of Medicine ClinicalTrials.gov. RejuvenAir® System Trial for COPD With Chronic Bronchitis (SPRAY-
O
CB) [accessed Oct 2023]. https://clinicaltrials.gov/ct2/show/NCT03893370.

-D
1130. U.S. National Library of Medicine ClinicalTrials.gov. Clinical Study of the RheOx Bronchial Rheoplasty System in Treating
L
the Symptoms of Chronic Bronchitis [accessed Oct 2023]. https://www.clinicaltrials.gov/ct2/show/NCT04677465.

IA
ER
1131. Valipour A, Asadi S, Pison C, et al. Long-term safety of bilateral targeted lung denervation in patients with COPD. Int J
AT

1132. Valipour A, Shah PL, Pison C, et al. Safety and Dose Study of Targeted Lung Denervation in Moderate/Severe COPD
M
T
Patients. Respiration 2019; 98(4): 329-39 https://pubmed.ncbi.nlm.nih.gov/31220851.

H
1133. Slebos DJ, Shah PL, Herth FJF, et al. Safety and Adverse Events after Targeted Lung Denervation for Symptomatic
IG
R
Moderate to Severe Chronic Obstructive Pulmonary Disease (AIRFLOW). A Multicenter Randomized Controlled Clinical
PY
Trial. Am J Respir Crit Care Med 2019; 200(12): 1477-86 https://pubmed.ncbi.nlm.nih.gov/31404499.

O
1134. Mazzone PJ. Preoperative evaluation of the lung cancer resection candidate. Expert Rev Respir Med 2010; 4(1): 97-113
C
1135. Celli BR, MacNee W, Force AET. Standards for the diagnosis and treatment of patients with COPD: a summary of the
ATS/ERS position paper. Eur Respir J 2004; 23(6): 932-46 https://pubmed.ncbi.nlm.nih.gov/15219010.
1136. Schuurmans MM, Diacon AH, Bolliger CT. Functional evaluation before lung resection. Clin Chest Med 2002; 23(1): 159-
1137. Smetana GW. Preoperative pulmonary evaluation. N Engl J Med 1999; 340(12): 937-44
1138. Brunelli A, Charloux A, Bolliger CT, et al. ERS/ESTS clinical guidelines on fitness for radical therapy in lung cancer
patients (surgery and chemo-radiotherapy). Eur Respir J 2009; 34(1): 17-41
1139. Colice GL, Shafazand S, Griffin JP, Keenan R, Bolliger CT, American College of Chest P. Physiologic evaluation of the
patient with lung cancer being considered for resectional surgery: ACCP evidenced-based clinical practice guidelines
(2nd edition). Chest 2007; 132(3 Suppl): 161S-77S https://pubmed.ncbi.nlm.nih.gov/17873167.
1140. Spies R, Potter M, Hollamby R, et al. Sputum Color as a Marker for Bacteria in Acute Exacerbations of Chronic
Obstructive Pulmonary Disease: A Systematic Review and Meta-analysis. Ann Am Thorac Soc 2023; 20(5): 738-48
1141. Anthonisen NR, Manfreda J, Warren CP, Hershfield ES, Harding GK, Nelson NA. Antibiotic therapy in exacerbations of
chronic obstructive pulmonary disease. Ann Intern Med 1987; 106(2): 196-204
1142. Beghe B, Verduri A, Roca M, Fabbri LM. Exacerbation of respiratory symptoms in COPD patients may not be
exacerbations of COPD. Eur Respir J 2013; 41(4): 993-5 https://pubmed.ncbi.nlm.nih.gov/23543648.
1143. Stolz D, Breidthardt T, Christ-Crain M, et al. Use of B-type natriuretic peptide in the risk stratification of acute
exacerbations of COPD. Chest 2008; 133(5): 1088-94 https://pubmed.ncbi.nlm.nih.gov/18339792.
1144. Crisafulli E, Manco A, Ferrer M, et al. Pneumonic versus Nonpneumonic Exacerbations of Chronic Obstructive
Pulmonary Disease. Semin Respir Crit Care Med 2020; 41(6): 817-29 https://pubmed.ncbi.nlm.nih.gov/32726837.
1145. Torres A, Blasi F, Dartois N, Akova M. Which individuals are at increased risk of pneumococcal disease and why? Impact
of COPD, asthma, smoking, diabetes, and/or chronic heart disease on community-acquired pneumonia and invasive
pneumococcal disease. Thorax 2015; 70(10): 984-9 https://pubmed.ncbi.nlm.nih.gov/26219979.
1146. Couturaud F, Bertoletti L, Pastre J, et al. Prevalence of Pulmonary Embolism Among Patients With COPD Hospitalized
With Acutely Worsening Respiratory Symptoms. JAMA 2021; 325(1): 59-68
1147. Jimenez D, Agusti A, Tabernero E, et al. Effect of a Pulmonary Embolism Diagnostic Strategy on Clinical Outcomes in
Patients Hospitalized for COPD Exacerbation: A Randomized Clinical Trial. JAMA 2021; 326(13): 1277-85
1148. Calverley PMA, Martinez FJ, Vestbo J, et al. International Differences in the Frequency of Chronic Obstructive
Pulmonary Disease Exacerbations Reported in Three Clinical Trials. Am J Respir Crit Care Med 2022; 206(1): 25-33
1149. Althobiani MA, Shah AJ, Khan B, Hurst JR. Clinicians' and Researchers' Perspectives on a New Chronic Obstructive
Pulmonary Disease Exacerbation Definition: Rome Wasn't Built in a Day. Am J Respir Crit Care Med 2023; 207(8): 1095-7
1150. Reumkens C, Endres A, Simons SO, Savelkoul PHM, Sprooten RTM, Franssen FME. Application of the Rome severity
classification of COPD exacerbations in a real-world cohort of hospitalised patients. ERJ Open Res 2023; 9(3):
TE
U
1151. Wilkinson TM, Donaldson GC, Hurst JR, Seemungal TA, Wedzicha JA. Early therapy improves outcomes of exacerbations
IB
TR
of chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2004; 169(12): 1298-303
D
1152. Vijayasaratha K, Stockley RA. Reported and unreported exacerbations of COPD: analysis by diary cards. Chest 2008;
T

O
N
1153. Konstantinoudis G, Minelli C, Vicedo-Cabrera AM, Ballester J, Gasparrini A, Blangiardo M. Ambient heat exposure and
O
COPD hospitalisations in England: a nationwide case-crossover study during 2007-2018. Thorax 2022; 77(11): 1098-104
-D
L
1154. Li N, Ma J, Ji K, Wang L. Association of PM2.5 and PM10 with Acute Exacerbation of Chronic Obstructive Pulmonary
IA
ER
Disease at lag0 to lag7: A Systematic Review and Meta-Analysis. COPD 2022; 19(1): 243-54
AT
1155. Liu S, Zhou Y, Liu S, et al. Association between exposure to ambient particulate matter and chronic obstructive
M
T
pulmonary disease: results from a cross-sectional study in China. Thorax 2017; 72(9): 788-95
H
IG
R
1156. Liang L, Cai Y, Barratt B, et al. Associations between daily air quality and hospitalisations for acute exacerbation of
PY
chronic obstructive pulmonary disease in Beijing, 2013-17: an ecological analysis. Lancet Planet Health 2019; 3(6): e270-
O
C
1157. White AJ, Gompertz S, Stockley RA. Chronic obstructive pulmonary disease . 6: The aetiology of exacerbations of
chronic obstructive pulmonary disease. Thorax 2003; 58(1): 73-80 https://pubmed.ncbi.nlm.nih.gov/12511727.
1158. Woodhead M, Blasi F, Ewig S, et al. Guidelines for the management of adult lower respiratory tract infections. Eur
1159. Bafadhel M, McKenna S, Agbetile J, et al. Aspergillus fumigatus during stable state and exacerbations of COPD. Eur
1160. Huerta A, Soler N, Esperatti M, et al. Importance of Aspergillus spp. isolation in Acute exacerbations of severe COPD:
prevalence, factors and follow-up: the FUNGI-COPD study. Respir Res 2014; 15(1): 17
1161. Mir T, Uddin M, Khalil A, et al. Mortality outcomes associated with invasive aspergillosis among acute exacerbation of
chronic obstructive pulmonary disease patient population. Respir Med 2022; 191: 106720
1162. Hammond EE, McDonald CS, Vestbo J, Denning DW. The global impact of Aspergillus infection on COPD. BMC Pulm Med
1163. Gu Y, Ye X, Liu Y, et al. A risk-predictive model for invasive pulmonary aspergillosis in patients with acute exacerbation
of chronic obstructive pulmonary disease. Respir Res 2021; 22(1): 176 https://pubmed.ncbi.nlm.nih.gov/34107968.
1164. Tiew PY, Narayana JK, Quek MSL, et al. Sensitisation to recombinant Aspergillus fumigatus allergens and clinical
outcomes in COPD. Eur Respir J 2023; 61(1): https://pubmed.ncbi.nlm.nih.gov/35926878.
1165. Bulpa P, Duplaquet F, Dimopoulos G, Vogelaers D, Blot S. Invasive Pulmonary Aspergillosis in Chronic Obstructive
Pulmonary Disease Exacerbations. Semin Respir Crit Care Med 2020; 41(6): 851-61
1166. Papi A, Bellettato CM, Braccioni F, et al. Infections and airway inflammation in chronic obstructive pulmonary disease
severe exacerbations. Am J Respir Crit Care Med 2006; 173(10): 1114-21 https://pubmed.ncbi.nlm.nih.gov/16484677.
1167. Bafadhel M, McKenna S, Terry S, et al. Acute exacerbations of chronic obstructive pulmonary disease: identification of
biologic clusters and their biomarkers. Am J Respir Crit Care Med 2011; 184(6): 662-71
1168. Baines KJ, Pavord ID, Gibson PG. The role of biomarkers in the management of airways disease. Int J Tuberc Lung Dis
1169. Groenke L, Disse B. Blood eosinophil counts as markers of response to inhaled corticosteroids in COPD? Lancet Respir
Med 2015; 3(8): e26 https://pubmed.ncbi.nlm.nih.gov/26282478.
1170. Bafadhel M, McKenna S, Terry S, et al. Blood eosinophils to direct corticosteroid treatment of exacerbations of chronic
obstructive pulmonary disease: a randomized placebo-controlled trial. Am J Respir Crit Care Med 2012; 186(1): 48-55
1171. Seemungal TA, Donaldson GC, Bhowmik A, Jeffries DJ, Wedzicha JA. Time course and recovery of exacerbations in
1172. Halpin DMG, Birk R, Brealey N, et al. Single-inhaler triple therapy in symptomatic COPD patients: FULFIL subgroup
analyses. ERJ Open Res 2018; 4(2): 00119-2017 https://pubmed.ncbi.nlm.nih.gov/29750142.
1173. Donaldson GC, Law M, Kowlessar B, et al. Impact of Prolonged Exacerbation Recovery in Chronic Obstructive Pulmonary
Disease. Am J Respir Crit Care Med 2015; 192(8): 943-50 https://pubmed.ncbi.nlm.nih.gov/26151174.
1174. Hurst JR, Donaldson GC, Quint JK, Goldring JJ, Baghai-Ravary R, Wedzicha JA. Temporal clustering of exacerbations in
TE
U
IB
TR
1175. Donaldson GC, Mullerova H, Locantore N, et al. Factors associated with change in exacerbation frequency in COPD.
Respir Res 2013; 14(1): 79 https://pubmed.ncbi.nlm.nih.gov/23899210.IS
D
1176. Han MK, Kazerooni EA, Lynch DA, et al. Chronic obstructive pulmonary disease exacerbations in the COPDGene study:
T
associated radiologic phenotypes. Radiology 2011; 261(1): 274-82 https://pubmed.ncbi.nlm.nih.gov/21788524.

O
N
1177. Burgel PR, Nesme-Meyer P, Chanez P, et al. Cough and sputum production are associated with frequent exacerbations
O
and hospitalizations in COPD subjects. Chest 2009; 135(4): 975-82 https://pubmed.ncbi.nlm.nih.gov/19017866.

-D
1178. Rafiq R, Aleva FE, Schrumpf JA, et al. Vitamin D supplementation in chronic obstructive pulmonary disease patients with
L
low serum vitamin D: a randomized controlled trial. Am J Clin Nutr 2022; 116(2): 491-9
IA
ER
AT
1179. Martinez FJ, Han MK, Flaherty K, Curtis J. Role of infection and antimicrobial therapy in acute exacerbations of chronic
obstructive pulmonary disease. Expert Rev Anti Infect Ther 2006; 4(1): 101-24
M
T
H
1180. Celli BR, Thomas NE, Anderson JA, et al. Effect of pharmacotherapy on rate of decline of lung function in chronic
IG
R
obstructive pulmonary disease: results from the TORCH study. Am J Respir Crit Care Med 2008; 178(4): 332-8
PY
O
1181. Celli BR, Barnes PJ. Exacerbations of chronic obstructive pulmonary disease. Eur Respir J 2007; 29(6): 1224-38
C
1182. Hoogendoorn M, Hoogenveen RT, Rutten-van Molken MP, Vestbo J, Feenstra TL. Case fatality of COPD exacerbations: a
meta-analysis and statistical modelling approach. Eur Respir J 2011; 37(3): 508-15
1183. Piquet J, Chavaillon JM, David P, et al. High-risk patients following hospitalisation for an acute exacerbation of COPD.
Eur Respir J 2013; 42(4): 946-55 https://pubmed.ncbi.nlm.nih.gov/23349446.
1184. Singanayagam A, Schembri S, Chalmers JD. Predictors of mortality in hospitalized adults with acute exacerbation of
chronic obstructive pulmonary disease. Ann Am Thorac Soc 2013; 10(2): 81-9
1185. Guo Y, Zhang T, Wang Z, et al. Body mass index and mortality in chronic obstructive pulmonary disease: A dose-
response meta-analysis. Medicine (Baltimore) 2016; 95(28): e4225 https://pubmed.ncbi.nlm.nih.gov/27428228.
1186. Garcia-Aymerich J, Serra Pons I, Mannino DM, Maas AK, Miller DP, Davis KJ. Lung function impairment, COPD
hospitalisations and subsequent mortality. Thorax 2011; 66(7): 585-90 https://pubmed.ncbi.nlm.nih.gov/21515553.
1187. Chen J, Yang J, Zhou M, et al. Cold spell and mortality in 31 Chinese capital cities: Definitions, vulnerability and
implications. Environ Int 2019; 128: 271-8 https://pubmed.ncbi.nlm.nih.gov/31071590.
1188. Howcroft M, Walters EH, Wood-Baker R, Walters JA. Action plans with brief patient education for exacerbations in
chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2016; 12(12): CD005074
1189. National Institute for Health and Care Excellence. Chronic obstructive pulmonary disease in over 16s: diagnosis and
management. 2018. https://www.nice.org.uk/guidance/NG115.
1190. van Geffen WH, Douma WR, Slebos DJ, Kerstjens HA. Bronchodilators delivered by nebuliser versus pMDI with spacer or
DPI for exacerbations of COPD. Cochrane Database Syst Rev 2016; 2016(8): CD011826
1191. Barr RG, Rowe BH, Camargo CA, Jr. Methylxanthines for exacerbations of chronic obstructive pulmonary disease: meta-
analysis of randomised trials. BMJ 2003; 327(7416): 643 https://pubmed.ncbi.nlm.nih.gov/14500434.
1192. Duffy N, Walker P, Diamantea F, Calverley PM, Davies L. Intravenous aminophylline in patients admitted to hospital
with non-acidotic exacerbations of chronic obstructive pulmonary disease: a prospective randomised controlled trial.
1193. Bardsley G, Pilcher J, McKinstry S, et al. Oxygen versus air-driven nebulisers for exacerbations of chronic obstructive
pulmonary disease: a randomised controlled trial. BMC Pulm Med 2018; 18(1): 157
1194. Davies L, Angus RM, Calverley PM. Oral corticosteroids in patients admitted to hospital with exacerbations of chronic
obstructive pulmonary disease: a prospective randomised controlled trial. Lancet 1999; 354(9177): 456-60
1195. Maltais F, Ostinelli J, Bourbeau J, et al. Comparison of nebulized budesonide and oral prednisolone with placebo in the
treatment of acute exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial. Am J Respir
Crit Care Med 2002; 165(5): 698-703 https://pubmed.ncbi.nlm.nih.gov/11874817.
1196. Niewoehner DE, Erbland ML, Deupree RH, et al. Effect of systemic glucocorticoids on exacerbations of chronic
obstructive pulmonary disease. Department of Veterans Affairs Cooperative Study Group. N Engl J Med 1999; 340(25):
1197. Thompson WH, Nielson CP, Carvalho P, Charan NB, Crowley JJ. Controlled trial of oral prednisone in outpatients with
acute COPD exacerbation. Am J Respir Crit Care Med 1996; 154(2 Pt 1): 407-12
TE
1198. Alia I, de la Cal MA, Esteban A, et al. Efficacy of corticosteroid therapy in patients with an acute exacerbation of chronic
U
obstructive pulmonary disease receiving ventilatory support. Arch Intern Med 2011; 171(21): 1939-46
IB
TR
1199. IS
Aaron SD, Vandemheen KL, Hebert P, et al. Outpatient oral prednisone after emergency treatment of chronic
D
obstructive pulmonary disease. N Engl J Med 2003; 348(26): 2618-25 https://pubmed.ncbi.nlm.nih.gov/12826636.
T
1200. Leuppi JD, Schuetz P, Bingisser R, et al. Short-term vs conventional glucocorticoid therapy in acute exacerbations of
O
N
chronic obstructive pulmonary disease: the REDUCE randomized clinical trial. JAMA 2013; 309(21): 2223-31
O
-D
1201. Sivapalan P, Ingebrigtsen TS, Rasmussen DB, et al. COPD exacerbations: the impact of long versus short courses of oral
L
corticosteroids on mortality and pneumonia: nationwide data on 67 000 patients with COPD followed for 12 months.
IA
ER
BMJ Open Respir Res 2019; 6(1): e000407 https://pubmed.ncbi.nlm.nih.gov/31179005.

AT
1202. de Jong YP, Uil SM, Grotjohan HP, Postma DS, Kerstjens HA, van den Berg JW. Oral or IV prednisolone in the treatment
of COPD exacerbations: a randomized, controlled, double-blind study. Chest 2007; 132(6): 1741-7
M
T
H
1203. Gunen H, Hacievliyagil SS, Yetkin O, Gulbas G, Mutlu LC, In E. The role of nebulised budesonide in the treatment of
IG
R
exacerbations of COPD. Eur Respir J 2007; 29(4): 660-7 https://pubmed.ncbi.nlm.nih.gov/17251232.

PY
1204. Stallberg B, Selroos O, Vogelmeier C, Andersson E, Ekstrom T, Larsson K. Budesonide/formoterol as effective as

O
prednisolone plus formoterol in acute exacerbations of COPD. A double-blind, randomised, non-inferiority, parallel-
C
group, multicentre study. Respir Res 2009; 10(1): 11 https://pubmed.ncbi.nlm.nih.gov/19228428.

1205. Ding Z, Li X, Lu Y, et al. A randomized, controlled multicentric study of inhaled budesonide and intravenous
methylprednisolone in the treatment on acute exacerbation of chronic obstructive pulmonary disease. Respir Med
2016; 121: 39-47 https://pubmed.ncbi.nlm.nih.gov/27888990.
1206. Stolz D, Hirsch HH, Schilter D, et al. Intensified Therapy with Inhaled Corticosteroids and Long-Acting beta(2)-Agonists at
the Onset of Upper Respiratory Tract Infection to Prevent Chronic Obstructive Pulmonary Disease Exacerbations. A
Multicenter, Randomized, Double-Blind, Placebo-controlled Trial. Am J Respir Crit Care Med 2018; 197(9): 1136-46
1207. Waljee AK, Rogers MA, Lin P, et al. Short term use of oral corticosteroids and related harms among adults in the United
States: population based cohort study. BMJ 2017; 357: j1415 https://pubmed.ncbi.nlm.nih.gov/28404617.
1208. Sivapalan P, Lapperre TS, Janner J, et al. Eosinophil-guided corticosteroid therapy in patients admitted to hospital with
COPD exacerbation (CORTICO-COP): a multicentre, randomised, controlled, open-label, non-inferiority trial. Lancet
1209. Seemungal T, Harper-Owen R, Bhowmik A, et al. Respiratory viruses, symptoms, and inflammatory markers in acute
exacerbations and stable chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2001; 164(9): 1618-23
1210. Vollenweider DJ, Jarrett H, Steurer-Stey CA, Garcia-Aymerich J, Puhan MA. Antibiotics for exacerbations of chronic
obstructive pulmonary disease. Cochrane Database Syst Rev 2012; 12: CD010257
1211. Miravitlles M, Kruesmann F, Haverstock D, Perroncel R, Choudhri SH, Arvis P. Sputum colour and bacteria in chronic
bronchitis exacerbations: a pooled analysis. Eur Respir J 2012; 39(6): 1354-60
1212. Ram FS, Rodriguez-Roisin R, Granados-Navarrete A, Garcia-Aymerich J, Barnes NC. Antibiotics for exacerbations of
chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2006; (2): CD004403
1213. Quon BS, Gan WQ, Sin DD. Contemporary management of acute exacerbations of COPD: a systematic review and
metaanalysis. Chest 2008; 133(3): 756-66 https://pubmed.ncbi.nlm.nih.gov/18321904.
1214. Wilson R, Anzueto A, Miravitlles M, et al. Moxifloxacin versus amoxicillin/clavulanic acid in outpatient acute
exacerbations of COPD: MAESTRAL results. Eur Respir J 2012; 40(1): 17-27 https://pubmed.ncbi.nlm.nih.gov/22135277.
1215. van Velzen P, Ter Riet G, Bresser P, et al. Doxycycline for outpatient-treated acute exacerbations of COPD: a randomised
double-blind placebo-controlled trial. Lancet Respir Med 2017; 5(6): 492-9 https://pubmed.ncbi.nlm.nih.gov/28483402.
1216. Clark TW, Medina MJ, Batham S, Curran MD, Parmar S, Nicholson KG. C-reactive protein level and microbial aetiology in
patients hospitalised with acute exacerbation of COPD. Eur Respir J 2015; 45(1): 76-86
1217. Peng C, Tian C, Zhang Y, Yang X, Feng Y, Fan H. C-reactive protein levels predict bacterial exacerbation in patients with
chronic obstructive pulmonary disease. Am J Med Sci 2013; 345(3): 190-4 https://pubmed.ncbi.nlm.nih.gov/23221507.
1218. Prins HJ, Duijkers R, van der Valk P, et al. CRP-guided antibiotic treatment in acute exacerbations of COPD in hospital
admissions. Eur Respir J 2019; 53(5): https://pubmed.ncbi.nlm.nih.gov/30880285.
1219. Butler CC, Gillespie D, White P, et al. C-Reactive Protein Testing to Guide Antibiotic Prescribing for COPD Exacerbations.
N Engl J Med 2019; 381(2): 111-20 https://pubmed.ncbi.nlm.nih.gov/31291514.
1220. Christ-Crain M, Jaccard-Stolz D, Bingisser R, et al. Effect of procalcitonin-guided treatment on antibiotic use and
outcome in lower respiratory tract infections: cluster-randomised, single-blinded intervention trial. Lancet 2004;
TE
U
1221. Schuetz P, Christ-Crain M, Thomann R, et al. Effect of procalcitonin-based guidelines vs standard guidelines on antibiotic
IB
TR
use in lower respiratory tract infections: the ProHOSP randomized controlled trial. JAMA 2009; 302(10): 1059-66
D
1222. Schuetz P, Muller B, Christ-Crain M, et al. Procalcitonin to initiate or discontinue antibiotics in acute respiratory tract
T
infections. Cochrane Database Syst Rev 2012; 2012(9): CD007498 https://pubmed.ncbi.nlm.nih.gov/22972110.

O
N
1223. Wang JX, Zhang SM, Li XH, Zhang Y, Xu ZY, Cao B. Acute exacerbations of chronic obstructive pulmonary disease with
O
low serum procalcitonin values do not benefit from antibiotic treatment: a prospective randomized controlled trial. Int J
-D
Infect Dis 2016; 48: 40-5 https://pubmed.ncbi.nlm.nih.gov/27155210.

L
1224. Chen K, Pleasants KA, Pleasants RA, et al. Procalcitonin for Antibiotic Prescription in Chronic Obstructive Pulmonary
IA
ER
Disease Exacerbations: Systematic Review, Meta-Analysis, and Clinical Perspective. Pulm Ther 2020; 6(2): 201-14
AT
1225. Daubin C, Valette X, Thiolliere F, et al. Procalcitonin algorithm to guide initial antibiotic therapy in acute exacerbations
M
T
of COPD admitted to the ICU: a randomized multicenter study. Intensive Care Med 2018; 44(4): 428-37
H
IG
R
1226. Masterton RG, Burley CJ. Randomized, double-blind study comparing 5- and 7-day regimens of oral levofloxacin in
PY
patients with acute exacerbation of chronic bronchitis. Int J Antimicrob Agents 2001; 18(6): 503-12
O
C
1227. Llor C, Moragas A, Miravitlles M, Mesquita P, Cordoba G. Are short courses of antibiotic therapy as effective as standard
courses for COPD exacerbations? A systematic review and meta-analysis. Pulm Pharmacol Ther 2022; 72: 102111
1228. Adams S, J. M, Luther M. Antibiotics are associated with lower relapse rates in outpatients with acute exacerbations of
chronic obstructive pulmonary disease. Chest 2000; 117: 1345-52
1229. Miravitlles M, Espinosa C, Fernandez-Laso E, Martos JA, Maldonado JA, Gallego M. Relationship between bacterial flora
in sputum and functional impairment in patients with acute exacerbations of COPD. Study Group of Bacterial Infection
in COPD. Chest 1999; 116(1): 40-6 https://pubmed.ncbi.nlm.nih.gov/10424501.
1230. Soler N, Torres A, Ewig S, et al. Bronchial microbial patterns in severe exacerbations of chronic obstructive pulmonary
disease (COPD) requiring mechanical ventilation. Am J Respir Crit Care Med 1998; 157(5 Pt 1): 1498-505
1231. Rizkallah J, Man SFP, Sin DD. Prevalence of pulmonary embolism in acute exacerbations of COPD: a systematic review
and metaanalysis. Chest 2009; 135(3): 786-93 https://pubmed.ncbi.nlm.nih.gov/18812453.
1232. Gunen H, Gulbas G, In E, Yetkin O, Hacievliyagil SS. Venous thromboemboli and exacerbations of COPD. Eur Respir J
1233. Bertoletti L, Quenet S, Laporte S, et al. Pulmonary embolism and 3-month outcomes in 4036 patients with venous
thromboembolism and chronic obstructive pulmonary disease: data from the RIETE registry. Respir Res 2013; 14(1): 75
1234. Kahn S, Lim W, Dunn A, et al. American College of Chest Physicians. Prevention of VTE in nonsurgical patients:
Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based
Pracice Guidelines. Chest 2012; 141((2 Suppl)): e195S-226S
1235. Austin MA, Wills KE, Blizzard L, Walters EH, Wood-Baker R. Effect of high flow oxygen on mortality in chronic
obstructive pulmonary disease patients in prehospital setting: randomised controlled trial. BMJ 2010; 341: c5462
1236. Sjoding MW, Dickson RP, Iwashyna TJ, Gay SE, Valley TS. Racial Bias in Pulse Oximetry Measurement. N Engl J Med
1237. McKeever TM, Hearson G, Housley G, et al. Using venous blood gas analysis in the assessment of COPD exacerbations: a
prospective cohort study. Thorax 2016; 71(3): 210-5 https://pubmed.ncbi.nlm.nih.gov/26628461.
1238. Roca O, Hernandez G, Diaz-Lobato S, et al. Current evidence for the effectiveness of heated and humidified high flow
nasal cannula supportive therapy in adult patients with respiratory failure. Crit Care 2016; 20(1): 109
1239. Fraser JF, Spooner AJ, Dunster KR, Anstey CM, Corley A. Nasal high flow oxygen therapy in patients with COPD reduces
respiratory rate and tissue carbon dioxide while increasing tidal and end-expiratory lung volumes: a randomised
crossover trial. Thorax 2016; 71(8): 759-61 https://pubmed.ncbi.nlm.nih.gov/27015801.
1240. Mauri T, Turrini C, Eronia N, et al. Physiologic Effects of High-Flow Nasal Cannula in Acute Hypoxemic Respiratory
Failure. Am J Respir Crit Care Med 2017; 195(9): 1207-15 https://pubmed.ncbi.nlm.nih.gov/27997805.
1241. Frat JP, Coudroy R, Marjanovic N, Thille AW. High-flow nasal oxygen therapy and noninvasive ventilation in the
management of acute hypoxemic respiratory failure. Ann Transl Med 2017; 5(14): 297
1242. Lin SM, Liu KX, Lin ZH, Lin PH. Does high-flow nasal cannula oxygen improve outcome in acute hypoxemic respiratory
failure? A systematic review and meta-analysis. Respir Med 2017; 131: 58-64
TE
U
1243. Nagata K, Kikuchi T, Horie T, et al. Domiciliary High-Flow Nasal Cannula Oxygen Therapy for Patients with Stable
IB
TR
Hypercapnic Chronic Obstructive Pulmonary Disease. A Multicenter Randomized Crossover Trial. Ann Am Thorac Soc
2018; 15(4): 432-9 https://pubmed.ncbi.nlm.nih.gov/29283682. IS
D
1244. Braunlich J, Dellweg D, Bastian A, et al. Nasal high-flow versus noninvasive ventilation in patients with chronic
T
hypercapnic COPD. Int J Chron Obstruct Pulmon Dis 2019; 14: 1411-21 https://pubmed.ncbi.nlm.nih.gov/31308647.
O
N
1245. Bruni A, Garofalo E, Cammarota G, et al. High Flow Through Nasal Cannula in Stable and Exacerbated Chronic
O
Obstructive Pulmonary Disease Patients. Rev Recent Clin Trials 2019; 14(4): 247-60
-D
L
1246. Bonnevie T, Elkins M, Paumier C, et al. Nasal High Flow for Stable Patients with Chronic Obstructive Pulmonary Disease:
IA
ER
A Systematic Review and Meta-Analysis. COPD 2019; 16(5-6): 368-77 https://pubmed.ncbi.nlm.nih.gov/31656111.

AT
1247. Fu C, Liu X, Zhu Q, et al. Efficiency of High-Flow Nasal Cannula on Pulmonary Rehabilitation in COPD Patients: A Meta-
Analysis. Biomed Res Int 2020; 2020: 7097243 https://pubmed.ncbi.nlm.nih.gov/33083481.
M
T
1248. Nagata K, Horie T, Chohnabayashi N, et al. Home High-Flow Nasal Cannula Oxygen Therapy for Stable Hypercapnic
H
COPD: A Randomized Clinical Trial. Am J Respir Crit Care Med 2022; 206(11): 1326-35
IG
R
PY
1249. Xia J, Gu S, Lei W, et al. High-flow nasal cannula versus conventional oxygen therapy in acute COPD exacerbation with
O
mild hypercapnia: a multicenter randomized controlled trial. Crit Care 2022; 26(1): 109
C
1250. Oczkowski S, Ergan B, Bos L, et al. ERS clinical practice guidelines: high-flow nasal cannula in acute respiratory failure.
Eur Respir J 2022; 59(4): https://pubmed.ncbi.nlm.nih.gov/34649974.
1251. Osadnik CR, Tee VS, Carson-Chahhoud KV, Picot J, Wedzicha JA, Smith BJ. Non-invasive ventilation for the management
of acute hypercapnic respiratory failure due to exacerbation of chronic obstructive pulmonary disease. Cochrane
1252. Brochard L, Mancebo J, Wysocki M, et al. Noninvasive ventilation for acute exacerbations of chronic obstructive
pulmonary disease. N Engl J Med 1995; 333(13): 817-22 https://pubmed.ncbi.nlm.nih.gov/7651472.
1253. Meyer TJ, Hill NS. Noninvasive positive pressure ventilation to treat respiratory failure. Ann Intern Med 1994; 120(9):
1254. Consensus development conference committee. Clinical indications for noninvasive positive pressure ventilation in
chronic respiratory failure due to restrictive lung disease, COPD, and nocturnal hypoventilation--a consensus
conference report. Chest 1999; 116(2): 521-34 https://pubmed.ncbi.nlm.nih.gov/10453883.
1255. Bott J, Carroll MP, Conway JH, et al. Randomised controlled trial of nasal ventilation in acute ventilatory failure due to
chronic obstructive airways disease. Lancet 1993; 341(8860): 1555-7 https://pubmed.ncbi.nlm.nih.gov/8099639.
1256. Kramer N, Meyer TJ, Meharg J, Cece RD, Hill NS. Randomized, prospective trial of noninvasive positive pressure
ventilation in acute respiratory failure. Am J Respir Crit Care Med 1995; 151(6): 1799-806
1257. Plant PK, Owen JL, Elliott MW. Early use of non-invasive ventilation for acute exacerbations of chronic obstructive
pulmonary disease on general respiratory wards: a multicentre randomised controlled trial. Lancet 2000; 355(9219):
1258. Sellares J, Ferrer M, Anton A, et al. Discontinuing noninvasive ventilation in severe chronic obstructive pulmonary
disease exacerbations: a randomised controlled trial. Eur Respir J 2017; 50(1):
1259. Conti G, Antonelli M, Navalesi P, et al. Noninvasive vs. conventional mechanical ventilation in patients with chronic
obstructive pulmonary disease after failure of medical treatment in the ward: a randomized trial. Intensive Care Med
1260. Esteban A, Anzueto A, Frutos F, et al. Characteristics and outcomes in adult patients receiving mechanical ventilation: a
28-day international study. JAMA 2002; 287(3): 345-55 https://pubmed.ncbi.nlm.nih.gov/11790214.
1261. Wildman MJ, Sanderson C, Groves J, et al. Implications of prognostic pessimism in patients with chronic obstructive
pulmonary disease (COPD) or asthma admitted to intensive care in the UK within the COPD and asthma outcome study
(CAOS): multicentre observational cohort study. BMJ 2007; 335(7630): 1132
1262. Gunen H, Hacievliyagil SS, Kosar F, et al. Factors affecting survival of hospitalised patients with COPD. Eur Respir J 2005;
1263. Kong CW, Wilkinson TMA. Predicting and preventing hospital readmission for exacerbations of COPD. ERJ Open Res
1264. Jennings JH, Thavarajah K, Mendez MP, Eichenhorn M, Kvale P, Yessayan L. Predischarge bundle for patients with acute
exacerbations of COPD to reduce readmissions and ED visits: a randomized controlled trial. Chest 2015; 147(5): 1227-34
1265. Alqahtani JS, Njoku CM, Bereznicki B, et al. Risk factors for all-cause hospital readmission following exacerbation of
TE
COPD: a systematic review and meta-analysis. Eur Respir Rev 2020; 29(156): epub 30 Jun
U
IB
TR
1266. Singh G, Zhang W, Kuo YF, Sharma G. Association of Psychological Disorders With 30-Day Readmission Rates in Patients
IS
With COPD. Chest 2016; 149(4): 905-15 https://pubmed.ncbi.nlm.nih.gov/26204260.
D
1267. Ringbaek T, Green A, Laursen LC, Frausing E, Brondum E, Ulrik CS. Effect of tele health care on exacerbations and
T
hospital admissions in patients with chronic obstructive pulmonary disease: a randomized clinical trial. Int J Chron
O
N

O
1268. Hartl S, Lopez-Campos JL, Pozo-Rodriguez F, et al. Risk of death and readmission of hospital-admitted COPD
-D
exacerbations: European COPD Audit. Eur Respir J 2016; 47(1): 113-21 https://pubmed.ncbi.nlm.nih.gov/26493806.
L
1269. Jordan RE, Majothi S, Heneghan NR, et al. Supported self-management for patients with moderate to severe chronic
IA
ER
obstructive pulmonary disease (COPD): an evidence synthesis and economic analysis. Health Technol Assess 2015;
AT

1270. Walker PP, Pompilio PP, Zanaboni P, et al. Telemonitoring in Chronic Obstructive Pulmonary Disease (CHROMED). A
M
T
Randomized Clinical Trial. Am J Respir Crit Care Med 2018; 198(5): 620-8 https://pubmed.ncbi.nlm.nih.gov/29557669.
H
1271. Gavish R, Levy A, Dekel OK, Karp E, Maimon N. The Association Between Hospital Readmission and Pulmonologist
IG
R
Follow-up Visits in Patients With COPD. Chest 2015; 148(2): 375-81 https://pubmed.ncbi.nlm.nih.gov/25611698.
PY
1272. Oga T, Tsukino M, Hajiro T, Ikeda A, Nishimura K. Predictive properties of different multidimensional staging systems in
O
patients with chronic obstructive pulmonary disease. Int J Chron Obstruct Pulmon Dis 2011; 6: 521-6
C
1273. Spece LJ, Epler EM, Duan K, et al. Reassessment of Home Oxygen Prescription after Hospitalization for Chronic
Obstructive Pulmonary Disease. A Potential Target for Deimplementation. Ann Am Thorac Soc 2021; 18(3): 426-32
1274. Martinez-Garcia MA, de la Rosa Carrillo D, Soler-Cataluna JJ, et al. Prognostic value of bronchiectasis in patients with
moderate-to-severe chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2013; 187(8): 823-31
1275. Alsallakh MA, Sivakumaran S, Kennedy S, et al. Impact of COVID-19 lockdown on the incidence and mortality of acute
exacerbations of chronic obstructive pulmonary disease: national interrupted time series analyses for Scotland and
Wales. BMC Med 2021; 19(1): 124 https://pubmed.ncbi.nlm.nih.gov/33993870.
1276. Chan KPF, Ma TF, Kwok WC, et al. Significant reduction in hospital admissions for acute exacerbation of chronic
obstructive pulmonary disease in Hong Kong during coronavirus disease 2019 pandemic. Respir Med 2020; 171: 106085
1277. Huh K, Kim YE, Ji W, et al. Decrease in hospital admissions for respiratory diseases during the COVID-19 pandemic: a
nationwide claims study. Thorax 2021; 76(9): 939-41 https://pubmed.ncbi.nlm.nih.gov/33782081.
1278. Tan JY, Conceicao EP, Wee LE, Sim XYJ, Venkatachalam I. COVID-19 public health measures: a reduction in hospital
admissions for COPD exacerbations. Thorax 2021; 76(5): 512-3 https://pubmed.ncbi.nlm.nih.gov/33273024.
1279. Ahmad FB, Anderson RN. The Leading Causes of Death in the US for 2020. JAMA 2021; 325(18): 1829-30
1280. Barnes PJ, Celli BR. Systemic manifestations and comorbidities of COPD. Eur Respir J 2009; 33(5): 1165-85
1281. Sin DD, Anthonisen NR, Soriano JB, Agusti AG. Mortality in COPD: Role of comorbidities. Eur Respir J 2006; 28(6): 1245-
1282. Iversen KK, Kjaergaard J, Akkan D, et al. The prognostic importance of lung function in patients admitted with heart
failure. Eur J Heart Fail 2010; 12(7): 685-91 https://pubmed.ncbi.nlm.nih.gov/20395261.
1283. Almagro P, Soriano JB, Cabrera FJ, et al. Short- and medium-term prognosis in patients hospitalized for COPD
exacerbation: the CODEX index. Chest 2014; 145(5): 972-80 https://pubmed.ncbi.nlm.nih.gov/24077342.
1284. Campo G, Napoli N, Serenelli C, Tebaldi M, Ferrari R. Impact of a recent hospitalization on treatment and prognosis of
ST-segment elevation myocardial infarction. Int J Cardiol 2013; 167(1): 296-7
1285. Fabbri LM, Luppi F, Beghe B, Rabe KF. Complex chronic comorbidities of COPD. Eur Respir J 2008; 31(1): 204-12
1286. Divo M, Cote C, de Torres JP, et al. Comorbidities and risk of mortality in patients with chronic obstructive pulmonary
1287. Krahnke JS, Abraham WT, Adamson PB, et al. Heart failure and respiratory hospitalizations are reduced in patients with
heart failure and chronic obstructive pulmonary disease with the use of an implantable pulmonary artery pressure
monitoring device. J Card Fail 2015; 21(3): 240-9 https://pubmed.ncbi.nlm.nih.gov/25541376.
1288. Yeoh SE, Dewan P, Serenelli M, et al. Effects of mineralocorticoid receptor antagonists in heart failure with reduced
ejection fraction patients with chronic obstructive pulmonary disease in EMPHASIS-HF and RALES. Eur J Heart Fail 2022;
1289. Maclagan LC, Croxford R, Chu A, et al. Quantifying COPD as a risk factor for cardiac disease in a primary prevention
cohort. Eur Respir J 2023; 62(2): https://pubmed.ncbi.nlm.nih.gov/37385658.
TE
1290. Bhatt SP, Dransfield MT. Chronic obstructive pulmonary disease and cardiovascular disease. Transl Res 2013; 162(4):
U
IB
TR
1291. Matamis D, Tsagourias M, Papathanasiou A, et al. Targeting occult heart failure in intensive care unit patients with
IS
acute chronic obstructive pulmonary disease exacerbation: effect on outcome and quality of life. J Crit Care 2014; 29(2):
D
315 e7-14 https://pubmed.ncbi.nlm.nih.gov/24369757.
T
1292. MacDonald MI, Shafuddin E, King PT, Chang CL, Bardin PG, Hancox RJ. Cardiac dysfunction during exacerbations of
O
N
chronic obstructive pulmonary disease. Lancet Respir Med 2016; 4(2): 138-48
O
-D
1293. Masa JF, Utrabo I, Gomez de Terreros J, et al. Noninvasive ventilation for severely acidotic patients in respiratory
L
intermediate care units : Precision medicine in intermediate care units. BMC Pulm Med 2016; 16(1): 97
IA
ER
AT
1294. National Heart Lung & Blood Institute. Assessing Cardiovascular Risk: Systematic Evidence Review from the Risk
Assessment Work Group. 2013. https://www.nhlbi.nih.gov/health-topics/assessing-cardiovascular-risk (accessed Oct
M
T
2021).
H
1295. Dransfield MT, Criner GJ, Halpin DMG, et al. Time-Dependent Risk of Cardiovascular Events Following an Exacerbation in
IG
R
Patients With Chronic Obstructive Pulmonary Disease: Post Hoc Analysis From the IMPACT Trial. J Am Heart Assoc 2022;
PY
11(18): e024350 https://pubmed.ncbi.nlm.nih.gov/36102236.

O
1296. Wang M, Lin EP, Huang LC, Li CY, Shyr Y, Lai CH. Mortality of Cardiovascular Events in Patients With COPD and Preceding
C
Hospitalization for Acute Exacerbation. Chest 2020; 158(3): 973-85 https://pubmed.ncbi.nlm.nih.gov/32184108.

1297. Adamson PD, Anderson JA, Brook RD, et al. Cardiac Troponin I and Cardiovascular Risk in Patients With Chronic
Obstructive Pulmonary Disease. J Am Coll Cardiol 2018; 72(10): 1126-37 https://pubmed.ncbi.nlm.nih.gov/30165984.
1298. Hoiseth AD, Neukamm A, Karlsson BD, Omland T, Brekke PH, Soyseth V. Elevated high-sensitivity cardiac troponin T is
associated with increased mortality after acute exacerbation of chronic obstructive pulmonary disease. Thorax 2011;
1299. Liu X, Chen Z, Li S, Xu S. Association of Chronic Obstructive Pulmonary Disease With Arrhythmia Risks: A Systematic
Review and Meta-Analysis. Front Cardiovasc Med 2021; 8: 732349 https://pubmed.ncbi.nlm.nih.gov/34660734.
1300. Buch P, Friberg J, Scharling H, Lange P, Prescott E. Reduced lung function and risk of atrial fibrillation in the Copenhagen
City Heart Study. Eur Respir J 2003; 21(6): 1012-6 https://pubmed.ncbi.nlm.nih.gov/12797497.
1301. Terzano C, Romani S, Conti V, Paone G, Oriolo F, Vitarelli A. Atrial fibrillation in the acute, hypercapnic exacerbations of
COPD. Eur Rev Med Pharmacol Sci 2014; 18(19): 2908-17 https://pubmed.ncbi.nlm.nih.gov/25339486.
1302. Singh S, Loke YK, Enright P, Furberg CD. Pro-arrhythmic and pro-ischaemic effects of inhaled anticholinergic
medications. Thorax 2013; 68(1): 114-6 https://pubmed.ncbi.nlm.nih.gov/22764216.
1303. Wilchesky M, Ernst P, Brophy JM, Platt RW, Suissa S. Bronchodilator use and the risk of arrhythmia in COPD: part 2:
reassessment in the larger Quebec cohort. Chest 2012; 142(2): 305-11 https://pubmed.ncbi.nlm.nih.gov/22871756.
1304. Salpeter SR, Ormiston TM, Salpeter EE. Cardiovascular effects of beta-agonists in patients with asthma and COPD: a
meta-analysis. Chest 2004; 125(6): 2309-21 https://pubmed.ncbi.nlm.nih.gov/15189956.
1305. Tashkin DP, Fabbri LM. Long-acting beta-agonists in the management of chronic obstructive pulmonary disease: current
and future agents. Respir Res 2010; 11(1): 149 https://pubmed.ncbi.nlm.nih.gov/21034447.
1306. Calverley P, Pauwels R, Vestbo J, et al. Combined salmeterol and fluticasone in the treatment of chronic obstructive
pulmonary disease: a randomised controlled trial. Lancet 2003; 361(9356): 449-56
1307. Szafranski W, Cukier A, Ramirez A, et al. Efficacy and safety of budesonide/formoterol in the management of chronic
1308. Calverley PM, Boonsawat W, Cseke Z, Zhong N, Peterson S, Olsson H. Maintenance therapy with budesonide and
formoterol in chronic obstructive pulmonary disease. Eur Respir J 2003; 22(6): 912-9
1309. Calverley PM, Anderson JA, Celli B, et al. Cardiovascular events in patients with COPD: TORCH study results. Thorax
1310. Wilchesky M, Ernst P, Brophy JM, Platt RW, Suissa S. Bronchodilator use and the risk of arrhythmia in COPD: part 1:
Saskatchewan cohort study. Chest 2012; 142(2): 298-304 https://pubmed.ncbi.nlm.nih.gov/22871755.
1311. January CT, Wann LS, Alpert JS, et al. 2014 AHA/ACC/HRS guideline for the management of patients with atrial
fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice
guidelines and the Heart Rhythm Society. Circulation 2014; 130(23): e199-267
1312. Ohta K, Fukuchi Y, Grouse L, et al. A prospective clinical study of theophylline safety in 3810 elderly with asthma or
COPD. Respir Med 2004; 98(10): 1016-24 https://pubmed.ncbi.nlm.nih.gov/15481279.
1313. Sessler CN, Cohen MD. Cardiac arrhythmias during theophylline toxicity. A prospective continuous electrocardiographic
study. Chest 1990; 98(3): 672-8 https://pubmed.ncbi.nlm.nih.gov/2394145.
1314. Houben-Wilke S, Jorres RA, Bals R, et al. Peripheral Artery Disease and Its Clinical Relevance in Patients with Chronic
Obstructive Pulmonary Disease in the COPD and Systemic Consequences-Comorbidities Network Study. Am J Respir Crit
TE
1315. Abusaid GH, Barbagelata A, Tuero E, Mahmood A, Sharma G. Diastolic dysfunction and COPD exacerbation. Postgrad
U
IB
TR
1316. Lopez-Sanchez M, Munoz-Esquerre M, Huertas D, et al. High Prevalence of Left Ventricle Diastolic Dysfunction in Severe
IS
COPD Associated with A Low Exercise Capacity: A Cross-Sectional Study. PLoS One 2013; 8(6): e68034
D
T
1317. Dransfield MT, McAllister DA, Anderson JA, et al. beta-Blocker Therapy and Clinical Outcomes in Patients with
O
N
Moderate Chronic Obstructive Pulmonary Disease and Heightened Cardiovascular Risk. An Observational Substudy of
O
SUMMIT. Ann Am Thorac Soc 2018; 15(5): 608-14 https://pubmed.ncbi.nlm.nih.gov/29406772.

-D
1318. Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major
L
patterns in GLOBOCAN 2012. Int J Cancer 2015; 136(5): E359-86 https://pubmed.ncbi.nlm.nih.gov/25220842.

IA
ER
1319. Tanoue LT, Tanner NT, Gould MK, Silvestri GA. Lung cancer screening. Am J Respir Crit Care Med 2015; 191(1): 19-33
AT
1320. Lopez-Encuentra A, Astudillo J, Cerezal J, et al. Prognostic value of chronic obstructive pulmonary disease in 2994 cases
M
T
of lung cancer. Eur J Cardiothorac Surg 2005; 27(1): 8-13 https://pubmed.ncbi.nlm.nih.gov/15736303.

H
1321. Mannino DM, Aguayo SM, Petty TL, Redd SC. Low lung function and incident lung cancer in the United States: data
IG
R
From the First National Health and Nutrition Examination Survey follow-up. Arch Intern Med 2003; 163(12): 1475-80
PY
O
1322. de Torres JP, Marin JM, Casanova C, et al. Lung cancer in patients with chronic obstructive pulmonary disease--
C
incidence and predicting factors. Am J Respir Crit Care Med 2011; 184(8): 913-9
1323. Caramori G, Casolari P, Cavallesco GN, Giuffre S, Adcock I, Papi A. Mechanisms involved in lung cancer development in
COPD. Int J Biochem Cell Biol 2011; 43(7): 1030-44 https://pubmed.ncbi.nlm.nih.gov/20951226.
1324. Celli BR. Chronic obstructive pulmonary disease and lung cancer: common pathogenesis, shared clinical challenges. Proc
Am Thorac Soc 2012; 9(2): 74-9 https://pubmed.ncbi.nlm.nih.gov/22550249.
1325. Houghton AM. Mechanistic links between COPD and lung cancer. Nat Rev Cancer 2013; 13(4): 233-45
1326. de Torres JP, Bastarrika G, Wisnivesky JP, et al. Assessing the relationship between lung cancer risk and emphysema
detected on low-dose CT of the chest. Chest 2007; 132(6): 1932-8 https://pubmed.ncbi.nlm.nih.gov/18079226.
1327. Wilson DO, Leader JK, Fuhrman CR, Reilly JJ, Sciurba FC, Weissfeld JL. Quantitative computed tomography analysis,
airflow obstruction, and lung cancer in the pittsburgh lung screening study. J Thorac Oncol 2011; 6(7): 1200-5
1328. Dhariwal J, Tennant RC, Hansell DM, et al. Smoking cessation in COPD causes a transient improvement in spirometry
and decreases micronodules on high-resolution CT imaging. Chest 2014; 145(5): 1006-15
1329. International Early Lung Cancer Action Program I, Henschke CI, Yankelevitz DF, et al. Survival of patients with stage I
lung cancer detected on CT screening. N Engl J Med 2006; 355(17): 1763-71
1330. U. S. Preventive Services Task Force, Krist AH, Davidson KW, et al. Screening for Lung Cancer: US Preventive Services
Task Force Recommendation Statement. JAMA 2021; 325(10): 962-70 https://pubmed.ncbi.nlm.nih.gov/33687470.
1331. Aldrich MC, Mercaldo SF, Sandler KL, Blot WJ, Grogan EL, Blume JD. Evaluation of USPSTF Lung Cancer Screening
Guidelines Among African American Adult Smokers. JAMA Oncol 2019; 5(9): 1318-24
1332. Bandiera FC, Assari S, Livaudais-Toman J, Perez-Stable EJ. Latino and Black smokers in the Health and Retirement Study
are more likely to quit: the role of light smoking. Tob Induc Dis 2016; 14: 23
1333. Haiman CA, Stram DO, Wilkens LR, et al. Ethnic and racial differences in the smoking-related risk of lung cancer. N Engl J
1334. Kaplan RC, Bangdiwala SI, Barnhart JM, et al. Smoking among U.S. Hispanic/Latino adults: the Hispanic community
health study/study of Latinos. Am J Prev Med 2014; 46(5): 496-506 https://pubmed.ncbi.nlm.nih.gov/24745640.
1335. Lin HH, Murray M, Cohen T, Colijn C, Ezzati M. Effects of smoking and solid-fuel use on COPD, lung cancer, and
tuberculosis in China: a time-based, multiple risk factor, modelling study. Lancet 2008; 372(9648): 1473-83
1336. Park HY, Kang D, Shin SH, et al. Chronic obstructive pulmonary disease and lung cancer incidence in never smokers: a
cohort study. Thorax 2020; 75(6): 506-9 https://pubmed.ncbi.nlm.nih.gov/32241883.
1337. Centers for Disease Control and Prevention. Lung Cancer Among People Who Never Smoked, November 2020,
https://www.cdc.gov/cancer/lung/nonsmokers/index.htm [accessed Oct 2023].
1338. de-Torres JP, Casanova C, Marin JM, et al. Exploring the impact of screening with low-dose CT on lung cancer mortality
in mild to moderate COPD patients: a pilot study. Respir Med 2013; 107(5): 702-7
1339. Lam VK, Miller M, Dowling L, Singhal S, Young RP, Cabebe EC. Community low-dose CT lung cancer screening: a
TE
prospective cohort study. Lung 2015; 193(1): 135-9 https://pubmed.ncbi.nlm.nih.gov/25503535.
U
1340. Ashraf H, Saghir Z, Dirksen A, et al. Smoking habits in the randomised Danish Lung Cancer Screening Trial with low-dose
IB
TR
CT: final results after a 5-year screening programme. Thorax 2014; 69(6): 574-9
D
1341. Raymakers AJN, Sadatsafavi M, Sin DD, FitzGerald JM, Marra CA, Lynd LD. Inhaled corticosteroids and the risk of lung
T
cancer in COPD: a population-based cohort study. Eur Respir J 2019; 53(6):

O
N
O
1342. Seijo LM, Soriano JB, Peces-Barba G. New evidence on the chemoprevention of inhaled steroids and the risk of lung
-D
cancer in COPD. Eur Respir J 2019; 53(6): https://pubmed.ncbi.nlm.nih.gov/31167885.

L
1343. Ge F, Feng Y, Huo Z, et al. Inhaled corticosteroids and risk of lung cancer among chronic obstructive pulmonary disease
IA
ER
patients: a comprehensive analysis of nine prospective cohorts. Transl Lung Cancer Res 2021; 10(3): 1266-76
AT
1344. Kiri VA, Fabbri LM, Davis KJ, Soriano JB. Inhaled corticosteroids and risk of lung cancer among COPD patients who quit
M
T
smoking. Respir Med 2009; 103(1): 85-90 https://pubmed.ncbi.nlm.nih.gov/18793832.

H
1345. Lee YM, Kim SJ, Lee JH, Ha E. Inhaled corticosteroids in COPD and the risk of lung cancer. Int J Cancer 2018; 143(9):
IG
R
PY
1346. Parimon T, Chien JW, Bryson CL, McDonell MB, Udris EM, Au DH. Inhaled corticosteroids and risk of lung cancer among
O
C
1347. Sandelin M, Mindus S, Thuresson M, et al. Factors associated with lung cancer in COPD patients. Int J Chron Obstruct
1348. Raymakers AJ, McCormick N, Marra CA, Fitzgerald JM, Sin D, Lynd LD. Do inhaled corticosteroids protect against lung
cancer in patients with COPD? A systematic review. Respirology 2017; 22(1): 61-70
1349. Sorli K, Thorvaldsen SM, Hatlen P. Use of Inhaled Corticosteroids and the Risk of Lung Cancer, the HUNT Study. Lung
1350. Wu MF, Jian ZH, Huang JY, et al. Post-inhaled corticosteroid pulmonary tuberculosis and pneumonia increases lung
cancer in patients with COPD. BMC Cancer 2016; 16(1): 778 https://pubmed.ncbi.nlm.nih.gov/27724847.
1351. O'Brien C, Guest PJ, Hill SL, Stockley RA. Physiological and radiological characterisation of patients diagnosed with
chronic obstructive pulmonary disease in primary care. Thorax 2000; 55(8): 635-42
1352. Jemal A, Ward E, Hao Y, Thun M. Trends in the leading causes of death in the United States, 1970-2002. JAMA 2005;
1353. Mannino DM, Gagnon RC, Petty TL, Lydick E. Obstructive lung disease and low lung function in adults in the United
States: data from the National Health and Nutrition Examination Survey, 1988-1994. Arch Intern Med 2000; 160(11):
1354. Young T, Palta M, Dempsey J, Skatrud J, Weber S, Badr S. The occurrence of sleep-disordered breathing among middle-
aged adults. N Engl J Med 1993; 328(17): 1230-5 https://pubmed.ncbi.nlm.nih.gov/8464434.
1355. Flenley DC. Sleep in chronic obstructive lung disease. Clin Chest Med 1985; 6(4): 651-61
1356. Chaouat A, Weitzenblum E, Krieger J, Ifoundza T, Oswald M, Kessler R. Association of chronic obstructive pulmonary
disease and sleep apnea syndrome. Am J Respir Crit Care Med 1995; 151(1): 82-6
1357. Shepard JW, Jr., Garrison MW, Grither DA, Evans R, Schweitzer PK. Relationship of ventricular ectopy to nocturnal
oxygen desaturation in patients with chronic obstructive pulmonary disease. Am J Med 1985; 78(1): 28-34
1358. Bradley TD, Rutherford R, Grossman RF, et al. Role of daytime hypoxemia in the pathogenesis of right heart failure in
the obstructive sleep apnea syndrome. Am Rev Respir Dis 1985; 131(6): 835-9
1359. Weitzenblum E, Krieger J, Apprill M, et al. Daytime pulmonary hypertension in patients with obstructive sleep apnea
syndrome. Am Rev Respir Dis 1988; 138(2): 345-9 https://pubmed.ncbi.nlm.nih.gov/3143285.
1360. Sterling KL, Pepin JL, Linde-Zwirble W, et al. Impact of Positive Airway Pressure Therapy Adherence on Outcomes in
Patients with Obstructive Sleep Apnea and Chronic Obstructive Pulmonary Disease. Am J Respir Crit Care Med 2022;
1361. Luyster FS, Boudreaux-Kelly MY, Bon JM. Insomnia in chronic obstructive pulmonary disease and associations with
healthcare utilization and costs. Respir Res 2023; 24(1): 93 https://pubmed.ncbi.nlm.nih.gov/36964552.
1362. Hobbins S, Chapple IL, Sapey E, Stockley RA. Is periodontitis a comorbidity of COPD or can associations be explained by
shared risk factors/behaviors? Int J Chron Obstruct Pulmon Dis 2017; 12: 1339-49
1363. Sapey E, Yonel Z, Edgar R, et al. The clinical and inflammatory relationships between periodontitis and chronic
obstructive pulmonary disease. J Clin Periodontol 2020; 47(9): 1040-52 https://pubmed.ncbi.nlm.nih.gov/32567697.
TE
1364. Shen TC, Chang PY, Lin CL, et al. Risk of Periodontal Diseases in Patients With Chronic Obstructive Pulmonary Disease: A
U
Nationwide Population-based Cohort Study. Medicine (Baltimore) 2015; 94(46): e2047
IB
TR
1365. IS
Takahashi T, Muro S, Tanabe N, et al. Relationship between periodontitis-related antibody and frequent exacerbations
D
in chronic obstructive pulmonary disease. PLoS One 2012; 7(7): e40570 https://pubmed.ncbi.nlm.nih.gov/22792372.
T
1366. Apessos I, Voulgaris A, Agrafiotis M, Andreadis D, Steiropoulos P. Effect of periodontal therapy on COPD outcomes: a
O
N
systematic review. BMC Pulm Med 2021; 21(1): 92 https://pubmed.ncbi.nlm.nih.gov/33736634.

O
1367. Zaigham S, Tanash H, Nilsson PM, Muhammad IF. Triglyceride-Glucose Index is a Risk Marker of Incident COPD Events in
-D
Women. Int J Chron Obstruct Pulmon Dis 2022; 17: 1393-401 https://pubmed.ncbi.nlm.nih.gov/35746923.
L
1368. Cebron Lipovec N, Beijers RJ, van den Borst B, Doehner W, Lainscak M, Schols AM. The Prevalence of Metabolic
IA
ER
Syndrome In Chronic Obstructive Pulmonary Disease: A Systematic Review. COPD 2016; 13(3): 399-406
AT
1369. Martinez CH, Okajima Y, Murray S, et al. Impact of self-reported gastroesophageal reflux disease in subjects from
M
T
COPDGene cohort. Respir Res 2014; 15(1): 62 https://pubmed.ncbi.nlm.nih.gov/24894541.

H
1370. Ingebrigtsen TS, Marott JL, Vestbo J, Nordestgaard BG, Hallas J, Lange P. Gastro-esophageal reflux disease and
IG
R
exacerbations in chronic obstructive pulmonary disease. Respirology 2015; 20(1): 101-7

PY
O
1371. Sasaki T, Nakayama K, Yasuda H, et al. A randomized, single-blind study of lansoprazole for the prevention of
C
exacerbations of chronic obstructive pulmonary disease in older patients. J Am Geriatr Soc 2009; 57(8): 1453-7
1372. Baumeler L, Papakonstantinou E, Milenkovic B, et al. Therapy with proton-pump inhibitors for gastroesophageal reflux
disease does not reduce the risk for severe exacerbations in COPD. Respirology 2016; 21(5): 883-90
1373. Benson VS, Mullerova H, Vestbo J, et al. Associations between gastro-oesophageal reflux, its management and
exacerbations of chronic obstructive pulmonary disease. Respir Med 2015; 109(9): 1147-54
1374. Madsen H, Brixen K, Hallas J. Screening, prevention and treatment of osteoporosis in patients with chronic obstructive
pulmonary disease - a population-based database study. Clin Respir J 2010; 4(1): 22-9
1375. Bon J, Fuhrman CR, Weissfeld JL, et al. Radiographic emphysema predicts low bone mineral density in a tobacco-
exposed cohort. Am J Respir Crit Care Med 2011; 183(7): 885-90 https://pubmed.ncbi.nlm.nih.gov/20935108.
1376. Bolton CE, Cannings-John R, Edwards PH, et al. What community measurements can be used to predict bone disease in
patients with COPD? Respir Med 2008; 102(5): 651-7 https://pubmed.ncbi.nlm.nih.gov/18308533.
1377. Bolton CE, Ionescu AA, Shiels KM, et al. Associated loss of fat-free mass and bone mineral density in chronic obstructive
1378. Jaramillo JD, Wilson C, Stinson DS, et al. Reduced Bone Density and Vertebral Fractures in Smokers. Men and COPD
Patients at Increased Risk. Ann Am Thorac Soc 2015; 12(5): 648-56 https://pubmed.ncbi.nlm.nih.gov/25719895.
1379. Jaramillo J, Wilson C, Stinson D, et al. Erratum: reduced bone density and vertebral fractures in smokers. men and COPD
patients at increased risk. Ann Am Thorac Soc 2015; 12(7): 1112 https://pubmed.ncbi.nlm.nih.gov/26203620.
1380. Yohannes AM, Ershler WB. Anemia in COPD: a systematic review of the prevalence, quality of life, and mortality. Respir
Care 2011; 56(5): 644-52 https://pubmed.ncbi.nlm.nih.gov/21276321.
1381. Balasubramanian A, Henderson RJ, Putcha N, et al. Haemoglobin as a biomarker for clinical outcomes in chronic
obstructive pulmonary disease. ERJ Open Res 2021; 7(3): https://pubmed.ncbi.nlm.nih.gov/34322549.
1382. Boutou AK, Karrar S, Hopkinson NS, Polkey MI. Anemia and survival in chronic obstructive pulmonary disease: a
dichotomous rather than a continuous predictor. Respiration 2013; 85(2): 126-31
1383. Chambellan A, Chailleux E, Similowski T, Group AO. Prognostic value of the hematocrit in patients with severe COPD
receiving long-term oxygen therapy. Chest 2005; 128(3): 1201-8 https://pubmed.ncbi.nlm.nih.gov/16162707.
1384. Cote C, Zilberberg MD, Mody SH, Dordelly LJ, Celli B. Haemoglobin level and its clinical impact in a cohort of patients
with COPD. Eur Respir J 2007; 29(5): 923-9 https://pubmed.ncbi.nlm.nih.gov/17251227.
1385. Martinez-Rivera C, Portillo K, Munoz-Ferrer A, et al. Anemia is a mortality predictor in hospitalized patients for COPD
exacerbation. COPD 2012; 9(3): 243-50 https://pubmed.ncbi.nlm.nih.gov/22360381.
1386. Xu Y, Hu T, Ding H, Chen R. Effects of anemia on the survival of patients with chronic obstructive pulmonary disease: a
systematic review and meta-analysis. Expert Rev Respir Med 2020; 14(12): 1267-77
1387. Schneckenpointner R, Jorres RA, Meidenbauer N, Kollert F, Pfeifer M, Budweiser S. The clinical significance of anaemia
and disturbed iron homeostasis in chronic respiratory failure. Int J Clin Pract 2014; 68(1): 130-8
1388. Vasquez A, Logomarsino JV. Anemia in Chronic Obstructive Pulmonary Disease and the Potential Role of Iron Deficiency.
COPD 2016; 13(1): 100-9 https://pubmed.ncbi.nlm.nih.gov/26418826.
TE
1389. Andreas S, Herrmann-Lingen C, Raupach T, et al. Angiotensin II blockers in obstructive pulmonary disease: a randomised
U
controlled trial. Eur Respir J 2006; 27(5): 972-9 https://pubmed.ncbi.nlm.nih.gov/16446313.
IB
TR
1390. Bakris GL, Sauter ER, Hussey JL, Fisher JW, Gaber AO, Winsett R. Effects of theophylline on erythropoietin production in
IS
normal subjects and in patients with erythrocytosis after renal transplantation. N Engl J Med 1990; 323(2): 86-90
D
T
1391. Ferrucci L, Maggio M, Bandinelli S, et al. Low testosterone levels and the risk of anemia in older men and women. Arch
O
N
Intern Med 2006; 166(13): 1380-8 https://pubmed.ncbi.nlm.nih.gov/16832003.

O
1392. Ilan Y, Dranitzki-Elhallel M, Rubinger D, Silver J, Popovtzer MM. Erythrocytosis after renal transplantation. The response
-D
to theophylline treatment. Transplantation 1994; 57(5): 661-4 https://pubmed.ncbi.nlm.nih.gov/8140628.

L
1393. Incalzi RA, Corsonello A, Pedone C, et al. Chronic renal failure: a neglected comorbidity of COPD. Chest 2010; 137(4):
IA
ER
AT
1394. Mrug M, Stopka T, Julian BA, Prchal JF, Prchal JT. Angiotensin II stimulates proliferation of normal early erythroid
progenitors. J Clin Invest 1997; 100(9): 2310-4 https://pubmed.ncbi.nlm.nih.gov/9410909.
M
T
1395. Oren R, Beeri M, Hubert A, Kramer MR, Matzner Y. Effect of theophylline on erythrocytosis in chronic obstructive
H
pulmonary disease. Arch Intern Med 1997; 157(13): 1474-8 https://pubmed.ncbi.nlm.nih.gov/9224226.

IG
R
1396. Similowski T, Agusti A, MacNee W, Schonhofer B. The potential impact of anaemia of chronic disease in COPD. Eur
PY

O
1397. Vlahakos DV, Marathias KP, Madias NE. The role of the renin-angiotensin system in the regulation of erythropoiesis. Am
C
J Kidney Dis 2010; 56(3): 558-65 https://pubmed.ncbi.nlm.nih.gov/20400218.

1398. Ferrari M, Manea L, Anton K, et al. Anemia and hemoglobin serum levels are associated with exercise capacity and
quality of life in chronic obstructive pulmonary disease. BMC Pulm Med 2015; 15: 58
1399. Zhang J, DeMeo DL, Silverman EK, et al. Secondary polycythemia in chronic obstructive pulmonary disease: prevalence
and risk factors. BMC Pulm Med 2021; 21(1): 235 https://pubmed.ncbi.nlm.nih.gov/34261472.
1400. Kent BD, Mitchell PD, McNicholas WT. Hypoxemia in patients with COPD: cause, effects, and disease progression. Int J
1401. Zeng Z, Song Y, He X, et al. Obstructive Sleep Apnea is Associated with an Increased Prevalence of Polycythemia in
Patients with Chronic Obstructive Pulmonary Disease. Int J Chron Obstruct Pulmon Dis 2022; 17: 195-204
1402. Calverley PM, Leggett RJ, McElderry L, Flenley DC. Cigarette smoking and secondary polycythemia in hypoxic cor
pulmonale. Am Rev Respir Dis 1982; 125(5): 507-10 https://pubmed.ncbi.nlm.nih.gov/7081807.
1403. Chambellan A, Coulon S, Cavailles A, Hermine O, Similowski T. [COPD and erythropoiesis: interactions and
consequences]. Rev Mal Respir 2012; 29(2): 213-31 https://pubmed.ncbi.nlm.nih.gov/22405115.
1404. Nakamura A, Kasamatsu N, Hashizume I, et al. Effects of hemoglobin on pulmonary arterial pressure and pulmonary
vascular resistance in patients with chronic emphysema. Respiration 2000; 67(5): 502-6
1405. Samareh Fekri M, Torabi M, Azizi Shoul S, Mirzaee M. Prevalence and predictors associated with severe pulmonary
hypertension in COPD. Am J Emerg Med 2018; 36(2): 277-80 https://pubmed.ncbi.nlm.nih.gov/28797558.
1406. Guo L, Chughtai AR, Jiang H, et al. Relationship between polycythemia and in-hospital mortality in chronic obstructive
pulmonary disease patients with low-risk pulmonary embolism. J Thorac Dis 2016; 8(11): 3119-31
1407. Xu L, Chen Y, Xie Z, et al. High hemoglobin is associated with increased in-hospital death in patients with chronic
obstructive pulmonary disease and chronic kidney disease: a retrospective multicenter population-based study. BMC
Pulm Med 2019; 19(1): 174 https://pubmed.ncbi.nlm.nih.gov/31533673.
1408. Kunik ME, Roundy K, Veazey C, et al. Surprisingly high prevalence of anxiety and depression in chronic breathing
disorders. Chest 2005; 127(4): 1205-11 https://pubmed.ncbi.nlm.nih.gov/15821196.
1409. Ng TP, Niti M, Tan WC, Cao Z, Ong KC, Eng P. Depressive symptoms and chronic obstructive pulmonary disease: effect
on mortality, hospital readmission, symptom burden, functional status, and quality of life. Arch Intern Med 2007;
1410. Maurer J, Rebbapragada V, Borson S, et al. Anxiety and depression in COPD: current understanding, unanswered
questions, and research needs. Chest 2008; 134(4 Suppl): 43S-56S https://pubmed.ncbi.nlm.nih.gov/18842932.
1411. Eisner MD, Blanc PD, Yelin EH, et al. Influence of anxiety on health outcomes in COPD. Thorax 2010; 65(3): 229-34
1412. Bolton CE, Bevan-Smith EF, Blakey JD, et al. British Thoracic Society guideline on pulmonary rehabilitation in adults.
Thorax 2013; 68 Suppl 2: ii1-30 https://pubmed.ncbi.nlm.nih.gov/23880483.
1413. Coventry PA, Bower P, Keyworth C, et al. The effect of complex interventions on depression and anxiety in chronic
obstructive pulmonary disease: systematic review and meta-analysis. PLoS One 2013; 8(4): e60532
1414. Himelhoch S, Lehman A, Kreyenbuhl J, Daumit G, Brown C, Dixon L. Prevalence of chronic obstructive pulmonary
disease among those with serious mental illness. Am J Psychiatry 2004; 161(12): 2317-9
TE
1415. Jones DR, Macias C, Barreira PJ, Fisher WH, Hargreaves WA, Harding CM. Prevalence, severity, and co-occurrence of
U
chronic physical health problems of persons with serious mental illness. Psychiatr Serv 2004; 55(11): 1250-7
IB
TR
1416. IS
Sampaio MS, Vieira WA, Bernardino IM, Herval AM, Flores-Mir C, Paranhos LR. Chronic obstructive pulmonary disease
D
as a risk factor for suicide: A systematic review and meta-analysis. Respir Med 2019; 151: 11-8
T
O
N
1417. Siraj RA, McKeever TM, Gibson JE, Bolton CE. Incidence of depression and antidepressant prescription in patients with
O
COPD: A large UK population-based cohort study. Respir Med 2022; 196: 106804
-D
L
1418. van Beers M, Janssen DJA, Gosker HR, Schols A. Cognitive impairment in chronic obstructive pulmonary disease: disease
IA
ER
burden, determinants and possible future interventions. Expert Rev Respir Med 2018; 12(12): 1061-74
AT
1419. Yohannes AM, Chen W, Moga AM, Leroi I, Connolly MJ. Cognitive Impairment in Chronic Obstructive Pulmonary Disease
M
T
and Chronic Heart Failure: A Systematic Review and Meta-analysis of Observational Studies. J Am Med Dir Assoc 2017;
H
18(5): 451 e1- e11 https://pubmed.ncbi.nlm.nih.gov/28292570.

IG
R
1420. Pierobon A, Ranzini L, Torlaschi V, et al. Screening for neuropsychological impairment in COPD patients undergoing
PY
rehabilitation. PLoS One 2018; 13(8): e0199736 https://pubmed.ncbi.nlm.nih.gov/30067787.

O
1421. Cleutjens FA, Franssen FM, Spruit MA, et al. Domain-specific cognitive impairment in patients with COPD and control
C
subjects. Int J Chron Obstruct Pulmon Dis 2017; 12: 1-11 https://pubmed.ncbi.nlm.nih.gov/28031706.
1422. Cleutjens F, Spruit MA, Ponds R, et al. Cognitive impairment and clinical characteristics in patients with chronic
obstructive pulmonary disease. Chron Respir Dis 2018; 15(2): 91-102 https://pubmed.ncbi.nlm.nih.gov/28553720.
1423. Rusanen M, Ngandu T, Laatikainen T, Tuomilehto J, Soininen H, Kivipelto M. Chronic obstructive pulmonary disease and
asthma and the risk of mild cognitive impairment and dementia: a population based CAIDE study. Curr Alzheimer Res
1424. Xie F, Xie L. COPD and the risk of mild cognitive impairment and dementia: a cohort study based on the Chinese
Longitudinal Health Longevity Survey. Int J Chron Obstruct Pulmon Dis 2019; 14: 403-8
1425. Baird C, Lovell J, Johnson M, Shiell K, Ibrahim JE. The impact of cognitive impairment on self-management in chronic
obstructive pulmonary disease: A systematic review. Respir Med 2017; 129: 130-9
1426. Martinez CH, Richardson CR, Han MK, Cigolle CT. Chronic obstructive pulmonary disease, cognitive impairment, and
development of disability: the health and retirement study. Ann Am Thorac Soc 2014; 11(9): 1362-70
1427. von Siemens SM, Perneczky R, Vogelmeier CF, et al. The association of cognitive functioning as measured by the
DemTect with functional and clinical characteristics of COPD: results from the COSYCONET cohort. Respir Res 2019;
1428. Schure MB, Borson S, Nguyen HQ, et al. Associations of cognition with physical functioning and health-related quality of
life among COPD patients. Respir Med 2016; 114: 46-52 https://pubmed.ncbi.nlm.nih.gov/27109810.
1429. Chang SS, Chen S, McAvay GJ, Tinetti ME. Effect of coexisting chronic obstructive pulmonary disease and cognitive
impairment on health outcomes in older adults. J Am Geriatr Soc 2012; 60(10): 1839-46
1430. Dodd JW, Charlton RA, van den Broek MD, Jones PW. Cognitive dysfunction in patients hospitalized with acute
exacerbation of COPD. Chest 2013; 144(1): 119-27 https://pubmed.ncbi.nlm.nih.gov/23349026.
1431. Fried LP, Tangen CM, Walston J, et al. Frailty in older adults: evidence for a phenotype. J Gerontol A Biol Sci Med Sci
2001; 56(3): M146-56 https://pubmed.ncbi.nlm.nih.gov/11253156.
1432. Roberts MH, Mapel DW, Ganvir N, Dodd MA. Frailty Among Older Individuals with and without COPD: A Cohort Study of
Prevalence and Association with Adverse Outcomes. Int J Chron Obstruct Pulmon Dis 2022; 17: 701-17
1433. Xu J, Xu W, Qiu Y, Gong D, Man C, Fan Y. Association of Prefrailty and Frailty With All-Cause Mortality, Acute
Exacerbation, and Hospitalization in Patients With Chronic Obstructive Pulmonary Disease: A Meta-Analysis. J Am Med
Dir Assoc 2023; 24(7): 937-44.e3 https://pubmed.ncbi.nlm.nih.gov/37150209.
1434. Osadnik CR, Brighton LJ, Burtin C, et al. European Respiratory Society statement on frailty in adults with chronic lung
disease. Eur Respir J 2023; 62(2): https://pubmed.ncbi.nlm.nih.gov/37414420.
1435. Mahase E. Covid-19: Increased demand for steroid inhalers causes "distressing" shortages. BMJ 2020; 369: m1393
1436. Hoffmann M, Kleine-Weber H, Schroeder S, et al. SARS-CoV-2 Cell Entry Depends on ACE2 and TMPRSS2 and Is Blocked
by a Clinically Proven Protease Inhibitor. Cell 2020; 181(2): 271-80 e8 https://pubmed.ncbi.nlm.nih.gov/32142651.
1437. Maes T, Bracke K, Brusselle GG. COVID-19, Asthma, and Inhaled Corticosteroids: Another Beneficial Effect of Inhaled
Corticosteroids? Am J Respir Crit Care Med 2020; 202(1): 8-10 https://pubmed.ncbi.nlm.nih.gov/32437628.
1438. Leung JM, Yang CX, Tam A, et al. ACE-2 expression in the small airway epithelia of smokers and COPD patients:
implications for COVID-19. Eur Respir J 2020; 55(5): epub 2020/04/10 https://pubmed.ncbi.nlm.nih.gov/32269089.
TE
1439. Higham A, Mathioudakis A, Vestbo J, Singh D. COVID-19 and COPD: a narrative review of the basic science and clinical
U
outcomes. Eur Respir Rev 2020; 29(158): 200199 https://pubmed.ncbi.nlm.nih.gov/33153991.
IB
TR
1440. Higham A, Singh D. Increased ACE2 Expression in Bronchial Epithelium of COPD Patients who are Overweight. Obesity
IS
(Silver Spring) 2020; 28(9): 1586-9 https://pubmed.ncbi.nlm.nih.gov/32428380.
D
1441. Watson A, Oberg L, Angermann B, et al. Dysregulation of COVID-19 related gene expression in the COPD lung. Respir
T
Res 2021; 22(1): 164 https://pubmed.ncbi.nlm.nih.gov/34051791.

O
N
1442. Peters MC, Sajuthi S, Deford P, et al. COVID-19-related Genes in Sputum Cells in Asthma. Relationship to Demographic
O
Features and Corticosteroids. Am J Respir Crit Care Med 2020; 202(1): 83-90
-D
L
1443. Jacobs M, Van Eeckhoutte HP, Wijnant SRA, et al. Increased expression of ACE2, the SARS-CoV-2 entry receptor, in
IA
ER
alveolar and bronchial epithelium of smokers and COPD subjects. Eur Respir J 2020; 56(2):
AT
1444. Milne S, Li X, Yang CX, et al. Inhaled corticosteroids downregulate SARS-CoV-2-related genes in COPD: results from a
M
T
randomised controlled trial. Eur Respir J 2021; 58(1): https://pubmed.ncbi.nlm.nih.gov/33795322.

H
1445. Halpin DMG, Rabe AP, Loke WJ, et al. Epidemiology, Healthcare Resource Utilization, and Mortality of Asthma and
IG
R
COPD in COVID-19: A Systematic Literature Review and Meta-Analyses. J Asthma Allergy 2022; 15: 811-25
PY
O
1446. Rentsch CT, Kidwai-Khan F, Tate JP, et al. Covid-19 Testing, Hospital Admission, and Intensive Care Among 2,026,227
C
United States Veterans Aged 54-75 Years. medRxiv 2020: 2020.04.09.20059964

1447. de Lusignan S, Dorward J, Correa A, et al. Risk factors for SARS-CoV-2 among patients in the Oxford Royal College of
General Practitioners Research and Surveillance Centre primary care network: a cross-sectional study. Lancet Infect Dis
1448. Hippisley-Cox J, Young D, Coupland C, et al. Risk of severe COVID-19 disease with ACE inhibitors and angiotensin
receptor blockers: cohort study including 8.3 million people. Heart 2020; 106(19): 1503-11
1449. Leung JM, Niikura M, Yang CWT, Sin DD. COVID-19 and COPD. Eur Respir J 2020; 56(2):
1450. Halpin DMG, Faner R, Sibila O, Badia JR, Agusti A. Do chronic respiratory diseases or their treatment affect the risk of
SARS-CoV-2 infection? Lancet Respir Med 2020; 8(5): 436-8 https://pubmed.ncbi.nlm.nih.gov/32251625.
1451. Beltramo G, Cottenet J, Mariet AS, et al. Chronic respiratory diseases are predictors of severe outcome in COVID-19
hospitalised patients: a nationwide study. Eur Respir J 2021; 58(6): https://pubmed.ncbi.nlm.nih.gov/34016619.
1452. Docherty AB, Harrison EM, Green CA, et al. Features of 20 133 UK patients in hospital with covid-19 using the ISARIC
WHO Clinical Characterisation Protocol: prospective observational cohort study. BMJ 2020; 369: m1985
1453. Lippi G, Henry BM. Chronic obstructive pulmonary disease is associated with severe coronavirus disease 2019 (COVID-
19). Respir Med 2020; 167: 105941 https://pubmed.ncbi.nlm.nih.gov/32421537.
1454. Grasselli G, Greco M, Zanella A, et al. Risk Factors Associated With Mortality Among Patients With COVID-19 in
Intensive Care Units in Lombardy, Italy. JAMA Intern Med 2020; 180(10): 1345-55
1455. Singh AK, Gillies CL, Singh R, et al. Prevalence of co-morbidities and their association with mortality in patients with
COVID-19: A systematic review and meta-analysis. Diabetes Obes Metab 2020; 22(10): 1915-24
1456. Aveyard P, Gao M, Lindson N, et al. Association between pre-existing respiratory disease and its treatment, and severe
COVID-19: a population cohort study. Lancet Respir Med 2021; 9(8): 909-23
1457. Bloom CI, Drake TM, Docherty AB, et al. Risk of adverse outcomes in patients with underlying respiratory conditions
admitted to hospital with COVID-19: a national, multicentre prospective cohort study using the ISARIC WHO Clinical
Characterisation Protocol UK. Lancet Respir Med 2021; 9(7): 699-711 https://pubmed.ncbi.nlm.nih.gov/33676593.
1458. Reyes FM, Hache-Marliere M, Karamanis D, et al. Assessment of the Association of COPD and Asthma with In-Hospital
Mortality in Patients with COVID-19. A Systematic Review, Meta-Analysis, and Meta-Regression Analysis. J Clin Med
1459. Petrilli CM, Jones SA, Yang J, et al. Factors associated with hospital admission and critical illness among 5279 people
with coronavirus disease 2019 in New York City: prospective cohort study. BMJ 2020; 369: m1966
1460. Gupta S, Hayek SS, Wang W, et al. Factors Associated With Death in Critically Ill Patients With Coronavirus Disease 2019
in the US. JAMA Intern Med 2020; 180(11): 1436-47 https://pubmed.ncbi.nlm.nih.gov/32667668.
1461. Calmes D, Graff S, Maes N, et al. Asthma and COPD Are Not Risk Factors for ICU Stay and Death in Case of SARS-CoV2
Infection. J Allergy Clin Immunol Pract 2021; 9(1): 160-9 https://pubmed.ncbi.nlm.nih.gov/33038592.
1462. Stridsman C, Vanfleteren L, Konradsen JR, et al. Predictors of severe COVID-19 in a registry-based Swedish cohort of
TE
patients with COPD. Eur Respir J 2021; 58(5): https://pubmed.ncbi.nlm.nih.gov/34413151.
U
1463. Elbeddini A, Tayefehchamani Y. Amid COVID-19 pandemic: Challenges with access to care for COPD patients. Res Social
IB
TR
Adm Pharm 2021; 17(1): 1934-7 https://pubmed.ncbi.nlm.nih.gov/32513515.
1464. IS
Press VG, Gershon AS, Sciurba FC, Blagev DP. Concerns About Coronavirus Disease-Related Collateral Damage for
D
Patients With COPD. Chest 2020; 158(3): 866-8 https://pubmed.ncbi.nlm.nih.gov/32473947.
T
1465. Berghaus TM, Karschnia P, Haberl S, Schwaiblmair M. Disproportionate decline in admissions for exacerbated COPD
O
N
during the COVID-19 pandemic. Respir Med 2022; 191: 106120 https://pubmed.ncbi.nlm.nih.gov/32839072.
O
1466. Jones R, Davis A, Stanley B, et al. Risk Predictors and Symptom Features of Long COVID Within a Broad Primary Care
-D
Patient Population Including Both Tested and Untested Patients. Pragmat Obs Res 2021; 12: 93-104
L
IA
ER
1467. Munblit D, Bobkova P, Spiridonova E, et al. Incidence and risk factors for persistent symptoms in adults previously
AT
hospitalized for COVID-19. Clin Exp Allergy 2021; 51(9): 1107-20 https://pubmed.ncbi.nlm.nih.gov/34351016.
1468. World Health Organization. Smoking and COVID-19: Scientific Brief 30 June 2020; online article available here:
M
T
https://www.who.int/news-room/commentaries/detail/smoking-and-covid-19 [accessed Oct 2023].

H
1469. Patanavanich R, Glantz SA. Smoking Is Associated With COVID-19 Progression: A Meta-analysis. Nicotine Tob Res 2020;
IG
R

PY
1470. Fang Y, Zhang H, Xie J, et al. Sensitivity of Chest CT for COVID-19: Comparison to RT-PCR. Radiology 2020; 296(2): E115-
O
E7 https://pubmed.ncbi.nlm.nih.gov/32073353.
C
1471. Yue H, Zhang M, Xing L, et al. The epidemiology and clinical characteristics of co-infection of SARS-CoV-2 and influenza
viruses in patients during COVID-19 outbreak. J Med Virol 2020; 92(11): 2870-3
1472. Gousseff M, Penot P, Gallay L, et al. Clinical recurrences of COVID-19 symptoms after recovery: Viral relapse, reinfection
or inflammatory rebound? J Infect 2020; 81(5): 816-46 https://pubmed.ncbi.nlm.nih.gov/32619697.
1473. Mammen MJ, Sethi S. COPD and the microbiome. Respirology 2016; 21(4): 590-9
1474. Khatiwada S, Subedi A. Lung microbiome and coronavirus disease 2019 (COVID-19): Possible link and implications. Hum
Microb J 2020; 17: 100073 https://pubmed.ncbi.nlm.nih.gov/32835135.
1475. European Respiratory Society. Recommendation from ERS Group 9.1 (Respiratory function technologists /Scientists).
Lung function testing during COVID-19 pandemic and beyond; online document available here:
https://ers.app.box.com/s/zs1uu88wy51monr0ewd990itoz4tsn2h [accessed Oct 2023].
1476. American Thoracic Society. Pulmonary Function Laboratories: Advice Regarding COVID-19; online article available here:
https://www.thoracic.org/professionals/clinical-resources/disease-related-resources/pulmonary-function-
laboratories.php [accessed Oct 2023].
1477. Borg BM, Osadnik C, Adam K, et al. Pulmonary function testing during SARS-CoV-2: An ANZSRS/TSANZ position
statement. Respirology 2022; 27(9): 688-719 https://pubmed.ncbi.nlm.nih.gov/35981737.
1478. British Thoracic Society. Guidance for the resumption and continuation of urgent and elective outpatient respiratory
services. Available online at: https://www.brit-thoracic.org.uk/covid-19/covid-19-resumption-and-continuation-of-
respiratory-services [accessed Oct 2023].
1479. Wilson KC, Kaminsky DA, Michaud G, et al. Restoring Pulmonary and Sleep Services as the COVID-19 Pandemic Lessens.
From an Association of Pulmonary, Critical Care, and Sleep Division Directors and American Thoracic Society-
coordinated Task Force. Ann Am Thorac Soc 2020; 17(11): 1343-51 https://pubmed.ncbi.nlm.nih.gov/32663071.
1480. Jithoo A, Enright PL, Burney P, et al. Case-finding options for COPD: results from the Burden of Obstructive Lung Disease
study. Eur Respir J 2013; 41(3): 548-55 https://pubmed.ncbi.nlm.nih.gov/22743668.
1481. Mahboub B, Alzaabi A, Soriano JB, et al. Case-finding of chronic obstructive pulmonary disease with questionnaire, peak
flow measurements and spirometry: a cross-sectional study. BMC Res Notes 2014; 7: 241
1482. Perez-Padilla R, Vollmer WM, Vazquez-Garcia JC, et al. Can a normal peak expiratory flow exclude severe chronic
obstructive pulmonary disease? Int J Tuberc Lung Dis 2009; 13(3): 387-93 https://pubmed.ncbi.nlm.nih.gov/19275802.
1483. Aggarwal AN, Gupta D, Jindal SK. The relationship between FEV1 and peak expiratory flow in patients with airways
obstruction is poor. Chest 2006; 130(5): 1454-61 https://pubmed.ncbi.nlm.nih.gov/17099024.
1484. Pothirat C, Chaiwong W, Phetsuk N, et al. Peak expiratory flow rate as a surrogate for forced expiratory volume in 1
second in COPD severity classification in Thailand. Int J Chron Obstruct Pulmon Dis 2015; 10: 1213-8
1485. Llewellin P, Sawyer G, Lewis S, et al. The relationship between FEV1 and PEF in the assessment of the severity of
airways obstruction. Respirology 2002; 7(4): 333-7.
1486. Carpenter DM, Jurdi R, Roberts CA, Hernandez M, Horne R, Chan A. A Review of Portable Electronic Spirometers:
Implications for Asthma Self-Management. Curr Allergy Asthma Rep 2018; 18(10): 53
1487. Ramos Hernandez C, Nunez Fernandez M, Pallares Sanmartin A, et al. Validation of the portable Air-Smart Spirometer.
PLoS One 2018; 13(2): e0192789 https://pubmed.ncbi.nlm.nih.gov/29474502.
1488. Wahidi MM, Lamb C, Murgu S, et al. American Association for Bronchology and Interventional Pulmonology (AABIP)
TE
Statement on the Use of Bronchoscopy and Respiratory Specimen Collection in Patients With Suspected or Confirmed
U
COVID-19 Infection. J Bronchology Interv Pulmonol 2020; 27(4): e52-e4 https://pubmed.ncbi.nlm.nih.gov/32195687.
IB
TR
1489. Wahidi MM, Shojaee S, Lamb CR, et al. The Use of Bronchoscopy During the Coronavirus Disease 2019 Pandemic:
IS
CHEST/AABIP Guideline and Expert Panel Report. Chest 2020; 158(3): 1268-81
D
T
1490. Wong HYF, Lam HYS, Fong AH, et al. Frequency and Distribution of Chest Radiographic Findings in Patients Positive for
O
N
COVID-19. Radiology 2020; 296(2): E72-E8 https://pubmed.ncbi.nlm.nih.gov/32216717.

O
1491. Rubin GD, Ryerson CJ, Haramati LB, et al. The Role of Chest Imaging in Patient Management during the COVID-19
-D
Pandemic: A Multinational Consensus Statement from the Fleischner Society. Radiology 2020; 296(1): 172-80
L
IA
ER
1492. Rodriguez-Morales AJ, Cardona-Ospina JA, Gutierrez-Ocampo E, et al. Clinical, laboratory and imaging features of
AT
COVID-19: A systematic review and meta-analysis. Travel Med Infect Dis 2020; 34: 101623
M
T
1493. Kulkarni S, Down B, Jha S. Point-of-care lung ultrasound in intensive care during the COVID-19 pandemic. Clin Radiol
H
2020; 75(9): 710 e1- e4 https://pubmed.ncbi.nlm.nih.gov/32405081.

IG
R
1494. Inui S, Fujikawa A, Jitsu M, et al. Chest CT Findings in Cases from the Cruise Ship Diamond Princess with Coronavirus
PY
Disease (COVID-19). Radiol Cardiothorac Imaging 2020; 2(2): e200110 https://pubmed.ncbi.nlm.nih.gov/33778566.

O
1495. Salehi S, Abedi A, Balakrishnan S, Gholamrezanezhad A. Coronavirus Disease 2019 (COVID-19): A Systematic Review of
C
Imaging Findings in 919 Patients. AJR Am J Roentgenol 2020; 215(1): 87-93 https://pubmed.ncbi.nlm.nih.gov/32174129.
1496. Wu F, Zhou Y, Wang Z, et al. Clinical characteristics of COVID-19 infection in chronic obstructive pulmonary disease: a
multicenter, retrospective, observational study. J Thorac Dis 2020; 12(5): 1811-23
1497. Tittaferrante S, Gupta R, Kim V, Temple University C-RG. Thoracic Computed Tomography Features of Coronavirus
Disease 2019 Patients with Emphysema. Chronic Obstr Pulm Dis 2020; 7(3): 290-6
1498. Mossa-Basha M, Meltzer CC, Kim DC, Tuite MJ, Kolli KP, Tan BS. Radiology Department Preparedness for COVID-19:
Radiology Scientific Expert Review Panel. Radiology 2020; 296(2): E106-E12
1499. Han H, Yang L, Liu R, et al. Prominent changes in blood coagulation of patients with SARS-CoV-2 infection. Clin Chem Lab
1500. Driggin E, Madhavan MV, Bikdeli B, et al. Cardiovascular Considerations for Patients, Health Care Workers, and Health
Systems During the COVID-19 Pandemic. J Am Coll Cardiol 2020; 75(18): 2352-71
1501. Guan WJ, Ni ZY, Hu Y, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med 2020; 382(18):
1502. Tang N, Bai H, Chen X, Gong J, Li D, Sun Z. Anticoagulant treatment is associated with decreased mortality in severe
coronavirus disease 2019 patients with coagulopathy. J Thromb Haemost 2020; 18(5): 1094-9
1503. Llitjos JF, Leclerc M, Chochois C, et al. High incidence of venous thromboembolic events in anticoagulated severe
COVID-19 patients. J Thromb Haemost 2020; 18(7): 1743-6 https://pubmed.ncbi.nlm.nih.gov/32320517.
1504. Helms J, Tacquard C, Severac F, et al. High risk of thrombosis in patients with severe SARS-CoV-2 infection: a
multicenter prospective cohort study. Intensive Care Med 2020; 46(6): 1089-98
1505. Talic S, Shah S, Wild H, et al. Effectiveness of public health measures in reducing the incidence of covid-19, SARS-CoV-2
transmission, and covid-19 mortality: systematic review and meta-analysis. BMJ 2021; 375: e068302
1506. Esposito S, Principi N, Leung CC, Migliori GB. Universal use of face masks for success against COVID-19: evidence and
implications for prevention policies. Eur Respir J 2020; 55(6): 2001260 https://pubmed.ncbi.nlm.nih.gov/32350103.
1507. Long Y, Hu T, Liu L, et al. Effectiveness of N95 respirators versus surgical masks against influenza: A systematic review
and meta-analysis. J Evid Based Med 2020; 13(2): 93-101 https://pubmed.ncbi.nlm.nih.gov/32167245.
1508. American College of Chest Physicians, American Lung Association, American Thoracic Society, COPD Foundation. Joint
Statement on Importance of Patients with Chronic Lung Disease Wearing Facial Coverings During COVID-19 Pandemic
[accessed Oct 2023]. https://www.chestnet.org/News/Press-Releases/2020/07/Joint-Statement-on-Importance-of-
Facial-Coverings.
1509. Kyung SY, Kim Y, Hwang H, Park JW, Jeong SH. Risks of N95 Face Mask Use in Subjects With COPD. Respir Care 2020;
1510. Samannan R, Holt G, Calderon-Candelario R, Mirsaeidi M, Campos M. Effect of Face Masks on Gas Exchange in Healthy
Persons and Patients with Chronic Obstructive Pulmonary Disease. Ann Am Thorac Soc 2021; 18(3): 541-4
1511. Hopkins SR, Dominelli PB, Davis CK, et al. Face Masks and the Cardiorespiratory Response to Physical Activity in Health
and Disease. Ann Am Thorac Soc 2021; 18(3): 399-407 https://pubmed.ncbi.nlm.nih.gov/33196294.
TE
1512. Perencevich EN, Diekema DJ, Edmond MB. Moving Personal Protective Equipment Into the Community: Face Shields
U
and Containment of COVID-19. JAMA 2020; 323(22): 2252-3
IB
TR
1513. Ergan B, Akgun M, Pacilli AMG, Nava S. Should I stay or should I go? COPD and air travel. Eur Respir Rev 2018; 27(148):
180030 https://pubmed.ncbi.nlm.nih.gov/29898904. IS
D
1514. Tran K, Cimon K, Severn M, Pessoa-Silva CL, Conly J. Aerosol generating procedures and risk of transmission of acute
T
respiratory infections to healthcare workers: a systematic review. PLoS One 2012; 7(4): e35797
O
N
O
1515. Neufeld Z, Khataee H, Czirok A. Targeted adaptive isolation strategy for COVID-19 pandemic. Infect Dis Model 2020; 5:
-D
L
1516. SSHAP. Considerations and principles for shielding people at high risk of severe outcomes from COVID-19 (April 2020).
IA
ER
Online article available here: https://www.ids.ac.uk/publications/considerations-and-principles-for-shielding-people-at-

AT
high-risk-of-severe-outcomes-from-covid-19-april-2020/ [accessed Oct 2023].

1517. Tal-Singer R, Crapo JD. COPD at the Time of COVID-19: A COPD Foundation Perspective. Chronic Obstr Pulm Dis 2020;
M
T

H
1518. Tenforde MW, Kim SS, Lindsell CJ, et al. Symptom Duration and Risk Factors for Delayed Return to Usual Health Among
IG
R
Outpatients with COVID-19 in a Multistate Health Care Systems Network - United States, March-June 2020. MMWR
PY
Morb Mortal Wkly Rep 2020; 69(30): 993-8 https://pubmed.ncbi.nlm.nih.gov/32730238.

O
1519. Greenhalgh T, Knight M, A'Court C, Buxton M, Husain L. Management of post-acute covid-19 in primary care. BMJ 2020;
C
370: m3026 https://pubmed.ncbi.nlm.nih.gov/32784198.

1520. Carfi A, Bernabei R, Landi F, Gemelli Against C-P-ACSG. Persistent Symptoms in Patients After Acute COVID-19. JAMA
1521. Singanayagam A, Glanville N, Girkin JL, et al. Corticosteroid suppression of antiviral immunity increases bacterial loads
and mucus production in COPD exacerbations. Nat Commun 2018; 9(1): 2229
1522. Skevaki CL, Christodoulou I, Spyridaki IS, et al. Budesonide and formoterol inhibit inflammatory mediator production by
bronchial epithelial cells infected with rhinovirus. Clin Exp Allergy 2009; 39(11): 1700-10
1523. Thomas BJ, Porritt RA, Hertzog PJ, Bardin PG, Tate MD. Glucocorticosteroids enhance replication of respiratory viruses:
effect of adjuvant interferon. Sci Rep 2014; 4: 7176 https://pubmed.ncbi.nlm.nih.gov/25417801.
1524. Yamaya M, Nishimura H, Deng X, et al. Inhibitory effects of glycopyrronium, formoterol, and budesonide on coronavirus
HCoV-229E replication and cytokine production by primary cultures of human nasal and tracheal epithelial cells. Respir
Investig 2020; 58(3): 155-68 https://pubmed.ncbi.nlm.nih.gov/32094077.
1525. Halpin DMG, Singh D, Hadfield RM. Inhaled corticosteroids and COVID-19: a systematic review and clinical perspective.
Eur Respir J 2020; 55(5): 2001009 https://pubmed.ncbi.nlm.nih.gov/32341100.
1526. Schultze A, Walker AJ, MacKenna B, et al. Inhaled corticosteroid use and risk COVID-19 related death among 966,461
patients with COPD or asthma: an OpenSAFELY analysis. Lancet Respir Med 2020:
1527. Singh D, Halpin DMG. Inhaled corticosteroids and COVID-19-related mortality: confounding or clarifying? Lancet Respir
1528. Griesel M, Wagner C, Mikolajewska A, et al. Inhaled corticosteroids for the treatment of COVID-19. Cochrane Database
1529. O'Neil CA, Li J, Leavey A, et al. Characterization of Aerosols Generated During Patient Care Activities. Clin Infect Dis
1530. Simonds AK, Hanak A, Chatwin M, et al. Evaluation of droplet dispersion during non-invasive ventilation, oxygen
therapy, nebuliser treatment and chest physiotherapy in clinical practice: implications for management of pandemic
influenza and other airborne infections. Health Technol Assess 2010; 14(46): 131-72
1531. van Doremalen N, Bushmaker T, Morris DH, et al. Aerosol and Surface Stability of SARS-CoV-2 as Compared with SARS-
CoV-1. N Engl J Med 2020; 382(16): 1564-7 https://pubmed.ncbi.nlm.nih.gov/32182409.
1532. Heinzerling A, Stuckey MJ, Scheuer T, et al. Transmission of COVID-19 to Health Care Personnel During Exposures to a
Hospitalized Patient - Solano County, California, February 2020. MMWR Morb Mortal Wkly Rep 2020; 69(15): 472-6
1533. Tashkin DP, Barjaktarevic IZ. Nebulized Treatments and the Possible Risk of Coronavirus Transmission: Where Is the
Evidence? Chronic Obstr Pulm Dis 2020; 7(3): 136-8 https://pubmed.ncbi.nlm.nih.gov/32413251.
1534. Respiratory Care Committee of Chinese Thoracic S. [Expert consensus on preventing nosocomial transmission during
respiratory care for critically ill patients infected by 2019 novel coronavirus pneumonia]. Zhonghua Jie He He Hu Xi Za
Zhi 2020; 43(4): 288-96 https://pubmed.ncbi.nlm.nih.gov/32294813.
1535. Demeyer H, Louvaris Z, Frei A, et al. Physical activity is increased by a 12-week semiautomated telecoaching programme
in patients with COPD: a multicentre randomised controlled trial. Thorax 2017; 72(5): 415-23
1536. American Thoracic Society. Assembly on Pulmonary Rehabilitation. Guidance for re-opening pulmonary rehabilitation
programs, online document [accessed Oct 2023].
TE
https://www.thoracic.org/members/assemblies/assemblies/pr/resources/ats-pr-assembly-re-opening-pr-document-
U
final.pdf.
IB
TR
1537. Nield M, Hoo GW. Real-time telehealth for COPD self-management using Skype. COPD 2012; 9(6): 611-9
D
1538. Recovery Collaborative Group, Horby P, Lim WS, et al. Dexamethasone in Hospitalized Patients with Covid-19. N Engl J
T

O
N
1539. World Health Organization. Therapeutics and COVID-19: Living guideline. Available online at:
O
https://www.who.int/publications/i/item/WHO-2019-nCoV-therapeutics-2022.5 [accessed Oct 2023].

-D
1540. Roche N, Crichton ML, Goeminne PC, et al. Update June 2022: management of hospitalised adults with coronavirus
L
disease 2019 (COVID-19): a European Respiratory Society living guideline. Eur Respir J 2022; 60(2): 2200803
IA
ER
AT
1541. Muhammad S, Long X, Salman M. COVID-19 pandemic and environmental pollution: A blessing in disguise? Sci Total
Environ 2020; 728: 138820 https://pubmed.ncbi.nlm.nih.gov/32334164.
M
T
1542. Alqahtani JS, Oyelade T, Aldhahir AM, et al. Reduction in hospitalised COPD exacerbations during COVID-19: A
H
systematic review and meta-analysis. PLoS One 2021; 16(8): e0255659 https://pubmed.ncbi.nlm.nih.gov/34343205.
IG
R
1543. Hewitt R, Farne H, Ritchie A, Luke E, Johnston SL, Mallia P. The role of viral infections in exacerbations of chronic
PY
obstructive pulmonary disease and asthma. Ther Adv Respir Dis 2016; 10(2): 158-74
O
C
1544. Ackermann M, Verleden SE, Kuehnel M, et al. Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in
Covid-19. N Engl J Med 2020; 383(2): 120-8 https://pubmed.ncbi.nlm.nih.gov/32437596.
1545. Calabrese F, Pezzuto F, Fortarezza F, et al. Pulmonary pathology and COVID-19: lessons from autopsy. The experience of
European Pulmonary Pathologists. Virchows Arch 2020; 477(3): 359-72 https://pubmed.ncbi.nlm.nih.gov/32642842.
1546. Wedzicha JA, Singh R, Mackay AJ. Acute COPD exacerbations. Clin Chest Med 2014; 35(1): 157-63
1547. Argenziano MG, Bruce SL, Slater CL, et al. Characterization and clinical course of 1000 patients with coronavirus disease
2019 in New York: retrospective case series. BMJ 2020; 369: m1996 https://pubmed.ncbi.nlm.nih.gov/32471884.
1548. Malik P, Patel U, Mehta D, et al. Biomarkers and outcomes of COVID-19 hospitalisations: systematic review and meta-
analysis. BMJ Evid Based Med 2021; 26(3): 107-8 https://pubmed.ncbi.nlm.nih.gov/32934000.
1549. Dagens A, Sigfrid L, Cai E, et al. Scope, quality, and inclusivity of clinical guidelines produced early in the covid-19
pandemic: rapid review. BMJ 2020; 369: m1936 https://pubmed.ncbi.nlm.nih.gov/32457027.
1550. Shang L, Zhao J, Hu Y, Du R, Cao B. On the use of corticosteroids for 2019-nCoV pneumonia. Lancet 2020; 395(10225):
1551. Arabi YM, Mandourah Y, Al-Hameed F, et al. Corticosteroid Therapy for Critically Ill Patients with Middle East
Respiratory Syndrome. Am J Respir Crit Care Med 2018; 197(6): 757-67 https://pubmed.ncbi.nlm.nih.gov/29161116.
1552. Lee N, Allen Chan KC, Hui DS, et al. Effects of early corticosteroid treatment on plasma SARS-associated Coronavirus
RNA concentrations in adult patients. J Clin Virol 2004; 31(4): 304-9 https://pubmed.ncbi.nlm.nih.gov/15494274.
1553. Lee N, Chan PK, Hui DS, et al. Viral loads and duration of viral shedding in adult patients hospitalized with influenza. J
Infect Dis 2009; 200(4): 492-500 https://pubmed.ncbi.nlm.nih.gov/19591575.
1554. Russell CD, Millar JE, Baillie JK. Clinical evidence does not support corticosteroid treatment for 2019-nCoV lung injury.
Lancet 2020; 395(10223): 473-5 https://pubmed.ncbi.nlm.nih.gov/32043983.
1555. World Health Organization. Clinical management of COVID-19. Interim guidance 27 May 2020; online document
available here: https://www.who.int/publications/i/item/clinical-management-of-covid-19 [accessed Aug 2022].
1556. Wu C, Chen X, Cai Y, et al. Risk Factors Associated With Acute Respiratory Distress Syndrome and Death in Patients With
Coronavirus Disease 2019 Pneumonia in Wuhan, China. JAMA Intern Med 2020; 180(7): 934-43
1557. WHO Rapid Evidence Appraisal for COVID-19 Therapies Working Group, Sterne JAC, Murthy S, et al. Association
Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19: A Meta-
analysis. JAMA 2020; 324(13): 1330-41 https://pubmed.ncbi.nlm.nih.gov/32876694.
1558. Rawson TM, Moore LSP, Zhu N, et al. Bacterial and Fungal Coinfection in Individuals With Coronavirus: A Rapid Review
To Support COVID-19 Antimicrobial Prescribing. Clin Infect Dis 2020; 71(9): 2459-68
1559. Verroken A, Scohy A, Gerard L, Wittebole X, Collienne C, Laterre PF. Co-infections in COVID-19 critically ill and antibiotic
management: a prospective cohort analysis. Crit Care 2020; 24(1): 410 https://pubmed.ncbi.nlm.nih.gov/32646494.
1560. Jiang DH, McCoy RG. Planning for the Post-COVID Syndrome: How Payers Can Mitigate Long-Term Complications of the
Pandemic. J Gen Intern Med 2020; 35(10): 3036-9 https://pubmed.ncbi.nlm.nih.gov/32700223.
1561. Borczuk AC, Salvatore SP, Seshan SV, et al. COVID-19 pulmonary pathology: a multi-institutional autopsy cohort from
Italy and New York City. Mod Pathol 2020; 33(11): 2156-68 https://pubmed.ncbi.nlm.nih.gov/32879413.
1562. Gattinoni L, Chiumello D, Rossi S. COVID-19 pneumonia: ARDS or not? Crit Care 2020; 24(1): 154
1563. Gattinoni L, Coppola S, Cressoni M, Busana M, Rossi S, Chiumello D. COVID-19 Does Not Lead to a "Typical" Acute
Respiratory Distress Syndrome. Am J Respir Crit Care Med 2020; 201(10): 1299-300
TE
U
1564. Panwar R, Madotto F, Laffey JG, van Haren FMP. Compliance Phenotypes in Early Acute Respiratory Distress Syndrome
IB
TR
before the COVID-19 Pandemic. Am J Respir Crit Care Med 2020; 202(9): 1244-52
D
1565. Brault C, Zerbib Y, Kontar L, et al. COVID-19- versus non-COVID-19-related Acute Respiratory Distress Syndrome:
T
Differences and Similarities. Am J Respir Crit Care Med 2020; 202(9): 1301-4
O
N
O
1566. Grieco DL, Bongiovanni F, Chen L, et al. Respiratory physiology of COVID-19-induced respiratory failure compared to
-D
ARDS of other etiologies. Crit Care 2020; 24(1): 529 https://pubmed.ncbi.nlm.nih.gov/32859264.

L
1567. Lechowicz K, Drozdzal S, Machaj F, et al. COVID-19: The Potential Treatment of Pulmonary Fibrosis Associated with
IA
ER
SARS-CoV-2 Infection. J Clin Med 2020; 9(6): 1917 https://pubmed.ncbi.nlm.nih.gov/32575380.

AT
1568. Remmelink M, De Mendonca R, D'Haene N, et al. Unspecific post-mortem findings despite multiorgan viral spread in
COVID-19 patients. Crit Care 2020; 24(1): 495 https://pubmed.ncbi.nlm.nih.gov/32787909.
M
T
1569. Palmer K, Monaco A, Kivipelto M, et al. The potential long-term impact of the COVID-19 outbreak on patients with non-
H
communicable diseases in Europe: consequences for healthy ageing. Aging Clin Exp Res 2020; 32(7): 1189-94
IG
R
PY
1570. Zaim S, Chong JH, Sankaranarayanan V, Harky A. COVID-19 and Multiorgan Response. Curr Probl Cardiol 2020; 45(8):
O
C
1571. Puelles VG, Lutgehetmann M, Lindenmeyer MT, et al. Multiorgan and Renal Tropism of SARS-CoV-2. N Engl J Med 2020;
1572. Dobesh PP, Trujillo TC. Coagulopathy, Venous Thromboembolism, and Anticoagulation in Patients with COVID-19.
Pharmacotherapy 2020; 40(11): 1130-51 https://pubmed.ncbi.nlm.nih.gov/33006163.
1573. Ambrosetti M, Ageno W, Spanevello A, Salerno M, Pedretti RF. Prevalence and prevention of venous thromboembolism
in patients with acute exacerbations of COPD. Thromb Res 2003; 112(4): 203-7
1574. Kim V, Goel N, Gangar J, et al. Risk Factors for Venous Thromboembolism in Chronic Obstructive Pulmonary Disease.
Chronic Obstr Pulm Dis 2014; 1(2): 239-49 https://pubmed.ncbi.nlm.nih.gov/25844397.
1575. Paranjpe I, Fuster V, Lala A, et al. Association of Treatment Dose Anticoagulation With In-Hospital Survival Among
Hospitalized Patients With COVID-19. J Am Coll Cardiol 2020; 76(1): 122-4 https://pubmed.ncbi.nlm.nih.gov/32387623.
1576. Wu Z, McGoogan JM. Characteristics of and Important Lessons From the Coronavirus Disease 2019 (COVID-19)
Outbreak in China: Summary of a Report of 72 314 Cases From the Chinese Center for Disease Control and Prevention.
1577. Qiu H, Tong Z, Ma P, et al. Intensive care during the coronavirus epidemic. Intensive Care Med 2020; 46(4): 576-8
1578. Johns Hopkins University. Coronavirus Resource Center; online resource available here: https://coronavirus.jhu.edu
1579. Rzymski P, Kasianchuk N, Sikora D, Poniedzialek B. COVID-19 vaccinations and rates of infections, hospitalizations, ICU
admissions, and deaths in Europe during SARS-CoV-2 Omicron wave in the first quarter of 2022. J Med Virol 2023; 95(1):
1580. Schunemann HJ, Khabsa J, Solo K, et al. Ventilation Techniques and Risk for Transmission of Coronavirus Disease,
Including COVID-19: A Living Systematic Review of Multiple Streams of Evidence. Ann Intern Med 2020; 173(3): 204-16
1581. Tandon P, Leibner E, Hackett A, et al. The fourth wave: vaccination status and intensive care unit mortality at a large
hospital system in New York City. Acute Crit Care 2022; 37(3): 339-46 https://pubmed.ncbi.nlm.nih.gov/36102004.
1582. Grasselli G, Zangrillo A, Zanella A, et al. Baseline Characteristics and Outcomes of 1591 Patients Infected With SARS-
CoV-2 Admitted to ICUs of the Lombardy Region, Italy. JAMA 2020; 323(16): 1574-81
1583. Kluge S, Janssens U, Welte T, Weber-Carstens S, Marx G, Karagiannidis C. German recommendations for critically ill
patients with COVID-19. Med Klin Intensivmed Notfmed 2020; 115(Suppl 3): 111-4
1584. Namendys-Silva SA. Respiratory support for patients with COVID-19 infection. Lancet Respir Med 2020; 8(4): e18
1585. Cheung JC, Ho LT, Cheng JV, Cham EYK, Lam KN. Staff safety during emergency airway management for COVID-19 in
Hong Kong. Lancet Respir Med 2020; 8(4): e19 https://pubmed.ncbi.nlm.nih.gov/32105633.
1586. Crimi C, Noto A, Cortegiani A, et al. Noninvasive respiratory support in acute hypoxemic respiratory failure associated
with COVID-19 and other viral infections. Minerva Anestesiol 2020; 86(11): 1190-204
1587. Patel M, Gangemi A, Marron R, et al. Use of High Flow Nasal Therapy to Treat Moderate to Severe Hypoxemic
Respiratory Failure in COVID-19. BMJ Open Respir Res 2020; 7: e000650
TE
1588. Demoule A, Vieillard Baron A, Darmon M, et al. High-Flow Nasal Cannula in Critically III Patients with Severe COVID-19.
U
IB
TR
1589. Frat JP, Thille AW, Mercat A, et al. High-flow oxygen through nasal cannula in acute hypoxemic respiratory failure. N
IS
D
1590. Ni YN, Luo J, Yu H, Liu D, Liang BM, Liang ZA. The effect of high-flow nasal cannula in reducing the mortality and the rate
T
of endotracheal intubation when used before mechanical ventilation compared with conventional oxygen therapy and
O
N
noninvasive positive pressure ventilation. A systematic review and meta-analysis. Am J Emerg Med 2018; 36(2): 226-33
O
-D
1591. Alhazzani W, Moller MH, Arabi YM, et al. Surviving Sepsis Campaign: Guidelines on the Management of Critically Ill
L
Adults with Coronavirus Disease 2019 (COVID-19). Crit Care Med 2020; 48(6): e440-e69
IA
ER
AT
1592. Telias I, Katira BH, Brochard L. Is the Prone Position Helpful During Spontaneous Breathing in Patients With COVID-19?
M
T
1593. Slutsky AS, Ranieri VM. Ventilator-induced lung injury. N Engl J Med 2013; 369(22): 2126-36
H
IG
R
1594. Berlin DA, Gulick RM, Martinez FJ. Severe Covid-19. N Engl J Med 2020; 383(25): 2451-60
PY
O
1595. Fan E, Beitler JR, Brochard L, et al. COVID-19-associated acute respiratory distress syndrome: is a different approach to
C
management warranted? Lancet Respir Med 2020; 8(8): 816-21 https://pubmed.ncbi.nlm.nih.gov/32645311.

1596. Bellani G, Laffey JG, Pham T, et al. Noninvasive Ventilation of Patients with Acute Respiratory Distress Syndrome.
Insights from the LUNG SAFE Study. Am J Respir Crit Care Med 2017; 195(1): 67-77
1597. Barbaro RP, MacLaren G, Boonstra PS, et al. Extracorporeal membrane oxygenation support in COVID-19: an
international cohort study of the Extracorporeal Life Support Organization registry. Lancet 2020; 396(10257): 1071-8
1598. Lorusso R, Combes A, Lo Coco V, et al. ECMO for COVID-19 patients in Europe and Israel. Intensive Care Med 2021;
1599. Ma X, Liang M, Ding M, et al. Extracorporeal Membrane Oxygenation (ECMO) in Critically Ill Patients with Coronavirus
Disease 2019 (COVID-19) Pneumonia and Acute Respiratory Distress Syndrome (ARDS). Med Sci Monit 2020; 26:
1600. Bartlett RH, Ogino MT, Brodie D, et al. Initial ELSO Guidance Document: ECMO for COVID-19 Patients with Severe
Cardiopulmonary Failure. ASAIO J 2020; 66(5): 472-4 https://pubmed.ncbi.nlm.nih.gov/32243267.
1601. MacLaren G, Fisher D, Brodie D. Preparing for the Most Critically Ill Patients With COVID-19: The Potential Role of
Extracorporeal Membrane Oxygenation. JAMA 2020; 323(13): 1245-6 https://pubmed.ncbi.nlm.nih.gov/32074258.
1602. Ramanathan K, Antognini D, Combes A, et al. Planning and provision of ECMO services for severe ARDS during the
COVID-19 pandemic and other outbreaks of emerging infectious diseases. Lancet Respir Med 2020; 8(5): 518-26
1603. Shekar K, Badulak J, Peek G, et al. Extracorporeal Life Support Organization Coronavirus Disease 2019 Interim
Guidelines: A Consensus Document from an International Group of Interdisciplinary Extracorporeal Membrane
Oxygenation Providers. ASAIO J 2020; 66(7): 707-21 https://pubmed.ncbi.nlm.nih.gov/32604322.
1604. Supady A, Combes A, Barbaro RP, et al. Respiratory indications for ECMO: focus on COVID-19. Intensive Care Med 2022;
1605. Hamele M, Neumayer K, Sweney J, Poss WB. Always ready, always prepared-preparing for the next pandemic. Transl
Pediatr 2018; 7(4): 344-55 https://pubmed.ncbi.nlm.nih.gov/30460186.
1606. Zochios V, Brodie D, Charlesworth M, Parhar KK. Delivering extracorporeal membrane oxygenation for patients with
COVID-19: what, who, when and how? Anaesthesia 2020; 75(8): 997-1001 https://pubmed.ncbi.nlm.nih.gov/32319081.
1607. Li J, Fink JB, Ehrmann S. High-flow nasal cannula for COVID-19 patients: low risk of bio-aerosol dispersion. Eur Respir J
1608. Raboud J, Shigayeva A, McGeer A, et al. Risk factors for SARS transmission from patients requiring intubation: a
multicentre investigation in Toronto, Canada. PLoS One 2010; 5(5): e10717
1609. Hautmann H, Gamarra F, Pfeifer KJ, Huber RM. Fiberoptic bronchoscopic balloon dilatation in malignant
tracheobronchial disease: indications and results. Chest 2001; 120(1): 43-9 https://pubmed.ncbi.nlm.nih.gov/11451814.
1610. Pfeifer M, Ewig S, Voshaar T, et al. Position Paper for the State-of-the-Art Application of Respiratory Support in Patients
with COVID-19. Respiration 2020; 99(6): 521-42 https://pubmed.ncbi.nlm.nih.gov/32564028.
1611. Shaw KM, Lang AL, Lozano R, Szabo M, Smith S, Wang J. Intensive care unit isolation hood decreases risk of
aerosolization during noninvasive ventilation with COVID-19. Can J Anaesth 2020; 67(10): 1481-3
1612. Needham DM, Davidson J, Cohen H, et al. Improving long-term outcomes after discharge from intensive care unit:
report from a stakeholders' conference. Crit Care Med 2012; 40(2): 502-9 https://pubmed.ncbi.nlm.nih.gov/21946660.
TE
1613. Needham DM, Feldman DR, Kho ME. The functional costs of ICU survivorship. Collaborating to improve post-ICU
U
disability. Am J Respir Crit Care Med 2011; 183(8): 962-4 https://pubmed.ncbi.nlm.nih.gov/21498817.
IB
TR
1614. Herridge MS, Chu LM, Matte A, et al. The RECOVER Program: Disability Risk Groups and 1-Year Outcome after 7 or
IS
More Days of Mechanical Ventilation. Am J Respir Crit Care Med 2016; 194(7): 831-44
D
T
1615. Griffith DM, Salisbury LG, Lee RJ, et al. Determinants of Health-Related Quality of Life After ICU: Importance of Patient
O
N
Demographics, Previous Comorbidity, and Severity of Illness. Crit Care Med 2018; 46(4): 594-601
O
-D
1616. Holm SE, Mu K. Discharge Planning for the Elderly in Acute Care: The Perceptions of Experienced Occupational
L
Therapists. Physical & Occupational Therapy In Geriatrics 2012; 30(3): 214-28

IA
ER
1617. Spruit MA, Holland AE, Singh SJ, Tonia T, Wilson KC, Troosters T. COVID-19: Interim Guidance on Rehabilitation in the
AT
Hospital and Post-Hospital Phase from a European Respiratory Society and American Thoracic Society-coordinated
International Task Force. Eur Respir J 2020; 56(6): 2002197 https://pubmed.ncbi.nlm.nih.gov/32817258.
M
T
1618. Antoniou KM, Vasarmidi E, Russell AM, et al. European Respiratory Society statement on long COVID follow-up. Eur
H
Respir J 2022; 60(2): https://pubmed.ncbi.nlm.nih.gov/35144991.

IG
R
1619. Centers for Disease Control and Prevention. Post-COVID Conditions: Information for Healthcare Providers. Available
PY
online at: https://www.cdc.gov/coronavirus/2019-ncov/hcp/clinical-care/post-covid-conditions.html [accessed Oct

O
2023].
C
1620. National Institute for Health and Care Excellence (NICE). COVID-19 rapid guideline: Managing the long-term effects of
COVID-19. Available online at: https://www.nice.org.uk/guidance/ng188 [accessed Oct 2023].
1621. Watanabe A, So M, Iwagami M, et al. One-year follow-up CT findings in COVID-19 patients: A systematic review and
meta-analysis. Respirology 2022; 27(8): 605-16 https://pubmed.ncbi.nlm.nih.gov/35694728.
1622. Alqahtani JS, Oyelade T, Aldhahir AM, et al. Prevalence, Severity and Mortality associated with COPD and Smoking in
patients with COVID-19: A Rapid Systematic Review and Meta-Analysis. PLoS One 2020; 15(5): e0233147
1623. Hosey MM, Needham DM. Survivorship after COVID-19 ICU stay. Nat Rev Dis Primers 2020; 6(1): 60
1624. Lamas D. Chronic critical illness. N Engl J Med 2014; 370(2): 175-7 https://pubmed.ncbi.nlm.nih.gov/24401058.
1625. Tracy CS, Bell SH, Nickell LA, Charles J, Upshur RE. The IMPACT clinic: innovative model of interprofessional primary care
for elderly patients with complex health care needs. Can Fam Physician 2013; 59(3): e148-55
1626. Bourbeau J, Nault D, Sedeno M. Action Plan from the Living Well with COPD series 2005. Available at
https://www.livingwellwithcopd.com/en/copd-treatment.html [accessed Oct 2023].
TE
U
IB
STR
I
D
T
O
N
O
-D
L
IA
TER
A
M
T
H
IG
R
PY
O
C

Copd 2024

Uploaded by

Copyright:

Available Formats

Copd 2024

Uploaded by

Document Information

Copyright

Available Formats

Share this document

Share or Embed Document

Sharing Options

Did you find this document useful?

Is this content inappropriate?

Copyright:

Available Formats

Copd 2024

Uploaded by

Copyright:

Available Formats

2024

Global Strategy for the Diagnosis, Management, and

GLOBAL STRATEGY FOR THE DIAGNOSIS, MANAGEMENT,

Important Purpose & Liability Disclaimer

Hospital Universitario de Caracas Gerard Criner, MD

Universidad Central de Venezuela Temple University School of Medicine Dave Singh, MD

Centro Médico de Caracas Philadelphia, Pennsylvania, USA University of Manchester

Caracas, Venezuela Manchester, UK

Obianuju Ozoh, MD University of Exeter Medical School Robert Stockley, MD DSc

University of Lagos College of Medicine and Health University Hospital

Lagos, Nigeria University of Exeter, Exeter Birmingham, UK

Sundeep Salvi, MD M. Victorina López Varela, MD– Retired, 2023

Pulmocare Research and Education MeiLan K. Han, MD MS Universidad de la República

(PURE) Foundation University of Michigan Hospital Maciel

Ann Arbor, MI, USA Montevideo, Uruguay

Fernando J. Martinez, MD MS Jadwiga A. Wedzicha, MD

GOLD EXECUTIVE DIRECTOR EDITORIAL ASSISTANCE ACKNOWLEDGEMENTS

Graphic Design: Imbue Creative

ARGENTINA IRAN RUSSIA

Neven Miculinic, MD Professor Mousa Khadadah Daiana Stolz, MD

Zagreb, Croatia Kuwait University Basel, Switzerland

CZECH REPUBLIC KYRGYZSTAN SYRIA

Stanislav Kos, MD, PhD., FCCP Talant Sooronbaev, MD Yousser Mohammad, MD

EGYPT LEBANON TRINIDAD & TOBAGO

FINLAND LITHUANIA Trinidad and Tobago

Helsinki, Finland Kaunas, Lithuania Prof Dr. Hakan Gunen

FRANCE MALTA Malatya, Turkey

Prof Gaetan Deslée Prof Joseph M Cacciotolo Prof Nurdan Kokturk, MD

Reims, France Pieta, Malta Ankara, Turkey

GEORGIA MEXICO UGANDA

Alvar G. Agusti, MD Claus Vogelmeier, MD

examined by the Committee is available on the GOLD website: www.goldcopd.org.

CHAPTER 1: DEFINITION AND OVERVIEW ....................................................................................................................................................... 4

KEY POINTS: ....................................................................................................................................................................................................4

Social burden ...................................................................................................................................................................................................8

Environmental risk factors ..............................................................................................................................................................................8

Genetic factors ..............................................................................................................................................................................................10

Trajectories of lung function: development and aging ..................................................................................................................................10

Asthma and airway hyper-reactivity .............................................................................................................................................................13

Chronic bronchitis .........................................................................................................................................................................................14

Race and ethnicity .........................................................................................................................................................................................15

Socioeconomic status ....................................................................................................................................................................................16

CHAPTER 2: DIAGNOSIS AND ASSESSMENT ...................................................................................................................................................20

KEY POINTS: ..................................................................................................................................................................................................20

IDENTIFY AND REDUCE EXPOSURE TO RISK FACTORS .........................................................................................................................................41

SMOKING CESSATION ................................................................................................................................................................................................43

Advice and counseling interventions .............................................................................................................................................................44

HOUSEHOLD AND OUTDOOR AIR POLLUTION ...................................................................................................................................................................45

Influenza vaccine ...........................................................................................................................................................................................46

Pneumococcal vaccines .................................................................................................................................................................................46

Respiratory syncytial virus (RSV) vaccine ......................................................................................................................................................47

Other vaccines ...............................................................................................................................................................................................47

PHARMACOLOGICAL TREATMENT OF STABLE COPD ..........................................................................................................................................47

ALGORITHMS FOR THE INITIATION AND FOLLOW-UP OF PHARMACOLOGICAL TREATMENT ...........................................................................................................49

Managing inhaled therapy ............................................................................................................................................................................53

NON-PHARMACOLOGICAL TREATMENT OF STABLE COPD .................................................................................................................................56

KEY POINTS: ..................................................................................................................................................................................................99

TREATMENT OPTIONS ......................................................................................................................................................................................104

Treatment setting .......................................................................................................................................................................................104

Pharmacological treatment ........................................................................................................................................................................106